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Abstract 
Selenium (Se) is an essential micronutrient in both human and animal nutrition that exists 
in a wide array of different forms, both organic and inorganic. Selenoamino acids 
(SeAAs), such as selenocystine (SeCys2), selenomethionine (SeMet), and 
methylselenocysteine (MSC) are organic species with reported health benefits of cancer 
prevention, increased fertility and improved immunological status. However, 
supplementation of SeAAs can be challenging, due to their reported narrow therapeutic 
range of indices, low bioavailability and increased susceptibility to oxidation. To address 
this, SeAAs were encapsulated into nanoparticles (NPs) to lower their toxicity profiles in 
comparison to their native form, in addition to offering them protection from the harsh 
conditions present in the gastrointestinal tract. The ionotropic gelation method was 
employed to produce NPs, using the cationic polyelectrolyte chitosan (Cs) crosslinked 
with the polyanion tripolyphosphate (TPP). The NP physicochemical properties were 
optimised using a Design of Experiments (DoE) and mathematical modelling approach.  
First, a central composite design (CCD) was used to identify a feasible region in which 
unloaded NPs with target properties for oral delivery (size~300 nm, PDI < 0.5 and ZP > 
30 mV) could be achieved, indicating that optimum conditions to be 6:1 mass ratios of 
Cs:TPP. Following that, SeMet was used as a prototype encapsulant and a second DoE 
approach was employed, namely a Box Behnken design (BBD). In that study, Cs:TPP 
ratio, Cs solvent pH, and drug load concentration were independently varied and the 
dependent variables assessed were encapsulation efficiency (EE%), particle size, PDI and 
ZP. The BBD highlighted the optimum conditions for NP production, although EE% 
remained relatively low (≈40 %). By varying the pH of the ionotropic solution 
components and coating the NPs with zein (a prolamine rich protein), EE% was doubled 
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(≈80 %), diameters increased from 187±58nm to 377±47nm and PDI and ZP values were 
maintained. The formulation performed well indicating good suitability for oral delivery, 
in terms of stability, cytotoxicity (intestinal and liver cell lines) and release profiles, as 
determined by in vitro techniques. The models generated from the BBD were then applied 
to the SeAAs, SeCys2 and MSC and further refinement of the zein coating was 
investigated. NPs with similar physicochemical properties to those of SeMet loaded Cs 
were produced, indicating the strength of the DoE models and their usefulness in 
formulation design. These NPs also performed well in in vitro assessments for stability 
and release profiles. However, SeCys2 showed cytotoxicity to liver cell lines which was 
reduced after encapsulation within the NP matrix, inferring its protective effects and thus 
use as a delivery system.  
Chitin was extracted from the cultivated mushroom Agaricus bisporus in order to derive 
fungal Cs (fCs) with equivalent physicochemical properties to the commercial Cs 
(CL113) that had been employed for NP production. fCs with comparable properties to 
CL113 were produced, although fCs possessed a higher molecular weight (MW) (180±19 
vs 110±4 kDa). Trimethyl chitosan was then synthesised from the fCs and assessed for 
permeation enhancing capabilities on intestinal cell monolayer models, which implicated 
its potential application as a permeation enhancer. 
fCs was used for the production of synthetic SeCys2 loaded NPs using the knowledge 
gained from the previously developed DoE models and in vitro methodologies. Lastly, a 
preliminary study to assess the feasibility of Irish mushrooms providing Se species for 
supplementation purposes was conducted, implicating them as a viable source for SeCys2.  
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1 INTRODUCTION 
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1.1 Background 
Drug discovery and development involves highly challenging, laborious, and 
expensive processes. On average, it can take 15 years, with an estimated cost of US 
$802 million, for the development of a new drug, from bench to bedside, which is 
markedly increasing at an annual rate of 7.4 % above general price inflation (Cousin 
et al., 2016). Technological advances such as quantitative structure activity 
relationships (QSAR) and high throughput screening (HTS) have assisted in the 
identification, synthesis and activity assessment of new bioactive (BA) compounds, 
more rapidly than that of conventional discovery (Park, 2014). However, in spite of 
QSAR and HTS techniques, most drugs fail to achieve favourable clinical outcomes 
in the clinical phase, due to their inability to reach the target site of action (Park et al., 
2010, Estanqueiro et al., 2015). Although BAs may show high potency for target sites 
in vitro, the oral delivery of such compounds in vivo can often raise a challenge, for 
example: 
• Stability in the gastrointestinal tract (GIT) -reducing bio-accessibility 
• Low permeability through intestinal epithelial and/or transporter restrictions 
• Instability under processing conditions (temperature, oxygen, light)  
• Degradation in the GIT by pH, enzymes or presence of other nutrients 
all of which may limit the activity and potential health benefits of nutraceutical 
molecules (Agrawal et al., 2014, Gleeson, Ryan and Brayden, 2016). 
Targeted drug delivery systems, that release drugs or BA agents at the desired site of 
action, are an effective approach to overcome these critical issues, as they can improve 
therapeutic efficacy through the modulation of pharmacokinetic and biodistribution 
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fate (Hagens et al., 2007). In this context, nanoparticle (NP) delivery systems have 
been investigated, as they have been shown to be more biologically active, due to their 
enhanced surface area per mass compared with larger-sized particles of the same 
chemistry (Oberdörster et al., 2005). By using NPs as a drug delivery vehicle, it might 
be possible to enhance a range of characteristics for a given BA, such as increased 
protection ensuring stability and better oral uptake (Nair et al., 2010).  
The gold standard for BA delivery is considered the oral route, due to ease of dosing, 
patient acceptance and compliance. Because of this, encapsulation systems now are 
of the upmost importance (Benshitrit et al., 2012). Recently, consumers, industry and 
researchers alike are recognising the potential of BA compounds naturally present in 
common food stuffs (Vattem and Maitin, 2016). There is a consumer perception on 
the need to reduce animal testing for everyday products and dietary supplements, 
favouring “naturally derived” BAs (Vanhonacker and Verbeke, 2014). Chitosan (Cs), 
a biocompatible, mucopolysaccharide, typically derived from crustaceans, has been 
investigated as a system for cargo delivery to the colon, due to its capacity to protect 
therapeutic agents from the hostile conditions of the upper gastrointestinal tract 
(Benshitrit et al., 2012) and to facilitate release of entrapped agents (Chen et al., 
2013), whilst its glycosidic linkages undergo degradation by colonic microflora 
(Amidon, Brown and Dave, 2015). Improving the bioavailability of drugs through NP 
drug delivery systems is possible using Cs prepared either as a hydrogel or as NPs, 
whereby its polycationic amino groups interact with the drug’s anionic groups, in the 
presence of an anionic crosslinker (Janes, Calvo and Alonso, 2001). However, 
because of its high solubility in acid gastric fluids (such as the stomach environment 
(pH 1.2)), Cs has limited suitability in colonic targeting of drugs, sometimes resulting 
in a burst release of the drug in this environment (Garapati et al., 2015). To alleviate 
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this problem, the coating of Cs NPs has been proposed, whereby an improved 
controlled release of encapsulated BA can be achieved, as the coating serves as a rate 
limiting barrier (Katouzian and Jafari, 2016). It is worth noting however, that the 
release from these NPs is strongly dependent on the chemical nature and physical 
structure of the coating material and its interaction with Cs. Zein, a prolamine rich 
protein derived from maize, has been employed for the formulation and coating of 
Cs:NP oral delivery systems, due to its ability to increase the encapsulation efficiency 
(EE%) of BAs and to improve their controlled release in the GIT (Luo et al., 2010; 
Luo and Wang, 2014; Paliwal and Palakurthi, 2014). This coating strategy harnesses 
both the protein (zein) and polysaccharide (Cs) properties in a NP delivery system in 
which a broader range of physical, chemical and colloidal stability can be achieved 
(Benshitrit et al., 2012).  
Selenium (Se) is an essential micronutrient that exists in different forms, both 
inorganic and organic and exerts its biological functions through >25 selenoproteins 
(Xia et al., 2005). Nutritional deficiency of the element decreases the expression of 
selenoproteins and thereby impairs selenium’s biological functions. Selenoamino 
acids (SeAAs) have attracted attention as Se supplements due to their potential 
immune enhancing, fertility improving and anti-cancer properties (El-Bayoumy, 
Sinha and Richie Jr, 2015; Kamwesiga et al., 2015; Shanmugam et al., 2015). 
However, Se from A. bisporus has been reported to have poor bioavailability (Thiry 
et al., 2012), which is further reduced upon cooking (Khanam and Platel, 2016). As 
such, there is substantial interest in developing an oral formulation of Se, although, 
due to its susceptibility to oxidation, this has not proved possible to date.  
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As a consequence of depleting finite resources, food shortages, and climate change, 
the concept of a circular economy and the importance of obtaining maximum value 
from organic resources have been highlighted (Walsh et al., 2017).  A. bisporus offers 
a renewable source for Cs which is more sustainable than that of crustacean sources 
and can potentially contribute to the creation of a circular economy for the mushroom 
industry (Kaur et al., 2014). More specifically, estimations of by-products produced 
globally from industrial mushroom cultivation per annum have been reported to be in 
excess of 50,000 tonnes (Wu et al., 2004) and as such may offer an opportunity to 
acquire high purity products such as fungal-derived Cs (fCs) and SeAAs. Within this 
sustainability view-point, fCs, due to the controlled environments in which the 
mushrooms are cultivated  may produce Cs with greater reproducible properties than 
those derived from crustaceans (Muzzarelli et al., 2012). Whereas Se-fortified A. 
bisporus have demonstrated the ability to assimilate inorganic Se (such as sodium 
selenite) from the growth substrate and convert it to organic Se, such as SeAAs 
(Maseko et al., 2013). 
This project aims to develop a robust formulation for SeAA loaded fCs NPs intended 
for oral delivery, using a systematic approach to design and extensive in vitro analysis. 
Additionally, the extraction and characterisation of SeAAs from Se supplemented A. 
bisporus will be conducted with the objective of demonstrating the feasibility of 
obtaining these compounds for supplement production.  
1.2 Delivery of bioactive peptides 
Bioactive peptides and proteins have garnered much interest in the nutraceutical and 
pharmaceutical industry over the last decade. This interest has been attributed to 
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several factors such as: selectivity (Arkin, 2005; Soudy et al., 2016), effective and 
potent actions (Frokjaer and Otzen, 2005; Elzoghby, Samy and Elgindy, 2012) and 
reduced side effects (Morishita and Peppas, 2006). Ophthalmic, dermatological and 
oral are delivery routes that have been investigated for peptides and proteins over the 
last few years (Van Der Walle, 2011), the latter typically identified as the most 
convenient and desired mode of delivery, due to its ease of administration and reported 
patient compliance, particularly when repeat administration is required (Mahato et al., 
2003).  
The oral delivery of peptides and proteins has proven challenging to date, due to their 
susceptibility to enzymatic degradation (Woodley, 1993) and poor intestinal 
absorption across epithelial cells found in the GIT (Hamman, Enslin and Kotzé, 2005). 
Several approaches to overcoming these limitations have been investigated, for 
example: enteric coatings (Toorisaka et al., 2005), permeation enhancers (Karavasili 
et al., 2015), protease inhibitors (Chuang et al., 2015) and the employment of carrier 
systems (Jain et al., 2013). Amongst these, the latter has shown particular promise in 
the form of NP delivery systems, particularly with regards to polymers that possess 
mucoadhesive properties and have the ability to protect molecules from the harsh 
conditions that are found in the GIT (Ensign, Cone and Hanes, 2012). Furthermore, 
NPs have been shown to possess the ability to be absorbed into mucosal tissue, 
although this has also been shown to be related to the size and surface charge, manifest 
as zeta potential (ZP), of the NP. In terms of oral delivery, optimum sizes for NPs 
have been reported as 100 – 500 nm, with ZP of approximately +30 mV being reported 
as a good indication of NP dispersibility (He et al., 2010). Additionally, the 
polydispersity index (PDI) of a NP suspension should be as close to zero as possible, 
a value of 0.5 generally accepted as the upper limit for PDI (Gaumet et al., 2008).  
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1.3 Selenium 
Selenium is a chemical element with the symbol Se and atomic number 34. Many 
health benefits of Se, such as cancer prevention (Abdulah et al., 2005; Nie et al., 2016) 
increased immunological status (Narayan et al., 2015) and increased fertility 
(Aréchiga et al., 1998; Shanmugam et al., 2015) have been identified in recent years. 
However, as a result of diverse geological conditions, the Se status of humans, plants 
and animals can differ significantly. Most rock types contain very low concentrations 
of Se, although high concentrations are associated with some phosphatic rocks, 
organic rich black shales, coals and sulphide mineralisation, which has led to more Se 
deficient soils than there are seleniferous ones, worldwide (Khanal and Knight, 2010). 
Soils containing > 0.5 mg Se kg-1 are considered to be seleniferous and the forages 
produced on such soils absorb Se to levels in excess of what is permissible for animal 
consumption (Fordyce, 2013). In seleniferous parts of the world, such as parts of 
Ireland, Canada, western USA and some zones in China, adverse effects on Se toxicity 
in livestock have been reported (Navarro-Alarcon and López-Martınez, 2000).  
The physical and chemical form of an element is referred to as speciation, meaning 
its oxidation state, stoichiometry or possible presence of various ligands (Reeder, 
Schoonen and Lanzirotti, 2006). Selenium is typically present as Se2-, Se2+, Se4+, or 
Se6+, associated with organic and inorganic species. The oxyanions selenite (SeO3
2- 
or Se(IV)) and selenate (SeO4
2- or Se(VI)) are some of the best-known inorganic 
species of Se, while selenomethionine (SeMet), selenocystine (SeCys2) and 
methylselenocysteine (MSC) are some of the best-known organic Se species (Uden et 
al., 2004). In amino acids, when an atom of Se replaces the atom of sulphur (S), such 
as methionine and cysteine, Se analogues are produced and referred to as selenoamino 
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acids (SeAAs). As the bioactivity of Se is highly dependent on its chemical form 
(Rayman, 2000), it is an important consideration when proposing a health supplement. 
Organic forms of Se, such as SeMet, SeCys2 and MSC, have been found to be more 
bioavailable than inorganic forms (Zeng et al., 2011) and several human health studies 
have shown their antioxidant and anticancer activity (Abdulah et al., 2005; Thiry et 
al., 2012). Health benefits of MSC and SeCys2 have been linked to the body’s 
endogenous antioxidant defence system, protecting cellular components such as cell 
membranes, lipids, lipoproteins and DNA from oxidative damage by free radicals, 
reactive oxygen and reactive nitrogen species (Ponnampalam et al., 2009). As 
oxidative damage is linked to the development of cardiovascular and 
neurodegenerative diseases as well as cancers, several experimental in vivo studies, 
on the effects of administration of Se compounds, have been undertaken (Valko et al., 
2007; Lobo et al., 2010; de Souza et al., 2014). For example, SeMet may have some 
potential in degenerative disease by decreasing oxidative stress of small molecule 
antioxidants used as a buffer for free radicals in brain tissue (Song et al., 2014; Reddy 
et al., 2017), SeCys2 has been shown to reduce tobacco-derived nitrosamine-induced 
lung tumour growth and enhance hepatic chemoprotective enzyme activities in mice 
(Fan et al., 2013), whereas MSC has been shown to offer selective protection against 
organ specific toxicity induced by clinically active antitumor agents, cisplatin, 
oxaliplatin, and irinotecan in rat models (Cao et al., 2014). A number of benefits 
regarding oncology treatments due the modulation of the therapeutic efficacy and 
selectivity of anticancer drugs has been reported for these SeAAs also (Evans, 
Khairuddin and Jameson, 2017).  
Although essential, Se possesses a low therapeutic index, meaning that there is a fine 
line between beneficial and toxic doses. Generally, organic Se shows a greater degree 
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of bioavailability than the inorganic forms, as well as a higher threshold for toxicity 
(Amoako, Uden and Tyson, 2009). For humans and animals, increased aging, 
increased risk of cardiovascular disease and an increased risk of other degenerative 
diseases are among the consequences of Se intake below the daily recommended 
amount of 42 µg per day (Levander, 1991). On the other hand, hair loss, nail 
brittleness, gastrointestinal disturbances, garlic breath, skin rash, irritability, fatigue 
and nervous system abnormalities are all side effects of a Se intake above the tolerable 
upper intake level of 400 µg per day (www.nap.edu). Despite the associated health 
benefits, Se intake in Ireland is remarkably low, whereby, nearly 50% of females and 
20% of males aged between 18 – 64 years fail to meet the average recommended 
requirement (ARR) of 40 µg per day (Murphy and Cashman, 2002). This low Se 
intake in the Irish population has been attributed to the drop in imports of high-protein 
wheat for bread-making flour from North America and Canada (Barclay and 
Macpherson, 1992), which are Se-rich in comparison to Irish flour varieties (Murphy 
and Cashman, 2001). Suffice to say, the narrow safety margin and form of Se must be 
carefully considered when designing an optimal Se supplement to ensure high 
bioactivity and low toxicity impact (Whanger, 2002) 
SeAAs possess lower bond energies for C-Se and Se-Se than those of C-S and S-S 
(C-S 272 kJ mol-1 , S-S 240 kJ mol-1 , C-Se 244 kJ mol-1 , Se-Se 172 kJ mol-1 ) 
respectively (Kildahl, 1995). As such, delivery of these compounds can be 
challenging, due to their distinctive electronegativity and atomic radius (i.e. larger 
radius and less E- than S), which makes oxidation easier vs their S analogue 
counterparts (Xu, Cao and Zhang, 2013). By using NPs as a drug delivery vehicle, it 
is possible to provide or enhance a wide range of optimal characteristics for a given 
BA compound, including: increased stability (Nair et al., 2010), reduction in 
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dose/toxicity of free drug to non-target organs in the body whilst maintaining 
therapeutic effects (De Jong and Borm, 2008), incorporation of both hydrophobic and 
hydrophilic substances (Ron et al., 2010) and suitability for the various routes of 
administration such as oral, pulmonary and topical applications (Helson, 2013). 
With this in mind, an opportunity arises to improve human and animal health by the 
provision of SeAAs through use of nanoparticulate delivery systems, as this strategy 
can potentially improve the bioavailability, decrease toxicity and confer protection 
from oxidative environments such found in the GIT. 
1.4 Chitosan 
Cs is a well-known, positively charged polyelectrolyte that has been extensively 
investigated for NP delivery systems (Kwon, 2008; Kleine-Brueggeney et al., 2015). 
This interest has been attributed to its high bio-compatibility, bio-degradability and 
muco-adhesive properties (Pillai, Paul and Sharma, 2009). Furthermore, it has been 
reported that Cs has the ability to transiently open the tight junctions found between 
epithelial cells (Dodane, Khan and Merwin, 1999; Smith, Wood and Dornish, 2004) 
which can in turn increase absorption of a given bioactive. 
Invertebrates (Crustacean shells and insect cuticles) and fungi are considered the 
predominant sources of Cs, the latter origin garnering much interest over the last 
decade (Muzzarelli et al., 2012). This is due to the fact that mushroom bodies are 
produced within a highly controlled production environment, which typically results 
in Cs with highly reproducible physicochemical properties being manufactured on a 
batch to batch basis (Plapied et al., 2010). Additionally, 50,000 tonnes of mushroom 
waste are produced annually (Wu et al., 2004) by the commercial industry and it is 
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considered a potential way of utilising by-products produced from the cultivation 
process. In contrast, animal derived Cs suffers from seasonal shortages, heavy metal 
contamination and inconsistent physicochemical characteristics (also attributed to 
seasonal circumstances) on a batch to batch basis (Brine and Austin, 1981; Plapied et 
al., 2010). In Ireland, the mushroom industry is the largest horticultural sector, 
employing over 3,500 people, with a farm gate value of €136 million, of which 
approximately 80% is exported to the UK (www.teagasc.ie). A. bisporus is the most 
commonly consumed cultivated mushroom in Ireland, consisting of the three main 
stages of maturity (Figure 1.1) (www.bordbia.ie). The Irish Food Board, Bord Bia, 
have indicated that the UK market for mushrooms is growing steadily in recent years 
at about 2% per year, with Button/Closed cup mushrooms holding the largest share of 
the market, followed by Flat/Breakfast mushrooms. However, during white 
mushroom (A. bisporus) cultivation, high quantities of by-products are generated, as 
between 5 and 20% of fruiting bodies are discarded due to misshaped cups and stalks 
that do not meet the specifications set by retailers (Wu et al., 2004). For example, in 
the USA alone, mushroom production results in nearly 50,000 metric tons of 
mushroom waste material per year, with no suitable commercial application 
(Philibert, Lee and Fabien, 2017). 
 
Figure 1.1 The different types of A. bisporus (pictures acquired from 
www.monaghan-mushrooms.com). 
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Production of Cs, predominately by acid and alkaline hydrolysis, is relatively straight-
forward, and is typically sourced from shellfish or mushroom waste. Depending on 
the source and treatment method employed for Cs manufacture, the physicochemical 
properties, such as the degree of deacetylation (DDA%) (which is defined in terms of 
the percentage of primary amino groups present in the polymer backbone) and 
molecular weight (MW) can range from 60-100% and 10-1000 kDa, respectively, and 
are important characteristics to consider when deciding on the application (Ravi 
Kumar, 2000). For example, DDA% and MW of the Cs have been shown to directly 
influence the size, zeta potential and colloidal stability of NPs in biological media 
(Kleine-Brueggeney et al., 2015). Generally, if the Cs is intended for use as a drug 
delivery vehicle, a medium molecular weight (110-225kDa) with high DDA% (≥80%) 
is considered ideal (Bowman and Leong, 2006). 
PROTASAN™ CL113, a commercial Cs, derived from crustacean shells and 
provided as a hydrochloride salt, has been previously promoted for its ability to 
encapsulate and deliver food derived BAs such as Retinyl Palmitate (a vitamin A 
isomer) and possesses the following physicochemical properties: MW of 110-150 
kDa, DDA% ≥80 % and minimal metal contamination (Fernández-Gutiérrez et al., 
2015). It has also been used to slow and control the drug release profile of Triclosan 
(an efficient anti-malarial drug) (Maestrelli, Mura and Alonso, 2004) and salmon 
calcitonin (a potential osteoarthritic drug) (Ryan et al., 2013) owing to both its known 
mucoadhesive and enhancer properties and its demonstrated effectiveness in 
optimally controlling drug release rate. To date, much of the research involving the 
employment of Cs as a nanocarrier, has been of animal origin (crustaceans) (Hamed, 
Özogul and Regenstein, 2016). However, high batch to batch variability of Cs from 
these sources have been reported, resulting in formulations with variable 
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physicochemical properties and with potential for inducing allergic responses (Smets 
and Rüdelsheim, 2018). Hence, an alternative source of Cs, for example edible A. 
bisporus mushrooms, could be well placed for pharmaceutical applications, 
particularly if available with batch to batch reproducibility and high control over its 
molecular characteristics, such as molecular weight and DDA%. 
1.5 Ionotropic Gelation 
A promising tool in the development of bio-compatible NP drug delivery systems is 
ionotropic gelation (IG). IG is a process whereby polyelectrolytes (of opposite 
charges) form inter- and intra- molecular cross-linkages mediated by the anionic 
molecules, in the presence of BAs, to form a hydrogel mesh structure with the 
bioactive encapsulated within (Calvo et al., 1997; Janes, Calvo and Alonso, 2001). It 
has also gained popularity due to the eco-friendly nature of the process, whereby only 
mildly acidic and basic solutions are required, in contrast to the expensive and toxic 
organic solvents which have been previously employed in delivery systems (Sailaja, 
Amareshwar and Chakravarty, 2011). The primary amino groups (-NH2) of Cs are 
predominantly protonated at acidic pH (-NH3
+), and it is this characteristic of Cs that 
provides it with the ability to form stable complexes when crosslinked with anionic 
polyelectrolytes, such as tripolyphosphate (TPP) (Janes, Calvo and Alonso, 2001). IG 
is considered a suitable technique for the development of NP vehicles for the delivery 
of sensitive drugs, as, once encapsulated within the hydrogel mesh work, their 
structural integrity has been shown to persist during release (Hennink and Van 
Nostrum, 2012). With regards to the optimum size of NPs, 100-300 nm in diameter 
has been found to be enough for a high payload, while smaller than 100 nm may pass 
through the GIT (Mohanraj and Chen, 2007). 
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1.6 Trimethyl chitosan as a permeation enhancer 
Trimethyl chitosan (TMC), a derivative of Cs in which the primary amine has been 
quarternised with methyl groups, has shown promising results as a permeation 
enhancer (PE), due to its intrinsic properties, including mucoadhesion and the ability 
to transiently open the tight junctions of the intestinal barrier, which can help facilitate 
both transcellular and paracellular transport of macromolecules (Chen et al., 2013). 
The transcellular route is both active and passive and is based on the activity of 
transmembrane pumps, channels, and carriers expressed in a polarised fashion. On the 
other hand, paracellular transport is only passive and driven by the gradients 
secondary to transcellular transport mechanisms (Figure 1.2) (Gleeson, Ryan and 
Brayden, 2016). The major barrier in the paracellular route is the tight junction, which 
is regulated and varies among epithelia in tightness and ion selectivity (Ghishan and 
Kiela, 2014). 
 
Figure 1.2 A schematic representation of Paracellular and Transcellular transport 
adapted from (Gleeson, Ryan and Brayden, 2016). 
This mucoadhesive feature of TMC may aid in its utility as a potential permeation 
enhancer for assisting the delivery of drugs to mucosal tissues, such as the GIT, by 
prolonging residence time through its ability to hold a positive charge at neutral pH. 
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1.7 Design of Experiments 
In the food industry, Design of Experiments (DoE) has become standard practice for 
research and development (R&D) of improved manufacturing processes (Carneiro 
and Azevedo, 2017). Employing such methodologies, it is possible to assess and select 
the most appropriate materials and equipment from available alternatives and 
subsequently identify variables for further study that can ensure a desired response 
outcome. Additionally, if more than two variables are under study, their interaction 
effects (if applicable) can also be evaluated.  
Typically, in the early stages of industrial R&D, the main focus is on screening 
designs, whereby extreme upper and lower bound level setting combinations of 
process variables are employed, to identify their potential effect on a given response 
(Politis et al., 2017). In the later stages of this work, the goal shifts from screening of 
variables, to product and process optimisation, through use of statistical experiment 
designs commonly termed "response surface methodologies (RSM)."  
In addition to trialling experiments with one or more variables at extreme levels, the 
benefits of RSM, are that midpoints of the study range are also included, allowing for 
information to be harnessed on direct, interactive and curvilinear variable effects. 
There are many variations of RSM. In this work, the main focus will be on two 
commonly employed designs the central composite design (CCD) and Box Behnken 
design (BBD) (discussed at length in Chapter 3, Section 3.1)) that were used to 
optimise unloaded and Se loaded Cs:TPP NPs.  
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1.8 Project Aims and Objectives  
The aim of this research is to produce oral formulations of nutraceutical SeAAs using 
ingredients from the food industry. 
To achieve this aim, the following objectives have been set: 
1. To assess the method of ionic gelation between the Cs and TPP, for production of 
NPs with physicochemical properties suitable for oral delivery using CCD 
optimisation. 
2. To employ the SeAA, SeMet as a prototype encapsulant and identify the main 
variables which affect EE%, particle size, PDI and ZP by use of BBD optimisation 
and coating with the prolamine rich protein zein 
3. To test the strength of the developed DoE models by encapsulating SeAAs with 
comparable ionisable groups (SeCys2 and MSC) with evaluation of oral 
compatibility in terms of stability, cytotoxicity and release profiles in vitro  
4. To extract chitin from the edible basidiomycete mushroom A. bisporus and derive 
to fCs with equivalent properties (DDA%, MW and purity) to that of an ultrapure 
Cs (CL113) product, for potential use in future NP formulations 
5. To chemically derive fCs to TMC and assess if it may offer potential use as a 
permeation enhancer  
6. To validate the strength of the developed DoE models by encapsulating synthetic 
SeCys2 with the fCs produced in this work 
7. To extract and characterise SeAAs in Irish mushrooms with the objective to 
demonstrate the possible availability of the species for supplement production in 
the Irish context. 
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1.9 Thesis outline 
Chapter 1 has introduced Se and its associated health benefits, alongside limitations 
that can occur when designing a Se supplement. The prospects of employing Cs based 
NPs for use in oral delivery of Se was introduced and the importance of NP 
physicochemical properties (size, PDI and ZP) for oral delivery purposes was 
highlighted. The fundamentals of ionotropic gelation were elucidated and its 
employment for the development of a SeAA loaded Cs NP delivery systems was 
recommended. TMC, a derivative of Cs that has shown promising results as a 
permeation enhancer, was also discussed. Finally RSM, a mathematical and statistical 
technique for empirical model building, was discussed. 
Chapter 2 is a review chapter that was published in Nutrition - Nutrient delivery. In: 
Nanotechnology in the Food Industry (Vozza et al., 2016) and gives the reader a 
broader outlook on nutrient delivery through nanoparticulate systems. Briefly, it 
discusses functional food and BAs in relation to nanotechnology in the food industry, 
basic concepts of NPs for nutrient and food grade delivery systems, in addition to 
common obstacles encountered. Attention is paid to nano systems based on 
encapsulation technology using polymeric NPs, and studies detailing the delivery of 
food derived nutraceuticals are presented. Key issues such as enhanced level of 
nutrient absorption consequences and nanotoxicology are also considered. Lastly, the 
need for labelling, regulation and recommendations for consumer acceptance of these 
products is highlighted.  
Chapter 3 introduces the key research methodologies employed in Chapters 4-8 and 
comprises five segments. Section 3.1 details NP experimental design using RSM 
techniques, specifically CCD and BBD. Section 3.2 describes the physicochemical 
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techniques employed to assess the produced NP properties (size, PDI and ZP), 
morphologies and EE%, via DLS, SEM and high performance liquid chromatography 
coupled with a diode array detector (HPLC-DAD). Section 3.3 details the in vitro 
techniques used to evaluate the produced NPs likelihood of oral compatibility in terms 
of stability, cytotoxicity and release profile. Section 3.4 describes the analytical 
techniques used to assess the physicochemical properties of chitin and Cs, such as 
DDA% and MW, with FTIR, NMR (1H and 13C) and Gel permeation chromatography 
(GPC), in addition to transepithelial electrical resistance (TEER, Ω cm2) for 
assessment of TMC as an intestinal permeation enhancer. Lastly, Section 3.5 
describes the extraction methods for qualitative and quantitative Se speciation 
analysis through use of HPLC-DAD. 
Chapter 4 details the production of unloaded Cs:TPP NPs via ionotropic gelation. A 
CCD statistical design was employed to generate a mathematical model that identified 
the optimum mass ratio of Cs:TPP for NPs, with properties reported to be beneficial 
for oral drug delivery. The results of the CCD identified a feasible region in which NP 
target properties could be achieved as determined by DLS. Evidence for the formation 
of NPs was acquired via FTIR analysis, through identification of key functional 
groups on Cs and TPP and identifying their shifts in the crosslinked matrices. The 
morphology of the NPs was then assessed by SEM analysis. 
Chapter 5 presents a manuscript submitted to the International Journal of 
Pharmaceutics (April 2018), detailing the study of SeMet, as a prototype encapsulant 
for Cs:TPP NPs (Vozza et al., 2018a). A BBD statistical design was employed to 
optimise the main variables that affected NP EE%, particle size, PDI and ZP. Two 
further studies were then conducted to increase the EE% of SeMet within the NP 
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matrix, 1) ionisation/protonation of NP formulation components and 2) The use of 
zein, as a co-formulation component for coating the NPs. Physicochemical properties 
of the NPs produced from the study were characterised via DLS, FTIR and SEM 
analysis. MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) studies were employed to test for potential cytotoxicity 
in the human intestinal epithelium (Caco-2), and human liver hepatocellular (HepG2), 
cell lines. Accelerated thermal stability of the loaded NPs was conducted to assess NP 
stability under normal storage conditions. Lastly, a compartmental, simulated gastric 
fluid and membrane analysis model enabled assessment the NP release profile in vitro. 
Chapter 6 presents a manuscript submitted to the Journal of Food Hydrocolloids 
(May 2018), detailing the encapsulation of the SeAAs, SeCys2 and MSC using the 
responses estimated from the derived quadratic polynomials identified previously 
with BBD (Vozza et al., 2018b). Further optimisation of the mass ratios of zein:Cs 
for NP coating was investigated. In vitro evaluation of the produced NPs was then 
conducted, using the previously developed methodologies, to assess the likelihood of 
oral compatibility in terms of stability, cytotoxicity and release profiles. Differences 
between the encapsulated SeAAs were then identified in terms of cytotoxicity profiles 
and release rates by the in vitro techniques. 
Chapter 7 details a manuscript submitted to the Journal of Carbohydrate Polymers 
(May 2018), for the extraction of chitin and derivatisation to Cs from the edible 
basidiomycete mushroom A. bisporus, using alkaline treatments coupled with 
microwave irradiation (Vozza et al., 2018c). The Cs produced was compared to that 
of CL113, an ultrapure Cs product that has been assessed extensively for drug delivery 
applications and assessed for equivalent properties (DDA%, MW and purity), using 
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FTIR, 13C/1H NMR and GPC. A commercially available, fungal sourced Cs, from 
Sigma Aldrich was also compared to the Cs produced in this work, as an additional 
reference check point. Following production of Cs with a satisfactory match to 
CL113, a further chemical modification of the product to TMC was performed to 
assess whether fungal derived TMC may offer potential use as a permeation enhancer 
and as an alternative to crustacean derived. 
Chapter 8 presents a manuscript to be submitted to the journal of Innovative Food 
Science and Emerging Technologies and considers the employment of fCs to 
formulate NPs loaded with synthetic SeCys2, by employing the optimised formulation 
conditions previously identified by the DoE approach. In vitro evaluation of the 
produced NPs was then conducted, using the previously developed methodologies, to 
assess the likelihood of oral compatibility in terms of stability, cytotoxicity and release 
profiles. Differences between the CL113 and fCs NPs were then identified in terms of 
physicochemical properties and release rates by the in vitro techniques. Finally, a 
preliminary study to assess the feasibility of Irish mushrooms providing Se species 
for supplementation purposes was conducted. In that study, a Reverse phase, high 
performance liquid chromatography, Photodiode Array Detector (RP-HPLC-PDA) 
method was validated to analyse Se supplemented A. bisporus 
Chapter 9 summarises the conclusions of the research findings and includes a 
detailed discussion on potential considerations and future perspectives.  
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2.1 Introduction 
A new area in research and development has been instigated in the functional food 
industry by the emergence of nanotechnology. In particular, the enhanced delivery of 
nutrients to both humans and animals has garnered much attention from both 
academic and industrial bodies over the past decade (Neves et al., 1999; Scrinis and 
Lyons, 2007; Srinivas et al., 2010; Yao, McClements and Xiao, 2015) . With 
consumers now acknowledging the ability of certain foods to reduce disease risk or 
improve health (Hasler, 2000), in addition to the food industry’s recognition that they 
may stand to gain a competitive edge over their competitors by satiating user specific 
dietary requirements and consumers’ diverse demands for foods, it is not surprising 
that the nutraceutical industry has expanded within the past two decades (DeFelice 
1995; Verbeke 2005; Lagos et al. 2015). It is estimated that the industry is currently 
worth $151 billion in annual worldwide sales, and is anticipated to grow to $207 
billion by 2016 (BCC research, 2015). 
The chief purpose of the diet is to deliver appropriate nutrients to an individual in 
order to meet their nutritional requirements. Foods and food constituents that provide 
health benefits beyond rudimentary nutrition are classified as nutraceuticals (Kalra 
2003). Nutraceuticals have elements of both foods and medicinal products. If the 
substance contributes only to the maintenance of healthy tissues and organs, then it 
may be considered to be a food ingredient. On the other hand, if it can be shown to 
have a modifying effect on the body's natural physiological functions and is supported 
by favorable scientific opinion, it is considered a nutraceutical (Ec.europa.eu, 2015). 
33 
In the EU, a substance is characterised based on its exhibited effects on the body (JRC 
Science Hub, 2015). The European Commission (EC) defines nutraceuticals as 
“substances which are not traditionally recognised nutrients but which have positive 
physiological effects on the human body” (Coppens, Da Silva and Pettman, 2006). A 
plethora of scientific evidence has been accumulating, particularly over the last 
decade, proposing the ability of nutraceuticals to reduce the risk of numerous chronic 
diseases which has led to a boom in the food supplementation market (Brown and 
Arthur, 2001; Dickinson and MacKay, 2014; Luo, 2014). In response to this, the EC 
have published regulation (EC) No 1170/2009, which includes a list of vitamin and 
mineral ingredients approved in foods and food supplements (European Commission, 
2009), in order to “harmonise the legislation and to ensure that these products are safe 
and appropriately labeled so that consumers can make informed choices” (European 
Parliament, 2006) 
2.2 Functional foods and bioactives 
Functional foods have been defined as foods that provide a health benefit beyond the 
basic nutritional requirements, by virtue of their physiologically active components 
(Hasler, 2000). For example, soy protein, associated with a reduction in 
cardiovascular disease, is referred to as a functional food because soy protein is not 
considered to be an essential nutrient (Song et al., 2007; Kuan et al., 2012). 
Most commonly, there are two ways in which a functional food may be presented. 
One is where the nutraceutical is trapped within the food matrix, for example 
polyphenol antioxidants found in blackberry fruiting bodies (de Souza et al., 2014), 
the other being processed foods in which the nutraceutical has been isolated prior to 
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manufacture and has subsequently been incorporated into the product during 
processing, for instance, nano-selenium-enriched Nanotea from Shenzhen Become 
Industry & Trade Co., Ltd (Blasco and Picó, 2011).  
Nutraceuticals with prospective health benefits have been identified in several 
traditional foods such as fruits, vegetables, dairy, soya and whole grains (Brouns, 
2002; Liu, 2007; Jelen, 2010; Thilakarathna and Rupasinghe, 2012; Mann, 2015). In 
addition to traditional foods, new foods have been developed in which isolated 
bioactives have been amalgamated with a specific food matrix in order to harness their 
potential health or physiological effects (Wang et al., 2014; McClements, 2015). 
The emergence of dietary compounds with health benefits offers an excellent 
opportunity to improve public health. Presently, a number of functional food 
components are being explored for their potential roles in disease prevention and/or 
beneficial health effects (Li-Chan, 2015). These include, but are not limited to 
vitamins, probiotics, bioactive peptides, anti-oxidants etc. (Ha and Zemel, 2003; 
Molina et al., 2012; Roberts et al., 2013; Blondeau, 2015). 
Nutraceuticals have also emerged in areas such as food supplementation, with more 
than 50,000 dietary supplements available to date, as well as in the area of oncology 
research (Nair et al. 2010; Braithwaite et al. 2014). Table 2.1 details examples of 
current research regarding common nutraceuticals. 
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Table 2.1 Examples of some common nutraceuticals . 
Nutraceutical Origin 
Physiological 
Function/Claim 
Reference 
Chitosan 
Fungal 
mycelium 
Reduction of low-density 
lipoprotein (LDL) 
cholesterol, triglycerides 
and increase high-density 
lipoprotein cholesterol 
(Rizzo et al., 2013) 
Guggulsterone Medicinal herbs 
Hypoglycemic and 
hypolipidemic effect for 
treatment of type 2 diabetes 
(Sharma et al., 
2009) 
Pomegranate 
juice 
Pomegranate Dyslipidemia treatment (Jadeja et al., 2010) 
Oleocantha Olive oil Anti-inflammatory effects 
(Guasch-Ferré et al., 
2014) 
Luteolin 
Rosemary, 
celery, and 
parsley 
Protective role of DNA 
against hydrogen peroxide-
induced toxicity and anti-
inflammatory actions 
(Seelinger et al., 
2008; Moncada-
Pazos et al., 2011; 
Nordeen et al., 
2013) 
Fucoxanthin Marine algae 
Antioxidant, anticancer and 
anti-obesity activities 
(Fung, Hamid and 
Lu, 2013) 
Omega-3 fatty 
acids 
Nuts seeds, 
plant and marine 
oils 
Decreased thrombus 
formation, lower LDL 
cholesterol; mood-
stabilising properties, 
cardiovascular disease 
(Simopoulos, 2002; 
Blondeau, 2015) 
Methyl 
selenocysteine 
Garlic 
Prostate cancer, 
Cholesterol-lowering 
effects 
(Arnault and Auger, 
2006) 
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2.3 Nutraceutical formulation challenges 
The effectiveness of nutraceutical products in preventing diseases depends on the 
preservation and effective provision of the targeted BA of the active ingredients (Ting 
et al., 2014). Innovative therapies are currently the focus of scientific research and 
there is a growing interest in optimizing dosage forms and formulation methods to 
increase the BA of promising natural candidates (Ubbink and Krüger, 2006; Acosta, 
2009; Harde, Das and Jain, 2011; Wang et al., 2014). 
There are, however, a number of challenges that can be encountered when 
supplementing a food with a nutraceutical (Augustin and Sanguansri, 2015). For 
instance, the solubility of the active component in the food product it is being 
introduced to must be considered. The physicochemical and physiological 
characteristics of the bioactive are also important: 
• Does it have low water solubility that would hinder its uptake in target cells? 
• Does it have a high melting point that would be able to withstand high temperature 
processing methods? 
• What is its’ chemical stability, does it need to be shielded from harsh pH 
environments? 
• Does it exhibit high or low BA in the body? If not, how can the component/s 
efficacy as a disease preventing agent be increased? 
These considerations must be borne in mind when designing a new product, as harsh 
conditions may lead to deleterious effects on the overall food properties, hindering 
food sensory properties and limiting the bio-accessibility and BA of the bioactive 
compounds (Handford et al., 2014).  
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Supplements (Bonifácio et al., 2014), food processing (Abbas et al., 2009), agriculture 
(Chen and Yada, 2011) and food packaging (Duncan, 2011) have been identified as 
the four major applications of nanotechnology by food technology experts (Institute 
of Medicine (US) Food Forum, 2009). However, this type of segregation is quite 
arbitrary, due to the fact that the most interesting applications can be seen when one 
or more of these areas intersect. For example, interdisciplinary efforts are gaining 
increasing popularity as food engineers and drug delivery scientists collaborate in 
order to develop new nutrient delivery systems (Chen, Remondetto and Subirade, 
2006; McClements and Li, 2010; Fathi, Mozafari and Mohebbi, 2012; Fathi, Martín 
and McClements, 2014). By adapting a pharmacological approach, various methods 
have previously been considered in the development of food-grade delivery systems, 
which offer the possibility to fabricate products that would protect, control and target 
the release of the bioactive ingredient to its desired location (Benshitrit et al., 2012). 
Most approaches share one key methodology: entrapment, encapsulation and coating 
(Augustin and Hemar, 2009). This not only helps shield the nutraceuticals from their 
exposure environment but can also enable the release of the active component in a 
more controlled way (Shoji and Nakashima, 2004; Velikov and Pelan, 2008; 
McClements and Li, 2010). 
Resultant nutraceutical particles occur in an extensive range of shapes and sizes 
(Figure 2.1). They can also be delivered in a wide array of formations, such as tablets, 
granules and micro/nanoparticles, the latter arising from the most recent development 
in drug delivery research areas (Lee, Yun and Park, 2015).  
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Figure 2.1 Scalar representation of various nutraceutical particles, ranging from 
nanoparticles to tablets. 
Microparticles (MP) have been applied to deliver bioactives and/or drugs over long 
periods of time (months/weeks) in a variety of formulations, such as, depot 
administration via subcutaneous or intramuscular injection, pulmonary routes and oral 
delivery (Chen et al., 2010; Nair et al., 2010; Zhou et al., 2015). MPs delivered 
intravenously have been shown to accumulate in the minute blood vessels of the lungs 
and have recently become an attractive approach in treating chronic obstructive 
pulmonary disease (Nair et al., 2010). Complications can, however, arise when using 
MPs for drug delivery, as they have been shown to induce higher immune responses 
than submicron particles (Gutierro et al., 2002).  
Table 2.2 details a number of approaches that have been used to formulate 
nutraceuticals in order optimize their health benefits and/or to avoid harsh conditions 
during consumption and processing.  
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Table 2.2 Formulation aspects of current marketed nutraceutical products . 
Brand Name Formulation 
Bioactive 
Compound 
Indication Company 
Zacol NMX® 
Tablets 
(controlled 
release matrix 
technology) 
Calcium Salt of 
Butyric Acid and 
Inulin 
Intestinal 
Disorders 
Da Cosmo 
Pharmaceuticals 
Berocin CZ Softgel Capsule Folic acid 
Treatment and 
prevention of 
folate 
deficiencies and 
megaloblastic 
anemia. 
Eros Pharma Ltd 
Meconerv® Injection Mecobalamin 
Peripheral 
neuropathies 
Micro Labs Ltd 
Pediasure® 
Liquid 
supplement 
Protein, vitamin 
and other natural 
supplementation 
Pediatric growth Abbott nutrition 
Betafactor® Capsules Beta–glucan 
Immune 
supplement 
Ameriden® 
International 
Inc.,USA 
Chaser® Tablet 
Activated calcium 
carbonate and 
vegetable carbon 
Hangover 
supplement 
Living Essentials, 
Walled Lake, MI, 
USA 
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2.4 Oral delivery 
The fundamental applications of nutraceuticals entail the delivery of nutrients, 
bioseparation of proteins, rapid sampling of biological/chemical contaminants, and 
entrapment of nutraceuticals (Sozer and Kokini, 2009). Oral delivery is regarded as 
the gold standard for nutraceutical delivery due to high levels of patient acceptance, 
long term compliance and ease of administration (Sastry, Nyshadham and Fix, 2000). 
Moreover, it is preferable to maintain the natural process of food and nutrient 
consumption. However, in order for the nutraceutical (such as bioactive peptides, 
minerals and vitamins) to elicit the desired physiological effects via the oral route, a 
number of challenges for oral administration must be overcome (Chen, Remondetto 
and Subirade, 2006). These include insufficient gastric residence time, low 
permeability and/or solubility within the gut, instability under food processing 
conditions (temperature, oxygen, light) or in the gastrointestinal tract (GIT) (pH, 
enzymes, presence of other nutrients), all of which may limit the activity and potential 
health benefits of nutraceutical molecules (Agrawal et al., 2014). 
In order to overcome these challenges, it is necessary to construct an appropriate 
formulation that will protect and maintain the active ingredient in the relevant location 
for it to deliver its physiological/therapeutic effect within the required timeframe 
(McClements 2012). Table 2.3 lists common oral delivery systems for nutraceuticals. 
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Table 2.3 Common oral delivery systems for nutraceuticals . 
Phospholipid based delivery systems References 
Amphipathic lipids that can orientate themselves into lipid bilayers, examples include Liposomes 
and Phytosomes. They have been shown to enhance potency and dose efficiency of both hydrophilic 
and lipophilic compounds. 
(Coimbra et al. 2011; Chen et al. 
2010; Mishra et al. 2012) 
Emulsion based delivery systems References 
Mixture of two or more immiscible liquids stabilised by amphipathic compounds, examples include 
micro/nano-emulsions and solid lipid NPs. They have been shown to enhance potency and dose 
efficiency of lipophilic compounds 
(Davidov-Pardo & McClements 
2014; Wang et al. 2014; Josef et al. 
2010;) 
Chemical modification References 
Involves the association of non-bioactive pro-moieties (such as functional groups and polymers) with 
bioactive compounds that can subsequently be dissociated within the body by the action of enzymes 
or other chemicals. They have been shown to enhance potency and dose efficiency of the parent 
compound from the molecular level. 
(Mulholland et al., 2001; Liang et 
al., 2013; Zhou et al., 2014) 
Chitosan-based delivery systems References 
Chitosan is a positively charged polyelectrolyte that is biocompatible, pH responsive and 
biodegradable. It has been formulated in both micro and nano-sized particles to deliver bioactives. 
They have been shown to possess muco-adhesive properties that facilitates tight junction widening 
thus increasing BA of target nutraceutical 
(Jang and Lee, 2008; Kwon, 2008; 
Akhtar, Rizvi and Kar, 2012; 
Mukhopadhyay et al., 2013) 
Nanodispersions References 
Bioactives > 100 nm homogeneously distributed within a carrier free solution. Allow for higher 
dosing of bioactive with minimal processing. They have been shown to enhance potency and dose 
efficiency of bioactive compounds. 
(Chu et al., 2007; Anarjan et al., 
2010; Adjonu et al., 2014) 
Mesoporous silica particles References 
Bioactives > 10 nm distributed within the nanopores of a micro scale silica particle. Allow for the 
further use of pH or Redox potential sensitive gates to maximise dosing of bioactive in a specific 
area of the GIT. 
(Pérez‐Esteve et al., 2015) 
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NPs have shown promise for oral drug delivery systems, as they posses the potential 
to provide a remedy to these obstacles whilst maintaining the aforementioned health 
benefits (Ensign, Cone and Hanes, 2012). For example, a protein or peptide drug can 
be encapsulated in a nanoparticle environment which can protect against enzymatic 
degradation, consequently improving the pharmacokinetics and stability of the 
molecule (Almeida and Souto, 2007; Patel, Cholkar and Mitra, 2014). By using NPs 
as a drug delivery vehicle, it is possible to provide or enhance a wide range of optimal 
characteristics for a given nutraceutical drug, including increased stability (Nair et al., 
2010), incorporation of both hydrophobic and hydrophilic substances (Ron et al., 
2010), high carrier capacity (Yao, McClements and Xiao, 2015) and suitability for the 
various routes of administration such as oral, pulmonary and topical applications 
(Helson, 2013).  
NPs can also help deliver drugs with low solubility, also providing controlled release 
in order to sustain the drug. These characteristics enable optimum drug BA and 
reduction of frequency of drug administration (Huang, Yu and Ru, 2010). NPs made 
from biocompatible and biodegradable materials found in food, which are generally 
regarded as safe (GRAS), have the potential to be approved by regulatory bodies faster 
than alternative compounds (Hans and Lowman, 2002). From here on in, the 
discussion will focus on an area that has garnered much interest in nutrient delivery 
the past decade -the use of nanoparticles (NPs) for nutraceutical delivery. 
2.5 Bioavailability enhancement with nanoparticles  
The drivers for utilizing nanotechnology in foods include taste or flavour 
enhancement, improved delivery and solubility, protection against oxidation and 
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enzymatic degradation, prolonged residence time and efficient permeation through 
the GIT and improved BA at the target site (Chen, Remondetto and Subirade, 2006). 
Recently, a number of nutraceuticals, such as omega 3 and omega 6 fatty acids, 
probiotics, prebiotics, vitamins and minerals, have been investigated as bioactive 
compounds in nanoparticle formulations (Anal and Singh, 2007; Gökmen et al., 2011; 
Rashidi and Khosravi-Darani, 2011; Luo, Teng and Wang, 2012). 
Nanoparticles can be generated both intentionally (for therapeutics or other 
applications) or unintentionally (e.g. by combustion). In the field of food and 
medicine, several nanoparticle applications have already been approved for clinical 
use, and many others are at different stages of development (Wacker, 2014). Table 
2.4 shows some examples of marketed nanoformulations of drugs, beverages, foods 
and health supplements developed from the Pharmaceutical and Food industry 
targeting the oral delivery route of administration. There are also a number of 
nanoformulations that are currently in pre-clinical development in order to assist 
targeting of oncology drugs, such as Folic acid-PAMAM dendrimers for Epithelial 
cancer (Thomas et al., 2013), Albumin-bound nanoparticles and Glycol chitosan 
nanoparticles for cancer treatment (Miele et al., 2009; Yoon et al., 2014), Starch-
coated iron oxide nanoparticles of magnetically guided Mitoxantrone for tumour 
angiogenesis (Wahajuddin and Arora, 2012) and Silica-based nanoparticles for 
photodynamic therapy (Couleaud et al., 2010).
    
   
4
4
 
Table 2.4 Current nanomaterial’s in the Food and Pharmaceutical industry (websites accessed 16/6/2015) . 
Current Marketed Drugs 
(Pharmaceutical) 
Function Trade name Company References 
Liposomal amphotericin B 
Fungal 
infections 
Abelcet® Sigm-Tau www.sigmatau.com 
PEG–L-asparaginase 
Acute 
lymphoblastic 
leukemia 
Oncaspar® Enzon www.oncaspar.com 
Current Marketed Nanomaterials 
in Foods/Beverages 
Function Trade name Company References 
Nano-sized self-assembled structured 
liquids (micelles) 
Food 
Canola Active 
Oil 
Shemen 
www.shemen.co.il 
(website only in Hebrew). 
Nano Zinc Oxide (food grade) Food additive AdNano® 
Evonik 
(Degussa) 
www.advancednanomaterials.com 
Current Marketed Nanomaterials 
in health supplements 
Function Trade name Company References 
Nano silver 
Health 
supplement 
Colloidal 
Silver Liquid 
Skybright 
Natural Health 
hwww.skybright.co.nz 
Nano humic and fulvic acid 
Health 
supplement 
Nano Humic 
and Fulvic 
Acid 
Nano Health 
Solutions 
www.fulvic.org 
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Studies have shown that the enhanced surface area per mass compared with larger-sized 
particles of the same chemistry renders nanosized particles more biologically active 
(Oberdörster et al., 2005; Heitbrink, Lo and Dunn, 2015). The biological interactions of 
a nanoparticle system are highly dependent on the nanoparticles size and size distribution 
(Hagens et al., 2007). Etheridge et al. (2013), state that the enhancement of a drugs BA 
at the systemic level results from the increased surface area provided by the submicron 
size of the nanoparticle formulation. For example, a given drug formulated within a 
smaller sized nanoparticle (approx. 100 nm) has an increased likelihood to be associated 
on or close to the surface of the particle allowing the drug to be released at a higher rate 
(Hans and Lowman, 2002). On the other hand, larger particles (>100nm) have a smaller 
initial burst release and longer sustained release than smaller particles as the load tends 
to be encapsulated in the core centre of the particle (Hans and Lowman, 2002). Generally, 
passive diffusion allows for the slow release of the drug into the systemic system, as a 
result of the drug releasing from the larger NP core (Mohanraj and Chen, 2007). 
The higher mobility and cellular uptake of NPs compared to microparticles is another 
advantage provided by nano-scale formulations. For example, when comparing the 
uptake of 1 and 10 µm particles against 100 nm particles in in vitro models, an increase 
of 2.5-6 fold higher uptakes were observed respectively (Mohanraj and Chen, 2007). 
Etheridge et al. (2013) also commented that the effect of particle size on cellular intake 
can be influenced by the constituent material and the particle geometry. With this in mind, 
it is important to consider the particle size and morphology on a case by case basis that 
will allow for specific evaluation for formulation processes that use different 
encapsulating materials for delivery of nutraceuticals (De Jong and Borm, 2008) 
Encapsulating nutraceuticals within engineered nanoparticle based delivery systems 
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presents the potential to improve BA and the ability to tailor a given particle in order to 
withstand detrimental pH, processing and enzymatic environments (Yao, McClements 
and Xiao, 2015). Further advantages of using nanoparticles as drug carriers can be seen 
in Table 2.5. 
Table 2.5 Advantages associated with Nano-carriers for drug delivery (Abbas, K. A. et 
al. (2009). 
Advantages of nanoparticles as drug carriers 
Controlled and sustained release profile of the drug to a given target site 
Several routes of administration can be applied 
High drug loading under mild conditions and in the absence of harsh chemicals 
Ability to manipulate particle physicochemical properties such as size and 
morphology to achieve optimum passive/active drug targeting 
Increased retention time of NPs at mucosal surfaces by exploiting mucoadhesive 
formulation components 
Increase the chemical stability of a drug by shielding it from harsh pH environments 
such that are found in the GIT 
Prevent aggregation of proteins/peptides when the pH of the surrounding 
environment approaches their isoelectric point 
It is also important to keep in mind that the main advantage for formulation of NPs is 
targeted drug delivery, which can be achieved using two different routes, passive 
targeting and active targeting (Singh and Lillard, 2009). Passive targeting occurs when 
NPs exhibit localization to specific organs or to sites of disease via biological 
mechanisms, such as the reticuloendothelial system (RES) or the enhanced permeability 
and retention (EPR) effect (Maeda et al., 2000). One example is PEGylatyed liposome-
doxorubicin, Doxil®, which encapsulates an anti-tumor drug, doxorubicin (Kroon et al., 
2014). On the other hand, active targeting is the conjugation of antibodies, peptides, or 
other ligands onto the nanocarrier surface which will recognise and bind to target cells 
through ligand–receptor interactions by the expression of receptors or epitopes on the cell 
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surface (Nobs et al., 2004). For example, monoclonal antibody-conjugated PLGA NPs 
formulated to actively target cancer cells, resulting in better cancer cell recognition of 
surface-modified NPs than non-coated NPs (Kocbek et al., 2007). 
The European commission recommends that a nanomaterial be defined as (Ec.europa.eu, 
2011): 
A natural, incidental or manufactured material containing particles, in an 
unbound state or as an aggregate or as an agglomerate and where, for 50 % 
or more of the particles in the number size distribution, one or more external 
dimensions is in the size range 1 nm - 100 nm. 
In specific cases and where warranted by concerns for the environment, 
health, safety or competitiveness the number size distribution threshold of 50 
% may be replaced by a threshold between 1 and 50 %. 
By derogation from the above, fullerenes, graphene flakes and single wall 
carbon nanotubes with one or more external dimensions below 1 nm should 
be considered as nanomaterial’s. 
With this in mind, it is worth noting that NPs in themselves are not easily categorised in 
terms of properties, as the physical size of a drug can greatly affect the drug’s effect when 
compared to a smaller or larger particle of the same makeup (Oberdörster, Oberdörster 
and Oberdörster, 2005). As nanoparticles can be any number of particles within the scale 
of 1-100 nm, the term nanoparticle is in itself broad, thus leading to a difficulty of clear 
and defining chemical and physical properties (Ju-Nam and Lead, 2008). 
In other words, variations in size and shape can have unpredictable effects on the physical 
and chemical properties of nanomaterials: a substance that is non-toxic at 50 nm may be 
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toxic at 1 nm or vice versa (Resnik and Tinkle, 2007). Because their properties are 
dependent on their microenvironment, nanomaterials may change in size or shape inside 
an organism. A 100 nm particle could disintegrate into 1 nm particles, or 1 nm particles 
could aggregate into a 100 nm particle (Resnik and Tinkle, 2007). 
By limiting size in the definition of nanotechnology to the 1–100 nm range, numerous 
materials and devices are excluded, in particular with regards to the pharmaceutical and 
agricultural fields, in which nanomaterials of 100 nm to 300 nm are considered of most 
interest with regards to oral delivery due to the toxicity issues that arise from smaller sizes 
(Umerska et al., 2012; Andreani et al., 2014; Koppolu et al., 2014; Sakai-Kato et al., 
2014). The driving force for the size restriction of the definition of nanoparticles is one 
of regulation, and therefore, in the following sections, a broader definition of nanoscale 
shall be considered. 
2.6 Food Grade delivery systems 
Nanoparticles in a size range of 100-300 nm have attracted a lot of attention as drug 
delivery nanocarriers and have shown remarkable therapeutic potential when formulated 
into different delivery systems, depending on the nature of the bioactive, release rate and 
compatibility with the carrier (Almeida and Souto, 2007; Sarvaiya and Agrawal, 2015). 
Most commonly used nanoparticle carrier systems are magnetic, dendritic, polymeric, 
solid-lipid liposomal, all of which exhibit different properties that are used in drug 
delivery. There are two ways in which nanoparticles can be made: by "bottom-up" and 
“top-down” approaches (Thiruvengadathan et al., 2013; Diaz Fernandez et al., 2014; 
McClements, 2015) represented in Figure 2.2. 
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Figure 2.2 Schematic representation of top-down and bottom-up techniques used to 
produce nano-delivery systems.  
In a “bottom-up” approach, materials and devices are built from molecular components 
which come together chemically by principles of molecular recognition (Chan and Kwok, 
2011). On the other hand, the "top-down" approach entails the construction of nano-
products from larger entities without atomic-level control (Acosta, 2009). Food grades, 
for example, are used to classify products according to certain quality characteristics. To 
establish an oral delivery system, all substances used which pass through the oral route 
should be classified as safe.  
By instigating a pharmacological approach in order to develop food grade delivery 
systems, products can be potentially produced which possess the ability to protect a given 
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bioactive during processing and storage stages, whilst allowing for controlled delivery of 
the therapeutic at its target site (Lawton, 2002; Zhang et al., 2015). It is generally accepted 
that food grade delivery systems can be classified in a wide variety of ways. However, 
most commonly, size and the main nutritional component are used when classifying 
systems (Benshitrit et al., 2012). 
With regards to size classification, this is considered an important means of assessment 
due to the behaviours of compounds on a scalar level. A given system’s functionality can 
generally be linked to the availability of the bioactive to the body according to size 
(Kumari, Yadav and Yadav, 2010). By changing size of the encapsulating vehicle of a 
molecule, the rate of its release, its solubility and it retention at a given target site can be 
tuned (Mohanraj and Chen, 2007), enabling the optimisation of a formulation in order to 
achieve specified results. An alternative, common way of classifying these delivery 
systems is via their main nutritional component (Benshitrit et al., 2012). Such food grade 
delivery systems can be divided into three groups: Protein-based delivery, Lipid-based 
delivery and Carbohydrate-based delivery (Benshitrit et al., 2012). These systems 
provide a wide array of potential in addition to some limitations and shall be discussed in 
the following sections. 
2.7 Protein-based nano-delivery systems 
Food biopolymers, specifically food proteins, are commonly used to formulate bioactives 
because of their high nutritional value, biodegradability, non-antigenicity, excellent water 
binding capacity, cost efficient and GRAS nature (Benshitrit et al., 2012; Elzoghby, Samy 
and Elgindy, 2012). It is also possible to exploit the delivery of bioactives over a wide 
range of platforms due to their physical and physicochemical diversity attributable to the 
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multiple functional groups present in the primary sequence of polypeptides (Chen, 
Remondetto and Subirade, 2006). With this in mind, it is possible to modulate protein 
carrier interactions with therapeutic agents and produce three dimensional networks 
allowing for a host of possibilities, for example, the reversible binding of active molecules 
to a given target site (Chen, Remondetto and Subirade, 2006). Additionally, studies have 
shown that the generation of bioactive peptides via enzymatic degradation in vivo can 
subsequently elicit a number of physiological effects, leading to an advantage regarding 
acceptability of protein carrier employment for drug delivery (Li-Chan, 2015). 
Proteins can be sourced from bacterial, fungal, plant and animal origin, with the latter 
two utilised as a food grade delivery system not only because of their cost effectiveness 
but also because they enable excellent delivery of both hydrophilic and hydrophobic 
bioactives (Elzoghby, Samy and Elgindy, 2012). The preparation methods that can be 
employed in order to produce protein based carriers has also been cited as a major 
advantage of this particular delivery vehicle (Chen, Remondetto and Subirade, 2006). 
Techniques such as gelation, emulsification, extrusion, spray drying and coacervation are 
commonly used to produce delivery systems such as hydrogels, hydrocolloids, micelles, 
nano-assemblies, films and micro and nanoparticles (Ibrahim 2015; Zhang et al. 2014; 
Park et al. 2013,Yang et al., 2014). Common protein carriers investigated from animal 
sources are gelatine, collagen, casein, elastin, albumin and whey proteins, and from plant 
sources are soy glycinin, wheat gliadin and zein (Kimura et al. 2014; Song et al. 2009; 
Xiao et al. 2011; Nӓgele et al. 1991).  
Nanoparticulate protein carriers from vegetal origin have garnered interest in the field 
due to their potential advantages over their animal derived counterparts (Ezpeleta et al., 
1996; Lai and Guo, 2011; Elzoghby, Samy and Elgindy, 2012) It is hypothesised that, by 
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exploiting the low solubility and high hydrophobicity characteristics of these particular 
proteins, it is possible to negate the need for further chemical and/or physical treatments 
of the nanoparticles in order to harden them (Ezpeleta et al., 1996). As an alternative to 
hydrophilic animal protein carriers such as albumin and casein, hydrophobic plant 
proteins such as gliadin and zein have been investigated for their ability to increase the 
amount of bioactive entrapped within a given carrier system in addition to their ability to 
improve the controlled release of target bioactives (Ezpeleta et al., 1996; Xijun et al., 
2014; Zhang et al., 2015). Moreover, they are less expensive to produce, and satisfactory 
supplies can be assured due to the nature of their growth and harvest processes. Plant 
proteins can also be regarded as a safer therapeutic delivery system due to the reduced 
risk of spread of disease associated with animal origin compounds, for example, bovine 
spongiform encephalitis (Elzoghby, Samy and Elgindy, 2012). An example of a plant 
derived protein carrier that has begun garnering much interest for nutrient delivery is Zein 
(Lawton, 2002; Paliwal and Palakurthi, 2014). 
Zein is a class of alcohol soluble prolamine storage proteins found in corn (Esen, 1987). 
It is extracted from the endosperm of corn kernels, where it is predominantly present 
(Larkins et al., 1984; Dombrinkkurtzman and Bietz, 1993), during corn wet milling 
processes. It exists as a mixture of proteins, of varying molecular weights and can be 
categorized by sequence homology and solubility into four main classes known as: α-zein 
(19 and 22 kDa), β-zein (14k Da), γ-zein (16 and 27 kDa) and δ-zein (10 kDa) (Esen, 
1987). The most abundant of these, α-zein, accounts for 70-80% of the total mass fraction 
of zein, whilst, γ-zein, the second most abundant, accounts for 10-20% (Wilson, 1991). 
All groups of zein possess a fairly abundant amount of neutral and hydrophobic amino 
acids (AA) (e.g. proline) with a more moderate amount of polar AA residues such as 
serine (Zhang et al., 2015). In addition, what differentiates zein from most other proteins 
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is that it contains negligible amounts of lysine and tryptophan, as well as low amounts of 
arginine and histidine residues (Zhang et al., 2015). It is this inherent AA composition 
that lends to zein proteins unique solubility properties, whereby it is insoluble in pure 
water and alcohol but soluble in aqueous alcohol and alkaline solutions as well as acetic 
acid and acetone (Lawton, 2002). 
As zein has been GRAS approved by the United States Food and Drug Administration as 
a pharmaceutical drug excipient since 1985 (Accessdata.fda.gov, 2014), it has been 
proposed as a nanodrug delivery vehicle (Paliwal and Palakurthi, 2014). It has been 
shown to possess the ability to improve the colloidal stability and encapsulation 
efficiency of bioactive components in addition to tailoring of their release profile (Zhang 
et al., 2015). In studies conducted by Luo et al. 2010, zein was used to coat chitosan 
nanoparticles loaded with selenite and was shown to not only increase the encapsulation 
efficiency of the mineral from 60% to 96% but also protected the drug from the harsh 
conditions of the GI tract. This allowed for a slower sustained release of selenite at the 
intestinal target site, reducing the release of selenite from 85% in the first 4 hrs to 30% 
(Luo et al., 2010). Zein has also been used to successfully deliver fat soluble compounds 
due to its high hydrophobicity (Zhong, Tian and Zivanovic, 2009). 
2.8 Lipid-based nano-delivery systems 
It is sometimes important to deliver lipophilic bioactives in a more edible form. For 
example, fatty acids such as conjugated linoleic acid and butyric acid have shown 
potential health benefits for Coronary Heart Disease (Haug, Hostmark and Harstad, 
2007). In order to do so, lipid-based delivery systems have been shown to be a promising 
approach. These lipophilic components may be a diverse range of substances, including 
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bioactive lipids, vaccines, flavors, antimicrobials, antioxidants, and drugs (H du Plessis 
et al., 2014). 
It is advantageous for lipid bioactives to be encapsulated in a liquid form, which has 
shown to increase their palatability, desirability, and bioactivity due to the differing 
molecular, physicochemical and psychological properties (McClements, Decker and 
Weiss, 2007). Consequently, all of these differing properties of each lipid bioactive need 
to be addressed to produce the optimal formulation and effect. The most commonly used 
lipophilic nutraceuticals investigated recently are fatty acids (ω-3 fatty acids, conjugated 
linoleic acid, butyric acid), carotenoids (β-carotene, lycopene, lutein, zeaxanthin), 
antioxidants (tocopherols, flavonoids, polyphenols) and phytosterols (stigmasterol, β-
sitosterol, campesterol) (Pol and Patravale, 2009; Puri et al., 2009; Bassaganya-Riera and 
Hontecillas, 2010; Leong et al., 2011; Song et al., 2011). 
The principle used to formulate a lipid based delivery system is emulsification, as oil in 
water (O/W) microemulsions, liposomes, multilayer emulsions, filled hydrogel particles, 
or solid lipid nanoparticles (Spernath and Aserin, 2006; Iglesias et al., 2013; Han et al., 
2014). Phospholipid-based microemulsions (ME) use food-grade ingredients, soybean oil 
and soybean lecithin, to replace ethyl oleate and purified lecithin (Patel, Schmid and 
Lawrence, 2006). However, the formation of multiphase colloidal dispersions into 
nanoscale droplets enables the production of nanoemulsions (NE).  
NE (also known as submicron emulsions) can be prepared by the physical shear induced 
by rupturing of one liquid within another immiscible liquid (Mukherjee, Ray and Thakur, 
2009). NE have interesting properties compared to their micro sized counterparts in that 
they have the ability to remain stable in diluted water without a change to their relative 
size distribution (Gutiérrez et al., 2008). Consequently, the droplet sizes in 
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nanoemulsions allow for optically transparent formulations due to their scalar size being 
smaller than visible wavelengths. Microparticles, on the other hand, usually show 
multiple scattering of visible light resulting in formulations with opaque appearances 
(McClements 2012). With this in mind, it is fair to conclude that NE may be more 
advantageous for nutrient delivery in commercial food products, for example, beverages, 
in that they will allow for no discernible change in photoreception sensory properties of 
the product (Fathi, Mozafari and Mohebbi, 2012). 
An example of a lipid based nutraceutical carrier system that has begun garnering interest 
for nutrient delivery is Solid Lipid NPs (Almeida and Souto, 2007; Harde, Das and Jain, 
2011; Fathi, Mozafari and Mohebbi, 2012). Solid Lipid NPs (SLNs) have the ability to 
solubilize lipophilic molecules and generally exist as spherical particles ranging from 10–
1000 nm (Almeida and Souto, 2007). They contain a solid or semi-solid lipid core matrix 
and are typically stabilized by surfactants (Kalepu, Manthina and Padavala, 2013). When 
compared to other lipid based carries such as nanoemulsions and liposomes, SLNs have 
been shown to possess some distinct advantages over their alternative counterparts (Fathi, 
Mozafari and Mohebbi, 2012). For example, they have been shown to offer robust 
protection against GI tract degradation due to the reduction in crystalline mobility of the 
lipid structure, particularly beneficial for the delivery of bioactive peptides which are 
susceptible to enzymatic and or acidic degradation in the GI environment (Almeida and 
Souto, 2007; Ting et al., 2014).  
In addition, SLNs have the ability to provide controlled release profiles of a given 
bioactive due to the intrinsically slow degradation rate of the crystalline lipid core. These 
advantages have been shown to improve the pharmacokinetic profiles of bioactives 
delivered via SLNs, typically resulting in slow evolution of peak therapeutic responses 
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and more stable plasma concentration trends in comparison to lipid-lipid emulsion 
systems (Ting et al., 2014).  
There are many ways in which SLNs can be produced (Chattopadhyay et al., 2007; 
Mehnert and Mäder, 2012; Nabi-Meibodi et al., 2013). Typically, on the laboratory scale, 
SLNs can be simply prepared by the emulsification-evaporation and subsequent 
sonication methods (Fathi, Mozafari and Mohebbi, 2012). Usually, the oil phase is mixed 
with organic solvents, emulsifiers and bioactive(s) in order to form a coarse emulsion 
known as the pre-emulsion (PE). After combining, the PE is then subjected to sonication 
for a specified amount of time, at a temperature above the melting point of the lipid 
carrier. The SLNs are then finally produced upon addition of the hot PE to cold surfactant 
containing water, under constant mixing, in order to allow for solvent evaporation (Fathi, 
Mozafari and Mohebbi, 2012). 
Previously, it has been shown that SLNs size may remain stable in aqueous dispersions 
for 12-36 months (Mehnert, 2001). Nevertheless, SLNs may become unstable and 
increase in size during storage and, as a result lyophilisation, has been proposed as a 
technique to be employed in order to avoid the sample becoming physically and/or 
chemically unstable (Fathi, Mozafari and Mohebbi, 2012). It is important to note that, 
although freeze drying has been shown to increase physicochemical stability, there is a 
possibility that the SLNs may acquire changes in their osmolarity and zeta potential 
(known as the freezing out effect) resulting in instability of the sample (Abdelwahed et 
al., 2006; Fathi, Mozafari and Mohebbi, 2012; Soares et al., 2013). With this in mind, 
cryoprotective agents such as trehalose (Augustin and Hemar, 2009) and glucose (Soares 
et al., 2013) have been recommended as formulation components due to their ability to 
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reduce the osmotic activity of water and also to prompt the frozen sample to favour the 
glassy state (Hauser and Strauss, 1988; Mehnert, 2001). 
Spray drying is another technique that has been used in order to increase the stability of 
SLNs as an alternative to lyophilisation. It does, however, have some disadvantages over 
freeze drying due to the fact that the SLNs may aggregate upon exposure to the high 
temperatures and shear forces imposed during the process (Freitas and Müller, 1998). To 
overcome the obstacles encountered during spray drying, it is recommended to use lipids 
with melting points greater than 70°C (Mehnert, 2001). 
Studies by Wang et al. (2013) involving SLNs used in the delivery of nutrients, include 
the encapsulation of Curcumin (CUR) (a hydrophobic polyphenol present in the rhizomes 
of Curcuma longa) and the evaluation of its effects in vitro and in vivo, whereby CUR-
loaded SLNs (SLN-curcumin) showed a significantly higher anti-cancer efficiency on 
A549 lung cancer cell lines and xenografts in mouse models. SLN-CUR was shown to 
reduce tumour volume by 65.3% compared with a 19.5% of reduction when using CUR 
in its native form. In addition, in 2014, Pandita et al. incorporated resveratrol, a bioactive 
polyphenolic phytoalexin found in common foods such as grapes, peanuts, and red wine 
into SLNs (Pandita et al., 2014). This bioactive has been shown to provide a range of 
health benefits such as cancer prevention (Savouret and Quesne, 2002), increased 
immune cell function (Falchetti et al., 2001) and increased fertility (Özcan et al., 2015). 
In the study by Pandita et al., the formulation of resveratrol into SLNs produced a 
significant 8 fold improvement in the oral BA of the drug as compared to the native drug 
suspension (Pandita et al., 2014). 
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2.9 Carbohydrate-based nano- delivery systems  
Carbohydrate-based delivery systems are widely used in the nutraceutical and 
pharmaceutical industry for targeted and controlled release (Sunasee et al., 2014). These 
are classified as mono, oligo and polysaccharides. Mono and oligosaccharides are often 
used as constituents of the encapsulating matrix (Benshitrit et al., 2012), polysaccharides 
most often being used as the carrier component due to their massive molecular structure 
and thus ability for greater bioactive entrapment (Fathi, Martín and McClements, 2014). 
Polysaccharides exist as natural polymers of monosaccharaides, varying in type, 
distribution, number and bonding of the monomers in the chain (Fathi, Martín and 
McClements, 2014). They can be derived from animal, algal, microbial and protein 
sources and are typically subdivided into three groups: neutral, anionic and cationic 
(Daniel-da-Silva and Trindade, 2011). Polysaccharide examples include starch & 
cellulose (neutral), alginate & xanthan gum (anionic) and chitosan (cationic) for which 
the magnitude of electrical charge depends on the pH relative to the pKa (Liu et al., 2008). 
For example, anionic polysaccharides are neutral at pH values below their pKa value but 
negative above, whereas cationic polysaccharides tend to be neutral at pH values above 
their pKa value but positive below (Kumari, Yadav and Yadav, 2010). 
Alginate is an example of an anionically charged polysaccharide that has been used for 
NP production. It is composed of 1,4-linked-β-d-mannuronic acid and α-l-guluronic acid 
residues, exhibits a propensity for gelation upon exposure to proper conditions and has 
been shown to be both biocompatible and non-toxic (Josef, Zilberman and Bianco-Peled, 
2010).When being formulated as a nano-carrier system, alginate is cross-linked with a 
divalent ion such as calcium chloride and magnesium chloride, the former being the most 
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employed counter ion for complexing alginate-based nanoparticles (Alg-NPs). Alg-NPs 
have been applied to deliver drugs and nutraceuticals such as insulin (Sarmento et al., 
2006) and vitamin D3 (Sun et al., 2012). 
Various modifications have been explored to date, in order to improve the functionality 
of these carbohydrate-based delivery systems. For example, hydrophobically modified 
starch was used to increase water solubility and in vitro anti-carcinogenic activity of 
CURNPs (Ha et al., 2012). Mahjub et al. (2014) used N-aryl derivatives of chitosan for 
insulin nanoparticles to produce a permanent positive charge causing the polymer to be 
soluble in wide range of pH values. 
The type of environmental and solution conditions present within a particular food is 
often important for selecting the most appropriate polysaccharide building blocks, in 
order to provide protection and targeted/controlled delivery (Cushen et al., 2012). 
Carbohydrate-based delivery systems have proven useful not only in the oral delivery 
route but in topical delivery too. For example, Calcium alginate was chosen to design the 
delivery system of L. plantarum as a polymer widely used in burn wound treatment due 
to its haemostatic, gel-forming and granulation-encouraging properties (Brachkova, 
Duarte and Pinto, 2012). More specifically, polysaccharides appear to be the most 
promising materials in the preparation of nanometric carriers. In fact, over the past few 
years, these systems have emerged as potential carriers for delivering agents across a 
variety of different routes, such as nasal (Amidi et al., 2006), oral (El-Shabouri, 2002) 
and pulmonary (Al-Qadi, Grenha and Remuñán-López, 2011). 
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2.10 Polysaccharide Nanoparticles for nutrient delivery  
Due to their biocompatible and biodegradable nature, polysaccharide based delivery 
systems have found many uses in industrial applications (Fathi, Martín and McClements, 
2014). Part of the reason they have attracted the attention of both industrial and academic 
institutions is the fact that it is possible to modify polysaccharides to exhibit requisite 
properties. Unlike lipid carriers, carbohydrate based carriers possess the ability to interact 
with a wide array of both hydrophobic and hydrophilic bioactives (Joye, Davidov-Pardo 
and McClements, 2014). This is due to the presence of functional groups that allow for 
complex formation with bioactives via electrostatic interactions, both hydrophobic and 
ionic in nature (Rinaudo, 2006b).  
Another important aspect of polymeric materials that is particularly engaging to the 
industrial researcher is the robustness the compound can exhibit under high temperatures 
(Fathi, Martín and McClements, 2014). This is particularly useful from a manufacturing 
standpoint, as polysaccharides can then also be used as a protective coat during 
processing steps (Jang and Lee, 2008). In contrast to their protein and lipid counterparts, 
polysaccharide systems are unlikely to become denatured or melt due to their high 
temperature stability. Moreover, naturally occurring polysaccharides are considered safe 
and already have found wide usage as food ingredients (Blanshard and Mitchell, 2013). 
In fact, their functional attributes are generally custom-made by their biological origins, 
isolation methods or physical and/or chemical modifications (Fathi, Martín and 
McClements, 2014), which lends to them being viewed as an ideal carrier for 
nutraceuticals (Hans and Lowman, 2002). For example, non-ionic Pullulan can be 
modified by hydrophobic molecules such as curcumin. This was evidenced by studies 
conducted by Yuan et al. (2014) that showed self-assembled NPs could be synthesized 
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from Glycyrrhetic Acid-Modified Pullulans with varying molecular weight and/or degree 
of substitution and exhibited increased solubilization, stabilization, and controlled 
delivery of CUR when compared to its native form (Yuan et al., 2014).  
Similarly, Dextran, a neutral, water soluble and bio-friendly polysaccharide, has proven 
a useful tool in the field of nano-medicine, being chosen by a lot of researchers as 
biomaterial in the preparation of nanosystems. For example studies conducted by Susa et 
al. (2009) showed that nanoparticles loaded with doxorubicin showed increased apoptosis 
compared to free doxorubicin on both wild type and the MDR osteosarcoma cells in vitro 
by drug accumulation in the nucleus. 
2.11 Chitosan-based delivery systems 
An emerging polymeric nutraceutical carrier that has received attention for nutrient 
delivery is chitosan (Cs) NPs (Luo et al., 2010; Akhtar, Rizvi and Kar, 2012; Chen et al., 
2013; Fathi, Martín and McClements, 2014; Sarvaiya and Agrawal, 2015). Chitosan is a 
linear polysaccharide, prepared by N-deacetylation of chitin (Figure 2.3). It is positively 
charged, biocompatible, non-immunogenic, nontoxic, pH responsive and biodegradable, 
making it a choice as a component of oral drug delivery systems and attractive for 
biomedical and drug delivery applications (Agnihotri, Mallikarjuna and Aminabhavi, 
2004; Bezerra et al., 2008; Saini et al., 2014). Given that chitosan has a GRAS status, 
this potentially can be translated to applications of delivery of nutraceuticals (Kean and 
Thanou, 2010). Chitosan has been extensively used in a number of areas in medicine, for 
example in tissue engineering (Suh and Matthew, 2000), bioimaging (Agrawal, Strijkers 
and Nicolay, 2010), wound-healing and drug delivery formulations (films, hydrogel 
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system and particulate system) (Agnihotri, Mallikarjuna and Aminabhavi, 2004; 
Jayakumar et al., 2010). 
 
Figure 2.3 Chemical structure of chitosan. 
Chitosan has an isoelectric point of 6.5 and at this pKa value it exhibits its lowest 
solubility, as the net charge is 0. Chitosan salts are soluble in water, the solubility 
depending on the degree of deacetylation and the pH of the solution.  
The degree of chitosan deacetylation (DD) from chitin signifies the percentage of 
deacetylated primary amine groups along the molecular chain, which can determine the 
positive charge density when chitosan is dissolved in acidic conditions. The higher the 
DD, the more soluble the chitosan will be at acidic conditions (Hejazi and Amiji, 2003) 
and subsequently the more it will exhibit its muco-adhesive properties in the GI tract 
(Ting et al., 2014). 
Chitosan with a low degree of deacetylation (<40%) is soluble up to a pH of 9, whereas 
highly deacetylated chitosan (>85%) is soluble only up to a pH of 6.5 (Rinaudo, 2006a). 
A high degree of deacetylation more readily allows ionization of Cs as increasing the 
degree of deacetylation increases the viscosity and results in an extended conformation 
with a more flexible chain because of the charge repulsion in the molecule (Kumirska et 
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al., 2010). Hence, chitosan with a high degree of deacetylation is commonly used for drug 
delivery research. Table 2.6 summaries the main chemical and biological properties of 
chitosan. 
Table 2.6 Chemical and Biological Properties of Chitosan (Adapted from Hejazi and 
Amiji 2003). 
Chemical and Biological Properties of Chitosan 
Chemical Properties Biological Properties 
Cationic polyamine Biocompatible 
High charge density Natural Polymer 
Forms gels with polyanions Biodegradable 
Amiable to chemical modification Spermicidal 
Reactive amino/hydroxyl groups Anticancerogen, Anticholesteromic 
Swelling properties Mucoadhesive 
High mol wgt linear polyelectrolyte Safe and non-toxic 
Chelates certain transitional metals Hemostatic, bacteriostatic, 
2.12 Regulations surrounding nanomaterial safety 
Nano-engineered particles have been used to enhance the drug delivery of actives, but 
due to the small sizes, increased surface area and reactive nature of the nano materials, 
the effectiveness and safety is a key consideration in Nanomedicine and even though the 
successful implementation of nanotechnology is pertinent for the growth of the global 
economy, there is also a need to consider the possible environmental health and safety 
impact for nanoparticles that could lead to hazardous biological outcomes (Martirosyan 
and Schneider, 2014).  
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The FDA (Food and Drug Administration) is one of the main regulatory nanotechnology 
bodies in the US and collaborates with the National Nanotechnology Initiative (NNI). In 
Europe, the Institute for Health and Consumer Protection (IHCP) is the main regulatory 
body actively involved in research into nanomaterials safety, identification and detection. 
For both agencies, their key goal is to deal with questions about the potential effects on 
health and the environment with particular emphasis on the risks and benefits to the 
public. With regards to foods, the European Food Safety Authority (EFSA) works closely 
with the IHCP to examine the behaviour of engineered nanomaterials in foods and to 
validate methods of characterisation.  
Following a report by the European Nanoforum, a food product is considered a 
“Nanofood when nanoparticles and nanotechnology techniques or tools are applied 
during cultivation, production, processing or packaging of the food, not intending to 
produce atomically modified food or food produced by nanomachines” (Joseph and 
Morrison, 2006). Due to the increasing use of nanomaterials in foods, recent EU 
legislation (No 1169/2011) on novel foods has introduced obligatory labelling of 
nanomaterials on packaging (European Parliament, 2011). 
2.13 Uptake of nanoparticles and potential toxicity  
Micro- and nano-particles have been shown to permeate through GI barriers, with the 
latter estimated to have a 15-250 times higher absorption (Fröhlich and Roblegg, 2012). 
Ingestion, inhalation and dermal absorption are the main physiological routes in which 
NPs can enter the body, consequently resulting in the potential ability to distribute 
themselves to a given organ over several exposure points (Smolkova et al., 2015). 
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Absorption, Distribution, Metabolism and Elimination (ADME) are the characteristics 
that effect the extent of NP exposure to a given system (Hagens et al., 2007).  
Previous investigations have shown that the uptake of NPs is low in healthy oro-
gastrointestinal mucous. However, the level of absorption varies dependent upon type of 
GI cell, for example absorption is higher in the lumen in comparison to the oral cavity 
(Roblegg et al., 2012). Epithelial barriers allow for the separation of NPs from the blood 
and as a result translocation of NPs into secondary organs can occur due to their ability 
to reach the connective tissue that is present beneath the epithelial layer surrounding the 
intestines (Smolkova et al., 2015). For example, previous studies have found that titanium 
oxide (TiO2) NPs when acutely exposed to both ex vivo and in vivo systems, possessed 
the ability to pass through both the follicle-associated epithelium (composed of 
enterocytes and microfold cells) and regular intestinal epithelium (mucous secreting 
cells) becoming localized in the tissues situated below both epithelial layers (Brun et al., 
2014). Other studies have indicated that accumulation of TiO2 inside epithelial lining can 
give rise to detrimental outcomes such as inflammation and may be involved in 
inflammatory bowel disease pathogenesis (Lomer, Thompson and Powell, 2002; 
Nogueira et al., 2012). 
The surface properties and size of ingested NPs are affected by several environmental 
factors such as pH, ionic strength, protein, sugar and lipid content that are naturally 
present in foods such as the mucus of the saliva (Roblegg et al., 2012). In addition, upon 
NP entrance to the system, interactions can occur between plasma proteins, platelets, 
peripheral blood cells as well as with the organelles and DNA of the cells (Smolkova et 
al., 2015). Due to some NPs low excretion rate, it is plausible to suggest that more often 
than not, long term dose exposures occur. In spite of the fact that NP penetration into the 
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body is low, toxicity screening is based predominantly on high dose, short exposures 
(Oberdörster, 2010). This lends to acute toxicity issues being reported whilst minor 
changes resulting from long term accumulation in a given system go unidentified.  
NPs derived from occurring nontoxic substances in the body (i.e. protein and 
carbohydrates) should pose less of a risk to the body than inorganic nano-delivery 
systems. However, the effects from the increased bioavailability of these compounds may 
have significant consequences on the body and must be considered also. In addition, 
alterations in protein and carbohydrate structure have been shown to potentially increase 
the allergenicity of said molecules (Říhová, 2007; Dobrovolskaia et al., 2008).  
Regarding the increased bioavailability of compounds when delivered in a nano-enabled 
format, currently safe upper levels and recommended daily allowances (RDAs) only 
consider the delivery of essential nutrients in their macromolecule form (Chaudhry and 
Castle, 2011). The use of nanotechnology to deliver these compounds may have 
implications when estimating a given value (Food Safety Authority of Ireland, 2006; 
Bouwmeester et al., 2009). Conversely, inherently toxic materials (for instance some 
inorganic particulate metals) produced in a nano format and introduced to an environment 
in which it can solubilise may give rise to greater exhibited toxicity than organic forms; 
in fact several studies have exhibited that this may be the case in which many NPs have 
shown greater reactivity in in silico and/or in vitro models (Papageorgiou et al., 2007; 
Singh et al., 2007; Puzyn et al., 2011).  
Due to the complexity of accessing the penetration and biological effects of ingested NPs 
on the body it can be difficult to ascertain which chemical or physical properties can be 
exploited for commercial use whilst avoiding potential toxicity effects on cells and tissues 
(Singh et al., 2007). For example, properties such as physical dimensions and surface 
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charge determine a particles ability to penetrate an organ or cell, in addition to the 
likelihood that it will be uptaken and phagocytosed by leucocytes (Owens and Peppas, 
2006). Retention time of particles, together with their solubility is another facet that needs 
consideration, as it is well documented that increased residence time of particles at cell 
membrane surfaces give rise to greater toxic reactions and damage (Dowling et al., 2004; 
Nel et al., 2009).  
Particle interactions represent another specific caveat that deems consideration. For 
example, particle contact with endogenous compounds present in the body or food matrix 
give rise to biomolecule coronas that may assist the absorption of novel entities into the 
small bowel lumen (Lomer, Thompson and Powell, 2002; Nel et al., 2009). These 
considerations must be kept in mind when assessing the effects of using NPs for food or 
supplementation purposes with the intent to increase bioavailability. However, to date, 
there is limited information available on ADME and toxic properties of NPs, leading to 
recommendations to consider each NP formulation on a “case by case” basis (SCENIHR, 
2007). For example, Cs NPs are insoluble yet ultimately biodegradable; they will 
breakdown to their substituent counterparts at a rate dependent on their physicochemical 
properties (Xu and Du, 2003). In contrast TiO2 NPs lack the ability to be broken down in 
the body and thus have been shown to accumulate in the RES of the liver and spleen 
(Elgrabli et al., 2015).  
It is important to note that humans have been exposed to NPs throughout evolution, and 
there is even evidence that we have adapted strategies to benefit from dietary and 
physiological use of NPs in the gut (Powell et al., 2010). In addition, many foods are 
already comprised of compounds such as proteins, carbohydrates and fats which exist in 
a range of sizes, at present outspreading from macromolecules to the nano scale (Food 
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Safety Authority of Ireland, 2006). Generally, food ingested in macro scale format is 
subsequently digested to the nano scale in order to exploit the energy contained in the 
molecule for body gains. For example, it has been shown that nanoparticulate ferritin may 
be utilised by gut epithelial cells as a source of dietary iron post endocytosis (Pan et al., 
2009). With this in mind, it is fair to state that nanoparticulates cannot be considered 
inherently safe or toxic. They do, however, need to be assessed such that their molecular 
structure, biological environment, degree of exposure and host acceptability are 
understood and consequently assigned a potential hazard risk value accordingly (Food 
Safety Authority of Ireland, 2006). 
2.14 Conclusion and future directions 
There is growing emphasis on health and welfare derived from food, which is being 
driven by demographic and social factors, such as larger emphasis on healthy living in 
industrial societies, the ageing of the population within the developed world in addition 
to the increasing prevalence of sickness and diseases related to high-fat and high 
cholesterol foods in rising and industrial economies (Verbeke, 2005; Annunziata and 
Vecchio, 2013). Innovation in food merchandise has capitalised on these trends to 
develop the growing marketplace for practical and/or health enhancing foods. Matching 
specific foods or food decisions with an individual’s exact health desires appears to be 
the way forward for the nutrition and food business future.  
Whilst it is recognised that the application of nanotechnology to nutrient delivery can 
give rise to several challenges within safety, ethical and regulatory perspectives 
(Bouwmeester et al., 2009), it is important to keep in mind the major scope of potential 
benefits it can offer to both consumers and manufacturers alike. At this moment in time, 
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the long-term effects of nanomaterial exposure to human health remains largely 
unknown. However, by ensuring enhanced knowledge is acquired during the realisation 
of NP incorporation into food products it is possible to ensure consumer acceptance 
remains in favour of this highly promising technology (Ravichandran, 2010).  
With regards to global economic effects anticipated as a result of nano-enabled 
nutraceuticals being applied in food product markets, undoubtedly nations who are able 
to develop products that deliver smarter and healthier foods whilst maintaining increased 
food production at cost effective margins can expect to profit in the economic long term. 
If regulated correctly, the sustainability of nanomaterials in foods, alongside the potential 
health and environmental benefits of the more efficient delivery of nutraceuticals, can be 
expected to hugely impact the future direction of the food industry (Ravichandran, 2010). 
With this in mind, it is of importance to ensure that human and environmental concerns 
are addressed and subsequently not compromised as new products hit the market. In order 
to assure this approach is embodied, the rate at which nanotechnology is introduced into 
food products should be sufficiently reduced in order to allow for potential risks to be 
identified and rectified prior to successful implementation on the food market.  
Special attention should also be given to public opinion regarding the use of 
nanotechnology in foods in order to mitigate negative consumer responses such that was 
seen upon the introduction of genetically modified foods (Costa-Font, Gil and Traill, 
2008; Hudson, Caplanova and Novak, 2015). As with any new technology, it is pertinent 
that the potential benefits and risks are thoroughly discussed in addition to appropriate 
labelling and regulation guidelines, in order to safeguard increased consumer 
acceptability. 
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3.1 Design of experiments: Response Surface Methodology  
Response surface methodology (RSM) is an empirical modelling approach for defining 
the relationship between various process parameters and responses with various desired 
criteria and searching the significance of these process parameters on the coupled 
responses. Originally developed by Box & Wilson (1952), RSM is based on the fit of 
mathematical models (linear, square polynomial functions and others) to experimental 
results produced from a designed experiment and the verification of the model obtained 
by means of statistical techniques. In situations where several variables may influence 
system properties, RSM is a useful technique to employ as it allows for the relationships 
between a given response and independent variables (or factors) to be identified and 
optimised (Anderson and Whitcomb, 2005). RSM is a more efficient approach to 
experimentation than one factor at a time (OFAT) experiments due to the fact that it: 
1. Reduces the number of experimental runs typically required to gather the same 
information as OFAT, thus reducing resource requirements. 
2. Is useful in detecting interaction amongst variables that would not be typically 
identified during OFAT experiments. 
3. Improves the prediction of a response through use of gathered information from a 
larger space. 
Two of the most commonly applied RSM designs for process optimisation are the CCD 
and BBD (Dayal et al., 2005; Singh, Chakkal and Ahuja, 2006; Varshosaz, Tabbakhian 
and Mohammadi, 2010; Anarjan et al., 2011; Nabi-Meibodi et al., 2013; Maleki Dizaj et 
al., 2015). Both methods require the user to supply minimum and maximum values for 
each factor that defines the experimental domain to be investigated during the 
optimisation procedure (Ferreira et al., 2007). The combinations of the different factor 
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levels used to perform the actual experiments are subjected to multivariate optimisation 
by employing the following steps (Ferreira et al., 2007). 
1. Run experiments in random order to mitigate bias 
2. Fit a full polynomial regression model on the obtained data.  
3. Identify the significant terms via analysis of variance (ANOVA). 
4. Assess the R2 or R2 adjusted to determine how well the constructed model explains 
variation (ideally as close to 1 as possible). 
5. Ensure that there is no evidence of lack of fit for the produced model of the 
representative data. 
6. Construct an objective function either with the individual response or the linear 
combination of all the responses (Desirability function) 
7. Examine contour and surface plots and perform canonical analysis in order to identify 
optimum variable conditions. 
CCD considers 5 levels of factors with three different design points: edge points as in 
two-level designs (±1), star points at (±α), that take care of quadratic effects and centre 
points (α) that allow for the estimation of error (Bezerra et al., 2008). CCD designs 
provide predictions over the entire design space, although, when factor levels are at 
extreme points in the design, loss of information may occur (Singh, Chakkal and Ahuja, 
2006).  
BBD is an independent quadratic design approach in which factor combinations are 
considered at 3 levels: the midpoints of edges of the process space and the centre. The 
primary advantage is in addressing the issue of where the experimental boundaries should 
be, and in particular to avoiding treatment combinations that are extreme (Sivamani and 
Baskar, 2015). As the design avoids extreme experiment points, a reduced number of 
experimental runs is required for BBDs than that of CCDs. However, it should be 
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emphasised that the vertices of the cube are not covered by the design, and therefore, 
prediction at these points is an extrapolation and should be avoided (Zolgharnein, 
Shahmoradi and Ghasemi, 2013) 
3.1.1 Nanoparticle characterisation  
As discussed in chapter 1 (section 1.2), to ensure activity of a bioactive within a NP oral 
delivery system, it is recommended to achieve specific physicochemical properties such 
as a NP size of 100-500 nm, PDI ≤ 0.5 and ZP ≥ 30 mV (des Rieux et al., 2006). In this 
work, these properties were measured using the following methodologies. 
3.1.2 Particle Size and Zeta Potential Characterisation using DLS 
A powerful technique employed for the sizing of NPs and their and characterisation in 
the liquid phase is DLS, in which a laser beam is passed through the NPs (in suspension) 
and is scattered by the particles. DLS measures random Brownian motion, whereby the 
smaller the particle, the more rapidly it moves, the viscosity of the solution also playing 
a role in the analysis. Fundamentally, the Stokes-Einstein equation allows us to link 
Brownian motion with the NP size, by measuring the time dependant fluctuations in the 
scattering intensity, allowing for determination of the translational diffusion coefficient 
(D), and subsequently the hydrodynamic radius (Uskoković, 2012). The ZP of NPs can 
be indirectly detected with DLS based on electrophoretic mobility of particles and 
calculated by the application of the Henry equation. This provides information of the 
colloidal stability of the nanoparticles (Malvern Instruments Ltd., 2007). 
In Chapters 4, 5, 6 & 8, freshly prepared NP solutions were analysed. The mean particle 
size and PDI of the NP formulations were determined by DLS. The ZP values were 
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measured with the use of laser Doppler velocimetry (LDV). Both DLS and LDV analysis 
were performed in triplicate at 25 °C with a Zetasizer Nano series Nano-ZS ZEN3600, 
fitted with a 633 nm laser (Malvern Instruments Ltd., UK), using a folded capillary 
cuvette (Folded capillary cell-DTS1060, Malvern, UK). The values presented herein were 
acquired from three separate experiments, each of which included three replicates, N=3. 
3.1.3 Scanning electron microscopy (SEM) 
SEM produces images of a sample by scanning it with a focused beam of electrons. 
Different types of electron signals, emitted at or near the specimen surface, arise as a 
consequence of interactions between the sample and the electron beam that scans across 
the sample surface. These electronic signals are then collected, processed, and eventually 
translated as pixels on a monitor to form an image of the specimen’s surface topography 
that appears three dimensional (Carter et al., 2015). SEM can achieve a resolution of up 
to 1 nm. Specimens can be observed in high vacuum, in low vacuum, in wet conditions 
(in environmental SEM), and at a wide range of cryogenic or elevated temperatures 
(Stokes, 2003). 
In this work (Chapters 4, 5, 6 & 8), NP morphology was evaluated by SEM (Hitachi, 
SU6600 FESEM, USA), at an accelerating voltage of 20 kV, using the secondary electron 
detector. The fresh NP solutions were spin coated onto Si wafers, dried at room 
temperature and then sputter coated with 4 nm Au/Pd prior to imaging (Mukhopadhyay 
et al., 2013). 
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3.1.4 Encapsulation efficiency  
Encapsulation efficiency (EE%), refers to the percentage amount of a given bioactive 
entrapped within a colloidal system, after the formulation process (Koppolu et al., 2014). 
Personal communication with various industrial stakeholders in this project set the target 
of EE% to be ≥ 80%. 
In this work (Chapters 5, 6 & 8), the EE% of organic Se entrapped within the produced 
NPs was determined by the separation and quantification of Se left in the supernatant. 
This was performed by ultracentrifugation of the loaded NPs at 3000 rpm, 4 °C for 30 
min. Unentrapped Se in the supernatant was then quantified by reverse phase high 
performance liquid chromatography (RP-HPLC), as previously described (Ward, 
Connolly and Murphy, 2012) with the following modifications. Samples were analysed 
with a Waters 2998 HPLC and Photodiode Array Detector, (Waters, USA), using a 
Poroshell 120, EC-C8 column, 3.0 x 100 mm, 2.7 μm, (Agilent Technologies, UK). 
Isocratic elution was carried out at a flow rate of 0.4 mL/min, column temperature 45.0 
± 5.0 °C with a mobile phase of water/methanol/trifluoroacetic acid (97.9:2.0:0.1). 
Samples were monitored according to their UV absorbance at 218 nm. The encapsulation 
efficiency was calculated according to Equation 3.1 (Xu and Du, 2003): 
𝑬𝑬% =
𝑻𝒐𝒕𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑺𝒆 𝑴𝒆𝒕−𝑭𝒓𝒆𝒆 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑺𝒆𝑴𝒆𝒕
𝑻𝒐𝒕𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑺𝒆𝑴𝒆𝒕
  X 100 
(Equation 3.1) 
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3.2 Nanoparticle in vitro assessment 
 
3.2.1 Cytotoxicity 
The cytotoxicity of a specific material or carrier for a specific in vivo application is 
initially accessed via in vitro testing. In this work, a commonly employed cytotoxicity 
assay which employs a tetrazolium salt, MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), was used.  
This assay is based on the reduction of MTS tetrazolium compound by viable cells to 
generate a coloured soluble formazan product. This conversion is due to NAD(P)H-
dependent dehydrogenase enzymes in metabolically active cells. The formazan dye 
produced by viable cells can be quantified by measuring the absorbance at 490-500 nm. 
MTS is a derivative of the more commonly employed MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) test, which produces a dye within cells with 
functioning mitochondrial activity. The MTS assay has the advantage that the reagent is 
added directly into the cell culture media without the intermittent steps which are required 
in the routine MTT assay (Malich, Markovic and Winder, 1997).  
Generally, it is accepted that an early indication of cellular damage is related to the 
reduction of cellular metabolic activity (Rodrigues et al. 2012). Regardless of whether 
one uses MTS or MTT, both indicate mitochondrial activity dysfunction, which can be 
used to detect disrupted cell function (Rodrigues et al. 2012). The higher the assay 
response, the higher the amount of metabolically active cells, which indicates higher cell 
viability.  
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Cytotoxicity was assessed using human cell lines: Caco-2 (derived from continuous cells 
of heterogeneous human epithelial colorectal adenocarcinoma) and HepG2 (derived 
from, human hepatocellular carcinoma), to assess whether the NPs formed would be 
suitable for oral delivery.  
In Chapters 5, 6 & 8, Caco-2 and HepG2, were seeded at a cell density of 2 x 104 cells/well 
and cultured on 96 well plates in Dulbecco's Modified Eagle Medium (DMEM) and 
Eagle's Minimum Essential Medium (EMEM), respectively, supplemented with 10% 
foetal bovine serum, 1% L-glutamine, 1% penicillin-streptomycin and 1% non-essential 
amino acids at 37°C in a humidified incubator with 5% CO2 and 95% O2. The assay was 
carried out using 4 h exposure times for the test compounds on Caco-2 cells (Neves et 
al., 2016) and 72 h on HepG2 cells (Gleeson et al., 2015), using Triton X-100™ (0.05%) 
as a positive control. The time points were selected to mimic in vivo conditions for each 
cell type. The concentrations of the test compounds applied were 25, 50 and 100 uM. 
After exposure, treatments were removed and replaced with MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium). 
Optical density (OD) was measured at 490 nm using a microplate reader (TECAN 
GENios, Grodig, Austria). Each value measured was normalised against untreated control 
and calculated from three separate experiments, each of which included six replicates.  
3.2.2 Accelerated stability studies 
The principle aim of accelerated stability testing is to provide reasonable assurance that 
the product will remain at an acceptable level of fitness/quality throughout its timespan 
in the market place (Bajaj et al., 2012). Broadly speaking, real-time, retained sample, 
cyclic temperature and acceleration, are the four categories into which stability testing 
procedures fall (Bhagyashree et al., 2015). In the latter, the product is subjected to 
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elevated temperatures and/or humidity well above ambient values, to determine the 
temperature at which product failure (i.e. degradation) will occur. 
The Arrhenius equation, upon which the interpretation of accelerated stability testing is 
based, allows for the determination of the activation energy and consequently, the ability 
to extrapolate the degradation rate of a product at lower temperatures (i.e. ambient, 
refrigerated etc.). In this instance, the data acquired can then be used to project the shelf 
life of the product in a much shorter time than that of real time assessments (Ema, 2003). 
This is a beneficial approach to stability testing, as it results in a greatly reduced product 
development schedule and provides a good indication of the temperature sensitivity of 
the product. 
In this work (Chapters 5, 6 & 8), NPs were stored at accelerated conditions: 60°C for 
720min, 70°C for 300min and 80°C for 120min (Danish et al., 2017). The particle size, 
PDI and ZP were measured over different time intervals, to determine the degree of 
degradation. The temperature dependence of the kinetic parameters of organic Se-loaded 
NPs stability was measured by calculating the observed rate constants.  
This was plotted in an Arrhenius representation and apparent activation energy, Ea and 
reaction rate, kref were calculated according to Equation 3.2: 
𝑪(𝒕) = 𝑪𝒐 + 𝒆
𝒍𝒏 (𝒌)−
𝑬𝒂
𝑹
(
𝟏
𝑻−
𝟏
𝑻𝒓𝒆𝒇
)
𝒕 
(Equation 3.2) 
where C(t) is the property (particle size, PDI or ZP) at time t, Co is the initial property 
conditions, k is the apparent zero order reaction constant, Ea is the energy of activation, 
R is the universal gas constant, T is the temperature of the experiment (K) and Tref is the 
reference temperature (343 K). 
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3.2.3 In vitro controlled release studies  
In vitro techniques are advantageous for modelling potential interactions between NPs 
and the in vivo environment of the GI tract. Simulated gastric fluid and membrane 
analysis models enable assessment of in vivo environments without the use of human cell 
lines. The site of target for Se is in the jejunum, in the small intestine. Therefore, it is 
important to bypass the acidic stomach environment. Three basic mechanisms that are 
typically applied to describe the release of drugs from polymeric particles, are 
swelling/erosion, diffusion, and degradation (Liechty et al., 2010). 
In this work (Chapters 5, 6 & 8), the total cumulative release of organic Se (SeMet, 
SeCys2 or MSC) from the zein coated NPs was carried out using a dialysis bag diffusion 
technique (Hosseinzadeh et al., 2012) over 6 hr (Calderon et al., 2013; Yoon et al., 2014). 
Freeze dried Se loaded NPs were suspended in 5 mL H2O and probe sonicated (Branson 
Ultrasonics; Ultrasonic processor VCX-750W, Wilmington, North Carolina, USA) at 35 
% amplitude for 30 s with 5 s intervals and placed into a Float-A-Lyzer®G2 dialysis 
membrane with a pore size of 25 kDa (Spectrum Laboratories, USA). The sample was 
placed into 40 mL of simulated gastric fluid (SGF) or simulated intestinal fluid (SIF), 
specified according to the British Pharmacopoeia (Pharmacopoeia, 2016). SGF was 
composed of 0.1 M HCL and SIF was composed of 1 volume of 0.2 M trisodium 
phosphate dodecahydrate and 3 volumes of 0.1 M HCL (adjusted to pH 6.8), without 
enzymes (British Pharmacopoeia Commission, 2016). Samples were placed in a 
thermostatic shaker at 37 ºC and agitated at 100 rpm. At predetermined time points, 1mL 
of release fluid was analysed and replaced with simulated fluid to maintain sink 
conditions. 
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Se release was measured by RP-HPLC (section 3.2.3), whereby Equation 3.3 was used to 
determine the % drug release; 
𝑫𝒓𝒖𝒈𝒓𝒆𝒍 % =
𝑫(𝒕)
𝑫(𝒍)
∗ 𝟏𝟎𝟎 
(Equation 3.3) 
where 𝑫𝒓𝒖𝒈𝒓𝒆𝒍 is the percentage of SeMet released, D(l) represents the concentration of 
drug loaded and D(t) represents the amount of drug released at time t, respectively. 
3.3 Chitin/Chitosan characterisation 
In Chapter 7, several techniques were employed in the characterisation of chitin (CT), 
chitosan (Cs) and trimethyl chitosan (TMC) produced during this project, as detailed in 
the following subsections. 
3.3.1 Fourier Transform Infrared spectroscopy– Quantitative analysis 
In the infrared (IR) region of the electromagnetic spectrum, all covalent compounds have 
the capability to absorb frequencies of electromagnetic radiation. Fourier Transform 
Infrared spectroscopy (FTIR) is a useful technique for identifying functional groups 
within a molecule as it identifies these groups based on the stretching and/or bending of 
their bonds rather than on any given property of the atoms themselves. The wavenumber 
unit (cm-1) in the IR energy spectrum represents the inverse of wavelength and is 
proportional to frequency, typically extending from 4000-400 cm-1 (Pretsch et al., 2000). 
This scale is directly proportional to energy, whereby a higher bond energy corresponds 
to a higher wavenumber. Compounds with unsymmetrical bond stretching (such as NH2, 
OH and C=O) are particularly suited for this type of analysis, attributable to the increased 
energy required to vibrate the bond and increased intensity resultant from the change of 
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dipole moment when the bond is stretched (Duarte et al., 2002) and as such this was 
employed for the quantitative analysis of CT and Cs extracted in this work (Chapter 7). 
 
Figure 3.1 Functional groups present in chitin and chitosan structures, particularly 
sensitive to IR analysis. 
3.3.2 Gel permeation chromatography - MW determination 
MW is an important physical property of Cs and is typically determined via viscosity 
measurements or gel permeation chromatography (Baxter et al. 2005; Zielinska et al. 
2014). GPC is a useful technique for determination of the molecular weight of polymers 
where analytes are separated based on the size or hydrodynamic volume (radius of 
gyration) of the analytes. Smaller analytes tend to be retained in the column longer than 
larger molecules, owing to their ability to enter the pores present within the column 
packing. This contrasts with other chromatographic techniques (e.g. HPLC), which 
depend upon chemical interactions between the columns surface chemistry (stationary 
phase) and the analyte of interest during separation. Polymers can be defined according 
to a number of conventions for molecular weight, including the number average 
molecular weight (Mn), the weight average molecular weight (Mw), the size average 
molecular weight (Mz), or the viscosity molecular weight (Mv). GPC allows for the 
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determination of PDI as well as Mv and, based the concentration of molecules on a 
weight/volume basis, the Mn, Mw, and Mz can be determined (Agilent Technologies Inc., 
2015). Essentially, what GPC truly measures is the molecular volume and shape function 
as defined by the intrinsic viscosity. If comparable standards are used, this relative data 
can be used to determine molecular weights within ± 5% accuracy. 
3.3.3 Nuclear magnetic resonance -NMR 
Nuclear magnetic resonance (NMR) techniques, such as proton NMR (1H NMR) and 
carbon NMR (13C NMR) have been developed and employed to determine: the degree of 
acetylation (DA%) of CT (Heux et al., 2000); degree of deacetylation (DDA%) of Cs 
(Lavertu et al., 2003) and the degree of quaternisation (DQ %) of TMC (Verheul et al., 
2008). CT is effectively insoluble in most solvents and, as such, solid-state NMR 
spectroscopy is suitable tool to analyse its structure, as it mitigates the requirement for 
solubilisation. Figure 3.2 displays a typical 13C-NMR spectra of CT which exhibits eight 
main peaks, whereby the peaks at 175 and 25 ppm are assigned to the carbonyl and methyl 
carbons, respectively, and the peaks at 103, 82, 74, 72, 59 and 55 ppm were ascribable to 
the resonances of C1, C4, C5, C3, C6, and C2 on the N-acetyl-D-glucosamine unit of CT, 
respectively (Heux et al., 2000).  
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Figure 3.2 Chemical structure of chitin and 13C-NMR chemical shifts associated to each 
carbon (adapted from Duan et al., 2013). 
The DA% of the CT can then be calculated using the relative integrals of methyl or 
carbonyl groups related to the carbon integrals of the polysaccharidic backbone (Equation 
3.4,) (Heux et al., 2000). 
𝑫𝑨 =  
𝑨𝑼𝑪𝟐𝟓 𝒑𝒑𝒎
𝑨𝑼𝑪𝟏𝟕𝟓𝒑𝒑𝒎
× 𝟏𝟎𝟎 
(Equation 3.4) 
Several methods have been established in order to determine the DDA% of Cs, namely 
FTIR (Beil et al. 2012), potentiometric titration (Jiang et al. 2003), UV-Visible 
spectrophotometry (Wu & Zivanovic 2008) and 1H-NMR spectroscopy (Lavertu et al. 
2003; Hirai et al. 1991), the latter being considered the “gold standard” analytical 
methodology for DDA% analysis due to the lack of requirement for a calibration curve 
or reference sample of known DDA% (Kasaai 2010, Bellich et al., 2016).  
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A typical 1H-NMR spectra of Cs, outlining its structure and characteristic functional 
groups, is represented in Figure 3.3 (Kumirska et al., 2011). C-H linkages are produced, 
via the six hydrogen and seven carbon atoms present on each unit residue. Likewise, due 
to the presence of four hydroxyl groups in each unit residue, O-H linkages are established 
(Rinaudo, 2006; Kumirska et al., 2011) also. The characteristics of these unique bond 
environments result in each proton possessing its own unique chemical shift. Essentially, 
the 1H-NMR spectrum of Cs reflects a superposition of the individual unit residues which 
become marginally modified due to their linkages to one another (Kasaai, 2010). 
 
Figure 3.3 Chemical structure of chitosan and 1H-NMR chemical shifts associated to 
each hydrogen (adapted from Weinhold et al. 2009). 
The DDA% can then be calculated using Equation 3.5 (Lavertu et al. 2003): 
𝑫𝑫𝑨 (%) =  
(𝟏 − (
𝟏
𝟑 𝑯𝑨𝒄)
(
𝟏
𝟔 𝑯𝟐𝟔)
 × 𝟏𝟎𝟎 
(Equation 3.5) 
where HAc corresponds to the methyl protons of the acetyl group and H26 represents the 
signal from protons H2, H3, H4, H5, H6, H6 of both monomers, through use of the 
integral peak intensity values (Lavertu et al. 2003). 
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Synthesis of TMC entails the methylation of the amino groups in the C-2 position of Cs 
to form quaternary amino groups (with fixed positive charges) on the repeating units of 
the TMC polymer chain (Figure 3.4 A) (Sieval, et al, 1998). There is also some degree 
of methylation on the 3 and 6 hydroxyl groups of the Cs polymer and partial 
quaternisation on the amine unit that can reduce the aqueous solubility of the product 
(Figure 3.4 B) (Verheul et al., 2008).  
 
Figure 3.4 Chemical structure of TMC. TMC can vary in degree of quaternisation (A), 
and O-methylation (B). The various substitutions are randomly distributed throughout 
the polymer and mono and di-methylation (incomplete quaternisation) may occur on the 
amine unit also (B) (Verheul et al., 2008). 
Figure 3.5 shows the typical structure and characteristic functional groups of TMC as 
observed in 1H-NMR spectra. The degree of quaternisation (% DQ) and O-methylation 
(OMe) can then be calculated using the following equations (Zarifpour, 2013): 
𝑫𝑸 =
[(𝑪𝑯𝟑)𝟑]
[𝑯]
×
𝟏
𝟗
× 𝟏𝟎𝟎%  
(Equation 3.6) 
𝑶𝑴𝒆 =
[(𝑪𝑯𝟑)]
[𝑯]
×
𝟏
𝟑
× 𝟏𝟎𝟎%  
 (Equation 3.7) 
where DQ is the degree of quaternisation, in mole percentage of free amine, [(CH3)3] is 
the integral of chemical shift of the hydrogens of trimethyl amino groups at 3.3 ppm, 
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[(CH3)] the methylated hydroxyl groups at either 3.4 (OMe-6) or 3.5 (OMe-3) ppm and 
[H] is the integral of H-1 peaks between 4.7 and 5.7 ppm, related to hydrogen atoms 
bound to carbon 1 of the chitosan molecule, which is taken as the reference signal.  
 
Figure 3.5 Chemical structure of TMC and 1H-NMR chemical shifts associated to each 
hydrogen (adapted from Verheul et al., 2008). 
3.4 TEER-Permeation enhancement 
Cs extracted from A. bisporus was assessed as an intestinal permeation enhancer using 
Caco-2 monolayers via an electrical method known as transepithelial electrical resistance 
(TEER, Ω cm2). TEER is measured across the monolayers using an EVOM® voltammeter 
with a chopstick-type electrode (EVOM®, WPI, UK). It allows for the assessment of 
transport of a molecule through tight junction (TJ) pores (paracellular route) (Hidalgo, 
2001). Hydrophilic molecules must rely on transport between adjacent cells through the 
paracellular pathway, unless they are substrates for membrane transporters and so are not 
likely to transverse lipid rich cell membranes (Upadhyay, 2014). A schematic 
representation of paracellular and transcellular transport is shown in Figure 1.2. 
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In essence, the cell membrane can be thought of as an electrical insulator, in which the 
lipophilic components that constitute the cell membrane are responsible for maintenance 
of the membrane’s electrical potential, in addition to inhibiting the movement of water. 
The tight junctions (TJs), on the other hand, possess open pores that allow the passage of 
water and ions through fluid filled routes and as such can be considered as electrical 
conductance pathways. An electrical potential difference, which is measurable as 
electrical resistance, is created due to the TJs of the monolayers of epithelial cells 
restricting the movement of ions (Anderson and Van Itallie, 2009). With a decrease in 
TEER, in conjunction with an increased ionic conductance, an increase in paracellular 
permeability of ions across a monolayer is indicated rather than transcellular 
permeability. Even in the presence of ion channels, significantly lower resistance and 
concordantly higher conductance to ion flow is seen in the paracellular space, as opposed 
to the cell membranes. 
TEER has been applied to study the permeation enhancing effects of compounds such as 
polyacrylic acid, polycarbophil and Cs, over recent years (Aungst, 2000; Liu et al., 2008; 
Maher, Mrsny and Brayden, 2016). The latter has been shown to exhibit a reversible time 
and dose dependant decrease in TEER values in Caco-2 cells, indicating its ability to open 
the TJs (Ranaldi et al., 2002). The effect of Cs on TJs was confirmed by increasing the 
permeation coefficient of mannitol when applied in conjunction with 0.1-0.5 w/v % Cs 
solution for 60 min, compared to cells treated with mannitol in the absence of Cs (Dodane, 
Khan and Merwin, 1999). Additionally, observations by Sonaje et al. (2012) have also 
suggested that the opening of TJs by Cs at 0.2 mg/mL is transient and reversible in Caco-
2 cell monolayers, further indicating it as an effective permeation enhancer. 
It has been shown that specific MWs of Cs significantly influence its permeation 
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enhancement (Chae, Jang and Nah, 2005). For example, studies by Opanasopit et al. 
2007, showed that, as the MW of Cs is increased from 20 to 460 kDa, the reduction in 
TEER significantly decreased in the order: 20 < 45 < 200 < 460 kDa, observed in Caco-
2 cell lines. 
3.5 Selenium speciation 
As the bioavailability of Se is highly dependent on its speciation, organic formats are 
typically sought after when proposing a health supplement (Rayman, 2000). Typically, 
Se is supplemented with SeMet, produced from Saccharomyces cerevisiae, a strain of 
yeast which, when cultivated with minimal S in the presence of inorganic Se, possesses 
the ability to accumulate up to 1400 µg SeMet per g of dried sample (Suhajda et al., 
2000). The high yield of Se from selenised yeast is one of the main factors for its 
employment. However, an alternative source of Se has been investigated in recent years, 
the edible mushroom A. bisporus. 
The Irish mushroom industry produces in the region of 200,000 tonnes of spent 
mushroom substrate (SMS) every year (Teagasc Mushroom Stakeholder Consultative 
Group, 2013). Naturally, A. bisporus, contains an average of >1 µg Se/g dw (Savic et al., 
2012). However, when cultivated in substrates containing Se in either inorganic or 
organic forms, they exhibit much higher concentrations, ranging from 354 ± 0.19 to 707 
± 37.3 µg of Se per g of dried sample (Gergely et al., 2006; Savic et al., 2012). Previous 
studies conducted in DIT identified high levels of SeCys2 (≈60 µg/g) in A. bisporus 
samples supplied by Monaghan mushrooms (Vozza, 2013). However, identification of 
the source and total Se content in the fruiting bodies was beyond the scope of the research, 
at that time. Regardless, the levels of SeCys2 alone reflected Se fortification had occurred 
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during cultivation and that these Irish mushrooms may potentially offer an alternative 
source of Se to S. cerevisiae. 
In order to use Se species sourced from A. bisporus in the NP formulation, it is first 
necessary to isolate fractions of Se from the fruiting bodies of the mushrooms and identify 
the species present. However, to date, no robust method for complete extraction and 
analysis of Se from food sources has been developed (Thiry et al., 2012). Careful 
optimisation of extraction procedures is an essential requirement for Se speciation 
analysis of solid samples, in order to achieve high extraction efficiencies that also 
mitigate interconversion of the original species present (Dumont, Vanhaecke and 
Cornelis, 2006). It is generally recognised that a single step extraction is insufficient for 
Se liberation due to the varied matrix associations of Se in real samples (Pyrzyńska, 
1996). For example, hot water extraction has been employed as a Se leaching solution for 
three edible wild mushroom species (Macrolepiota procera, Lepista luscina and Boletus 
luridus). However, it was shown that merely 47% of the total Se content present in the 
sample (present in water soluble proteins) could be recovered (Huerta, Sánchez and Sanz-
Medel, 2005). 
As many Se species are protein bound, several authors have utilised strong acids in 
extraction procedures, in order to increase liberation of Se from various matrices (Casiot 
et al., 1999; Wrobel et al., 2003). Additionally, proteolytic enzymes have been employed 
for extracting SeAAs incorporated into proteins due to their ability to cleave peptide 
bonds (Montes-Bayón et al., 2006). Also, inorganic forms of Se have been found to 
become entrapped physically or chemically into cell walls and as such, acids and non-
proteolytic enzymes such as driselase have been used in Se extraction (Infante, Hearn and 
Catterick, 2005). 
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In this work, Se species were extracted from Se supplemented A. bisporus samples, using 
protease enzymes, under microwave energy following the procedure detailed by (Ward, 
Connolly and Murphy, 2012). Once optimised, the entire procedure was subjected to a 
validation protocol, based on approved guidelines (EMEA, 1995), to assess its suitability 
for routine work. 
3.5.1 HPLC-DAD 
High Performance Liquid Chromatography (HPLC) is a powerful technique for 
separating complex mixtures and quantitating their components. HPLC equipment can be 
as simple as a specialised pump, a means of permitting sample injection, a specialised 
column and a suitable detector. In this work, a HPLC system coupled with a diode array 
detector (DAD) was employed for Se species quantification. A DAD detects the 
absorption in the UV to visible region of the spectrum. While a UV-VIS detector has only 
one sample-side light-receiving section, a beneficial feature of a DAD is that it has 
multiple (1024) photodiodes to obtain information over a wide range of wavelengths at 
one time. DADs differ from conventional UV-VIS detectors in that, light from the lamps 
is shone directly onto the flow cell, light that passes through the flow cell is dispersed by 
the diffraction grating, and the amount of the dispersed light is estimated for each 
wavelength in the DAD (Figure 3.6). 
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Figure 3.6 Schematic representation of a DAD optical system (picture acquired from 
www.crawfordscientific.com). 
3.6 Summary 
This chapter has presented the experimental techniques used throughout this thesis and 
provided relevant information and theory about each of the techniques employed. 
Experimental procedures were described, with specifications and parameters used given 
for each relevant procedure replicated throughout this thesis. The following chapter (4) 
will present the results of the optimisation and the characterisation of unloaded chitosan 
NPs that were formulated to ascertain formulation constituents and quantities that were 
requisite to hit target physicochemical and morphological properties. Finally, the specific 
detail on the applications of each technique will be described in the experimental section 
of the subsequent chapters (5, 6, 7 & 8), which are presented in the form of papers. 
  
 112 
3.7 References 
Agilent Technologies Inc. (2015) ‘An Introduction to Gel Permeation Chromatography and 
Size Exclusion Chromatography’, Primer, pp. 1–32. Available at: 
https://www.agilent.com/cs/library/primers/Public/5990-6969EN GPC SEC Chrom 
Guide.pdf. (Accessed: 10 Jan 2018). 
Anarjan, N. et al. (2011) ‘Effect of processing conditions on physicochemical properties of 
sodium caseinate-stabilized astaxanthin nanodispersions’, LWT - Food Science and 
Technology, 44(7), pp. 1658–1665. 
Anderson, J. M. and Van Itallie, C. M. (2009) ‘Physiology and function of the tight junction’, 
Cold Spring Harbor Perspectives in Biology, 1(2), p. a002584. 
Anderson, M. J. and Whitcomb, P. J. (2005) RSM simplified: optimizing processes using 
response surface methods for design of experiments. Productivity press. 
Aungst, B. J. (2000) ‘Intestinal permeation enhancers’, Journal of Pharmaceutical Sciences, 
89(4), pp. 429–442.  
Bajaj, S. et al. (2012) ‘Stability Testing of Pharmaceutical Products’, Journal of Applied 
Pharmaceutical Science, 2(2012), pp. 129–138.  
Bellich, B. et al. (2016) ‘“The good, the bad and the ugly” of chitosans’, Marine Drugs, 14(5), 
p. 99. 
Bezerra, M. A. et al. (2008) ‘Response surface methodology (RSM) as a tool for optimization 
in analytical chemistry.’, Talanta, 76(5), pp. 965–77.  
Bhagyashree, P. et al. (2015) ‘Recent trends in stability testing of pharmaceutical products: 
A review’, Research Journal of Pharmaceutical, Biological and Chemical Sciences, 6(1), pp. 
1557–1569. 
British Pharmacopoeia Commission (2016) British Pharmacopoeia: Appendix XII B. 
Dissolution. London: TSO. 
Calderon L. et al. (2013) ‘Nano and microparticulate chitosan-based systems for antiviral 
topical delivery’, European Journal of Pharmaceutical Sciences, 48, pp. 216–222.  
  
 113 
Carter, M. et al. (2015) ‘Microscopy’, in Guide to Research Techniques in Neuroscience, pp. 
117–144.  
Casiot, C. et al. (1999) ‘Sample preparation and HPLC separation approaches to speciation 
analysis of selenium in yeast by ICP-MS’, Journal of Analytical Atomic Spectrometry, 14(4), 
pp. 645–650. 
Chae, S. Y., Jang, M.-K. and Nah, J.-W. (2005) ‘Influence of molecular weight on oral 
absorption of water soluble chitosans’, Journal of Controlled Release, 102(2), pp. 383–394. 
Danish, M. K. et al. (2017) ‘Formulation, Characterization and Stability Assessment of a 
Food-Derived Tripeptide, Leucine-Lysine-Proline Loaded Chitosan Nanoparticles’, Journal 
of Food Science, 82(9), pp. 2094–2104.  
Dayal, P. et al. (2005) ‘Box-Behnken experimental design in the development of a nasal drug 
delivery system of model drug hydroxyurea: characterization of viscosity, in vitro drug 
release, droplet size, and dynamic surface tension.’, AAPS PharmSciTech, 6(4), pp. E573–
E585.  
Dodane, V., Khan, M. A. and Merwin, J. R. (1999) ‘Effect of chitosan on epithelial 
permeability and structure’, International Journal of Pharmaceutics, 182(1), pp. 21–32. 
Duan, B. et al. (2013) ‘High strength films with gas-barrier fabricated from chitin solution 
dissolved at low temperature’, Journal of Materials Chemistry A, 1(5), pp. 1867–1874. 
Duarte, M. L. et al. (2002) ‘An optimised method to determine the degree of acetylation of 
chitin and chitosan by FTIR spectroscopy’, International Journal of Biological 
Macromolecules, 31(1), pp. 1–8. 
Dumont, E., Vanhaecke, F. and Cornelis, R. (2006) ‘Selenium speciation from food source 
to metabolites: a critical review’, Analytical and Bioanalytical Chemistry, 385(7), pp. 1304–
1323. 
EMA (2003) ‘European Medicines Agency’, ICH-Stability Testing of new Drug Substances 
and Products, pp. 1–20.  
EMEA (1995) ‘Validation of analytical procedures: definitions and methodology’, ICH 
Harmonised Tripartite Guideline, 20(121), p. 278. 
  
 114 
Ferreira, S. L. C. et al. (2007) ‘Statistical designs and response surface techniques for the 
optimization of chromatographic systems’, Journal of Chromatography A, 1158(1), pp. 2–
14. 
Gergely, V. et al. (2006) ‘Selenium speciation in Agaricus bisporus and Lentinula edodes 
mushroom proteins using multi-dimensional chromatography coupled to inductively coupled 
plasma mass spectrometry’, Journal of Chromatography A, 1101(1–2), pp. 94–102.  
Gleeson, J. P. et al. (2015) ‘Stability, toxicity and intestinal permeation enhancement of two 
food-derived antihypertensive tripeptides, Ile-Pro-Pro and Leu-Lys-Pro. TL  - 71’, Peptides, 
71 VN-r, pp. 1–7.  
Gleeson, J. P., Ryan, S. M. and Brayden, D. J. (2016) ‘Oral delivery strategies for 
nutraceuticals: Delivery vehicles and absorption enhancers’, Trends in Food Science & 
Technology, 53, pp. 90–101. 
Heux, L. et al. (2000) ‘Solid state NMR for determination of degree of acetylation of chitin 
and chitosan.’ Biomacromolecules, 1(4), pp.746-751. 
Hidalgo, I. J. (2001) ‘Assessing the absorption of new pharmaceuticals’, Current Topics in 
Medicinal Chemistry, 1(5), pp. 385–401. 
Hosseinzadeh, H. et al. (2012) ‘Chitosan-Pluronic nanoparticles as oral delivery of anticancer 
gemcitabine: Preparation and in vitro study’, International Journal of Nanomedicine, 7, pp. 
1851–1863.  
Huerta, V. D., Sánchez, M. L. F. and Sanz-Medel, A. (2005) ‘Qualitative and quantitative 
speciation analysis of water soluble selenium in three edible wild mushrooms species by 
liquid chromatography using post-column isotope dilution ICP–MS’, Analytica Chimica 
Acta, 538(1), pp. 99–105. 
Infante, H. G., Hearn, R. and Catterick, T. (2005) ‘Current mass spectrometry strategies for 
selenium speciation in dietary sources of high-selenium’, Analytical and Bioanalytical 
chemistry, 382(4), pp. 957–967. 
Kasaai, M. R. (2010) ‘Determination of the degree of N-acetylation for chitin and chitosan 
by various NMR spectroscopy techniques: A review’, Carbohydrate Polymers, 79(4), pp. 
801–810.  
  
 115 
Koppolu, B. P. et al. (2014) ‘Controlling chitosan-based encapsulation for protein and 
vaccine delivery’, Biomaterials, 35(14), pp. 4382–4389.  
Kumirska, J. et al. (2011) ‘Biomedical Activity of Chitin/Chitosan Based Materials—
Influence of Physicochemical Properties Apart from Molecular Weight and Degree of N-
Acetylation’, Polymers, 3(4), pp. 1875–1901.  
Lavertu, M. et al. (2003) ‘A validated 1H NMR method for the determination of the degree 
of deacetylation of chitosan’, Journal of Pharmaceutical and Biomedical Analysis, 32(6), pp. 
1149–1158.  
Liechty, W. B. et al. (2010) ‘Polymers for Drug Delivery Systems’, Annual Review of 
Chemical and Biomolecular Engineering, 1, pp. 149–173.  
Liu, Z. et al. (2008) ‘Polysaccharides-based nanoparticles as drug delivery systems.’, 
Advanced Drug Delivery Reviews, 60(15), pp. 1650–62.  
Maher, S., Mrsny, R. J. and Brayden, D. J. (2016) ‘Intestinal Permeation Enhancers for Oral 
Peptide Delivery’, Advanced Drug Delivery Reviews, 106, pp.277-319. 
Maleki Dizaj, S. et al. (2015) ‘Box-Behnken experimental design for preparation and 
optimization of ciprofloxacin hydrochloride-loaded CaCO3 nanoparticles’, Journal of Drug 
Delivery Science and Technology, 29, pp. 125–131.  
Malich, G., Markovic, B. and Winder, C. (1997) ‘The sensitivity and specificity of the MTS 
tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell 
lines’, Toxicology, 124(3), pp. 179–192. 
Montes-Bayón, M. et al. (2006) ‘Evaluation of different sample extraction strategies for 
selenium determination in selenium-enriched plants (Alliumsativum and Brassicajuncea) and 
Se speciation by HPLC-ICP-MS’, Talanta, 68(4), pp. 1287–1293. 
Mukhopadhyay, P. et al. (2013) ‘Oral insulin delivery by self-assembled chitosan 
nanoparticles: in vitro and in vivo studies in diabetic animal model.’, Materials science & 
engineering. C, Materials for Biological Applications, 33(1), pp. 376–82.  
Nabi-Meibodi, M. et al. (2013) ‘Optimized double emulsion-solvent evaporation process for 
production of solid lipid nanoparticles containing baclofene as a lipid insoluble drug’, 
Journal of Drug Delivery Science and Technology, 23(3), pp. 225–230.  
Neves, A. R. et al. (2016) ‘Nanoscale delivery of resveratrol towards enhancement of 
supplements and nutraceuticals’, Nutrients, 8(3), p. 131. 
 116 
Opanasopit, P. et al. (2007) ‘Effect of salt forms and molecular weight of chitosans on in 
vitro permeability enhancement in intestinal epithelial cells (Caco-2)’, Pharmaceutical 
Development and Technology, 12(5), pp. 447–455. 
Pharmacopoeia, B. (2016) ‘British Pharmacopoeia Commission: London’. UK. 
Pretsch, E. et al. (2000) Structure Determination of Organic Compounds. Springer. 
Pyrzyńska, K. (1996) ‘Speciation analysis of some organic selenium compounds. A review’, 
Analyst, 121(8), p. 77R–83R. 
Ranaldi, G. et al. (2002) ‘The effect of chitosan and other polycations on tight junction 
permeability in the human intestinal Caco-2 cell line’, The Journal of Nutritional 
Biochemistry, 13(3), pp. 157–167. 
Rayman, M. P. (2000) ‘The importance of selenium to human health.’, Lancet, 356(9225), 
pp. 233–241.  
des Rieux, A. et al. (2006) ‘Nanoparticles as potential oral delivery systems of proteins and 
vaccines: a mechanistic approach’, Journal of Controlled Release, 116(1), pp. 1–27. 
Rinaudo, M. (2006) ‘Chitin and chitosan: Properties and applications’, Progress in Polymer 
Science, 31(7), pp. 603–632. 
Savic, M. et al. (2012) ‘The fungistatic activity of organic selenium and its application to the 
production of cultivated mushrooms Agaricus bisporus and Pleurotus spp.’, Archives of 
Biological Sciences, 64(4), pp. 1455–1463. 
Sieval, A. B. et al. (1998) ‘Preparation and NMR characterization of highly substitutedN-
trimethyl chitosan chloride’, Carbohydrate Polymers, 36(2–3), pp. 157–165.  
Singh, B., Chakkal, S. K. and Ahuja, N. (2006) ‘Formulation and optimization of controlled 
release mucoadhesive tablets of atenolol using response surface methodology.’, AAPS 
PharmSciTech, 7(1), p. E3.  
Sivamani, S. and Baskar, R. (2015) ‘Optimization of bioethanol production from cassava peel 
using statistical experimental design’, Environmental Progress & Sustainable Energy, 34(2), 
pp. 567–574.  
Sonaje, K. et al. (2012) ‘Opening of epithelial tight junctions and enhancement of paracellular 
permeation by chitosan: microscopic, ultrastructural, and computed-tomographic 
observations’, Molecular Pharmaceutics, 9(5), pp. 1271–1279. 
  
 117 
Stokes, D. J. (2003) ‘Recent advances in electron imaging, image interpretation and 
applications: environmental scanning electron microscopy’, Philosophical Transactions of 
the Royal Society of London Series a-Mathematical Physical and Engineering Sciences, 
361(1813), pp. 2771–2787.  
Suhajda, A. et al. (2000) ‘Preparation of selenium yeasts I. Preparation of selenium-enriched 
Saccharomyces cerevisiae’, Journal of Trace Elements in Medicine and Biology, 14(1), pp. 
43–47. 
Teagasc Mushroom Stakeholder Consultative Group (2013) ‘Mushroom Sector Development 
Plan to 2020’, pp. 16, 14. Available at: 
http://www.teagasc.ie/publications/2013/2916/Mushroom_ Conference_ 
Proceedings_web.pdf. (Accessed: 10 Jan 2018) 
Thiry, C. et al. (2012) ‘Current knowledge in species-related bioavailability of selenium in 
food’, Food Chemistry, 130(4), pp. 767–784.  
Uskoković, V. (2012) ‘Dynamic Light Scattering Based Microelectrophoresis: Main 
Prospects and Limitations’, Journal of Dispersion Science and Technology, 33(12), pp. 
1762–1786.  
Varshosaz, J., Tabbakhian, M. and Mohammadi, M. Y. (2010) ‘Formulation and optimization 
of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability’, 
Journal of Liposome Research, 20(4), pp. 286–296. 
Verheul, R. J. et al. (2008) ‘Synthesis, characterization and in vitro biological properties of 
O-methyl free N,N,N-trimethylated chitosan’, Biomaterials, 29(27), pp. 3642–3649.  
Vozza, G. (2013) Identification and quantitative analysis of selenium species present in 
Agaricus bisporus by gas chromatography mass spectrometry. Dublin institute of 
Technology. 
Ward, P., Connolly, C. and Murphy, R. (2012) ‘Accelerated Determination of 
Selenomethionine in Selenized Yeast: Validation of Analytical Method’, Biological Trace 
Element Research, 151(3), pp. 446–450.  
Weinhold, M. X. et al. (2009) ‘Strategy to improve the characterization of chitosan for 
sustainable biomedical applications: SAR guided multi-dimensional analysis’, Green 
Chemistry, 11(4), pp. 498–509.  
  
 118 
Wrobel, K. K. et al. (2003) ‘Hydrolysis of proteins with methanesulfonic acid for improved 
HPLC-ICP-MS determination of seleno-methionine in yeast and nuts’, Analytical and 
Bioanalytical Chemistry, 375(1), pp. 133–138. 
Xu, Y. and Du, Y. (2003) ‘Effect of molecular structure of chitosan on protein delivery 
properties of chitosan nanoparticles’, International Journal of Pharmaceutics, 250(1), pp. 
215–226.  
Yoon, H. Y. et al. (2014) ‘Glycol chitosan nanoparticles as specialized cancer therapeutic 
vehicles: Sequential delivery of doxorubicin and Bcl-2 siRNA’, Scientific Reports, 4, p. 6878.  
Zielinska, K., Shostenko,  a. G. and Truszkowski, S. (2014) ‘Analysis of chitosan by gel 
permeation chromatography’, High Energy Chemistry, 48(2), pp. 72–75.  
Zolgharnein, J., Shahmoradi, A. and Ghasemi, J. B. (2013) ‘Comparative study of Box–
Behnken, central composite, and Doehlert matrix for multivariate optimization of Pb (II) 
adsorption onto Robinia tree leaves’, Journal of Chemometrics, 27(1–2), pp. 12–20. 
 
 119 
4 FORMULATION AND 
CHARACTERISATION OF UNLOADED 
CHITOSAN NANOPARTICLES 
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4.1 Introduction 
Cs is a linear polysaccharide, prepared by N-deacetylation of chitin, the second most 
abundant biopolymer in nature (next to cellulose) (Prochazkova, Vårum and Ostgaard, 
1999). Cs holds a unique positive charge when dissolved in acid media (owing to the 
primary amines present on its backbone), is biocompatible, non-immunogenic, 
nontoxic and biodegradable, making it a choice component for oral drug delivery 
systems and attractive for biomedical applications (Agnihotri, Mallikarjuna and 
Aminabhavi, 2004; Bezerra et al., 2008; Saini et al., 2014). Cs nanoparticles (NPs) 
are emerging polymeric bioactive carriers that have received attention for nutrient 
delivery (Luo et al., 2010; Akhtar, Rizvi and Kar, 2012; Chen et al., 2013; Fathi, 
Martín and McClements, 2014; Sarvaiya and Agrawal, 2015).  
Specifically, Cs NPs can be made using a variety of techniques, such as complex 
coacervation (Diop et al., 2015), co-precipitation (Bhattarai et al., 2006), 
polyelectrolyte complexation (Kouchak and Azarpanah, 2015), solvent evaporation 
(Nagpal, Singh and Mishra, 2010), emulsification solvent diffusion (Fathi, Martín and 
McClements, 2014), micro-emulsion (El-Shabouri, 2002) and ionotropic gelation 
(IG) (Yan et al., 2012; Ramasamy et al., 2014; Wu et al., 2014). The latter has been 
considered more favourable for the stability of the cargo, owing to the ease with which 
the NPs can be produced under mild operating conditions (room temperature, low 
stirring rates) and mild solvents (dilute acids and bases) (Koppolu et al., 2014).  
This research work has used the IG technique for the preparation of Cs NPs, by 
ionically cross-linking Cs with a counter ion sodium tripolyphosphate (TPP) 
(Sureshkumar et al., 2010). IG is based on the interaction between the negatively 
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charged phosphate groups of TPP and the positively charged amino groups of Cs 
Figure 4.1. When the concentrations of the cationic polymer Cs and oppositely 
charged anionic polyelectrolytes are at appropriate pH values to induce sufficient 
protonation/ionisation charge, electrostatic crosslinking can occur resulting in the 
generation of NPs (Calvo et al., 1997).  
 
Figure 4.1 Schematic representation of cross-linking between Cs and TPP 
(adapted from Sureshkumar et al. (2010)).  
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There are several process variables known to affect the properties of Cs NPs produced 
via the IG technique, the most commonly studied being: 
1. The pKa of Cs itself and the target BA to be encapsulated (modulated through the 
formulation media pH) (Fonte et al., 2014) 
2. The mass ratio of Cs to its oppositely charged crosslinker/counter ion (Gupta and 
Karar, 2011) 
3. The stirring rate and stabilisation time the formulation is subjected to during the 
crosslinking process (Grenha, 2012) 
4. The DDA and MW of the Cs used (Aktaş et al., 2005) 
Research studies, regarding the encapsulation of bioactive nutrients within a Cs based 
NP delivery system, include the binding of curcumin (CUR) onto Cs NPs through 
passive diffusion, which produced a significant 3 fold reduction in the plasma 
concentration of Plasmodium yoelii infected mice, compared to the rapidly 
metabolised intact CUR drug (Akhtar, Rizvi and Kar, 2012). In another study, the oral 
administration of Cs insulin loaded Cs NPs formed via the complex coacervation 
method, was shown to be effective in lowering the blood glucose level of alloxan-
induced diabetic mice, showing promising effects as a potential insulin carrier system 
in animal models (Mukhopadhyay et al., 2013). In 2008, Kwon, showed successful 
systemic administration of the anticancer drug, paclitaxel, encapsulated in Cs NPs in 
SCC7 tumour-bearing mice, resulting in sensitive tumour-detection ability, ultimately 
leading to simultaneous early-stage cancer diagnosis, drug delivery, and therapy 
(Kwon, 2008). 
It is worth noting that the success of these NPs applicability strongly depends on the 
physicochemical properties of the produced NPs, such as particle size, ZP and PDI 
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(des Rieux et al., 2006). Despite the simplicity of IG, controlling the process for the 
reproducible, systematic, production and prediction of NP size, ZP and PDI is a 
difficult task, attributable to the large number of aforementioned variables that can 
affect the final product (Landriscina, 2015). Successful translation of NPs from bench 
to bedside, depends on overcoming obstacles in terms of scalability and 
reproducibility (Dong et al., 2013). Consequently, several attempts have been made 
to optimise this methods outcome, for example, the variations in Cs molecular weight, 
Cs concentration, Cs to TPP weight ratio and solution pH value have been investigated 
for their effects on NP size, ZP and PDI (Pan et al., 2002; Jonassen, Kjøniksen and 
Hiorth, 2012; Rampino et al., 2013; Kleine-Brueggeney et al., 2015). Often these 
studies employ a OFAT approach for NP process optimisation and, although useful in 
preliminary screening of factors and/or identification of the working ranges for these 
factors, limited knowledge of the process can be gained by this approach. In contrast, 
statistically designed experiments that vary several factors simultaneously are more 
efficient when studying two or more factors aiming for optimisation (Ferreira et al., 
2007). RSM is a collection of mathematical and statistical techniques for designing 
experiments, that: evaluates the relative significance of several independent variables 
and their interactions, allows for building of regression models and determines the 
optimum conditions for desirable responses, minimising the number of experiments 
(Anarjan et al., 2011; Xue et al., 2015). While OFAT experiments are more 
commonly adopted in the literature, designed experiments offer several advantages 
over the OFAT counterparts (Politis et al., 2017): 
• First, RSM reduces the number of experimental runs typically required to gather 
the same information as OFAT, thus reducing resource requirements.  
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• Second, RSM is useful in detecting interdependencies of variables that would not 
be typically identified during OFAT experiments  
• Third, RSM improves the prediction of a response through use of gathered 
information from a larger parameter space (Abdel-Hafez, Hathout and Sammour, 
2014). 
• Fourth, RSM provides an iterative approach to experimental design where the 
previous knowledge will contribute to the design specification of the next 
experiment. 
Recently, RSM experimental designs such as the Central composite and Box–
Behnken have been investigated for NP formulation optimisation (Hao et al., 2012; 
De Carvalho et al., 2013; Zolgharnein, Shahmoradi and Ghasemi, 2013). The CCD is 
a suitable approach to understand the effects of formulation variables (independent 
factors) and the interactions between factors on the responses (dependent factors). 
Commonly employed CCDs take factors at five levels (two-level factorial design 
points, axial or star points, and centre points), resulting in a fully rotatable design (Hao 
et al., 2012). 
In this work, the mass ratios of Cs:TPP ranging from 4:1-27.5:1 were selected for 
investigation, as these high and low levels were identified from previous preliminary 
studies as feasible ranges for Cs NP production (Khalid, 2014). Further investigation 
of these variables allowed for supplementary information on the characteristics of Cs 
NP formation and their dependency on the Cs and TPP interaction. Overlaid contour 
plots were used for optimisation purposes to produce NPs at a targeted diameter of 
200-300 nm. The formulated NPs were characterised by DLS, SEM and FTIR 
spectroscopy. 
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4.2 Materials and Methods 
 
4.2.1 Materials 
The Cs compound PROTASAN™ UP (CL113) was purchased from NovaMatrix, 
FMC Corporations, Norway. Sodium tripolyphosphate, technical grade, 85%, sodium 
acetate anhydrous, for molecular biology, ≥99%, acetic acid, ACS reagent, ≥99.7 were 
obtained from Sigma Aldrich, Ireland. Ultrapure water was obtained from a Milli-Q 
(Millipore Corporation, USA) water purification system and was used for all aqueous 
solution preparations throughout. 
4.2.2 Central composite design  
CCD (Bulmer, Margaritis and Xenocostas, 2012) was used to (i) determine the 
optimum concentration ratio of Cs to cross linker, TPP and (ii), produce NPs with the 
optimum physicochemical properties recommended for oral delivery (~300 nm 
particle size, PDI < 0.5 and ZP > 30 mV). DoE software (Minitab™ 17, Pennsylvania, 
USA) produced a two factor design with 5 levels. Centre points were replicated 5 
times in order to estimate the experimental error and curvature associated with the 
design. The formulation variables, concentration of CL113 (mg/mL) and 
concentration of TPP (mg/mL), in addition to their high and low levels were identified 
from previous preliminary studies (Khalid, 2014).  
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A second order polynomial model (Equation 4.1) was used to approximate the 
response surface: 
Ri = b0 + b1A + b2B + b11A2 + b22B2 + b12AB+ ε 
(Equation 4.1) 
where Ri is the measure of the response associated with each factor level combination, 
b0 is an intercept, b1…b22 are the regression coefficients, A and B are the independent 
variables, and A2, B2 and AB denote the quadratic terms and interactive term 
respectively and  the error term. The responses selected were size, PDI and ZP with 
the following criteria of minimise, minimise, and maximise adopted respectively. The 
translation of coded levels into the actual variables natural units of measurement 
(concentration (mg/mL) of CL113 and TPP) are denoted in Table 4.1. 
In this experiment, the desirability function was created to give equal weight to 
particle size, PDI and ZP, with EE% not included. 
Table 4.1 Variables and levels employed in the CCD design (α=1.414)  
Coded level -α -1 0 1 +α 
A: CL113 (mg/mL) 1.10 1.20 1.45 1.70 1.80 
B: TPP (mg/mL) 0.04 0.10 0.25 0.40 0.46 
4.2.3 Preparation of unloaded Cs:TPP NPs 
Cs solution (10 mg/mL) was prepared by adding 100 mg of CL113 to 10 mL of sodium 
acetate-acetic acid buffer (pH 3) and stirring at 700 rpm for 4 hrs. Once fully 
dissolved, the Cs solution was then filtered through a 0.22 μm syringe filter (Millex 
Millipore) and diluted to experimental requirements with pH 3 buffer. Cs:TPP NPs 
were then formed according to the ionotropic gelation process (Calvo et al., 1997) 
with slight modifications. Aqueous TPP solution (10 mg/mL) was prepared and 
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diluted with H2O to experimental requirements and subsequently added via burette 
droplet addition to the Cs solution. The NPs formed were then left to stabilise for a 
further 30 min whilst the stirring speed of the solution was maintained at 700 rpm. 
After stabilisation, NPs were then transferred to a 20 kDa MWCO (Vivaspin 20, 
Sartorius) centrifugal filter and isolated by centrifugation at 3000 rpm for 30 min. 
Filtered H2O (equivalent in volume to the recovered supernatant) was then added to 
the purified NPs and the suspension was subsequently sonicated at 35 % amplitude 
for 30 s with 5 s pulse intervals. Physicochemical properties of the NPs (size, PDI and 
ZP) were then determined using a Malvern Zetasizer NanoZS (Worcestershire, UK), 
under the conditions described in Chapter 3, Section 3.2.1.  
4.2.4 Fourier transform infrared spectroscopy (FTIR) 
FTIR spectra of CL113, TPP and Cs:TPP NPs were acquired via a Spotlight 400 series 
spectrometer (Perkin Elmer, USA), using the attenuated total reflectance spectroscopy 
method (ATR-FTIR), in the range of 650-4000 cm-1. Prior to analysis, NP samples 
were lyophilised using a FreeZone 6 L bench top freeze dry system (Labconco, USA) 
at -40 °C for 20 hrs. The dried solids were then placed on the ATR crystal prism 
(ZnSe), and 32 scans were acquired at 4 cm−1 resolution with background subtraction 
(Vongchan et al., 2011). 
4.2.5 Morphology assessment of formulated NPs- SEM 
SEM analysis was used to ascertain the morphology of the formed CS:TPP NPs, under 
conditions described in Chapter 3, Section 3.2.2. 
 128 
4.3 Results and Discussion 
 
4.3.1 CCD  
The observed values for all 13 experiments encompassed by the CCD are presented 
in Table 4.2. Minimum and maximum values obtained for particle size, PDI, and ZP 
were (194, 850 nm), (0.396, 0.799) and (24, 47.3 mV) respectively. 
Table 4.2 CCD design matrix and corresponding results for dependant va riables. 
Batch A:CL113 (mg/mL) B:TPP (mg/mL) 
Size 
(nm) 
PDI 
ZP 
(mV) 
1 1.10 0.25 233 0.500 34.0 
2 1.45 0.46 203 0.420 24.3 
3 1.45 0.25 186 0.412 52.5 
4 1.45 0.25 194 0.421 47.3 
5 1.45 0.25 194 0.406 44.1 
6 1.45 0.04 850 0.723 31.0 
7 1.80 0.25 274 0.396 38.5 
8 1.45 0.25 189 0.535 41.5 
9 1.20 0.40 199 0.430 24.0 
10 1.20 0.10 608 0.799 28.0 
11 1.70 0.10 661 0.543 29.0 
12 1.45 0.25 220 0.461 40.0 
13 1.70 0.40 233 0.411 27.0 
The significance of independent variables and their interactions was assessed by 
statistical software (Minitab™,17) to generate regression models. Through 
bidirectional elimination (testing at each step for variables to be included or excluded), 
non-significant terms were removed from the model in order to calculate regression 
equations with significant terms only (Wang et al., 2013). The calculated regression 
coefficients and standard errors for size, PDI and ZP of the reduced models are shown 
in Table 4.3, in which coefficients related to the independent variables with significant 
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t-values (p ≤0.05) were used. Higher significant effects of the independent variable 
on the response are indicated by a lower p-value. 
As discussed in Chapter 3 (Section 3.3), RSM allows for the construction of a 
mathematical model to identify the optimum level of each factor to produce a target 
response (Reddy et al., 2017). As such, the application of CCD to map the response 
(particle size (nm), PDI and ZP (mV)) over the experimental domain studied, was 
used to identify and tune an optimal formulation with desirable properties (des Rieux 
et al., 2006) for oral delivery and is explored in the following section. 
Regarding the size of the NPs, the model shows that two linear [concentration of 
CL113 (A) and TPP (B)] and two quadratic [(AA) (BB)], terms were significant (p< 
0.05). Size was mostly affected by the quadratic effects of the B*B term, whereby a 
positive correlation was observed such that, at minimum and upper levels of B, size 
increased. It is also worth noting that, the linear term of B showed a negative 
coefficient, indicating that B has a negative effect on size until a turning point is 
reached, after which the B*B term has a positive impact on size. This is in agreement 
with the contour plot (Figure 4.2, B) and findings by Calvo et al. (1997), which 
showed that intermediate concentrations (ratio of Cs:TPP of 5:1) of TPP gave rise to 
smaller NPs compared to lower and higher concentrations. Additionally, they found 
that formation of NPs was only possible at specific concentrations of Cs and TPP, 
with a maximum concentration of 3 mg/mL and 0.75 mg/mL respectively (Calvo et 
al., 1997). 
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Table 4.3 The normalised estimated regression coefficients and standard errors, for 
size, PDI and ZP of the reduced models. All parameters statistically significant 
(p<0.05). 
As PDI reflects the NP size distribution (whereby samples with a wider range of 
particle sizes have higher PDI values and vice versa), it is highly desirable that NP 
formulations consist of monodisperse populations, to ensure that the system can 
deliver its cargo over a sustained period of time (Nagpal, Singh and Mishra, 2010). 
Table 4.3 shows that PDI was mostly affected by the linear effect of B (TPP 
concentration mg/mL), i.e. PDI decreases as B increases one unit from median levels. 
Estimated regression Coefficients for size (nm) 
Term Coef SE Coef 
Constant 196.83 9.79 
A: CL113 mg/mL 25.4 10.9 
B: TPP mg/mL -307.9 10.9 
A2: CL113 
mg/mL*CL113 mg/ml 
72.6 16.5 
B2: TPP mg/mL*TPP 
mg/mL 
345.6 16.5 
Model summary R2 = 99.36 % 𝑹𝒂𝒅𝒋
𝟐 =99.04 % 
Estimated regression Coefficients for PDI 
Term Coef SE Coef 
Constant 0.4532 0.0167 
A: CL113 mg/mL -0.0743 0.0230 
B: TPP mg/mL -0.1635 0.0230 
B2: TPP mg/mL*TPP 
mg/mL 
0.1399 0.0345 
A*B: CL113 
mg/mL*TPP mg/mL 
0.1161 0.0452 
Model summary R2 = 91.32 % 𝑹𝒂𝒅𝒋
𝟐 = 86.98 % 
Estimated regression Coefficients for ZP (mV) 
Term Coef SE Coef 
Constant 45.10 1.91 
A:CL113 mg/mL 1.82 2.13 
B:TPP mg/mL -2.72 2.13 
A2: CL113 
mg/mL*CL113 mg/ml 
-11.22 3.22 
B2: TPP mg/mL*TPP 
mg/mL 
-19.77 3.22 
Model summary R2 = 85.62 % 𝑹𝒂𝒅𝒋
𝟐 = 78.44 % 
 131 
Consequently, the quadratic terms of B*B showed a positive correlation, signifying 
that PDI increases at upper and lower levels of B. This agrees with the contour plot 
(Figure 4.2, C). This finding supports the work of other authors that observed the free 
primary amino groups of Cs decreasing upon the addition of TPP, indicating the 
formation of monodisperse Cs:TPP via anionic and cation linkages of both 
polyelectrolytes (Masarudin et al., 2015). 
In terms of ZP, the two quadratic terms [(A*A), (B*B)] were found to have a negative 
effect on ZP, whereas the linear terms were shown to have a positive effect on ZP. 
Table 4.3 shows the quadratic effect of TPP on the highest effect on ZP, indicating 
that, at concentrations above and below median levels, a decrease in ZP is observed. 
The positive correlation observed for the linear term of B indicates that, at one unit 
above median level, ZP is increased signifying curvature in the model and a maximum 
value for ZP can be achieved at this level. Figure 4.2A indicates that the optimum 
value (maximum) for ZP can be found within the range of variables studied: ≈ 1.5 
mg/mL Cs to 0.25 mg/mL TPP (Ratio 6:1). This is in agreement with other authors’ 
findings, as several studies investigating the optimum ratio of Cs to TPP have 
indicated that a ratios of 4:1 – 8:1 give rise to the most stable NP complexes (Pan et 
al., 2002; Kouchak and Azarpanah, 2015), attributable to sufficient quantities of TPP 
that allow for the formation of crosslinked NPs, yet are not in an excess of that which 
would result in complete neutralisation of the cationic charge on the free primary free 
amines of Cs (Huang, Cai and Lapitsky, 2015)
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Figure 4.2 Contour plots for Zeta potential (mV) (A), PDI (B), and size (nm) (C) vs TPP (mg/mL), CL113 (mg/mL)  
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4.3.2 Optimisation of CL113 and TPP concentrations for Cs:TPP NP 
formation 
Overlaid contour plots for the fitted polynomials predicting the change of PDI, ZP and 
particle size with Cs and TPP concentration were employed in order to identify optimum 
conditions for the formulation, whereby NPs with sizes between 200-300 nm, PDI <0.5 
and ZP >30 mV could be produced. Figure 4.3 details the results and shows that 
increasing concentrations of Cs ≈ 1.68-1.8 mg/mL and intermediate TPP concentrations 
≈ 0.20-0.37 mg/mL give rise to a region in which NP target properties can be achieved. 
Figure 4.3 Overlapped contour plots for the fitted polynomials predicting the change 
of PDI, Zeta potential and particle size with Cs and TPP concentration. The feasible 
zone with PDI< 0.5, Zeta< 30 (mV) and Size> 200 (nm) is indicated in white.  
By employing the constructed models from the CCD evaluation, response optimisation 
could be used to establish an optimum NP formulation. In this approach, the value of each 
response for a given combination of controllable factors is first translated to a number 
between zero and one, known as individual desirability (Bezerra et al., 2008). An optimal 
minimum (size (nm)), minimum (PDI) and maximum (ZP (mV)) forecast has been 
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obtained with the present models and is presented in Figure 4.4, indicating that when the 
variable settings of CL113 mg/mL and TPP mg/mL are set at ratio ≈ 6:1 (1.53 mg/mL 
and 0.27 mg/mL respectively), NPs with the desired properties are produced. The 95% 
confidence interval ranges that these conditions would produce are presented in Table 
4.4. This is in agreement with previous authors’ findings (Janes, Calvo and Alonso, 2001; 
Antoniou et al., 2015). 
 
Figure 4.4 Desirability profiles for the optimisation problem, maximising the Zeta 
potential and minimising particle size and PDI of the particles.  
To verify the validity of the proposed models, n = 4 replicates of the optimised 
formulation was prepared, and each experimental response was compared with the 
predicted one. Table 4.4 shows the validation results of the model, whereby NPs 
presented sizes of 161.3 ± 43 nm, PDI of 0.391 ± 0.022, ZP of 41.5 ± 3.1. No statistically 
significant values (p>0.05) for predicted and measured responses (Size, PDI and ZP) were 
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observed, indicating that the models fit the data satisfactorily. Lastly, by employing a 
CCD, many additional experiments (in addition to time consuming laborious laboratory 
studies) were eliminated in comparison to a OFAT approach. 
Table 4.4 95% confidence intervals of the particle characteristics that optimal 
conditions would produce under the present experimental conditions of uncertainty . 
Response Fit SE fit 95% CI 
Size 181.5 9.6 (159.4, 236.6) 
PDI 0.4247 0.0175 (0.3843, 0.4651) 
ZP 44.5 1.9 (40.2,48.8) 
4.3.3 Characterisation of unloaded Cs:TPP NPs - FTIR 
Figure 4.5 shows the FTIR spectra of (A) TPP, (B) Cs and (C) Cs:TPP NPs and the 
characteristic peaks associated with TPP and Cs are presented in Table 4.5.
 
Figure 4.5 FTIR spectra of (A) TPP, (B) Cs and (C) Cs:TPP NPs. N=3. 
By observing the intermolecular interaction of Cs:TPP NPs via FTIR (Figure 4.5, C), it 
can be seen that the spectrum is different to that of the Cs matrix. If interaction between 
the Cs and TPP has occurred, it will lead to frequency shifts or splitting in absorption 
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peaks (Gan et al., 2005). For example, the peaks at 1514 cm-1 in the Cs spectrum have 
been shifted to 1529 cm-1, indicating electrostatic interaction between the phosphate 
groups of TPP and the amino groups present in the Cs NP matrix (Papadimitriou et al., 
2008). Additionally, the broadening and the reduced absorbance of the peak at 3272 cm-
1 indicate hydrogen bonding has been enhanced (Luo et al., 2010). The crosslinked Cs 
also showed a peak for P = O at 1155 cm–1. 
Table 4.5 FTIR analysis of characteristic peaks associated with TPP and Cs . 
TPP 
Bond 
Wavelength 
(cm-1) 
Reference 
P=O 1121, 886 (Bhumkar and Pokharkar, 2006) 
Chitosan 
Bond 
Wavelength 
(cm-1) 
Reference 
NH Stretch / OH in pyranose ring 3240 
(Luo et al., 2010; Mohammed, 
Williams and Tverezovskaya, 
2013) 
CH2 in CH2OH group 2879 
C=O in NHCOCH3 group (amide I) 1625 
NH2 in NHCOCH3 group (amide II) 1514 
CH3 in NHCOCH3 group 1376 
C-O-C (glycosidic linkage) 1063 
  
 139 
4.3.4 Scanning electron microscopy (SEM) 
Figure 4.6 shows the SEM image of unloaded Cs:TPP NPs. Spherical, monodisperse 
particles were observed and the particle size of the NPs after spin coating was in good 
agreement with the DLS measurements taken on the freshly prepared NPs. 
 
Figure 4.6 SEM image of unloaded Cs:TPP NPs.  
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4.4 Conclusion 
In this work, Cs:TPP NPs have been produced via ionotropic gelation. As one of the most 
influential variables that dominates the size, PDI, ZP and morphology of ionotropic 
formed Cs NPs has been established to be Cs:TPP mass ratios (Almalik et al., 2013), a 
CCD statistical design was employed to generate a mathematical model that identified 
the optimum ratio of Cs:TPP for NPs with properties reported to be beneficial for oral 
drug delivery (des Rieux et al., 2006). The results of the CCD design identified that, at 
approximate concentrations of Cs (1.68 - 1.8 mg/mL) and intermediate concentrations of 
TPP (0.20 - 0.37 mg/mL), a feasible region was produced in which NP target properties 
could be achieved. The physicochemical properties of the NPs produced from the 
validation of the CCD study were assessed by DLS, showing that, under optimum 
conditions of Cs:TPP (6:1), NPs with sizes of 161 ± 43 nm, PDI of 0.39 ± 0.02, ZP of 42 
± 3 could be produced. Evidence for the formation of NPs via ionotropic gelation was 
acquired via FTIR analysis, through identification of key functional groups on Cs and 
TPP and identifying their shifts in the crosslinked matrices. The morphology of the NPs 
was then assessed by SEM analysis, showing that spheroidal, well distributed particles 
were formed. The findings provide an overview to produce Cs NPs with desirable 
physicochemical properties for successful use in drug delivery. 
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5  APPLICATION OF BOX-BEHNKEN 
EXPERIMENTAL DESIGN FOR THE 
FORMULATION AND OPTIMISATION OF 
SELENOMETHIONINE-LOADED 
CHITOSAN NANOPARTICLES COATED 
WITH ZEIN FOR ORAL DELIVERY 
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Abstract 
Selenomethionine is an essential amino acid with a narrow therapeutic index and 
susceptibility to oxidation. Here it was encapsulated into a nanoparticle composed of 
chitosan cross-linked with tripolyphosphate for oral delivery. The formulation was 
optimised using a three-factor Box-Behnken experimental design. The 
chitosan:tripolyphosphate ratio, chitosan solvent pH, and drug load concentration 
were independently varied. The dependent variables studied were encapsulation 
efficiency, particle size, polydispersity index (PDI) and zeta potential (ZP). For 
optimisation, encapsulation efficiency and zeta potential were maximised, particle 
diameter was set to 300 nm and PDI was minimised. A 0.15mg/mL concentration of 
selenomethionine, chitosan solvent pH of 3, and chitosan:tripolyphosphate ratio of 6:1 
yielded optimum nanoparticles of size 187±58nm, PDI 0.24±0.01, ZP 36±6mV, and 
encapsulation efficiency of 39±3%. Encapsulation efficiency was doubled to 80±1.5% 
by varying pH of the ionotropic solution components and by subsequent coating of 
the NPs with zein, increasing NP diameter to 377±47nm, whilst retaining PDI and ZP 
values. Selenomethionine-entrapped nanoparticles were not cytotoxic to intestinal and 
liver cell lines. Accelerated thermal stability studies indicated good stability of the 
nanoparticles under normal storage conditions. In simulated gastrointestinal and 
intestinal fluid conditions, 60% cumulative release was obtained over 6 hours. 
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Abbreviations 
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5.1 Introduction 
Selenium is an essential micronutrient in human and animal nutrition (Rayman, 2000), 
that exists in a wide array of different formats, both organic and inorganic, better 
known as speciation. Selenomethionine (SeMet), the selenium analogue of 
methionine, is the predominant form of organic Se found in foods from the Brassica 
and Allium families (Reilly et al., 2014). SeMet is used for oral supplementation due 
to its capacity to be non-specifically incorporated into body proteins in place of 
methionine (Rayman, Infante and Sargent, 2008). The potential health benefits of 
selenium are dependent on its chemical species, and several studies have suggested a 
possible role in cancer prevention (Nie et al., 2016), increased immunological status 
(Narayan et al., 2015) and increased fertility (Shanmugam et al., 2015). SeMet may 
also to have a number of benefits regarding oncology treatments due to its modulation 
of the therapeutic efficacy and selectivity of anticancer drugs (Evans, Khairuddin and 
Jameson, 2017), capacity to provide protection of normal tissues from the toxicities 
associated with chemotherapy and radiation treatments, in addition to enhancing their 
anti-tumour effects (Chintala et al., 2012; Mix et al., 2015; Panchuk et al., 2016). It 
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may also have some potential in degenerative disease by decreasing oxidative stress 
of small molecule antioxidants used as a buffer for free radicals in brain tissue (Song 
et al., 2014; Reddy et al., 2017). However, the oral delivery of SeMet can be 
challenging due to the distinctive electronegativity and atomic radius of the selenium 
atom (i.e. larger radius and lower electronegativity than sulphur,) that makes it easier 
for low valence state Se compounds to be more readily oxidised compared to their 
sulphur counter parts (Xu, Cao and Zhang, 2013). SeMet is readily oxidised (Davies, 
2016) and, even though it is less toxic than inorganic selenium (Se), it still has a low 
therapeutic index (Takahashi, Suzuki and Ogra, 2017). Oral delivery formulations of 
SeMet therefore need to consider the balance between doses that exert beneficial 
effects and those which may potentially be toxic. 
Inorganic Se species such as selenite (SeO3
2-) and elemental selenium (Se0), together 
with methylseleninic acid, have been formulated to nano-enabled delivery systems 
which exhibited improved bioactivity with reduced cytotoxicity in vitro (Zhang, 
Wang and Xu, 2008; Forootanfar et al., 2014; Loeschner et al., 2014). Nanoparticles 
(NPs) can be more biologically active due to their enhanced surface area per mass 
compared with larger-sized particles of the same chemistry (Oberdörster et al., 2005). 
By using NPs as a drug delivery vehicle, it might be possible to enhance a range of 
characteristics for a given bioactive, including increased protection and stability (Nair 
et al., 2010) and suitability to increase bioavailability by non-parenteral routes of 
administration including oral, pulmonary and topical applications (Helson, 2013). 
The natural polymer chitosan (Cs) is a mucopolysaccharide, closely related to 
cellulose and obtained by deacetylation of the compound chitin, predominantly found 
in the exoskeletons of crustaceans (Nagpal, Singh and Mishra, 2010). Cs has been 
used for the development and formulation of nanoparticles by ionotropic gelation due 
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to its physicochemical and biological beneficial properties (H. Zhang et al., 2015; 
Mohammed et al., 2017). Benefits include improved adherence to mucosal surfaces, 
increased drug residence time (Ryan et al., 2012), and protection of the bioactive drug 
from intestinal proteases (Ryan et al., 2013; Amaro et al., 2015). In acidic medium, 
Cs can be dissolved, due to protonation of the amine residues present in the polymer 
backbone. Ionotropic gelation allows for the formation of NPs from Cs via 
crosslinking with oppositely-charged electrolytes under mild conditions in which 
amino acids and peptides will remain reasonably stable (Janes, Calvo and Alonso, 
2001; Wang et al., 2011; Chen et al., 2013). 
Zein a GRAS approved prolamine-rich protein derived from maize, has been used in 
the formulation and coating of peptide oral delivery systems (Y. Zhang et al., 2015), 
to increase encapsulation efficiency (Luo and Wang, 2014) and improve the control 
of gastric release of labile bioactives (Luo et al., 2010; Paliwal and Palakurthi, 2014). 
By exploiting the physical interactions between protein and polysaccharide (in this 
instance zein and Cs), it is possible to improve and broaden the physical and chemical 
stability properties of the NP delivery systems (Benshitrit et al., 2012). However, the 
formulation, characterisation and development of these multi-component systems can 
be more challenging than single component systems and as such, it is important to 
comprehensively optimise the formulation process. To the best of our knowledge, 
there are currently no reports which describe the formulation of biological Se species 
such as SeMet into a NP delivery system. The potential optimisation of this 
formulation could be significant, given that SeMet more effectively increases human 
and animal selenium levels and is less toxic than inorganic Se (Garousi, 2015). 
In situations where several variables may influence system properties, a useful 
technique to identify the relationships between a given response and independent 
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variables (or factors) and optimise the system, is Response Surface Methodology 
(RSM) (Anderson and Whitcomb, 2005). RSM is a more efficient approach to 
experimentation than one factor at a time (OFAT) experiments since it: 1) reduces the 
number of experimental runs typically required to gather the same information as 
OFAT, thus reducing resource requirements, 2) is useful in detecting 
interdependencies of variables that would not be typically identified during OFAT 
experiments and 3) improves the prediction of a response through use of gathered 
information from a larger parameter space. The Box-Behnken design (BBD) is an 
RSM for process optimisation with an independent quadratic design where factor 
combinations are considered at 3 levels: the midpoints of edges of the process space 
and the centre (Traynor et al., 2013; Zolgharnein, Shahmoradi and Ghasemi, 2013). 
After polynomial models for each of the different responses in a study have been 
completed, a desirability function may be constructed in order to estimate minima or 
maxima, provided such optima are within the design space (Bezerra et al., 2008). 
In this study, SeMet was formulated into nanoparticles consisting of Cs and zein using 
ionotropic gelation. After evaluating the main variables which affect encapsulation 
efficiency, particle size and drug loading, a systematic approach (RSM) was used to 
optimise the formulation of nanoparticles suitable for oral delivery. A three-level, 
three-factor BBD was utilised to build polynomial models for the three responses and 
a desirability function was then constructed to optimise the system. Optimised SeMet 
NPs were prepared based on the predicted optimum levels of the independent 
variables of the factorial design. To ensure stability of the optimised formulation after 
lyophilisation, a cryoprotectant (trehalose) was also included (Danish et al., 2017a). 
The physicochemical properties, storage stability, cytotoxicity, and the release profile 
in a simulated intestinal buffer were assessed.   
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5.2 Materials and Methods  
 
5.2.1 Materials 
The chitosan PROTASAN™ UP (CL113) was purchased from NovaMatrix, FMC 
Corporations, Norway. DL-selenomethionine, D(+)-Trehalose dihydrate, and zein, of 
≥99% purity, were obtained from ACROS Organics™, Fisher Scientific, Ireland. 
Ultra-pure water 18mΩcm-1 was obtained from a Millipore simplicity 185 model 
instrument, UK, and was used for all aqueous solution preparations throughout. All 
other reagents, chemicals and solvents were of analytical grade from Sigma Aldrich, 
Ireland. 
5.2.2 Optimisation of nanoparticle formulation physicochemical 
properties 
A BBD was used to optimise the formulation and EE% of SeMet into the nanoparticle. 
Selected physicochemical properties for oral delivery for the NPs were particle size 
~300 nm, PDI < 0.5 and ZP > 30 mV (des Rieux et al., 2006). A three level, three 
factor BBD (Zhao et al., 2013; Maleki Dizaj et al., 2015) of 15 random order 
experiments was designed using Minitab™ 17 (Pennsylvania, USA). The 3 
independent variables were, (X1) the pH of the Cs solvent - the isoelectric point (pI) 
of SeMet, (pH-pI) (X2), the load concentration of SeMet and (X3) the ratio of Cs:TPP, 
while (Y1) Particle size, (Y2) PDI, (Y3) ZP and (Y4) EE% were the dependent 
variables. The variable ranges (Table 5.1) were based on an exploratory study. 
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Each dependant variable was independently assessed by linear regression using a 2nd 
degree polynomial model with 1st order interactions (Equation 5.1). 
Yi = b0 + b1X1 + b2X2 + b3X3 + b12X1X2 + b13X1X3 + b23X2X3 + b11X1
2 + b22X2
2
 + 
b33X3
2+ε 
(Equation 5.1) 
where Yi is the measure of the response associated with each factor level combination, 
b0 is an intercept, b1-b33 are the regression coefficients, X1-X3 are the coded 
independent variables and the XiXj and Xi
2 (i,j = 1, 2, 3) denote the interactive and 
quadratic terms, respectively. The linear regression and the significance (p<0.05) test 
of independent variables and their interactions was assessed by statistical software 
(Minitab™,17) to generate regression models. Through bidirectional elimination 
(testing at each step for variables to be included or excluded), non-significant terms 
were removed from the model in order to calculate regression equations with 
significant terms only (Wang et al., 2013). Desirability functions to optimise all 
responses were built the weighted geometric mean of individual desirabilities 
presented in Table 5.1. 
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Table 5.1 Variables and levels employed in the BBD with desirability function for 
optimisation of nanoparticle formulation.  
Factor (Independent variables) 
Levels used, (Actual 
coded) 
X1 = pH of the Cs solvent – the pI of SeMet (pH- 
pI) 
0.5 1.5 2.5 
X2 = SeMet concentration (mg/mL) 0.05 0.15 0.25 
X3 = ratio of Cs:TPP 4:1 6:1 8:1 
Dependent Variables Composite desirability 
Y1= Size (nm) Target of 300nm 
Y2 = PDI Minimise 
Y3 = ZP (mV) Maximise 
Y4 = Encapsulation efficiency (EE%) Maximise 
Response surface plots, statistical testing of the linear models and identification of 
optimum formulations via feasibility and grid searches was performed to study the 
optimal area (Barrentine, 1999). Finally, repetitions (N=4) of the optimal point found 
were conducted experimentally to validate the study. 
5.2.3 Preparation of SeMet loaded Cs:TPP nanoparticles  
SeMet-entrapped NPs were produced using a modified ionic gelation method (Calvo 
et al., 1997). Briefly, Cs was dissolved in buffered pH medium (3, 4 or 5 pH) at a 
concentration of 3 mg/mL and filtered through a 0.22 μm syringe filter (Millex 
Millipore, UK) to remove undissolved Cs. A known amount of SeMet was then added 
to the Cs solution prior to crosslinking to obtain a final load concentration 0.05, 0.150 
or 0.250 mg/mL. TPP was added dropwise to the solution under stirring at 700 rpm 
and room temperature to yield final mass ratios of Cs:TPP NPs of 4:1, 6:1 or 8:1. All 
of these experimental parameters (pH, concentrations and ratios) were prepared 
according to the BBD design. The NP suspension was stirred at 700 rpm for 30 min 
at room temperature for further crosslinking. After stabilisation, NPs were then 
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transferred to a 30 kDa molecular weight cut off (Vivaspin 20, Sartorius) centrifugal 
filter and isolated by centrifugation at 3000 rpm for 30 min. Filtered H2O (equivalent 
in volume to the recovered supernatant) was then added to the isolated NPs and 
sonicated at 35 % amplitude for 30 s with 5 s pulse intervals. Physicochemical 
properties of the NPs were then determined as per Section 2.4, using a Malvern 
Zetasizer NanoZS (Worcestershire, UK) and the supernatant was retained for EE% 
determination as outlined in Section 2.7. The optimised formulation has a mass ratio 
6:1 (Cs:TPP), Cs media (pH 5), and a final SeMet load concentration of 0.15 mg/mL.  
5.2.4 Increase of Ionisation/Protonation states to increase EE% - 
Formulation I 
After optimising the general physicochemical properties via BBD (Section 2.2), the 
ionic gelation component preparation procedure was modified with the aim of 
increasing the EE%. Formulation I was produced as described in Section 2.3 with one 
exception: SeMet and TPP were dissolved and diluted with NaOH (0.01 M) prior to 
crosslinking. The rationale for the pH adjustment was to induce higher electrostatic 
interactions (i.e. maximise the cationic component of Cs and the anionic component 
of SeMet) between SeMet and Cs during the crosslinking process. 
5.2.5 Coating NPs with zein to increase EE% 
NPs were prepared as per formulation I (ratio 6:1 (Cs:TPP), Cs media (pH 3), 
TPP/SeMet NaOH solution (pH 11) and a final load concentration of 0.15 mg/mL), 
with the following modifications: after the NPs had stabilised, 8 mL of absolute EtOH 
were added dropwise to the formulation whilst the stirring speed of the solution was 
maintained at 700 rpm for 30 min at room temperature. Zein (10 mg/mL dissolved in 
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80 % EtOH and filtered) was added dropwise to yield zein:Cs mass ratios of 0.5:1, 
1:1 and 2:1, stabilised at 700 rpm for 30 min and isolated as per Section 2.3. The NP 
formulations were then concentrated under vacuum (175 mbar) at 40 °C until EtOH 
was completely removed. To ensure stability of the optimised formulation after 
lyophilisation, 10 mL of the cryoprotectant trehalose 5 % w/v in H2O was added to 
each formulation and lyophilised for 36 hr (Danish et al., 2017a).  
5.2.6 Particle size, PDI and surface charge 
Freshly prepared NP solutions were used for physicochemical analysis (Luo et al., 
2010). The mean particle size and PDI of the NP formulations were determined by 
dynamic light scattering (DLS). The ZP values were measured with the use of laser 
doppler velocimetry (LDV). Both DLS and LDV analysis were performed in triplicate 
at 25 °C with a Zetasizer Nano series Nano-ZS ZEN3600 fitted with a 633 nm laser 
(Malvern Instruments Ltd., UK), using a folded capillary cuvette (Folded capillary 
cell-DTS1060, Malvern, UK). The values presented herein were acquired from three 
separate experiments, each of which included three replicates; N=3. 
5.2.7 Scanning electron microscopy (SEM) 
NP morphology was evaluated by scanning electron microscopy (SEM) (Hitachi, 
SU6600 FESEM, USA), at an accelerating voltage of 20 kV, unless otherwise stated, 
using the secondary electron detector. The fresh NP solutions were then spin coated 
onto Si wafers, dried at room temperature and then sputter coated with 4 nm Au/Pd 
prior to imaging (Mukhopadhyay et al., 2013). 
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5.2.8 Fourier transform infrared spectroscopy (FTIR) 
FTIR spectra of CL113, TPP, Cs:TPP NPs, SeMet and SeMet loaded Cs:TPP NPs 
were acquired via a Spotlight 400 series spectrometer (Perkin Elmer, USA), using the 
attenuated total reflectance spectroscopy method (ATR-FTIR), in the range of 650-
4000 cm-1. Prior to analysis, NP samples were lyophilised using a FreeZone 6 L bench 
top freeze dry system (Labconco, USA) at -40 °C for 20 hr. The dried solids were then 
placed on the ATR crystal prism (ZnSe), and 32 scans were acquired at 4 cm−1 
resolution with background subtraction (Vongchan et al., 2011). 
5.2.9 Encapsulation efficiency of SeMet in Cs:TPP nanoparticles 
The EE% of SeMet in the NPs was determined by the separation and quantification 
of SeMet left in the supernatant. This was performed by ultracentrifugation at 3000 
rpm, 4 °C for 30 min. SeMet in the supernatant was quantified by reverse phase high 
performance liquid chromatography (RP-HPLC), as previously described (Ward, 
Connolly and Murphy, 2012) with the following modifications. Samples were 
analysed with a Waters 2998 HPLC and Photodiode Array Detector, (Waters, USA), 
using a Poroshell 120, EC-C8 column, 3.0 x 100 mm, 2.7 μm, (Agilent Technologies, 
UK). Isocratic elution was carried out at a flow rate of 0.4 mL/min, column 
temperature 45.0 ± 5.0 °C with a mobile phase of water/methanol/trifluoroacetic acid 
(97.9:2.0:0.1). Samples were monitored according to their UV absorbance at 218 nm. 
The encapsulation efficiency was calculated by Equation 5.2 (Xu and Du, 2003): 
𝑬𝑬% =
𝑻𝒐𝒕𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑺𝒆 𝑴𝒆𝒕 − 𝑭𝒓𝒆𝒆 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑺𝒆𝑴𝒆𝒕
𝑻𝒐𝒕𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑺𝒆𝑴𝒆𝒕
 𝑿 𝟏𝟎𝟎 
(Equation 5.2) 
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5.2.10 MTS assay 
The potential cytotoxicity of pure SeMet, SeMet loaded NPs and unloaded NPs 
(coated with zein) were examined on Caco-2 human epithelial cells, and HepG2 
human liver hepatocellular cells. Both cell lines are routinely employed to assess the 
potential toxicity of orally delivered compounds (Gleeson et al., 2015; Brayden et al., 
2015). Caco-2 and HepG2 cells, were seeded at a density of 2 x 104 cells/well and 
cultured on 96 well plates in Dulbecco's Modified Eagle Medium (DMEM) and 
Eagle's Minimum Essential Medium (EMEM) respectively, supplemented with 10 % 
foetal bovine serum, 1 % L-glutamine, 1 % penicillin-streptomycin and 1 % non-
essential amino acids at 37 °C in a humidified incubator with 5 % CO2 and 95 % O2. 
Time points were selected with the intention to mimic in vivo conditions for each cell 
type. As the maximum time NPs will be exposed to the intestine, a 4 hr exposure time 
was used in Caco-2 cell lines (Neves et al., 2016), to mimic the liver, a 72-h exposure 
time was used for HepG2 cell lines (Brayden, Gleeson and Walsh, 2014). Triton X-
100™ (0.05%) was used as a positive control. The concentrations of the test 
compounds applied were 25, 50 and 100 uM. After exposure, treatments were 
removed and replaced with MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium). Optical density (OD) 
was measured at 490 nm using a microplate reader (TECAN GENios, Grodig, 
Austria). Each value presented was normalised against untreated control and 
calculated from three separate experiments, each of which included six replicates. 
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5.2.11 Accelerated stability analysis 
NPs were suspended at a concentration of 0.1 mg/mL, in aqueous KCl solution (10 
mM) and stored at accelerated conditions: 60 °C for 720 min, 70 °C for 300 min and 
80 °C for 120 min (Danish et al., 2017b). The particle size, PDI and zeta potential 
were measured using the Nanosizer ZS (Malvern Instruments Ltd, UK) over time 
intervals to determine the degree of degradation. The generated data was then 
analysed via R software (R Core Team, 2016). The temperature dependence of the 
kinetic parameters of SeMet-loaded NPs stability was measured by calculating the 
observed rate constants. This was plotted in an Arrhenius representation and apparent 
activation energy, Ea and reaction rate constant, kref were calculated according to 
Equation 5.3: 
𝑷 = 𝑷𝒐 + 𝒆
𝒍𝒏 (𝒌)−
𝑬𝒂
𝑹 (
𝟏
𝑻−
𝟏
𝑻𝒓𝒆𝒇
)
𝒕 
(Equation 5.3) 
where P is the property (particle size, PDI or ZP) at time t, Po is the initial property 
conditions, k is the apparent zero order reaction constant, Ea is the energy of 
activation, R is the universal gas constant, T is the temperature of the experiment in 
Kelvin (K) and Tref is the reference temperature (343 K). 
5.2.12 In vitro controlled release studies 
SeMet release from the NPs was carried out using a dialysis bag diffusion technique 
(Hosseinzadeh et al., 2012) over 6 hr (Calderon L. et al., 2013; Yoon et al., 2014). 
Freeze dried SeMet loaded NPs were suspended in 5 mL H2O and sonicated at 35 % 
amplitude for 30 s with 5 s intervals and placed into a Float-A-Lyzer®G2 dialysis 
membrane with a pore size of 25 kDa (Spectrum Laboratories, USA). The sample was 
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placed into 40 mL of simulated gastric fluid (SGF) or simulated intestinal fluid (SIF) 
specified according to the British Pharmacopoeia (Pharmacopoeia, 2016). SGF was 
composed of 0.1 M HCL and SIF was composed of 1 volume of 0.2 M trisodium 
phosphate dodecahydrate and 3 volumes of 0.1 M HCL (adjusted to pH 6.8), without 
enzymes (British Pharmacopoeia Commission, 2016). Samples were placed in a 
thermostatic shaker at 37 ºC and agitated at 100 rpm. At predetermined time points, 1 
mL of release fluid was analysed and replaced with simulated fluid to maintain sink 
conditions. 
SeMet release was measured by RP-HPLC (Section 5.2.9). Equation 5.4 was used to 
determine the % drug release: 
𝑫𝒓𝒖𝒈𝒓𝒆𝒍 % =
𝑪(𝒕)
𝑪(𝒍)
∗ 𝟏𝟎𝟎 
(Equation 5.4) 
where 𝐷𝑟𝑢𝑔𝑟𝑒𝑙 is the percentage of SeMet released, C(l) represents the concentration 
of drug loaded and C(t) represents the amount of drug released at time t, respectively. 
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5.3 Results and Discussion 
 
5.3.1 Response Surface Modelling – Box Behnken design 
The observed values for all 15 experiments described by the BBD yielded minimum 
and maximum values for Size (Y1) (152, 318 nm), PDI (Y2) (0.218, 0.554), ZP (Y3) 
(26.0, 42.7 mV) and EE% (Y4) of, (24.7, 41.4 %). The reduced models resulting from 
the analysis are presented in Table 5.2. Response Y1 showed no significant terms in 
the model, suggesting that there was no evidence in the sample population that could 
prove the association of the independent variables with particle size. This finding is 
unsurprising, as the NPs produced in this study fell within a narrow target region (152, 
318 nm) and the regions of interest chosen in this study (e.g. Cs:TPP 4:1-8:1, pH 3-
5), to produce the Cs NPs, have been well established for yielding particle sizes within 
100-400 nm range (Hassani et al., 2015; Sipoli et al., 2015; Mohammed et al., 2017). 
Responses Y2-Y4 (PDI, ZP and EE% respectively) all showed a curvature with regards 
to X1-X3, as quadratic or interactive effects of some independent variables were 
statistically significant in all the models. 
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Table 5.2 Normalised variable estimated coefficients (Coef) with associated 
standard error (SE Coef.) and unnormalised reduced regression equations for Y 2-Y4. 
Y2 (PDI) Y3 (ZP) Y4 (EE%) 
Term Coef 
SE 
Coef 
Term Coef 
SE 
Coef 
Term Coef 
SE 
Coef 
Constant 0.3083 0.0063 Constant 35.534 0.293 Constant 31.731 0.814 
X1 (pH-pI) 0.0515 0.0039 X1 (pH-pI) 6.405 0.300 X1 (pH-pI) 6.113 0.599 
X2 (SeMet 
(mg/mL)) 
0.0084 0.0039 
X2 (SeMet 
(mg/mL)) 
- - 
X2 (SeMet 
(mg/mL)) 
- - 
X3 (Ratio 
of Cs:TPP) 
0.0521 0.0039 
X3 (Ratio 
of Cs:TPP) 
1.245 0.300 
X3 (Ratio 
of Cs:TPP) 
0.487 0.599 
X1*X1 -0.0613 0.0057 X1*X1 - - X1*X1 3.821 0.879 
X2*X2 0.1040 0.0057 X2*X2 - - X2*X2 - - 
X3*X3 0.0645 0.0057 X3*X3 -2.626 0.419 X3*X3 -3.529 0.879 
X1*X2 -0.0175 0.0054 X1*X2 - - X1*X2 - - 
X1*X3 0.0165 0.0054 X1*X3 - - X1*X3 - - 
X2*X3 -0.0402 0.0054 X2*X3 - - X2*X3 - - 
R2adjusted 98.66% R2adjusted 98.65% R2adjusted 90.82% 
Equation 
5.5 
Y2 = 0.592 + 
0.212 X1 - 1.565 
X2 - 0.1495 X3 - 
0.06 X1*X1 
+ 10.40 X2*X2 
+0.01611 X3*X3 -
0.175 X1*X2 
+0.00825 X1*X3 - 
0.2012 X2*X3 
Equation 
5.6 
Y3 = -1.21 + 
6.405 X1 + 
8.49 X3 - 0.6588 
X3*X3 
Equation 
5.7 
Y4 = -2.06 + 5.35 
X1 + 
10.83 X3 + 3.821 
X1*X1 
- 0.882 X3*X3 
In Table 5.2 (Equation 5.5), PDI was mostly affected by the quadratic effects of 
X2*X2, which showed a positive correlation such that, at -1 and +1 levels of X2, the 
PDI increased. It is also worth noting that the linear term of X2 showed a negative 
coefficient, indicating that X2 has a negative effect on PDI until a turning point is 
reached, whereafter X2*X2 has a positive impact on PDI. Similar findings were 
reported by Masarudin et al., (2015), who found that ratios of Cs:TPP less than 3:1 
and greater than 12:1, resulted in a significant increase of the formed NPs PDI values 
(>0.75). Additionally, they found that the NPs produced at ratios between (median 
levels) the aforementioned upper and lower bounds resulted in NPs with PDI values 
ranging from 0.15-0.32. A contour plot based on the regression model is presented in 
Figure 5.1(A) and highlights this, showing that, at medium load concentrations of 0.15 
mg/mL and medium/low ratios of Cs:TPP (4.75:1 to 5.5:1), a minimum value for PDI 
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can be achieved. Conversely, as the concentration of TPP passes median levels PDI 
increases, which may be attributable to TPP inducing cross-linking between the 
nanoparticles and thus the presence of smaller aggregates within the solution (Hu et 
al., 2008; Antoniou et al., 2015a). Furthermore, the reduction of PDI as the 
concentration of TPP approaches median levels, has been shown to relate with the 
increased availability of TPP molecules to interact with the free amino groups of Cs, 
thus allowing for additional incorporation of the anion within the NP Cs chains 
(Huang and Lapitsky, 2017). Although PDI can be minimised at these particular 
levels, it is worth noting that the PDI values for all formulations fell within optimum 
values for oral delivery (Wong, Al-Salami and Dass, 2017). 
The results presented in Table 5.2 (Equation 5.6) show that ZP was not affected by 
X2, although it was affected by X1 (pH-pI) and X3 (Cs:TPP), indicating that the pH of 
the formulation medium and the electrostatic forces between the ionizable groups of 
Cs and TPP determine the net charge of the produced particles. It is likely that this is 
a direct consequence of the binding between the anionic phosphate groups of TPP 
with the positively charged amino acid moieties of Cs (Rampino et al., 2013), for 
example, a positive correlation was observed, such that ZP increased with increasing 
ratios. In addition, X1 also showed a prominent effect on ZP, whereby an increase in 
ZP is observed as X1 increases. The contour plot representing the reduced regression 
model (Figure 5.1(B)), demonstrates that low X1 levels (pH 5 - 4.2) and low ratios of 
Cs:TPP (4.0/4.5:1) are the areas where NPs of ZP <30mV were obtained (with a 
minimum of 27 mV). As X1 increases (approximately pH 3.5), an increment in ZP 
was observed and maximum values of >39 mV are achieved between X3 (ratio) of 
4.5:1 - 7.5:1. This is in agreement with previous studies by Antoniou et al., (2015), 
that showed at Cs: TPP mass ratios of 7:1, the ZP of the produced NPs decreased 
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almost linearly with increasing pH of the formulation medium. As it has been shown 
that high ZP (either negative or positive), requires higher energy for bringing two 
particles in contact with each other (Dora et al., 2010), this pH-responsive behaviour 
can be attributed to the protonation of the primary amino groups present on the Cs 
chain, resulting in an increase of electron density and repulsion forces between the 
crosslinked Cs chains (Lai and Guo, 2011). For example, at pH 3.5, the charge 
interaction between these two molecules becomes strong enough, and stable Cs NPs 
are obtained. At pH approaching the pI of Cs, reduced availability of protonated amine 
residues (-NH3
+) present on the Cs polymer backbone chain results in a lower surface 
charge of the formed NPs (Huang, Cai and Lapitsky, 2015). 
EE% was not affected by load concentration (X2) but was mostly affected by the pH 
of the Cs media (pH-pI (X1)) (Table 5.2, Equation 5.7), demonstrating the notable 
effect of SeMet loading with the charge of both polyelectrolytes (Cs and TPP) and 
their subsequent interaction during the crosslinking process. As can be seen, a 
negative correlation was observed, indicating that, as X1 increases, the EE% 
decreases, most likely attributable to the reduced protonation of the primary amines 
present on Cs (Umerska, Corrigan and Tajber, 2014). It is also worth noting that the 
quadratic term X1*X1 showed a positive coefficient, indicating X1 had a negative 
effect on EE% until a turning point was reached, where after X1 had a positive impact 
on EE%. He et al., (2017), reported that by exploiting the ionic nature of insulin 
through modulation of the formulation media, the EE% of insulin into Cs:TPP NPs 
could be significantly enhanced, going from 37 to 94 %. This is evident in the contour 
plot produced by the regression model (Figure 5.1(C)) showing that, at maximum X1 
levels (approximately 2.5 unit distance from pI of SeMet) and minimum to 
median/high ratios of Cs:TPP (4:1 - 7.5:1), maximum EE% (>40 %) can be achieved, 
 166 
indicating that pH plays a significant role in the EE%. These findings agree with those 
of other research groups (Janes, Calvo and Alonso, 2001; Antoniou et al., 2015b), that 
reported a strategy to increase ionisable proteins (such as bovine serum albumin 
(BSA) and insulin) EE% (>80%) within a Cs NP matrix, by dissolving the load protein 
at a pH above its isoelectric point. By doing this, deprotonation of the hydroxy groups 
present on the load cargo occurs, inducing a predominantly negative state and thus 
has a higher affinity to Cs and increased EE%. Several other studies have mirrored 
these findings, showing that the electrostatic interactions between the acidic groups 
present on insulin and the amino groups of Cs play a role in the association of insulin 
to the Cs-NPs by mediation of the ionic interaction between both macromolecules 
(Pan et al., 2002; Mattu, Li and Ciardelli, 2013).  
 
Figure 5.1 Contour Plot of (A) PDI against ratio of Cs:TPP (X3) and SeMet (mg/mL) 
(X2), with pH-pI (X1) held at median level (1.5), (B) ZP against pH-pI (X1) and the 
ratio of Cs:TPP (X3) and (C) EE% against pH-pI (X1) vs ratio of Cs:TPP (X3) for the 
RSM models presented in Table 5.2.  
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5.3.2 Optimisation 
Employing the models constructed with the BBD evaluation in Table 5.2, response 
optimisation was employed in order to establish a formulation strategy to yield NPs 
with minimum PDI values, ZP of ≥30 mV and maximum EE% (des Rieux et al., 
2006). As the range of NP sizes within all experimental runs fell within recommended 
target values for oral delivery, this response was excluded from the optimisation 
analysis. 
Figure 5.2 shows the optimisation plot of the desired responses and indicates that, 
when the variable settings of X1, X2 and X3 are fixed at 2.5 (pH-pI), 0.15 (mg/mL) 
and 6 (Cs:TPP), respectively, NPs with the desired properties can be produced. 
Additionally, the 95 % confidence interval ranges of the predicted NP properties that 
these conditions would produce are presented in Table 5.3. 
 
Figure 5.2 Desirability profiles for optimisation of the formulation 
parameters; X1 (pH-pI), X2 (load concentration) and X3 (Ratio of Cs:TPP) - 
maximising ZP and EE%, whilst minimising PDI.  
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To verify the validity of the proposed models, n = 4 replicates of the optimised 
formulation were prepared, and each experimental response was compared with the 
predicted one. Table 5.3 shows the validation results of the model, whereby NPs 
presented sizes of 187 ± 58 nm, PDI of 0.284 ± 0.044, ZP of 39.7 ± 2.6 mV and a max 
EE% of 39 ± 3 %. 
Table 5.3 95% confidence interval for particle characteristics that optimal 
conditions would produce under the present experimental conditions of uncertainty.  
Response Fit 95 % CI Actual values 
Y2 (PDI) 0.299 ± 0.007 (0.282, 0.317) 0.284 ± 0.044 
Y3 (mV) 42.2 ± 2.0 (41.6, 42.7) 39.7 ± 2.6 
Y4 (EE%) 41.7 ± 1.0 (39.5, 43.8) 39 ± 3 
No statistically significant values (p>0.05) for predicted and measured responses (Y2-
Y4) were observed, indicating that the models fit the data satisfactorily and has 
adequate precision for the prediction of NP ZP, PDI and EE% in the chosen space of 
independent variables (in the domain of levels chosen for the independent variables). 
Additionally, several consuming and laborious laboratory studies were eliminated in 
this study by using the BBD, rather than a OFAT approach. 
5.3.3 EE% optimisation I: protonation and ionisation 
The results from the BBD were promising in terms of the NPs produced and their 
physicochemical properties. However, even when optimised, EE% remained low at 
approximately 40 %. A second study was undertaken with the aim of maximising the 
EE%, by controlling the ionisation process, given that this property primarily 
influenced the encapsulation efficiency in the desirability profile (Figure 5.2). In the 
previous BBD, it was noted that the highest EE% of SeMet within Cs:TPP NPs was 
obtained when the pH of the Cs medium was maintained at pH 3 and the SeMet load 
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was dissolved within it prior to crosslinking. The fundamentals of ionotropic gelation 
exploit the opposing charges between the protonated amine residues found on the 
glucosamine residue unit of Cs against the deprotonated hydroxyl groups on TPP 
(Janes, Calvo and Alonso, 2001). In order to increase the EE%, a modulation of the 
ionisation state of SeMet was achieved by dissolving it (and TPP) in a basic solution 
prior to crosslinking with Cs. The rationale for this approach is the observation that 
the pKa for the acid moiety of SeMet is pH 2.6, whereas the pKa for the basic moiety 
is at pH 8.9 (Foulkes, 2003) and as such, further electrostatic interactions can be 
induced at time of complexation (Qi et al., 2010). The effect of dissolving the TPP 
and SeMet in 0.01 M NaOH (pH 12) rather than H2O prior to crosslinking in the 
optimised formulation (ratio Cs:TPP 6:1, SeMet load concentration of 0.15 mg/mL 
and Cs medium pH of 3) was investigated, as a means to elicit greater interaction 
between Cs and SeMet and subsequently increase EE%. N= 3. 
By altering the pH of the formulation, the EE% increased from 39 ± 3 % to 66 ± 1 %, 
whilst the physicochemical properties of the NPs remained within the target range for 
oral delivery (Table 5.4) (des Rieux et al., 2006). This was most likely attributed to 
the electrostatic interactions between the now further ionised TPP and SeMet groups 
and protonated amine residues found on the glucosamine unit of Cs. This is consistent 
with the work by Pan et al., (2014) which showed curcumin (CUR) successful 
encapsulation (>90%) into casein NPs, through deprotonation of CUR at pH 12, 
enabling for its re-association and thus subsequent encapsulation into the NP matrix. 
Table 5.4 Size, PDI, ZP and EE% results for formulation I. N=3. 
SeMet NPs Ratio 6:1, SeMet in NaOH (0.15 mg/mL load conc.), Cs in pH 3 
SIZE (nm) PDI ZP (mV) EE (%) 
227 ± 17 0.448 ± 0.049 32 ± 1 66 ± 4 
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5.3.4 Improved Encapsulation Efficiency using zein 
The results from the first EE% optimisation study (Table 5.4) were promising, in 
terms of increasing EE% in addition to maintaining the desired NP physicochemical 
properties. Nevertheless, the maximum EE% obtained by modifying the pH remained 
at 66 ± 4 %. Therefore, a subsequent step, involving the coating of the optimised NPs 
with zein (at varying zein:Cs mass ratios), was pursued as a means to increase the 
encapsulation efficiency of SeMet into the Cs: TPP NPs. 
As shown in Table 5.5, as the ratio of zein in the formulation increased, the EE% 
improved. At 0.5:1, zein:Cs, the average EE% achieved was 75 % and approximately 
5 % increments in EE% were observed with subsequent increments of zein:Cs. The 
physicochemical properties of the NPs (PDI and ZP) were still within the target range 
for oral delivery for formulations with zein:Cs ratios ≤1:1, although an increase in NP 
size was observed upon increasing zein concentrations. At a ratio of 2:1, zein:Cs, the 
physicochemical properties of the NPs were less than ideal, as large particle sizes (721 
nm average) and high PDI values (0.783) were yielded, most likely as a consequence 
of a denser and thicker coating (Luo et al., 2010) provided by the partial deposition 
of the negatively charged protein on the particle surface, thus reducing the total net 
charge and inducing particle swelling (Rampino et al., 2013). For example, as the zein 
concentration increases, so does the viscosity of the dispersion, which can affect the 
nucleation process leading to the production of larger sized NPs (Zhong and Jin, 
2009). Similar results have been observed by others, whereby, an increase in zein 
concentration led to an increase in particle size of 6,7-dihydroxycoumarin loaded zein 
NPs (Podaralla and Perumal, 2012) or alpha-tocopherol loaded zein NPs, stabilised 
with Cs (Luo, Teng and Wang, 2012). Lastly, the ZP of this formulation was the 
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lowest observed (average of + 6 mV), which may be attributed to the increasing zein 
concentration, causing increased masking of the free positively charged amino groups 
of Cs (Krauland and Alonso, 2007). It is also possible that agglomeration occurred as 
a result of the reduced electrostatic repulsion between the NPs in suspension (Liu and 
Gao, 2009). 
Table 5.5 Physiochemical results for SeMet loaded NPs (Ratio 6:1, SeMet in NaOH 
(0.15 mg/mL load), Cs in pH 3) coated with zein. Size, PDI, ZP and EE% are 
presented for each NP using different mass ratio combinations of zein and Cs. N=3.  
Zein:Cs Size (nm) PDI ZP (mV) EE (%) 
0.5:1 319 ± 19 0.221 ± 0.040 27 ± 6 74 ± 1 
1:1 377 ± 47 0.325 ± 0.136 35 ± 6 81 ± 1 
2:1 721 ± 108 0.783 ± 0.281 6 ± 4 85 ± 1 
5.3.5 Characterisation Fourier transform infrared spectroscopy 
(FTIR) 
Figure 5.3 shows the FTIR spectra of (A) zein, (B) TPP, (C) Cs, (D) SeMet:Cs:TPP 
NPs and (E) SeMet:Cs:TPP:zein NPs. The zein spectrum (Figure 5.3, A) shows 
characteristic peaks at 3289, 2929, 1644, 1515 and 1233 cm-1 corresponding to NH 
stretching vibrations, CH stretching, amide I (C=O stretch), amide II (C-N and C-N-
H/ in plane bending) and amide III respectively (Podaralla and Perumal, 2012). 
Characteristic peaks for the phosphate ion (P=O) in TPP (Figure 5.3, B) were observed 
at 1121 cm-1 and 886 cm-1, respectively (Rampino et al., 2013). Cs spectra (Figure 
5.3, C) showed characteristic peaks at 3240, 2879, 1625, 1514, 1376 and 1063 cm-1. 
corresponding to NH Stretch / OH in pyranose ring, CH2 in CH2OH group, C=O in 
NHCOCH3 group (amide I), NH2 in NHCOCH3 group (amide II), CH3 in NHCOCH3 
group and C-O-C (glycosidic linkage) respectively (Luo et al., 2010; Mohammed, 
Williams and Tverezovskaya, 2013). 
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Figure 5.3 FTIR spectra of (A) zein, (B) TPP, (C) Cs, (D) SeMet:Cs:TPP NPs and 
(E) SeMet:Cs:TPP:zein NPs. Spectra are offset for clarity.  
The FTIR spectrum of SeMet:Cs:TPP NPs (Figure 5.3, D) is different to that of the 
Cs matrix, as a result of intermolecular interactions of the constituent components. If 
interaction between the Cs and TPP had occurred, it will lead to frequency shifts or 
splitting in absorption peaks (Gan et al., 2005). For example, the peaks at 1514 cm-1 
in the Cs spectrum have been shifted to 1560 cm-1, indicating electrostatic interaction 
between the phosphate groups of TPP and the amino groups present in the Cs NP 
matrix (Papadimitriou et al., 2008). Additionally, the broadening and the increased 
absorbance of the peak at 3272 cm-1 indicate hydrogen bonding has been enhanced 
(Luo et al., 2010). The band observed at 1644 cm−1 in the zein FTIR spectrum 
(assigned to N-H bond), has been shifted to 1648 cm−1 in the zein/Cs NPs spectrum 
(Figure 5.3, A and E respectively), indicating an interaction among the zein and Cs 
chains, possibly through hydrogen bonding among the amino groups present on both 
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Cs and zein chains (Müller et al., 2011). Another indication of Cs:zein interaction 
arises from the amide III bands at 1406 cm-1, not visible in the zein spectrum, but now 
visible in the zein/Cs NPs (Figure 5.3, A and E respectively) spectrum, most likely as 
a result of the C-N stretching and out of plane N-H deformation being highly sensitive 
to structural changes (Sessa, Mohamed and Byars, 2008). 
Lastly, the formation of zein/Cs NPs (E) is also characterised by the appearance of a 
band at 1041 cm−1 (assigned to C-O-C (glycosidic linkage)), which was observed in 
Cs/SeMet NPs (D) at 1028 cm−1 but not observed in the zein spectrum (A), supporting 
the presence of Cs within the NP matrix (Figure 5.3) (Müller et al., 2011). The 
crosslinked Cs also showed a peak for P = O at 1151 cm–1 (Bhumkar and Pokharkar, 
2006), further indicating electrostatic interaction between Cs and TPP (Figure 5.3, E). 
No significant SeMet peaks in either Cs/TPP/SeMet or Cs/TPP/SeMet/zein NPs 
spectra were observed, most likely due to the fact, that only 0.07 % of the dried 
formulation is contributed by SeMet and it is consequently masked by the other 
formulation components. 
5.3.6 Scanning electron microscopy  
Figure 5.4 shows the SEM images of uncoated and zein coated Se loaded NPs. The 
particle size of the NPs after spin coating was in good agreement with the DLS 
measurements taken on the freshly prepared NPs. Spherical, well distributed particles 
for both coated and uncoated SeMet loaded NPs were observed. However, it is 
interesting to note that the zein coated NPs displayed a smoother surface than that of 
the uncoated. This may be attributed to the use of the acetic acid buffer used during 
the formulation process, as similar results have been observed in spin-cast zein films 
prepared from an aqueous ethanol solvent compared to an acetic acid solution, 
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indicating that a rough and hydrophilic surface was acquired for the former, whilst the 
zein film produced from an acetic acid solution appeared to be smooth, featureless 
and more hydrophobic (Shi, Kokini and Huang, 2009; Y. Zhang et al., 2015). 
 
Figure 5.4 SEM image of (A) SeMet:Cs:TPP NPs and (B) SeMet:Cs:TPP NPs coated 
with zein. 
5.3.7 Accelerated stability analysis of SeMet-loaded NPs coated with 
zein 
The principle aim of accelerated stability testing is to provide reasonable assurance 
that a pharmaceutical or food consumable will remain at an acceptable level of quality 
throughout its timespan in the market place (Waterman and Adami, 2005; Bajaj et al., 
2012). Real-time, retained sample, cyclic temperature and acceleration, are the four 
categories into which stability testing procedures fall (Bhagyashree et al., 2015). In 
the latter, the product is subjected to elevated temperatures and/or humidity well 
above ambient values, to determine the temperature at which product failure (i.e. 
degradation) will occur. 
The Arrhenius equation, upon which the interpretation of accelerated stability testing 
is based, allows for the determination of the activation energy and consequently, the 
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degradation rate of a product at lower temperatures (i.e. ambient, refrigerated etc.). In 
this instance, the data acquired can then be used to project the shelf life of the product 
in a much shorter time than that of real time assessments (Ali et al., 2013; 
Bhagyashree et al., 2015). This is a beneficial approach to stability testing, as it results 
in a greatly reduced product development schedule. 
Figure 5.5 shows the kinetic behaviour of the NP properties: size (A), PDI (B) and ZP 
(C) at temperatures ranging from 60-80 °C. The stability of the NPs decreased with 
increasing temperature. Little change was detected for all properties at 60 °C, over the 
course of 720 min, whereas a more pronounced increment in size and PDI and a 
decrease in ZP was observed at 70 °C after 300 min. At 80 °C, destabilisation of the 
NP complexes was evident across all properties, whereby size increased from 
approximately 300 nm to > 800 nm, PDI from approximately 0.2 to >0.9 and ZP 
reduced from approximately 32 mV to < 18 mV, indicating that aggregation of the 
NPs had occurred (Wu, Zhang and Watanabe, 2011). 
 
Figure 5.5 (1) Particle size, (2) PDI and (3) ZP analysis of SeMet loaded NPs 
exposed to (a) 80 °C, (b) 70 °C and (c) 60 °C, over time periods of 120, 300 and 720 
min, respectively. N=3. 
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The one-step nonlinear regression analysis of the kinetic experiments shows that 
particle size and PDI fit to a zero-order kinetic behaviour, with an Arrhenius 
dependence of ln (kref@70 °C) = 1.66 ± 9.44 min
−1 and Ea = 452.57 ± 570.59 kJ/mol 
for size, and a ln (kref@70 °C) = 0.029 ± 0.014 min
−1, and an Ea = 182.31 ± 42.64 
kJ/mol for PDI respectively. In terms of ZP, an apparent first order mechanism fits 
the data better than that of an apparent zero order model, with an Arrhenius 
dependence of ln (kref@70 °C) = 0.038 ± 0.010 min
−1 and Ea = 205.71 ± 25.65 kJ/mol. 
Additionally, as can be seen in Figure 5.6, a linear correlation is evident between 1/T 
and ln k, indicating that the formulations will be stable under normal storage 
conditions. This was expected, as previous reports have shown that zein coatings can 
increase the colloidal stability of iron phosphate NPs (Van Leeuwen, Velikov and 
Kegel, 2014) and, when stabilised with Cs, results in high thermal resistance of the 
NPs over prolonged periods of time (Luo et al., 2013). 
Figure 5.6 Arrhenius plots for the (A) ZP, (B) PDI and (C) size accelerated studies 
of SeMet loaded NPs. N=3. 
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5.3.8 Cytotoxicity assessment of SeMet-loaded NPs 
The potential cytotoxicity of SeMet in its native form and unloaded or SeMet loaded 
NPs coated with zein, at different test concentrations (25, 50 and 100 uM), were 
examined on Caco-2 human epithelial cells, and HepG2 human liver hepatocellular 
cells, using the MTS assay. As the NPs will become exposed to the intestinal epithelia 
following oral delivery (leading to its facilitated transport and uptake), time points 
were selected with the intention to mimic in vivo conditions for each cell type, to 
assess the potential cytotoxicity of the formulated NPs (Gleeson et al., 2015; Brayden 
et al., 2015). Caco-2 cells were exposed for 4h (Figure 5.7(A)) and HepG2 cells for 
72h (Figure 5.7(B)). In Caco-2 exposures, no cytotoxicity was observed for unloaded 
or SeMet loaded NPs, in comparison to the negative control, across all tested 
concentrations. For HepG2 exposures, no cytotoxicity was observed for unloaded or 
SeMet loaded NPs coated with zein. Additionally, the lower concentrations (25 and 
50 uM) of native SeMet showed no cytotoxicity to either cell line, whereas a reduction 
in HepG2 cell viability (Figure 5.7(B)) for native SeMet, at the 100 uM test 
concentration, was observed (approx. 66% cell viability).  
Similar results were observed by Takahashi, Suzuki and Ogra, 2017, whereby SeMet 
showed no significant change on the viability of Caco-2 cell lines, although it did 
show marginal toxicity to HepG2 cells at concentrations > 80 ug/mL after prolonged 
exposure (48 hr). This finding is also in agreement with other works that showed 
SeMet toxicity occurred at concentrations ≥40 uM in various hepatoma cell lines 
(Kajander et al., 1991). It has previously been shown that Cs nanoparticles can 
enhance the delivery of inorganic Se compounds whilst reducing its toxicity (C. Zhang 
et al., 2015).  
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In this work, SeMet loaded NPs elicited no significant reduction in viability of either 
cell line at equivalent concentration (100 uM), indicating that, by encapsulating SeMet 
within the Cs NP matrix, the cytotoxic effects of pure SeMet, can be reduced. 
Figure 5.7: Cytotoxicity assessment of  SeMet,  unloaded NPs with zein 
coating and  SeMet loaded NPs with zein coating, exposed for (a) 4h in Caco -
2 cell lines and (b) 72h in HepG2 cell line at SeMet equivalent concentrations (25 
uM, 50 uM and 100 uM). Triton™ X-100 (0.05%) was used as positive control and 
percentage (%) of MTS converted was compared to untreated control. 1-Way 
ANOVA with Dunnetts’s post-test *** p< 0.001, ** p< 0.01, Each value presented 
was normalised against untreated control and calculated from three separate 
experiments, each of which included six replicates. N=3.  
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5.3.9 In vitro release studies 
In vitro techniques are advantageous for modelling potential interactions between NPs 
and the in vivo environment of the GI tract. Simulated gastric fluid and membrane 
analysis models enable assessment of in vivo environments without the use of human 
cell lines (Gamboa and Leong, 2013). Figure 5.8 shows the cumulative release profile 
of SeMet loaded NPs coated with zein, after subjection to 2 hr in an SGF environment 
(pH 1.2) representative of the stomach, followed by a compartmental change to SIF 
(pH 6.8), representative of the intestine, for 4 hr. As can be seen, 25±1 % of SeMet 
was released after 2 hr in SGF, followed by 33 ±3 % in SIF for 4 hr. No significant 
difference in the release profile of SeMet loaded NPs without zein coating was 
observed (data not shown). However, it was necessary to keep zein in the formulation 
due to the increase in EE (≥ 80 %). 
The target site of absorption of SeMet is the jejunum, in the small intestine. Therefore, 
it is important to withstand the acidic environment of the stomach. Three basic 
mechanisms that are typically applied to describe the release of drugs from polymeric 
particles, are swelling/erosion, diffusion, and degradation (Liechty et al., 2010). In 
this work, the total cumulative release of SeMet from the zein coated NPs, after 6 hr 
in simulated gastrointestinal tract environments, was 58 %, indicating that degradation 
of the NP was slow and thus the mechanism may be diffusion/relaxation oriented. As 
such, the release kinetics of SeMet NPs, under the SGF and SIF sequential controlled 
release experiments, were fitted using the following diffusive models derived from 
swellable systems (Siepmann and Peppas, 2011; Danish et al., 2017a). 
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For the SGF: 
𝑴𝒕
𝑴∞
= 𝒌𝒔𝟏 ∗ √𝒕𝒊𝒎𝒆 + 𝒌𝒔𝟐 ∗ 𝒕𝒊𝒎𝒆 
(Equation 5.8) 
where 𝑀𝑡 is the diffused mass at a given time, 𝑀∞ is the asymptotic diffused mass at 
infinite time, and ks1 and ks2 are the diffusive and relaxation rate constants 
respectively. 
For the SIF: 
𝑴𝒕
𝑴∞
−
𝑴𝟏𝟐𝟎
𝑴∞
= 𝒌𝒊𝟏 ∗ (√𝒕𝒊𝒎𝒆 − 𝟏𝟐𝟎) + 𝒌𝒊𝟐 ∗ (𝒕𝒊𝒎𝒆 − 𝟏𝟐𝟎) 
(Equation 5.9) 
where M120 is the predicted diffused mass at the time of changing from SGF to SIF 
(120 min), ki1 and ki2 are diffusive and relaxation rate constants. 
Table 5.6 Swellable model parameters for kinetic release studies SeMet NPs. ks 
represents the stomach compartment and ki the intestinal compartment, divided into 
diffusion and relaxation mechanisms (1 and 2). All parameters listed where 
statistically significant, *P < 0.05. 
Parameters Estimate Std. Error t-value 
Ks2 0.17082 0.04092 4.175 
Ki1 0.69145 0.33863 2.042 
Ki2 0.10817 0.02105 5.140 
R2adj 0.984 
Table 5.6 presents the fitted values for the rate constants in SGF (ks) and SIF (ki) for 
SeMet NPs, with ks1, representing a diffusion mechanism and ks2 a relaxation 
mechanism (Equation 5.8, 5.9). In terms of the stomach compartment (SGF, pH 1.2), 
no statistically significant ks1 parameter was found, indicating that the primary 
mechanism for release in the stomach was via relaxation, i.e. slower release, 
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approaching zero-order kinetics. After 2 hr subjected to the SGF environment, a 
compartmental change was employed to mimic the movement of the NPs to the 
intestinal environment (SIF, pH 6.8), whereupon a combination of diffusion (ki1) and 
relaxation (ki2) mechanisms were observed (p<0.05). Overall, the model employed 
(Equation 5.8, 5.9) predicted the experimental data well, with an R2adj >0.98. These 
results were expected, as polysaccharides generally undergo solvent penetration, 
swelling and chain disentanglement and relaxation, resulting in their ultimate 
dissolution (Fu and Kao, 2010). Additionally, this result is in agreement with previous 
studies, reporting a diffusion and zero order kinetic profile for IPP and LKP loaded 
Cs NPs, coated with zein (Danish et al., 2017a) and that of other researchers, who 
observed that zein proved to be a good coating for NPs, whereby, the stronger the 
interaction of the load material (in this instance phenolic monoterpenes) with that of 
the wall material (zein) was evidenced by its controlled release over time (da Rosa et 
al., 2015). 
 
Figure 5.8 Release kinetics of SeMet NPs coated with zein after 2 hr in SGF (pH 
1.2) and 4 hr in SIF (pH 6.8).  The continuous line indicates the model prediction.   
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5.4 Conclusion 
In this study, SeMet-loaded Cs NPs were produced via ionotropic gelation. BBD was 
used to identify optimum formulation variables that would result in NPs with 
physicochemical properties thought to be suitable for oral delivery. BBD highlighted 
the optimum conditions for NP production, although EE% remained relatively low. 
By varying the formulation media pH, increased electrostatic interaction between the 
crosslinking polyelectrolytes and drug were achieved, resulting in an increase in EE%. 
Coating the NPs at a 1:1 mass ratio of Cs:zein, resulted in NPs with a doubled EE 
accompanied by an increase in diameter. These NPs were then characterised via FTIR 
analysis, which identified the presence of key functional groups of the native 
components and identifying shifts in the crosslinked matrixes. SEM analysis showed 
that spherical, well distributed particles were observed. MTS cytotoxicity studies 
showed no decrease in cellular viability in either Caco-2 or HepG2 cell after 4 and 72 
hr exposures, respectively. Accelerated thermal stability of the loaded NPs indicated 
good stability under normal storage conditions. Lastly, after 6 hr exposure to 
simulated intestinal buffers, the release profile of the formulation showed that ≤ 60% 
of the drug had been released. These findings infer that encapsulation of SeMet into a 
NP delivery system comprising food-derived components reveals an oral 
administration approach for this molecule.  
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Abstract 
Organic forms of selenium, an essential micronutrient, such as selenoamino acids 
(SeAAs), have been shown to possess antioxidant and anticancer properties. However, 
their bioavailability is low, and they may be toxic above the recommended nutritional 
intake level, and thus improved, targeted oral delivery methods are desirable. In this 
work, the SeAAs, Methylselenocysteine (MSC) and selenocystine (SeCys2) were 
encapsulated into nanoparticles (NPs) using the mucoadhesive polymer chitosan (Cs), 
via ionotropic gelation with tripolyphosphate (TPP) and the NPs produced were then 
coated with zein (a maize derived prolamine rich protein). Optimum NP 
physicochemical properties for oral delivery were obtained at a 6:1 ratio of Cs:TPP, 
with a 1:0.75 mass ratio of Cs:zein coating (diameter ~260nm, polydispersity index 
~0.2, zeta potential >30mV). SEM analysis showed that spheroidal, well distributed 
particles were obtained. Encapsulation Efficiencies of 80.7% and 78.9% were 
achieved, respectively, for MSC an SeCys2 loaded NPs. Cytotoxicity studies of MSC 
loaded NPs showed no decrease in cellular viability in either Caco-2 (intestine) or 
HepG2 (liver) cells after 4 and 72 hr exposures. For SeCys2 loaded NPs, although no 
cytotoxicity was observed in Caco-2 cells after 4 hr, a significant reduction in 
cytotoxicity was observed, compared to pure SeCys2, across all test concentrations in 
HepG2 after 72 hr exposure. Accelerated thermal stability testing of both loaded NPs 
indicated good stability under normal storage conditions. Lastly, after 6 hr exposure 
to simulated gastrointestinal tract environments, the sustained release profile of the 
formulation showed that 62 ± 8 % and 69 ± 4% of MSC and SeCys2, had been released 
from the NPs respectively. 
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Keywords Selenium, selenocystine, methylselenocysteine, chitosan, zein 
nanoparticles, stability, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium (MTS), controlled release. 
Abbreviations 
Se, selenium; SeAAs, selenoamino acids; SeCys2, selenocystine; MSC, 
methylselenocysteine; BA, bioactive; Cs, chitosan; TPP, tripolyphosphate; GIT, 
gastrointestinal tract; GRAS, generally recognised as safe; NP, nanoparticle, DLS, 
dynamic light scattering; PDI, polydispersity index; ZP, zetapotential; EE% 
encapsulation efficiency 
6.1 Introduction 
In recent years, interest in preventative public health has increased through the 
emergence of nutraceuticals, bioactive (BA) food compounds, shown to offer a wide 
variety of physiological benefits in addition to reduced disease risks (Lagos et al., 
2015). By incorporating BA compounds (such as minerals or peptides) into food 
systems, a potentially simple means of ameliorating the risk of disease, and the 
subsequent development of an innovative functional food, can be achieved (Cencic 
and Chingwaru, 2010). Unfortunately, the ability for such products to affect disease 
prevention is highly dependent on the bioavailability and stability of these BA 
compounds (Tavano et al., 2014). Given that a substantial amount of BA molecules 
remain poorly available via oral administration, due to various factors such as, a lack 
of stability in the environmental conditions encountered in food processes 
(temperature, oxygen, light) and in the gastrointestinal tract (GIT) (pH, enzymes, 
presence of other nutrients), a short gastric residence time of the dosage form, and a 
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low permeability and/or solubility within the gut, all presenting a major formulation 
challenge (Chen, Remondetto and Subirade, 2006).  
Over the past few decades, encapsulation systems have been developed and employed 
to overcome these limitations, based to their potential to more effectively deliver BA 
agents to a selected target site of action (Vozza et al., 2016). Although several 
synthetic polymers have been employed for use in various delivery applications in the 
pharmaceutical industry, they are not suitable for deployment within the food industry 
unless they have a generally recognised as safe (GRAS) status. Nanoparticle (NP) 
delivery systems can offer an added advantage to the delivery of BA compounds, as 
they possess a higher mobility and cellular uptake compared to systems of larger size. 
As an illustration, He et al., (2012) found that particles 300 nm in size or less are ideal 
for oral drug delivery since they are preferentially internalized by both enterocytes 
and M cells and demonstrate higher intestinal transport compared to larger sized 
particles. Etheridge et al. (2013) observed that the effect of particle size on cellular 
intake can also be influenced by the constituent material and the particle geometry, a 
consequence of reduced intestinal clearance mechanisms and an increase in the mass 
to surface ratio interaction with the biological support.  
Chitosan (Cs), a polysaccharide derived from chitin, the second most abundant 
biopolymer (next to cellulose) in nature, has gained increasing popularity for 
numerous biomedical applications and more specifically for use in NP deliver systems 
(Kumari, Yadav and Yadav, 2010; Rodrigues et al., 2012; Mohammed et al., 2017) 
Given the combination of its GRAS approved status and its well documented 
biodegradable, biocompatible, and mucoadhesive properties, it is unsurprising that 
this compound has been targeted for use in the delivery of BA cargos (Hejazi and 
Amiji, 2003; Kumirska et al., 2011; Anitha et al., 2014). Due to the presence of 
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primary amine groups in the Cs backbone, it can readily become protonated and thus 
solubilised in acidic media, offering the ability to be cross linked with negatively 
charged polyelectrolytes and under relatively mild reaction conditions, a technique 
known as ionotropic gelation (Janes, Calvo and Alonso, 2001). Recent reports have 
indicated the capacity of Cs NPs to improve the bioavailability of nutraceuticals such 
as tea derived phenols, that are soluble yet poorly absorbed, through opening of tight 
junctions and/or direct uptake by epithelial cells via endocytosis (Liang et al., 2017). 
However, the oral administration of BA molecules contained within a Cs:NP matrix 
remains a challenge, due to its lack of stability in the low pH media typically found in 
the GIT (pH 1.2), in which rapid dissociation and thus degradation can lead to the 
destruction of sensitive nutraceutical cargo (Yan et al., 2012). 
Surface coating of Cs NPs has been proposed to confer increased protection to BA’s 
as they pass through the GIT after oral consumption (Luo and Wang, 2014). Zein, a 
GRAS approved prolamine rich protein derived from maize, has been employed for 
the coating of Cs:NP oral delivery systems in recent years due to its ability to increase 
the encapsulation efficiency (EE%) of BAs and to improve their controlled release in 
the GIT (Luo et al., 2010; Luo and Wang, 2014; Paliwal and Palakurthi, 2014). This 
coating strategy harnesses both the protein (zein) and polysaccharide (Cs) properties 
in a combined NP delivery system in which a broader range of physical, chemical and 
colloidal stability can be achieved (Benshitrit et al., 2012). 
Selenium (Se), is an essential micronutrient in human and animal nutrition (Rayman, 
2000) that exists in a wide array of different forms, both organic and inorganic. 
Selenite and selenate salts are the most common inorganic forms, whereas 
selenoamino acids (SeAAs), such as selenocystine (SeCys2), selenomethionine 
(SeMet), and methylselenocysteine (MSC) are the most commonly found forms in 
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foods from the Agaricus, Brassica and Allium families (Montes-Bayón et al., 2006; 
Maseko et al., 2013; Reilly et al., 2014). Although essential, Se possesses a low 
therapeutic index in which there is a fine line between beneficial and toxic doses. 
Generally, organic Se shows a greater bioavailability than that of the inorganic forms, 
in addition to showing a higher threshold for toxicity (Amoako, Uden and Tyson, 
2009). Health benefits of MSC and SeCys2 have been linked to the body’s endogenous 
antioxidant defence system, protecting cellular components such as cell membranes, 
lipids, lipoproteins and DNA from oxidative damage by free radicals, reactive oxygen 
and reactive nitrogen species (Ponnampalam et al., 2009). As oxidative damage is 
linked to the development of cardiovascular and neurodegenerative diseases as well 
as cancers, several experimental in vivo studies of the effects of administration of Se 
compounds have been undertaken (Valko et al., 2007; Lobo et al., 2010; de Souza et 
al., 2014). SeCys2 has been shown to reduce tobacco-derived nitrosamine-induced 
lung tumour growth and enhance hepatic chemoprotective enzyme activities in mice 
(Fan et al., 2013), whereas MSC has been shown to offer selective protection against 
organ specific toxicity induced by clinically active antitumor agents, cisplatin, 
oxaliplatin, and irinotecan in rat models (Cao et al., 2014). 
However, organometals such as MSC and SeCys2 are readily oxidised (Wasowicz et 
al., 2003; Davies, 2016) and although less toxic than inorganic Se, the adequate 
physiological range between deficient and excess doses is narrow, being one order of 
magnitude (0.1–1.0 µg/g diet) in experimental animals (Takahashi, Suzuki and Ogra, 
2017). Additionally, the site of target for SeAAs is the jejunum, in the small intestine 
(Cousins and Liuzzi, 2018). Therefore, it is important that the composition of the 
formulation offers a sufficient ability to withstand the acidic environment of the 
stomach whilst retaining the stability of the cargo. As such, the potential optimisation 
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of the delivery of these compounds in a NP formulation could be significant, given 
that both these organic species can more effectively increase both human and animal 
selenium levels and are less toxic than inorganic selenium (Garousi, 2015). 
This study builds directly on previous work (Vozza et al., 2018, Chapter 5) in which 
the production of Cs:TPP NPs via ionotropic gelation, using selenomethionine 
(SeMet) as a prototype encapsulant, was investigated. In that study, a Design of 
Experiments (DoE) approach was employed to establish optimum formulation 
conditions that would produce SeMet loaded NPs suitable for oral delivery. The 
conditions of mass ratio 6:1 (Cs:TPP), with TPP dissolved in NaOH (0.1 M) and Cs 
dissolved in acetate buffer (pH 3) prior to crosslinking, produced NPs with 
physicochemical properties (Size ~ 300 nm, PDI <0.5 and ZP >30 mV) suitable for 
oral delivery (des Rieux et al., 2006). By coating the NPs with zein, the encapsulation 
efficiency (EE%) was significantly improved from < 65% to >80%. In this work, the 
optimised formulation conditions, as previously identified by DoE, were employed to 
encapsulate SeCys2 and MSC, based on the rationale that SeCys2 (with a pKa of 4.7 
(Lacourciere and Stadtman, 1999)), and MSC (with a pKa of 4.9 (Mishra, Priyadarsini 
and Mohan, 2007)), contain comparably ionisable groups to SeMet. As such, it was 
hypothesised that by employing the previously established DoE parameters to the 
current Cs:TPP NP formulation of MSC and SeCys2, similar formulations (e.g. 
physicochemical properties and EE%) as those achieved for the SeMet loaded NPs 
could be produced. Once prepared, the cryoprotectant trehalose was employed, to 
ensure stability of the optimised formulations after lyophilisation (Danish, 2017a). 
NPs were then extensively assessed for their physicochemical properties, 
morphology, thermal stability, cytotoxicity and in vitro controlled release, utilising 
the methods developed in the previous studies (Vozza et al., 2018, Chapter 5). 
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6.2 Material and Methods 
 
6.2.1 Materials 
The chitosan compound PROTASAN™ UP (CL113) was purchased from 
NovaMatrix, FMC Corporations, Norway. D (+) - Trehalose dihydrate, and zein, of 
≥99 % purity, were obtained from ACROS Organics™, Fisher Scientific, Ireland. 
Seleno-DL-cystine (>98 % purity) and Se-methyl-seleno-L-cysteine (>98 % purity), 
were purchased from Sigma Aldrich, Ireland and LKT laboratories, UK, respectively. 
Ultra-pure water 18mΩcm-1 was obtained from a Millipore simplicity 185 model 
instrument, UK, and was used for all aqueous solution preparations. All other 
reagents, chemicals and solvents were of analytical grade, from Sigma Aldrich, 
Ireland.  
6.2.2 Formulation of MSC and SeCys2 loaded Cs NPs – coated with 
zein 
Cs:TPP NPs were formed according to (Vozza et al, 2018, Chapter 5) with the 
following modifications. Aqueous TPP solution (3 mg/mL) was prepared in NaOH 
(0.01 M), with a Se species (SeCys2 or MSC) concentration of 400 ug/mL. 
Subsequently, this mixture was added in equal volumetric proportions to CL113 
solution (3 mg/mL) via burette droplet addition. The NPs formed were then left to 
stabilise for a further 30 min whilst the stirring speed of the solution was maintained 
at 700 rpm. Once the NPs had stabilised, absolute EtOH (8 mL) was added dropwise 
to the formulation whilst the stirring speed of the solution was maintained (700 rpm, 
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30 min). Filtered Zein (2 mL, 5.625 mg/mL), dissolved in aqueous EtOH (80% v/v), 
was then added dropwise to the solution to yield Zein:Cs NPs of mass ratio 0.75:1. 
All formulations were left to stabilise at 700 rpm for 30 min, then transferred to a 20 
kDa MWCO (Vivaspin 20, Sartorius) centrifugal filter and isolated by centrifugation 
at 3000 rpm for 30 min. Filtered EtOH (80% v/v) (equivalent in volume to the 
recovered supernatant) was then added to the purified NPs and subsequently sonicated 
at 35% amplitude for 30 s with 5 s pulse intervals. The NP formulations were then 
concentrated under vacuum (175 mbar) at 40 °C until EtOH was completely removed. 
To ensure stability of the optimised formulation after lyophilisation, 10 mL of the 
cryoprotectant trehalose 5 % w/v in H2O were added to each formulation and they 
were lyophilised for 36 hr (Danish, 2017a). 
6.2.3 Physicochemical characterisation of MSC and SeCys2 loaded 
Cs NPs coated with zein 
Dynamic light scattering (DLS) was used to determine the mean particle size and 
polydispersity index (PDI) of the NP formulations. Laser doppler velocimetry (LDV) 
was used to measure the zeta potential (ZP). Both DLS and LDV analysis were 
performed with a Zetasizer Nano series Nano-ZS ZEN3600 fitted with a 633 nm laser 
(Malvern Instruments Ltd., UK), using a folded capillary cuvette (Folded capillary 
cell-DTS1060, Malvern, UK), at 25 °C. The values presented herein were acquired 
from three separate experiments, each of which included three replicates. N=3 
(Chapter 3, Section 3.2.1). 
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6.2.4 Scanning electron microscopy (SEM) 
SEM analysis was used to visualise the morphology of the NPs formed’ at an 
accelerating voltage of 20 kV, using a secondary electron detector (Hitachi, SU6600 
FESEM, USA). NP solutions were spin coated onto Si wafers, dried at room 
temperature and then sputter coated with 4 nm Au/Pd prior to imaging 
(Mukhopadhyay et al., 2013), (Chapter 3, Section 3.2.2).  
6.2.5 Encapsulation efficiency (EE%) 
The EE% of Se (MSC or SeCys2) in the NPs was determined by the separation and 
quantification of Se left in the supernatant. This was performed after 
ultracentrifugation of the formed NPs (3000 rpm, 4 °C, 30 min). Reverse phase high 
performance liquid chromatography (RP-HPLC), was employed to quantify 
unencapsulated Se in the supernatant, as previously described (Ward, Connolly and 
Murphy, 2012) with the following modifications. Samples were analysed with a 
Waters 2998 HPLC coupled to a Photodiode Array Detector, (Waters, USA), using a 
Pursuit 5 C18, 250 x 4.6 mm column, (Agilent Technologies, UK). Isocratic elution 
was carried out at a flow rate of 0.8 mL/min, column temperature 45.0 ± 5.0 °C with 
a mobile phase of water/methanol/trifluoroacetic acid (97.9:2.0:0.1). Samples were 
monitored according to their UV absorbance at 218 nm. The encapsulation efficiency 
was calculated using Equation 6.1 (Xu and Du, 2003), (Chapter 3, Section 3.2.3): 
𝑬𝑬% =
𝑻𝒐𝒕𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑺𝒆 𝑴𝒆𝒕 − 𝑭𝒓𝒆𝒆 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑺𝒆𝑴𝒆𝒕
𝑻𝒐𝒕𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑺𝒆𝑴𝒆𝒕
 𝑿 𝟏𝟎𝟎  
(Equation 6.1) 
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6.2.6 Cellular viability assay (MTS) 
The potential cytotoxicity of the different SeAA (MSC and SeCys2) loaded NPs, 
coated with zein, were examined on Caco-2 human epithelial cells, and HepG2 human 
liver hepatocellular cells, using the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay. Caco-2 and 
HepG2, were seeded at a cell density of 2 x 104 cells/well and cultured on 96 well 
plates in Dulbecco's Modified Eagle Medium (DMEM) and Eagle's Minimum 
Essential Medium (EMEM) respectively, supplemented with 10% foetal bovine 
serum, 1% L-glutamine, 1% penicillin-streptomycin and 1% non-essential amino acids 
at 37°C in a humidified incubator with 5% CO2 and 95% O2. The assay was carried 
out using 4 h exposure times for the test compounds on Caco-2 cells (Neves et al., 
2016) and 72 h on HepG2 cells (Gleeson et al., 2015), using Triton X-100™ (0.05%) 
as a positive control. The time points were selected to mimic in vivo conditions for 
each cell type. The concentrations of the test compounds applied were 25, 50 and 100 
uM. After exposure, treatments were removed and replaced with MTS. Optical 
density (OD) was measured at 490 nm using a microplate reader (TECAN GENios, 
Grodig, Austria). Each value presented was normalised to that of untreated control 
and calculated from three separate experiments, each of which included six replicates 
(Chapter 3, Section 3.3.1). 
6.2.7 Stability studies 
Accelerated stability studies of MSC and SeCys2 loaded NPs, were conducted to 
determine the change in physicochemical properties (particle size, PDI and ZP) stored 
at accelerated conditions: 60°C for 720min, 70°C for 300min and 80°C for 120min 
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(Danish, 2017a). In brief, aqueous KCl solution (10 mM) was used to suspend the 
NPs at a concentration of 0.1 mg/mL and the degree of degradation was measured 
using the Nanosizer ZS (Malvern Instruments Ltd, UK) over different time intervals. 
R software (R Core Team, 2016) was used to analyse the generated data. 
The temperatures dependence of the kinetic parameters of MSC or SeCys2 loaded NPs 
stability were measured by calculating the observed rate constants. This was plotted 
in an Arrhenius representation and apparent activation energy, Ea and reaction rate, 
kref were calculated according to Equation 6.2: 
𝑪 = 𝑪𝒐 + 𝒆
𝒍𝒏 (𝒌)−
𝑬𝒂
𝑹
(
𝟏
𝑻−
𝟏
𝑻𝒓𝒆𝒇
)
𝒕 
(Equation 6.2) 
where C is the property (particle size, PDI or zeta potential) at time t, Co is the initial 
property conditions, k is the apparent zero order reaction constant, Ea is the energy of 
activation, R is the universal gas constant, T is the temperature of the experiment (K) 
and Tref is the reference temperature (343 K), (Chapter 3, Section 3.3.2.). 
6.2.8 Release studies 
In vitro release studies of MSC and SeCys2 from the NPs were conducted using a 
dialysis bag diffusion technique (Hosseinzadeh et al., 2012) over 12 hr (Calderon et 
al., 2013; Yoon et al., 2014). In brief, freeze dried loaded (MSC or SeCys2) NPs were 
suspended in H2O (5 mL) and probe sonicated (Branson Ultrasonics; Ultrasonic 
processor VCX-750W, USA) at 35 % amplitude for 30 s with 5 s intervals and placed 
into a Float-A-Lyzer®G2 dialysis membrane (DM) with a pore size of 25 kDa 
(Spectrum Laboratories, USA). The DM was then placed into 40 mL of simulated 
gastric fluid (SGF) for 2 hr, followed by a compartmental change to simulated 
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intestinal fluid (SIF) for 4 hr. The composition of SGF was 0.1 M HCl and SIF 
comprised of a 3:1 mixture of 0.2 M trisodium phosphate dodecahydrate and 0.1 M 
HCl (adjusted to pH 6.8), without enzymes (British Pharmacopoeia Commission, 
2016). Samples were then placed in a thermostatic shaker (37 ºC, 100 rpm) and, at 7 
equidistant predetermined time points, release fluid was removed (1 mL) and replaced 
with fresh simulated fluid to maintain sink conditions. 
The % of drug (MSC or SeCys2) released was measured by RP-HPLC (Section 6.1). 
Equation 6.3 was used to determine the % drug release: 
𝑫𝒓𝒖𝒈𝒓𝒆𝒍 % =
𝑫(𝒕)
𝑫(𝒍)
∗ 𝟏𝟎𝟎 
(Equation 6.3) 
where Drugrel % is the percentage of drug released, D(l) represents the concentration 
of drug loaded and D(t) represents the amount of drug released at time t, respectively 
(Chapter 3, Section 3.3.3.). 
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6.3 Results and Discussion 
 
6.3.1 Particle size, PDI and Zeta potential and EE% 
The Se species (MSC or SeCys2) used to load the NPs did not have a significant effect 
on any of the NP properties (size (nm), PDI, ZP (mV) and EE (%) as shown in Table 
6.1. The effects of zein and zein:Cs ratio on particle characteristics and Se species 
EE% are also presented in Table 6.1. 
Table 6.1 Physicochemical analysis of SeAA loaded Cs NPs, coated with zein, at 
mass ratios of 1:1 and 1:0.75 (Cs:zein).  
Zein:Cs 1:1 
Se Species Size (nm) PDI ZP (mV) EE% 
SeCys2 335.2 ± 34.5 0.346 ± 0.070 23.8 ± 2.6 82.1± 1.2 
MSC 333.6 ± 15.8 0.374± 0.054 23.0±3.4 83.2 ± 2.5 
Zein:Cs 0.75:1 
Se Species Size (nm) PDI ZP (mV) EE% 
SeCys2 262.1 ± 11.1 0.243 ± 0.061 31.5 ± 1.0 78.9 ± 1.5 
MSC 271.2 ± 21.4 0.211 ± 0.148 32.2 ± 1.3 80.7 ± 0.7 
Zein:Cs 0:1 
Se Species Size (nm) PDI ZP (mV) EE% 
SeCys2 205.9 ± 14.3 0.271 ± 0.042 36.6 ± 2.0 61.9 ± 2.8 
MSC 226.5 ± 40.1 0.280± 0.034 38.6 ± 2.4 61.5 ± 1.0 
Zein was shown to significantly increase NP size (nm) and EE (%), in a linear fashion 
with respect to increasing mass ratio to Cs (Figure 6.1). For example, it was observed 
that the average size of MSC or SeCys2 loaded Cs NPs, before zein coating, increased 
from 227 ± 40 (weight ratio of 0:1), to 334 ± 16 (weight ratio of 1:1) and 206 ± 14 
(weight ratio of 0:1), to 352 ± 35 nm (weight ratio of 1:1), respectively.  
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Similar observations were made by Zhang et al. (2014) where zein to sodium 
caseinate (SC) mass ratios of 1:0.625–1:1.25, resulted in an increase in particle size 
from 176.85±1.06 nm to 204.75± 1.62 nm, most likely a consequence of NP coating. 
Additionally, this finding may be due to the larger size of zein (relative to TPP), and 
is consistent with our previous observations for SeMet loaded Cs NPs coated with 
zein (Vozza et al., 2018, Chapter 5) and that of others, whereby, an increase in zein 
concentration led to an increase in particle size of 6,7-dihydroxycoumarin loaded zein 
NPs (Podaralla and Perumal, 2012) or alpha-tocopherol loaded zein NPs, stabilised 
with Cs (Luo et al., 2011), evidenced by a denser and thicker coating of zein around 
the Cs NP.  
 
Figure 6.1 Interval plot showing the effect of Se Species and Cs:zein mass ratios on 
NP physicochemical properties (Size (nm), PDI, ZP (mV) and EE (%).  
PDI reflects the particle size distribution of dispersions, ranging from homogenous 
(0.0) to heterogeneous (1.0) (Win and Feng, 2005). For a NP formulation to be orally 
active, it is generally recognised that PDI values should be no greater than 0.5 (Avadi 
et al., 2010). In this work, The PDI of the formulations (with or without zein coating) 
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remained below 0.4 and neither Se species nor addition of zein significantly affected 
the size distribution of the NPs formed, indicating that they could be suitable for oral 
delivery (des Rieux et al., 2006). 
Additionally, to establish an industrially viable delivery system, it is recommended 
that a high degree of the drug cargo be encapsulated within the NP complex (> 80 %) 
(Sinead Bleiel, AnaBio Technologies Ltd, private communication). As can be seen in 
Table 6.1, the Se loaded Cs NPs, showed a higher EE (> 79%) for all formulations 
with zein coating (0.75-1:1 mass ratio), compared to < 62% for uncoated formulations. 
This is most likely attributable to zein facilitating the incorporation of a higher 
proportion of the SeAAs into the NP matrix. In other work, bovine serum albuminin 
has been encapsulated within hydrophobic polymers such as poly-lactic-co-glycolic 
acid (PLGA) and poly-ε-caprolactone (PCL), providing evidence that EE%, can 
greatly depend on the interactions between the polymer (in this instance Cs), protein 
(zein), and organic solvent (Lamprecht et al., 2000).  
Conversely, an inverse relationship was observed for ZP (mV), whereby the surface 
charge of the NPs reduced upon increasing the zein:Cs mass ratio. This trend is 
conceivable, as, as the concentration of zein increases, a higher proportion of the 
positively charged primary amines (-NH3
+) present in Cs, become neutralised during 
complexation with the negatively charged carboxyl (COO-) groups of zein 
(Mukhopadhyay et al., 2013) and thus a reduction in ZP occurs. 
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6.3.2 Scanning electron microscopy (SEM) 
SEM provides information on both the size and morphology of nanoscale particles, 
factors which may influence the colloidal and chemical stability of a given NP 
formulation. Figure 6.2 shows the SEM images of uncoated NPs (1, A, B), zein coated, 
MSC (2, A, B) and SeCys2 (3, A, B) loaded NPs. The uncoated NPs showed uniform 
spheroidal morphologies and the particle size, after spin coating, was in good 
agreement with that determined by DLS (Figure 6.2, (3 (A), (B)), and consistent with 
the works of several others (Luo et al., 2011; Park, Park and Kim, 2015). 
 
Figure 6.2 SEM images of uncoated NPs (1 (A), (B)). MSC loaded NPs - coated 
with zein (2 (A), (B)) and SeCys 2 loaded NPs - coated with zein (3 (A), (B)). 
Interestingly, the NPs coated with zein showed a slightly irregular surface 
morphology, with a denser core and brighter shell structure (Figure 6.2 (1 (A), (B)) 
and 2 (A), (B)) inferring that zein produces a less dense coating when compared to Cs 
NPs alone. This may be attributable to the electrostatic interaction of the negatively 
charged carboxyl groups of zein facilitating a thin layer membrane around the 
positively charged amines residues of Cs (Luo et al., 2011). 
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In terms of the particle size, comparing between SEM and DLS measurements, 
slightly larger sizes were observed under SEM imaging (approx. 80-120 nm larger), 
which may be due to the rapid evaporation of residual ethanol (present in the final 
suspension media) during the spin casting process and subsequent flattening of the 
particles on the grid (da Rosa et al., 2015). 
6.3.3 Stability studies 
Figure 6.3 shows the kinetic behaviour of the MSC loaded NP properties: size (A), 
PDI (B) and ZP (C), at temperatures ranging from 60-80 °C.  
 
Figure 6.3(1) Particle size, (2) PDI and (3) ZP analysis of MSC loaded NPs exposed 
to (a) 80 °C, (b) 70 °C and (c) 60 °C, over time periods of 120, 300 and 720 min, 
respectively. N=3. 
The stability of the NPs decreased with increasing temperature. Little change was 
detected for all properties at 60 °C, over the course of 720 min, whereas a more 
pronounced influence on size and PDI and a decrease in ZP was observed at 70 °C 
after 300 min. At 80 °C, destabilisation of the NP complexes was evident according 
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to all properties, whereby size increased from approximately 350 nm to > 700 nm, 
PDI from approximately 0.2 to >0.9 and ZP reduced from approximately 32 mV to < 
18 mV, indicating that aggregation of the NPs had occurred (Wu, Zhang and 
Watanabe, 2011). 
A linear relationship is evident between 1/T and ln k, indicating that the formulations 
three physical chemical properties follow Arrhenius law (Figure 6.4). 
 
Figure 6.4 Arrhenius plots for the (A) ZP, (B) PDI and (C) size accelerated studies 
of MSC loaded NPs. 
The one-step nonlinear regression analysis of the kinetic experiments at Tref the 
reference temperature (70°C) shows that the particle size and PDI of MSC loaded NPs 
fit to a zero-order kinetic behaviour, with an Arrhenius dependence of ln (kref@70 °C) 
= 4.45 ± 6.28 min−1 and Ea = 340.32 ± 139.20 kJ/mol for size, and a ln (kref@70 °C) 
= 0.0112 ± 0.0124 min−1, and an Ea = 314.30 ± 109.00 kJ/mol for PDI respectively 
(Figure 6.4). Regarding ZP, an apparent first order mechanism fits the data better than 
an apparent zero order model, with an Arrhenius dependence of ln (kref@70 °C) = 
0.047 ± 0.011 min−1 and Ea = 157.25 ± 19.95 kJ/mol. 
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Similar kinetic behaviour was observed for the SeCys2 loaded NPs properties (size 
(A), PDI (B) and ZP (C)) at temperatures ranging from 60-80 °C (Supplemental 
Figure S6.1). Again, as temperature increased destabilisation of the NPs occurred, 
whereby size and PDI fit to a zero-order kinetic behaviour, with an Arrhenius 
dependence of ln (kref@70 °C) = 5.22 ± 6.04 min
−1 and Ea = 301.87 ± 112.99 kJ/mol 
for size, and a ln (kref@70 °C) = 0.0267 ± 0.0101 min
−1, and an Ea = 200.53 ± 34.10 
kJ/mol for PDI respectively. Likewise, ZP, followed an apparent first order 
mechanism better than that of an apparent zero order model, with an Arrhenius 
dependence of ln (kref@70 °C) = 0.043 ± 0.007 min
−1 and Ea = 175.70 ± 15.12 kJ/mol. 
Lastly, a linear correlation is evident between 1/T and ln k, further indicating that the 
formulations will be stable under normal storage conditions (Supplemental Figure 
S6.2).  
As there was no significant difference observed between the Se species (MSC or 
SeCys2) used to load the NPs on the formulations stability, it can be concluded that 
the contributing factors are determined by the Cs:zein complex rather than the specific 
loaded SeAA. This is expected, as the complexation of protein (in this instance zein) 
with polysaccharide (Cs) systems, involves non-covalent interactions that can change 
the interfacial behaviour and stability of food colloids (Ghosh and Bandyopadhyay, 
2012).  
For example, by harnessing Cs’ thermal stability and combining it with zeins’ 
aromatic side groups and double bonds, it is possible to greatly increase the stability 
of labile nutraceuticals against thermal degradation and oligomerization (Luo et al., 
2013). Zein coated tablets exhibit stronger resistance to abrasion, high humidity and 
high temperatures than a variety of commercial sugar-coated tablets (Zhang et al., 
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2015). Moreover, it has been reported that the bi-layer approach for encapsulation of 
bioactives leads to a better control of the NP interface structure, charge, thickness and 
permeability, and substantially enhanced stability (Hu and McClements, 2014). 
Notably, the net attractive and net repulsive strength character of protein–
polysaccharide non-covalent physical interactions can vary substantially, depending 
primarily on environmental conditions such as pH, ionic strength, and temperature 
(Semenova et al., 2014). In this work, the conditions (presence of salt) used to prepare 
the NPs, in addition to the strong bonding between the zein and Cs complex may have 
been a contributing factor to the enhanced stability of the formulation and is consistent 
with our previous observations (Vozza et al., 2018, Danish et al., 2017b). 
6.3.4 Cellular viability 
Se loaded NPs become exposed to the intestinal epithelia following oral delivery, 
leading to its facilitated transport and uptake. Therefore, the potential cytotoxicity of 
the different Se species were examined on Caco-2 human epithelial cells, and HepG2 
human liver hepatocellular cells. Both cell lines are routinely used to assess 
cytotoxicity of orally delivered molecules (Gleeson et al., 2015; Brayden et al., 2015). 
The MTS assay was used to assess the cytotoxicity of both MSC and SeCys2 in native 
format and within the NP formulation (loaded and unloaded), at different test 
concentrations (25, 50 and 100 uM). 
Supplementary figures show the cytotoxicity assessment of MSC loaded NPs on 
Caco-2 (S6.3 (A)) and HepG2 cell lines (S6.3 (B)). In terms of Caco-2, no cytotoxicity 
was observed for all test formulations (native, loaded and unloaded NPs), after 4 hr 
exposure, in comparison to the negative control, across all tested concentrations (S6.3 
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(A)). The same response was observed for the HepG2 cell exposures for 72h (S6.3 
(B)). These results are in accordance with the observations of Barrera et al., (2013), 
who observed no apparent cytotoxicity on Caco-2 cells after a 72 hr exposure of MSC 
(0.2-100 uM) and Marschall et al., (2016), who reported no obvious cytotoxicity 
HepG2 cells incubated with MSC (2.5-200 uM) after 48 hr exposure. 
Regarding SeCys2 (native, loaded and unloaded NPs), although no cytotoxicity was 
observed in Caco-2 cells after 4 hr exposure (Figure 6.5 (A)), a significant reduction 
in cell viability was observed for both native and equivalent loaded NPs across all test 
concentrations, with native SeCys2 resulting in a reduction of ≥ 63% cell viability at 
50 and 100 uM test concentrations (Figure 6.5 (B)). Similar results were observed by 
Takahashi, Suzuki and Ogra (2017), who reported that SeCys2 elicited no significant 
change in the viability of Caco-2 cell lines after 6 hr, although it did show significant 
toxicity to HepG2 cells at 100 uM, comparable to that of the inorganic form selenite, 
after prolonged exposure (48 hr). 
Organic Se species, such as SeAAs have been reported to be less toxic than inorganic 
Se species and as such the high toxicity of SeCys2 is quite surprising (Suzuki et al., 
2010; Takahashi, Suzuki and Ogra, 2017). As the toxicity of SeCys2 has been shown 
to be comparable to that of selenite, it has been proposed by others that the cellular 
overload of metabolites (such as selenide moieties (-Se-) and (HSe-) produced during 
selenoprotein formation or excretion (Rayman, Infante and Sargent, 2008; Marschall 
et al., 2016) is responsible for this effect. Most likely, the reduction of SeCys2 to 
SeCys in the cell results in the generation of a highly reactive and sensitive to 
oxidation selenyl group (-SeH), whose relatively low pKa of 5.2 promotes the 
formation of (-Se-) at physiological pH (Iwaoka, 2014). As can be seen in Figure 6.5 
 216 
(B), the encapsulation of SeCys2 within the Cs:zein NP matrix conferred protection to 
the HepG2 cells after 72 hr exposure, indicating that, at the tested concentrations used 
in this study, the cytotoxic effects of pure SeCys2 can be reduced.  
Figure 6.5 Cytotoxicity assessment of  SeCys2,  unloaded NPs and  
SeCys2 loaded NPs, exposed for (a) 4h in Caco2 cell lines and (b) 72h in HepG2 cell 
line at 25 uM, 50 uM and 100 uM concentrations. Percentage (%) of MTS converted 
was compared to untreated control. 1-Way ANOVA with Dunnett’s post-test *** p< 
0.001. Each value presented was normalised against untreated control and calculated 
from three separate experiments, each of which included six replicates. N=3.  
Lastly, the unloaded NPs showed no significant effect on Caco-2 cells over the range 
of test concentrations, nor HepG2 at test concentrations of 25 and 50 uM. However, 
at 100 uM, a significant increase in cell viability was observed, indicating that the 
formulation elicits an enhanced proliferative effect at this concentration. This may be 
attributable to a combination of zein’s demonstrated cytocompatibility with NIH 3T3 
and human liver cells (HL-7702) in terms of cell adhesion and proliferation (Dong, 
Sun and Wang, 2004), and an increase in fibroblast production caused by the presence 
of Cs (Rajam et al., 2011). 
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6.3.5 Release studies 
Three basic mechanisms that are typically employed to describe the release of drugs 
from polymeric particles are, swelling/erosion, diffusion, and degradation (Liechty et 
al., 2010). The prominence of each can depend on the conditions of the environment. 
Therefore, the release kinetics of MSC NPs were monitored sequentially in SGF and 
SIF controlled release experiments. 
Figure 6.6 shows the cumulative release profile of MSC and SeCys2 loaded NPs, 
coated with zein, after subjection to 2 hrs in an SGF environment (pH 1.2) 
representative of the stomach, followed by a compartmental change to SIF (pH 6.8), 
representative of the intestine, for 4 hrs. As can be seen, 37 ± 11 % of MSC was 
released from the NP after 2 hr in SGF, followed by 25 ± 8 % release in SIF for 4 hr. 
Regarding SeCys2, 45 ± 4 % was released from the NPs after 2 hr in SGF, with a 
subsequent release of 24 ± 4 % after subjection to a SIF environment (4 hr).  
Despite the high-water solubility of the SeAAs, there was good control of drug release 
in the simulated physiological environment of stomach and small intestine. On 
exposure to the dissolution fluids (SGF and SIF), the Cs complex will become 
hydrated forming a viscous gel layer that slows down further seeping-in of dissolution 
fluids towards the core of the NP (Miladi et al., 2015). The subsequent Cs swelling 
under these conditions allows for the drug release to follow a diffusion oriented 
mechanism, which is then typically trailed by the mechanical erosion of the swollen 
Cs hydrogel (Mohammed et al., 2017). In tandem, subsequent hydration and swelling 
of the system is heavily dependent upon whether or not the Cs erodes further. With 
this in mind, it was observed that the release of both SeAAs from the Cs:zein NPs was 
pH dependent, indicative of Cs solubility in acidic media (Yuan et al., 2013). 
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Figure 6.6 Release kinetics of MSC and SeCys2 loaded NPs, coated with zein, aft er 
2 hr in SGF (pH 1.2) and 4 hrs in SIF (pH 6.8). Solid lines are a fit to the model of 
Equations 6.4 and 6.5. The continuous line indicates the model prediction.  
As two different simulated fluids were used for this study, representing the pH 
environment in the stomach (SGF) and the jejunum target site in the intestine (SIF), 
their release profile was modelled using a swelling, Peppas equation (6.4) and (6.5) 
(Siepmann and Peppas, 2011; Danish, 2017a).  
  
SGF SGF
SIF SIF
 219 
For the SGF: 
𝑴𝒕
𝑴∞
= 𝒌𝒔𝟏 ∗ (√𝒕𝒊𝒎𝒆) + 𝒌𝒔𝟐 ∗ 𝒕𝒊𝒎𝒆 
(Equation 6.4) 
where 𝑀𝑡 is the diffused mass at a given time, 𝑀∞ is the asymptotic diffused mass at 
infinite time, and ks1 and ks2 are the diffusive and relaxation rate constants 
respectively. 
For the SIF: 
𝑴𝒕
𝑴∞
−
𝑴𝟏𝟐𝟎
𝑴∞
= 𝒌𝒊𝟏 ∗ (√𝒕𝒊𝒎𝒆 − 𝟏𝟐𝟎) + 𝒌𝒊𝟐 ∗ (𝒕𝒊𝒎𝒆 − 𝟏𝟐𝟎) 
(Equation 6.5) 
where M120 is the predicted diffused mass at the time of changing from SGF to SIF 
(120 min), ki1 and ki2 are diffusive and relaxation rate constants. 
The release of SeCys2 and MSC from the nanoparticles was best fitted with a 
combination of diffusion and relaxation mechanisms. The fits of the model are 
illustrated by solid lines in Figure 6.6. Table 6.2 presents the fitted values for the rate 
constants in SGF (ks) and SIF (ki) for both Se loaded (MSC and SeCys2) NPs, divided 
into diffusion and relaxation mechanisms (1 and 2) (Eq. 6.4, 6.5).  
For SeCys2 loaded NPs, subjected to the simulated stomach environment (SGF, pH 
1.2), no statistically significant ks1 parameter was found, indicating that the primary 
mechanism for release in the stomach was via relaxation, i.e. slower release, 
approaching zero-order kinetics. After 2 hr subjected to the SGF environment, a 
compartmental change was employed to mimic the movement of the SeCys2 NPs to 
the intestinal environment (SIF, pH 6.8), whereupon a combination of diffusion (ki1) 
and relaxation (ki2) mechanisms were observed (p<0.05). In contrast, a combination 
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of ki1 and ki2 mechanisms in the stomach (SGF) was observed for the release of the 
MSC loaded NPs and no statistically significant ki1 parameter was found for the 
intestinal compartment, indicating that, in the small intestine (jejunum), at pH 6.8, 
relaxation is the primary mechanism of release for MSC.  
These findings corroborate previous studies, reporting a diffusion and zero order 
kinetic profile for IPP and LKP loaded Cs NPs, coated with zein (Danish et al., 2017a) 
and that of other researchers, who observed that zein proved to be a good coating for 
NPs, whereby, the stronger interaction of the load material (in this instance phenolic 
monoterpenes) with that of the wall material (zein) was evidenced by its controlled 
release over time (da Rosa et al., 2015).  
Table 6.2 Swellable model parameters for kinetic release studies of MSC and 
SeCys2 loaded NPs, coated with zein. ks represents the stomach compartment and 
ki the intestinal compartment, divided into diffusion and relaxation mechanisms ( 1 
and 2). All parameters listed where statistically significant, ( ∗P < 0.05). 
SeCys2 loaded NPs 
Coefficients Estimate (min-1/2) 
ks2 0.26±0.08 
ki1 1.86±0.28 
ki2 -0.023±0.05 
MSC loaded NPs 
Coefficients Estimate (min-1/2) 
ks1 -1.65±0.75 
ks2 0.46±0.08 
ki2 0.14±0.05 
R2adjusted 0.95 
In terms of significant differences between the common release parameters of the two 
SeAAs (Ks2 and Ki2, Table 6.2), MSC was found to exhibit a lower release rate in 
SGF than SeCys2, with a release of 37 ± 11 % observed for MSC vs 45 ± 4 % for 
SeCys2. This may be attributable to a number of different factors, for example the 
difference in the polar surface area (PSA) between the two compounds (MSC PSA = 
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63.32 A2 vs SeCys2 PSA = 126.44 A
2) allowing for MSC to become more physically 
entrapped into the NP matrix. Additionally, the electrostatic attractions between the 
NP matrix and SeCys2 becomes amplified at pH 1.2, whereby the SeCys2 charged 
state predominantly exists with both amine residues going to NH3+ (Rivail da Silva et 
al., 1997; Kotrebai et al., 2000), facilitating increased electrostatic repulsion with the 
primary amines of Cs. As other authors have observed that swelling rates, swelling 
capacity and release rates of drugs varying in hydrophobicity were pH dependent, 
because of the presence of charged groups on the drug molecules in varying pH release 
media (Katas, Raja and Lam, 2013; Bouman et al., 2016), it is reasonable to suggest 
that this may be the attributing factor to the faster release observed with SeCys2. No 
significant difference in the release profile of either MSC or SeCys2 loaded NPs 
against those without zein coating, was observed (data not shown), indicating that the 
release profile is influenced by the interaction of the active with Cs:TPP and is not 
significantly influenced by the zein coating. This may be related to the formulation 
media conditions employed in this study for TPP (pH 12) prior to crosslinking with 
Cs, which has been shown to decrease drug release rates. For example, Ajun et al., 
(2009) observed that aspirin’s release rate from Cs NPs could be reduced from 64 to 
40 % within 8 hr by increasing the basicity of the TPP media pH from 3 to 8.4, 
allowing for the production of high density structured NPs and consequently, the 
drugs slower release. Nonetheless, whether zein affected the release profile or not, it 
remained necessary to keep zein in the formulation to ensure an EE (≥80 %) for the 
encapsulated SeAAs. 
Lastly, the release profile of SeMet, previously assessed in Chapter 5 (Section 5.9, 
Figure 5.8), was compared to those of both MSC and SeCys2, SeMet was found to 
release in SGF at a slower rate than the other SeAAs, with a total release of 25±1 % 
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after 2 hr in the SGF environment, vs 37 ± 11 % and 45 ± 4 % for MSC and SeCys2 
respectively. Conversely, in the SIF environment SeMet was the fastest releasing 
SeAA, showing release of 33 ± 3 % vs 25 ± 8 for MSC and 24 ± 4 for SeCys2 
(Supplemental Table S6.1). From the Henderson–Hasselbalch equation it can be 
derived that any drug-like molecule (weak acid or base) will be predominantly ionised 
if the pH of the system is about two pH units higher than its pKa. Vice versa, at two 
pH units lower than its pKa the drug will be predominantly (99%) protonated. The 
pKas for the SeAAs are 4.66 < 4.93 < 5.53 (SeCys2, MSC, SeMet) (Supplemental 
Table S6.1) suggesting that the observed variance in release rates is attributable to 
their chargeable properties and interactions with the protonated 1º amines of Cs 
(Makhlof, Tozuka and Takeuchi, 2011). For example, SeCys2, the fastest releasing 
SeAA in SGF (45 ± 4%), would be the most protonated (pKa = 4.66) at pH 1.2, 
allowing for increased electrostatic repulsion between its two -NH3
+ moieties and that 
of Cs, thus driving the release from both the surface and within the NP structure. 
Conversely, SeMet with a pKa of 5.5 showing the slowest release in SGF (25 ± 1) 
(Supplemental Table S6.1), would be the least protonated out of the SeAAs allowing 
for less repulsion between its -NH2 and -NH3
+ and thus a slower release in SGF. As 
the target site for the SeAAs is the jejunum, sufficient ability of the NP to withstand 
the acidic environment of the stomach is important, with the findings showing that 
SeMet loaded NPs are the most resistant in this instance, followed by MSC and 
SeCys2.  
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6.4 Conclusion 
In this study, SeAA loaded Cs NPs, were produced via ionotropic gelation. NPs with 
optimum properties for oral delivery were formed by coating the produced NPs at a 
1:0.75 mass ratio of Cs:zein, resulting in MSC loaded NPs with sizes of 271.2 ± 21.4 
nm, PDI 0.211 ± 0.061, ZP 32.2 ± 1.3, EE% of 80.7 ± 0.7 and SeCys2 loaded NPs of 
262.1 ± 11.1 nm, PDI 0.243 ± 0.148, ZP 31.5 ± 1.0 and EE% 78.9 ± 1.5. SEM analysis 
showed that spheroidal, well distributed particles were observed. MTS cytotoxicity 
studies on MSC loaded NPs showed no decrease in cellular viability in either Caco-2 
(intestine) and HepG2 (liver) cell lines after 4 and 72 hr exposures, respectively. For 
SeCys2 loaded NPs, no cytotoxicity was observed in Caco-2 cell lines after 4 hr, 
however a significant reduction in cytotoxicity was observed, when compared to pure 
SeCys2, across all test concentrations on HepG2 after 72 hr exposure. Accelerated 
thermal stability of both loaded NPs indicated good stability under normal storage 
conditions. Lastly, after 6 hr exposure to simulated GIT environments, the sustained 
release profile of the formulation showed that 62 ± 8 % and 69 ± 4 of drug had been 
released from MSC and SeCys2 loaded NPs respectively. These findings infer that, by 
encapsulating SeAAs into a NP delivery system, improved oral administration of this 
molecule may be achieved, which could be of beneficial use for the supplementation 
of food products with these essential nutrients.  
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6.6 Supplemental Information 
 
Figure S6.1(1) Particle size, (2) PDI and (3) ZP analysis of SeCys 2 loaded NPs 
exposed to (a) 80 °C, (b) 70 °C and (c) 60 °C, over time periods of 120, 300 and 720 
min, respectively. N=3. 
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Figure S6.2 Arrhenius plots for the (A) ZP, (B) PDI and (C) size accelerated studies 
of SeCys2 loaded NPs.  
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Figure S6.3 Cytotoxicity assessment of  MSC,  unloaded NPs and  MSC 
loaded NPs, exposed for (a) 4h in Caco2 cell lines and (b) 72h in HepG2 cell line at 
25 uM, 50 uM and 100 uM concentrations. Percentage (%) of MTS converted was 
compared to untreated control. 1-Way ANOVA with Dunnett’s post-test *** p< 
0.001, ** p< 0.01, Each value presented was normalised. against untreated control 
and calculated from three separate experiments, each of which included six 
replicates. N=3. 
Table S6.1 Release (%) of SeAAs in SGF and SIF. 
SeAA loaded 
NP 
% Release in 
SGF 
% Release in 
SIF 
% 
Cumulative 
release 
pKa 
SeMet 25 ± 1 33 ± 3 58 ± 2 5.53 
MSC 37 ± 11 25 ± 8 62 ± 9 4.93 
SeCys2 45 ± 4 24 ± 4 69 ± 4 4.66 
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7 POTENTIAL OF MUSHROOM BY-
PRODUCTS FOR NUTRIENT DELIVERY 
APPLICATIONS: PRODUCTION AND 
CHARATERISATION OF CHITIN FROM 
AGARICUS BISPORUS AND ITS 
DERIVATISATION TO CHITOSAN AND 
TRIMETHYL CHITOSAN 
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Abstract 
In this work, chitin (CT) was extracted from A. bisporus using alkali reflux, yielding 
6.6 ± 2.2 % of dried mushroom powder determined to be CT. The CT produced 
showed equivalent purity and degree of acetylation (DA%) (≈ 100%) to a commercial 
standard, as determined by 13C NMR. The extracted CT was then derivatised to 
Chitosan (Cs), via microwave irradiation and conventional thermal heating methods, 
the optimum method for conversion being identified as microwave treatment (yield 
of 55 vs 33 %). The Cs produced using microwave irradiation showed equivalent 
purity and degree of deacetylation (DDA%) (≈86 %) to that of commercial fungal Cs 
and that of an ultrapure Cs typically employed for use in bioactive delivery 
formulations, as identified by 1H-NMR and FTIR spectroscopy. The extract was then 
chemically modified to water soluble trimethyl chitosan (fTMC), for assessment as a 
permeation enhancer, showing equivalent degrees of quaternisation (≈ 44 %) with low 
O-methylation values (≈ 25 %), as determined by 1H-NMR. Lastly, fTMC was 
assessed for permeation enhancing effects via the trans-epithelial electrical resistance 
(TEER) assay on human epithelial colorectal adenocarcinoma cell (Caco-2) 
monolayers, showing a time reversible reduction in TEER of ≈ 75 vs ≈ 90 against a 
well-established permeation enhancer, sodium caprate used as positive control. The 
findings indicate that A. bisporus can be considered as a good source of CT that can 
be easily isolated without aggressive treatments, subsequently deacetylated for the 
production of Cs and chemically modified to fTMC, supporting the proposition that 
these by-products have potential use for many different practical applications. 
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Keywords 
Fungal extracts, chitin, microwave treatment, chitosan, Trimethylchitosan, 
permeation enhancer. 
Abbreviations 
CT, Chitin; Cs, Chitosan; CL113, PROTASAN™ UP; DA%, Degree of Acetylation; 
DDA%, Degree of Deacetylation; TMC, Trimethyl chitosan; DDQ%, Degree of 
quaternisation; cTMC, commercial TMC, fTMC, fungal TMC; TEER, trans 
epithelial electrical resistance assay. 
7.1 Introduction 
Chitin (CT) is a polysaccharide consisting of adjacent monosaccharides, 2-
(acetylamino)-2-deoxy-d-glucose, bonded by glycosidic bonds in a linear or branched 
fashion, and is the second most abundant polymer found in nature (next to cellulose) 
(Rathke and Hudson, 1994). CT is insoluble in most regular solvents owing to the 
presence of acetyl, amino and hydroxyl groups in the polysaccharide chain, that 
generate hydrogen bonds (inter and intramolecular), and cause a high degree of 
aggregation (Pillai, Paul and Sharma, 2009). Today, CT, chitosan (Cs) and Cs are 
produced on a commercial scale for a variety of applications, e.g. cosmetics, 
pharmaceuticals, and wastewater treatment, with a market value of $2.0 billion (BCC 
research, 2016). However, CT insolubility affects the scaling up of the processes to 
produce CT-based products (Hamed, Özogul and Regenstein, 2016; Yang et al., 2016; 
Aranaz et al., 2018). 
Cs is a linear, semi-crystalline polysaccharide composed of (1, 4)-2-acetamido-2-
deoxy-β-D-glucan (N-acetyl D-glucosamine) and (1,4)-2-amino-2-deoxy-β-D-glucan 
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(D-glucosamine) units, that are not widely present in nature (Duarte et al., 2002). Cs 
is typically produced from CT by chemical hydrolysis under severe alkaline 
conditions, by removing the acetyl groups from the molecular chain of CT, which 
results in a high degree of the chemically reactive group (NH2) being left on the 
compound (Cs), thus allowing for its solubilisation in acidic aqueous solutions 
(Ospina Álvarez et al., 2014). The ratio of N-acetyl-D-glucosamine to D-glucosamine 
is what determines whether the polymer can be considered Cs or CT, whereby, if more 
than 60% of the partially deacetylated CT exists as D-glucosamine, it is considered 
Cs (de Alvarenga, Pereira de Oliveira and Roberto Bellato, 2010). For Cs this ratio 
percent is known as the degree of deacetylation (DDA%) (whereas for CT this ratio 
percent is known as the degree of acetylation (DA%)) and is an important property to 
consider in Cs production, as it determines its solubility properties, biodegradability 
and immunological activity (Tolaimate et al., 2000; Pillai, Paul and Sharma, 2009). 
A considerable amount of work on Cs and its chemically modified derivatives, for 
potential use in drug delivery systems, has been published over the past 20 years (Felt, 
Buri and Gurny, 1998; Prabaharan, 2008; Xing et al., 2018). Cs, in contrast to all other 
polysaccharides, holds a unique cationic character, owing to the primary amino groups 
present on its backbone. It has been used for the development and formulation of 
nanoparticles for drug delivery due to properties such as controlled drug release, 
mucoadhesion, in situ gelation, transfection and permeation enhancement (PE) 
properties (Bernkop-Schnürch and Dünnhaupt, 2012; Katas, Raja and Lam, 2013; 
Huang, Cai and Lapitsky, 2015). In terms of drug delivery properties, it has previously 
been reported that Cs with a higher DDA%, has the ability to achieve higher 
encapsulation of bioactives, due to the increased level of functional groups present 
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that can complex with reactive groups on the bioactive (BA) of interest (Xu and Du, 
2003). 
At present, crustacean shells are considered the most convenient available source for 
the commercial production of CT (Hamed, Özogul and Regenstein, 2016). However, 
due to seasonal availability and environmental pollution, the industrial isolation of CT 
from this source faces some challenges. For example, calcium carbonate, proteins, 
lipids and pigments associated with crustacean CT requires aggressive, successive, 
acid (HCL), alkali (KOH) and bleaching treatments (decolourising agent) at high 
temperatures, for purification (Barikani et al., 2014). Consequently, the final product 
produced can often undergo chemical changes such as the deacetylation and 
depolymerisation of CT thus reducing its overall quality and reproducible 
functionality (Kardas et al., 2012). Moreover, the release of waste containing alkali 
and degradation products into the surrounding environment has been identified as a 
contributing source of environmental pollution (Kaur et al., 2014). Enzymatic 
hydrolysis has also been reported as a method of Cs production, but it is not as 
commonly employed as chemical hydrolysis due to its higher cost (Kim and 
Rajapakse, 2005). 
PROTASAN™ CL113, a commercial Cs, derived from crustacean shells and sold by 
NovaMatrix, FMC Corporations, has been previously promoted for its ability to 
encapsulate and deliver food derived bioactives such as Retinyl Palmitate (a vitamin 
A isomer) and possesses the following physicochemical properties: molecular weight 
(MW) of 110-150 kDa, DDA% ≥80 % and minimal metal contamination (Fernández‐
Gutiérrez et al., 2015). It has also been used to slow and control the drug release 
profile of Triclosan (an efficient anti-malarial drug) (Maestrelli, Mura and Alonso, 
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2004) and salmon calcitonin (a potential osteoarthritic drug) (Ryan et al., 2013) owing 
to both its known mucoadhesive and enhancer properties and its demonstrated 
effectiveness in optimally controlling drug release rate. In fact, to date, much of the 
research involving its employment as a nanocarrier, has been of Cs of animal origin 
(crustaceans) (Hamed, Özogul and Regenstein, 2016). However, high batch to batch 
variability and climate change (David Brayden, TRANS-INT, private 
communication) of Cs from these sources have been reported, resulting in 
formulations with variable physicochemical properties and with potential for inducing 
allergic responses (Smets and Rüdelsheim, 2018). Hence, an alternative Cs produced, 
for example from edible A. bisporus mushrooms, could be well placed for 
pharmaceutical applications, particularly if available with batch to batch 
reproducibility and high control over its molecular characteristics, such as molecular 
weight and DDA%. 
During white mushroom (A. bisporus) cultivation, by-products are generated, 
whereby between 5 and 20% of fruiting bodies with misshaped cups and stalks do not 
meet the specifications set by retailers and are not utilised for human consumption 
(Figure 7.1). In the USA alone, mushroom production results in nearly 50,000 metric 
tons of mushroom material per year, with no suitable commercial application 
(Philibert, Lee and Fabien, 2017). Notably, however, under mild conditions, media 
optimisation and green conversion of agricultural industrial wastes, CT and Cs can be 
obtained from mushrooms and fungi and present an alternative to other uses of this 
by-product (Kulshreshtha, Mathur and Bhatnagar, 2014). Extraction of CT, which the 
European Food Safety Authority (EFSA) approved as a food additive in 2010, can 
potentially offer alternative revenue with significant economic potential (Tetens, 
2010). 
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Mariod (2016) reported that, for the isolation of CT from different marine sources, 
chemical treatments like deproteinisation with hot alkali (1 M NaOH at 65–100 ˚C for 
1–72 hr), demineralisation with acid to eliminate calcium carbonate (0.275–2 M HCl 
at near 100 ˚C for 1–48 hr) and decolouration to remove pigments are necessary. The 
fungal approach, however, has the advantage of easy handling, harvesting and control 
to produce high quality Cs, through enhanced control of environmental and nutritional 
conditions used during cultivation (Ghormade, Pathan and Deshpande, 2017). 
Feofilova (2010) extensively reviewed the contributions of the structural and matrix 
components of fungal cell walls, such as chitin/chitosan, glucans, proteins, lipids, 
uronic acids, etc, reporting that, for isolation of CT, the chemical treatments used are 
milder than that as reported for marine sources. 
 
Figure 7.1 Mushroom by-products and nonconforming mushroom bodies, not 
currently utilised for human consumption.  
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The most common procedure for obtaining Cs is based on the alkaline deacetylation 
of CT with strong alkaline solution at high temperature (Castelli et al., 1996), while 
other procedures include alkali treatment at high temperature and high pressure 
(autoclave) (Abdou et al., 2008), and enzymatic N-deacetylation (Martinou et al., 
1995). Recently, microwave irradiation as a non-conventional energy source has 
received increasing attention in organic chemistry, due to its ability to accelerate 
reactions, provide high batch-to-batch consistency, scalability and to increase the 
yield of product, in comparison to conventional heating (Singh, Kumar and Sanghi, 
2012). By exploiting the rapid energy transfer from the functional groups (-OH and -
NH2 groups) during dielectric heating using microwave energy, the reaction rate can 
be greatly enhanced, allowing for rapid breakage of covalent and glycosidic linkages 
between the glucosamine residues and thus faster production of Cs (Wasikiewicz and 
Yeates, 2013). Sagheer et al., (2009) studied the production of Cs from crustacean 
sources using microwave irradiation and found the reaction time was significantly 
reduced (15 min vs 10 hr), in addition to producing Cs with DDA and MW values 
higher than those of Cs produced by conventional methods. 
A particularly interesting application for Cs is its employment as a permeation 
enhancer (PE) for enhanced delivery of biopharmaceuticals, that are generally labile, 
large, hydrophilic and usually require parenteral administration (Boateng, Okeke and 
Khan, 2015). Oral delivery, considered the “gold standard” drug delivery method (in 
terms of patient compliance and reduced adverse effects related to injections) is an 
often sought-after alternative to methods such as inhalation or parenteral delivery 
(Gleeson, Ryan and Brayden, 2016). The limitation of delivering hydrophilic dugs 
orally arises from the low permeability of the epithelial barrier, as a result of which 
they must rely on active transport across the barrier, or passive transport between 
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adjacent cells through the paracellular pathway, known as tight junctions (TJs), 
present in the mucosal membrane (Upadhyay, 2014). Polymeric PEs, such as Cs, have 
been studied to enable the safe passage of drugs with low bioavailability. However, 
the pKa of 6.5 of Cs, and its low solubility, limits its application as a PE for mucosal 
surfaces when the pH is above 6.5 (Sonia and Sharma, 2011). 
N-trimethyl chitosan (TMC) is a quaternary derivative of Cs, in which partial 
trimethylation of the primary amine results in a permanent, pH independent positive 
charge and thus aqueous solubility at neutral pH. The degree to which TMC can act 
as a PE has varied in a number of reports, partially due to differences in the 
physicochemical properties of the Cs precursor (Benediktsdóttir, Baldursson and 
Másson, 2014). The structure of TMC can vary in O-methylation, DA%, degree of 
trimethylation (DQ) and MW and often, the potential mechanism of action for TMC 
as a PE, is suggested to be a consequence of mucoadhesion, arising from charge 
interactions between polymer and mucosal membrane (Mourya and Inamdar, 2009). 
Furthermore, it has been postulated that TMC can be used for the enhancement of 
antigen delivery for vaccines via nasal delivery, due to the increased interaction of the 
antigen with the epithelial cell barrier and thus increased antigen uptake (Amidi et al., 
2010). 
To date, a vast number of researchers have derived TMC from commercially available 
Cs derived from crustacean sources (Xu et al., 2010). Yet, to the best of our 
knowledge, none have synthesised TMC from Cs of fungal origin, which presents an 
opportunity that may address the variations typically associated with crustacean TMC 
products. Fungal Cs (fCs) offers several advantages over its crustacean counterparts, 
owing to the highly controlled environments in which it is cultivated, year-round 
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growth that is not seasonally dependant and significantly less heavy metal association 
than that of crustaceans (Muzzarelli et al., 2012). In this context, production and 
purification of CT from the cell walls of waste fungal mycelium, and its subsequent 
derivatisation to Cs and TMC, offer the advantage of being environmentally friendly 
with potential for a more consistent product. 
As such, the aim of this study was to extract CT from the edible basidiomycete 
mushroom A. bisporus and to produce Cs with the same properties (DDA%, MW and 
purity) to that of PROTASAN™ UP (CL113), a commercially available fungal 
sourced Cs from Sigma Aldrich was also compared to the Cs produced in this work, 
as an additional reference check point.  
Following production of fCs with a satisfactory match to CL113, a further chemical 
modification to TMC was performed to assess whether fungal derived TMC may offer 
potential use as a PE and as an alternative to crustacean derived. The permeation 
enhancing properties of this new fTMC were tested. 
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7.2 Materials and Methods 
 
7.2.1 Materials 
PROTASAN™ UP (CL113) was purchased from NovaMatrix, FMC Corporations, 
Norway. Commercial CT (SACT) and Cs from fungal origin (SACs) was purchased 
from Sigma Aldrich. Ireland. Acetic acid, ACS reagent, ≥99.7%, sodium hydroxide 
solution 50 wt % in H2O, hydrochloric acid (HCL) 37 wt % in H2O were purchased 
from Fisher Scientific, Ireland. All other reagents, chemicals and solvents were of 
analytical grade from Sigma Aldrich, Ireland. Deionised water (dH2O) ≥18 MΩcm 
was obtained using Millipore Simplicity® Water Purification System and used for all 
manipulations unless otherwise specified. 
7.2.2 Preparation of Mushroom Samples 
A. bisporus samples were sourced from Tyholland Farm, Monaghan Mushrooms. 
Mushroom bodies were freeze-dried, ground to a powder, sieved through a 500 uM 
sieve and stored in a desiccator at room temperature for further analyses and 
extraction. Extraction of CT was preformed according to the protocol of Sagheer et 
al., (2009), with the following modifications. Dried mushroom powder (DMP) (10 g), 
was suspended in NaOH (1 M, 300 mL) to give a final weight to volume ratio of 1:30. 
The resultant slurry was then heated in a thermostatic chamber (80 °C) and agitated 
at 120 rpm for 1.5 hr, thrice, to extract proteins, alkali soluble polysaccharides, and 
small molecules (e.g. monosaccharides, phenolics, amino acids, and salts). The slurry 
was then centrifuged at 5,500 rpm, for 20 min at 4 °C, to obtain alkaline insoluble 
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material (AIM). The supernatant was discarded and the pellet subjected to the 
previous digestion conditions (80 °C, 120 rpm for 1.5 hr). The AIM was then 
centrifuged (5500 rpm, 20 min, 4 °C) and the pellet washed to neutrality (pH 7-7.4) 
extensively by H2O. Once neutral, the AIM was washed twice with boiling absolute 
ethanol (30 ml), resuspended in dH2O and freeze dried for approximately 36 hr 
(FreeZone 6 L bench top freeze dry system (Labconco, USA)). The weight of the 
dried product was recorded and then it was ground to a fine powder. 
7.2.2.1 Extraction of chitin from A. bisporus 
To obtain insoluble, crude fungal CT, the AIM was refluxed in 5 % acetic acid (20 
mL) for 6 h at 95 °C and then centrifuged at 10,000 rpm for 20 min at 4 °C. The 
resultant pellet was then washed with dH2O and ethanol as described in 7.2.2. CT, if 
present, remained as an insoluble residue (crude CT), and was then freeze dried for 
approximately 36 hours. The weight of the dried product was recorded and then 
ground to a fine powder. 
7.2.2.2 Chitosan preparation from crude CT 
Two methods were employed to produce Cs, conventional and microwave 
derivatisation. For the conventional method, crude CT (250 mg) was suspended in 
concentrated KOH (50 mL, 45 w/v %) and heated on a boiling water bath under 
constant agitation for 3.5 hr. The solution was then centrifuged (10,000 rpm, 30 min, 
22 °C) to obtain a pellet of Cs. The Cs pellet was then washed extensively with H2O 
until pH 7-7.4 was achieved and lyophilised for approx. 36 hr. For the microwave 
method, crude CT (250 mg) was weighed into individual microwave vessels 
(EasyPrep™, CEM, UK) followed by the addition of NaOH (9 mL, 30% w/v). Vessels 
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were then placed under magnetic stirring for 30 min at 900 rpm to ensure homogenous 
distribution throughout the solvent. Samples were then subjected to microwave 
irradiation (MARS5, CEM, UK) for 15 mins, at 900 W followed by a 30 min cool 
down period. The resultant Cs was then centrifuged (5500 rpm, 20 min, 22 °C) and 
the pellet washed extensively until neutral pH was reached (7-7.4). The product was 
then freeze dried for approximately 36 hr and the dried weight recorded. 
7.2.3 CT-Determination of the degree of acetylation via 13C-NMR 
spectroscopy 
Solid state 13C-NMR is often used for quantifying and determining the degree of 
purity of carbohydrates, in particular CT and Cs (Heux et al., 2000) and, as such, was 
applied to determine the purity and DA% of the CT samples extracted from A. 
bisporus. In the CT molecular structure, the amine group of the glucosamine residue 
is acetylated and consequently shows two additional resonances in the 13C-NMR 
spectrum, one related to the carbonyl group at 175 ppm and the other one with the 
methyl group at 25 ppm. These two signals are very distinctive as they occur at both 
sides of the signals due to the backbone structure, making them easy to identify. 
Spectra were recorded using a procedure published Heux et al., 2000 and the DA% 
calculated using equation 7.1:  
𝑫𝑨 (%) =  
𝑨𝑼𝑪𝟐𝟓
𝑨𝑼𝑪𝟏𝟕𝟓
× 𝟏𝟎𝟎 
(Equation 7.1) 
where AUC25 relates to the methyl carbons on the glucosamine residue at 25 ppm and 
AUC175 the carbonyl carbons at 175 ppm (Heux, et al 2000). 
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7.2.4 Chitosan-Determination of the DDA% 1H-NMR spectroscopy 
DDA% of Cs samples were determined using a procedure published by (de Oliveira 
et al., 2014) with the following modifications: Cs (100 mg) was suspended in HCl (10 
mL, 0.07 M) at room temperature (RT) and left to stir at 800 rpm overnight. Sodium 
nitrate (15 uL, 1 M) was then added to the solution and then left to stir for four hours 
at RT. NaOH (1 M) was then added drop wise until pH 10 was reached and the Cs 
subsequently precipitated out. The Cs pellet was then recovered by centrifugation at 
10,000 rpm for 15 min, washing extensively with dH2O, lyophilising and ion 
exchanging with D2O three times. The Cs sample (approximately 10 mg) was then 
transferred to a 2 mL Eppendorf and D2O (1.96 mL) was added along with DCl (40 
uL, 20% w/v). The solution was then left to agitate for 30 min to ensure full dissolution 
and was then transferred to a Colorspec™ NMR (Aldrich) tube for 1H NMR analysis. 
Spectra were recorded on a Bruker Avance 400 spectrometer at 80°C after 128 scans 
with a delay time of 4 seconds. An elevated temperature was used, with the aim of 
shifting the HOD signal to a higher field, allowing for the quantification of the 
glucosamine residue H-1 signals. The DDA% was than calculated using Equation 7.2 
(Lavertu et al. 2003): 
𝑫𝑫𝑨 (%) =  
(𝟏 − (
𝟏
𝟑 𝑯𝑨𝒄)
(
𝟏
𝟔 𝑯𝟐𝟔)
 × 𝟏𝟎𝟎 
 (Equation 7.2) 
where HAc corresponds to the methyl protons of the acetyl group and H26 represents 
the signal from protons H2, H3, H4, H5, H6, H6 of both monomers, through use of 
the integral peak intensity values (Lavertu et al. 2003). 
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7.2.5 Fourier transform infrared spectroscopy (FTIR) 
The FTIR spectrum of the extracted Cs was acquired via a Spotlight 400 series 
spectrometer (Perkin Elmer, USA), using the attenuated total reflectance spectroscopy 
method (ATR-FTIR), in the range of 650-4000 cm-1. Prior to analysis, Cs samples 
were lyophilised -40 °C for 36 hrs. The dried Cs solids were then placed on the ATR 
crystal prism (ZnSe), and 32 scans were acquired at 4 cm−1 resolution with 
background subtraction. 
7.2.6 Chitosan molecular weight determination: gel permeation 
chromatography (GPC) 
For all samples, Cs solutions (4.0 mg/mL) were prepared by direct dissolution in 
mobile phase (acetate buffer: 0.15 M acetic acid:0.1 M sodium acetate:0.2 mM 
sodium azide) by agitating at 300 rpm, at room temperature for two days, and were 
then filtered with a syringe filter (0.45 μm, Millipore). Analyses were performed at 
room temperature using 2 X PL Aquagel-OH MIXED-H 8um 300 x 7.5mm columns 
(Agilent, UK), at a flow rate of 1 mL/min and a sample injection volume of 20 μL. 
GPC data was acquired using a Varian 350 refractive index detector coupled to a 
Varian 210 solvent delivery module. A calibration curve was made by using GPC 
dextran standards of known MW (25-670 kDa) at 2.0 mg/mL concentration. 
7.2.7 Synthesis of trimethyl chitosan  
During TMC synthesis, the number of positive charges on the polymer chain is 
increased (Synman, D. et al., 2002) through the addition of methyl groups to the 
primary amines present on Cs. The use of Iodomethane (MeI) and N-methyl-2-
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pyrrolidinone (NMP) allows quaternisation through the nucleophilic substitution of 
the amine group with MeI and Sodium iodide (NaI). The N-quaternisation process 
depends on the concentration of NaOH used, the reaction time and the reaction steps. 
The initial TMC iodide salt is then dissolved in NaCl for exchange of iodide ions with 
chloride (Sieval, et al, 1998) (Figure 7.2). Once produced, TMC can be assessed for 
its ability to open cellular tight junctions (as determined in a transepithelial electrical 
resistance (TEER) assay) and thus infer its potential usefulness as a PE. 
 
Figure 7.2 The synthesis of N-trimethyl chitosan (TMC). 
TMC chloride was synthesised by methylation of fungal (fTMC) or commercial Cs 
(cTMC) with methyl iodide (MeI) in the presence of NaOH, as per Sieval et al., 
(1998), with slight modifications. In detail, a mixture of Cs (1 g), sodium iodide (2.4 
g) and NaOH (5.5 mL, 15 % w/v) in N-methylpyrrolidinone (NMP) (40 mL) was 
maintained in an oil bath under magnetic stirring at 60 °C for 30 min in the presence 
of a Liebig condenser. Then, MeI (5.75 mL) was added to the mixture and the reaction 
was continued for another 75 min. The product was then precipitated by the addition 
of ethanol and isolated by centrifugation at 4000 rpm, 4 ºC, for 5 min. The pellet was 
washed with diethyl ether, dried under vacuum and then resuspended in NMP (40 
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mL), at 60 ºC and stirred continuously until the product dissolved. Once dissolved, 
NaI (2.4 g), NaOH (5.5 mL, 15 % w/v) and MeI (3.5 mL) were added to the flask and 
the reaction was left to proceed for 30 min. MeI (2 mL) and NaOH (0.3 g) pellets were 
then added to the flask and the reaction was left to proceed for a further 60 min. The 
product was then precipitated by the addition of ethanol and isolated by centrifugation 
at (4000 rpm, 4 ºC, 5 min). Resultant pellets were then resuspended in an aqueous 
NaCl solution (10 % w/v), to exchange iodide for chloride ions and the product was 
reprecipitated with ethanol, isolated by centrifugation at (4000 rpm, 4 ºC, 5 min). The 
final product was dissolved in H2O and centrifuged (5500 rpm, 4 ºC for 10 min) to 
remove insoluble material (such as demethylated Cs residues N-(CH3)2). The resultant 
supernatant was then dialysed against deionised water (changing buffer twice-daily) 
for 3 days and freeze dried for 36 hr to obtain white purified TMC powder. 
7.2.7.1 Water solubility of fTMC and cTMC 
Aqueous solubility of the different polymers (fTMC and cTMC) was determined in 
HPLC grade water (pH 7) solvent at room temperature. Samples were dissolved at 
concentrations ranging from 1-10 w/v %, and the transmittance of the solutions at 500 
nm was measured on an UV/VIS spectrophotometer (TECAN GENios, Grodig, 
Austria). The polymers were considered insoluble when the transmittance was less 
than 90% compared to the transmittance of the solvent (Verheul et al., 2008). 
7.2.8 Determination of the degree of quaternisation and O-
methylation by 1H-NMR 
To determine the degree of quaternisation (% DQ) and O-methylation (OMe) the 1H 
NMR spectrum of TMC was measured in D2O, using a 400 MHz spectrometer 
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(Bruker-Biospin, Rheinstetten, Germany) at 80 °C. The % DQ and OMe was 
calculated by the following equations (Zarifpour 2013): 
𝑫𝑸 =
[(𝑪𝑯𝟑)𝟑]
[𝑯]
×
𝟏
𝟗
× 𝟏𝟎𝟎%  
 (Equation 7.3) 
𝑶𝑴𝒆 =
[(𝑪𝑯𝟑)]
[𝑯]
×
𝟏
𝟑
× 𝟏𝟎𝟎%  
 (Equation 7.4) 
where DQ is the degree of quaternisation, in mole percentage of free amine, [(CH3)3] 
is the integral of chemical shift of the hydrogens of trimethyl amino groups at 3.3 
ppm, [(CH3)] the methylated hydroxyl groups at either 3.4 (OMe-6) or 3.5 (OMe-3) 
ppm and [H] is the integral of H-1 peaks between 4.7 and 5.7 ppm, related to hydrogen 
atoms bound to carbon 1 of the Cs molecule, which is taken as the reference signal.  
7.2.9 Transepithelial electrical resistance (TEER) measurements 
Caco-2, human colon adenocarcinoma cell lines, are regarded as representative of the 
small intestine (Brayden, Cryan, et al., 2015; Gleeson et al., 2015). When they are 
grown on semipermeable filters, they spontaneously differentiate in culture to form 
confluent, polarised, columnar cell monolayers (Woitiski et al., 2011). Therefore, they 
have widely been selected as an in vitro model for evaluation of intestinal drug 
absorption (Maher, Mrsny and Brayden, 2016). Caco-2 cells were seeded at a density 
of 6x105 cells per well on 12-transwell plates with a microporous membrane. The cells 
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 
L-glutamine (1%), Penicillin and streptomycin (PEST) (1%), non-essential amino 
acids (1%) and foetal bovine serum (10%), for 21 days until a confluent cell layer was 
formed. The medium was replaced by Hank’s Balanced Salt Solution (HBSS) at the 
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basolateral side and left to equilibrate for 1 hr before the start of the experiments. 
Then, 0.5 ml solution of TMC (0.1 w/v), derived from commercial Cs (cTMC) or 
fungal Cs (fTMC), was applied at the apical side of the cell monolayers. Sodium 
caprate (0.1 % w/v) was used as positive control and Hanks balanced salt solution 
(HBSS) as reference. The resistance of the membrane, measured without cells, was 
used as blank. The TEER of the Caco-2 cells was measured with an Epithelial 
Voltammeter (EVOM - World Precision Instruments Inc, USA), using the chopstick 
method (Verheul et al., 2008), at certain time points (0, 10, 30, 60 90 min and 120 
min) after addition of the stimuli. After 90 minutes, the cells were washed with HBSS 
and incubation of the cells was continued in DMEM for 24 hrs at 37 °C, CO2 5% to 
determine the recovery of the TEER. 
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7.3 Results and Discussion 
 
7.3.1 Percentage yield of chitin and chitosan 
The CT in cultivated A. bisporus, is a stable characteristic of the species and there are 
no significant differences between the CT content of pileus (cap) and stipes (stalk) of 
fruiting bodies (Vetter, 2007). In this work, CT was found to account for 6.6 ± 2.2 % 
of the DMP (Table 7.1), consistent with the observations of Vetter, (2007), who found 
that 6.68 and 7.25 % of A. bisporus pileus and stipes, respectively, existed as CT. 
After extraction of CT from the DMP used in this study, two derivatisation methods 
were employed to produce Cs, which were conventional, and microwave assisted 
(Section 7.2.2). As can be seen in Table 7.1, a significantly higher yield of Cs was 
obtained for microwave derived Cs (55%) vs conventional (33%). Moreover, the 
microwave method entails more than half the reaction time of conventional (45 min 
vs 3.5 hr). The lower yield recovery from the conventional method may be attributable 
to the highly basic solvent (KOH 45 w/v %) and the long reflux time (3.5 hr), causing 
depolymerisation of the CT backbone (through hydrolysation of the amide bond of N-
acetylglucosamine) allowing for its subsequent loss during the washing process 
(Anwar, Anggraeni and Amin, 2017). 
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Table 7.1 Yield and composition of material obtained during extraction of chitinous 
material from A. bisporus samples. aCT yield expressed as percent of DMP, bCs yield 
expressed as percent of CT, cCs conventionally derived, dCs microwave derived. 
Sample Yielda (%) Yieldb (%) 
DMP 100 - 
AIM 25 ± 4.7 - 
CT 6.6 ± 2.2 100 
cCs - 33.3 ± 6.8 
dCs - 55.4 ± 5.6 
In contrast to the applied, relatively simple and fast method for producing pure fCs 
with microwave irradiation described in this work, the more common extraction of Cs 
from crustaceans requires higher concentrations of sodium hydroxide at high 
temperature and, in general, the whole procedure is costlier and time consuming 
(Tajdini et al., 2010). Therefore, the fungi could be considered as a good alternative 
source of Cs. 
7.3.2 13C-NMR -Chitin DA% determination 
Figure 7.3 shows the 13C-NMR spectrum of the fungal CT, which exhibits eight main 
peaks: sharp peaks at 173 and 22 ppm were assigned to the carbonyl and methyl 
carbons, respectively; the peaks at 103, 82, 74, 72, 59 and 54 ppm were ascribable to 
the resonances of C1, C4, C5, C3, C6, and C2 on the N-acetyl-D-glucosamine unit of 
CT, respectively, also illustrated in Figure 7.3. The DA% of the extracted CT was 
then calculated using the relative integrals of methyl or carbonyl groups related to the 
carbon integrals of the polysaccharidic backbone (Equation 7.1,) and compared with 
the commercial CT purchased from Sigma Aldrich (Table 7.2). 
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Figure 7.3 Solid state 13C-NMR Spectra of CT extracted from A. bisporus. 
Well resolved, high purity spectra were observed for both commercial and extracted 
CT, both having a DA of around 100%. No significant difference in DA was observed 
between the commercial and extracted CT in this work (Table 7.2), and the high 
degree to which it is acetylated indicates that the CT produced is a suitable candidate 
for further derivatisation.  
Table 7.2 DA% of extracted CT and SACT, calculated as per Equation 7.1. 
Sample DA (%) 
SACT (commercial) 96 ± 4.5 
CT (extracted) 101 ± 5 
Extracted CT was also assessed to establish the crystalline form (α, β or γ) that was 
present in the A. bisporus sample. The α form has chains arranged alternately 
antiparallel; the β form has all chains parallel, while γ-CT is considered a form of α 
CT with alternating parallel and antiparallel chains (Figure 7.4 (Kumirska et al., 
2011)). It has been shown that β-CT is much more amenable to deacetylation than the 
α form (Abdou, Nagy and Elsabee, 2008), which is useful when trying to increase the 
DDA% in order to attain requisite Cs properties for a given application. Notably, the 
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signals assigned to C3 and C5 of the CT powder existed as a single peak, inferring 
that the CT extracted from A. bisporus was in the β crystal form (Duan et al., 2013). 
β-chitin has the unique feature of incorporating small molecules, including water, into 
its crystal lattice to form crystalline complexes (Li, Revol and Marchessault, 1999) 
and thus is more easily hydrated and soluble in water (Wan and Tai, 2013) The weaker 
hydrogen-bonding from the parallel-chain structure of β-chitin may account for its 
higher chemical reactivity (Kurita et al., 2005). 
 
Figure 7.4 Schematic representation of the three polymorphic forms of CT (a) α -
CT. (b) β-CT. (c) γ-CT (adapted from Kumirska, Mirko X. Weinhold, et al. 2011). 
7.3.3 1H-NMR -Chitosan DDA% determination 
Figures 7.5 and 7.6, show the 1H-NMR spectrum of A. bisporus Cs, conventionally 
and microwave derived, respectively. The peak present between 2.0-2.5 ppm 
represents the methyl protons of the N-acetyl-glucosamine unit (Ac) and the peak 
between 3.2-3.6 ppm denotes the H-2D proton of the glucosamine (H2, D) residues 
(Hirai, Odani and Nakajima, 1991). Similar chemical shifts are observed for the non-
anomeric protons (H2-H6, A and H3-H6, D) connected to the polymer backbone, due 
to their similar electron densities, resulting in their signals partially overlapping, 
causing a broad envelope of signals within the middle of the spectrum, in the range of 
approximately 3.78-4.32 ppm (Kasaai, 2010). Lastly, the anomeric protons can be 
seen at higher chemical shifts (approx. 5.33 and 5.01 for H1,D and H1,A respectively) 
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(Lavertu et al., 2003), attributable to their deshielding glycosidic and ring oxygen 
neighbours. Additionally, these proton bands possess the least resolution in the 1H-
NMR spectra, followed by H3, H4, H5, and H6, while, in contrast, the methyl protons 
retain the highest resolution of all peaks (Kasaai, 2010). 
 
Figure 7.5 1H-NMR spectra of A. bisporus Cs (conventional extraction) at 80°C in 
DCl 2 wt % in D2O. 
Table 7.3 details the 1H-NMR calculated DDA% of the commercial chitosans (SACs 
and CL113), which were found to be 85±4% and 81±4.5% respectively. The Cs 
conventionally derived from the A. bisporus was found to have a similar DDA% of 
75±6%, in comparison to the microwave extracted (86 ± 6) and, in addition, showed 
less peak resolution than the microwave Cs samples. This may be attributed to the fact 
that CT typically exists with associated minerals and proteins that may contain C=O 
and NH functional groups, similar to those found in Cs (Brugnerotto et al., 2001). 
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Figure 7.6 1H-NMR spectra of A. bisporus Cs (microwave extracted) at 80°C in DCl 
2 wt % in D2O. 
Contamination of Cs with impurities such as these may have contributed to the 
creation of interference peaks (in addition to change in position and intensity of the 
signal bands (Brugnerotto et al., 2001; Kasaai, 2010) and the conventional method 
may not possess the full capacity to remove these impurities. This is evident in the 
1H-NMR spectrum of the conventionally derived Cs (Figure 7.5), in which the signal 
of the H1-A proton appears to have been overlapped by the solvent peak at 
approximately 4.82 ppm and all other proton signals have been shifted slightly upfield 
compared to those of the microwave Cs samples (Figure 7.6). Furthermore, the fast 
and direct heating of reactants using microwave irradiation has been reported to not 
only give higher yields, but to improve the purity of the desired products (Singh, 
Kumar and Sanghi, 2012), as reflected in the 1H-NMR observations for microwave 
derived Cs (Figure 7.6), whereby the H1-A proton is well resolved at 5.1 ppm. Due to 
the reduction of chemicals usage, reaction time and significantly higher DDA%, 
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purity and yields (Section 7.3.1) of Cs obtained via microwave derivatisation, it was 
selected for use in the experiments from this point on. 
Table 7.3 DDA% of SACs, CL113 and Cs extracted by conventional or microwave 
method, calculated as per Equation 7.2. 
Sample DDA (%) Derivatisation method 
SACs 81 ± 4.5 - 
CL113 (NovaMatrix) 85 ± 4 - 
Cs (A. bisporus) 75 ± 6% Conventional 
Cs (A. bisporus 86 ± 6 Microwave 
7.3.4 FTIR analysis of extracted chitin and chitosan 
The structure of the extracted Cs was confirmed by FTIR analysis (Figure 7.7). Table 
7.4 provides a comprehensive list of all FTIR spectral bands observed in both 
commercial and extracted Cs and CT samples; it is worth noting the key peaks 
associated with the analysis of both compounds, for example the characteristic peak 
at ≈1550 cm-1 that is present in Cs (due to the presence of the primary amine on the 
D-glucosamine unit) but not in CT. 
CT was examined via FTIR (denoted A and B in Figure 7.7) in order to establish the 
crystalline form (α, β or γ) that was present in the A. bisporus sample. Typically, α-
CT shows two characteristic bands between ~1660-1620 cm-1 (amide I splitting), 
whereas β-CT displays one band in the amide I region only (Jang et al., 2004). As can 
be seen, neither commercial or extracted CT displayed peak splitting in the amide I 
region and, as such, were determined to be in the β crystal form (Raafat and Sahl, 
2009), further corroborating the 13C-NMR observations (Section 7.3.4). 
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Figure 7.7 IR spectra (off set for clarity) of CT and Cs obtained from, A; CT extracted from A. bisporus, B; Commercial CT (Sigma 
Aldrich), C; Commercial SACs (Cs, Sigma Aldrich), D; Commercial Cs ( NovaMatrix, CL113), E; Cs extracted from A. bisporus.
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Table 7.4 FTIR bands observed in A; CT extracted from A. bisporus, B; Commercial CT (Sigma Aldrich), C; Commercial SACs (Cs, 
Sigma Aldrich), D; Commercial Cs (NovaMatrix, CL113), E; Cs extracted from A. bisporus. 
Wavenumber (cm-1) frequency 
Figure 7.7 A B C D E 
Sample A. bisporus CT SA CT SACs CL113 A. bisporus Cs 
Bond Assignment cm-1 cm-1 cm-1 cm-1 cm-1 
NH Stretch, amine OH in pyranose ring 3271 3263 3262 3240 3261 
CH2 in CH2OH group 2925 2929 * 2879 * 
C=O in NHCOCH3 group (amide I band) 1632 1631 1621 1625 1627 
NH2 in NHCOCH3 group (amide II) * * 1553 1514 1555 
CH2 ending and CH3 deformation 1401 1401 * * * 
CH3 in NHCOCH3 group * * 1375 1376 1375 
CH in pyranose ring * * 1308 1315 * 
C-O-C (glycosidic linkage) * * * 1151 * 
C-O-C (glycosidic linkage) * 1078 1068 1063 * 
C-O in secondary OH group 1026 1022 1024 * 1028 
C-O in primary OH group * 931 * * * 
Pyranose ring skeletal vibrations 884 889 * * * 
*not observed 
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Regarding Cs analysis, the spectra of all samples analysed (denoted C, D and E in Figure 
7.7), both commercial and extracted, showed a broad absorption band in the range 3240 
cm-1- 3271 cm-1 which is attributed to stretching vibrations caused by the primary amine 
and pyranose ring hydroxyl groups (Kaya et al., 2014; Rumengan et al., 2014). Key 
characteristic bands such as amide I band at 1620 cm-1 (carbonyl (C=O)) and amide II at 
1550 cm-1 (amine (NH2 tensions) were also observed, which is in agreement with 
literature findings (Abdou, Nagy and Elsabee, 2008; Kaya et al., 2014). The peaks around 
2879, 1375 and 1068 cm-1 in the FTIR spectrum are due to the stretching vibrations of 
aliphatic C– H, Amide III and C–O–C bonds, respectively, and are the main 
characteristics of the Cs polysaccharide (Kaya et al., 2014; Rumengan et al., 2014). 
Furthermore, FTIR spectral similarities between, SACs, CL113 and chitosan produced 
from the A. bisporus samples in this work displayed a correlation percentage of 85.31% 
and 74.93% respectively (Figure 7.7). 
7.3.5 Molecular weight determination 
MW is another important physical property of Cs and is typically determined via viscosity 
measurements or gel permeation chromatography (GPC) (Baxter et al. 2005; Zielinska et 
al. 2014). The size range of fungal derived Cs has been reported as 17-450 kDa by various 
authors (Miyoshi et al. 1992; Niederhofer & Müller 2004; Badawy & Rabea 2009). In 
terms of determining what size of Cs to use for a given application, low MW Cs is 
considered to be 10-90 kDa, medium MW in the range of 90-310 kDa and high MW 310-
375 kDa (Zappino et al. 2015; Lal et al. 2012). In this work, GPC was employed to 
determine the MW of CL113, SACs, fCs and fTMC, and all tested compounds fell within 
the medium MW range (Table 7.5). 
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Table 7.5 MW (kDa) of CL113, SACs, fCs and fTMC as determined by GPC, means 
that do not share a letter are statistically different (p < 0.05) . 
Sample CL113 SACs fCs fTMC 
MW (kDa) 110.1±5.9a 165.5±39.9a,b 156.3±23.6 b 198.8±16.6 c 
It was observed that the MW of the produced fCs was significantly higher than that of 
CL113 (156 vs 110 kDa). Additionally, there was a larger spread of variation in the 
extracted fCs vs the CL113 (±24 vs ±6) respectively. This is expected, as CL113 is 
certified to possess a MW of 110-150 kDa and as such is most likely fractionated before 
sale in order to meet this requirement. Additionally, it has previously been shown that Cs 
produced via microwave heating tends to have a higher molecular weight than 
conventionally derived Cs (Sagheer et al., 2009) and this may also be an attributing factor 
to the higher MW. A strategy to match the fCs further with CL113 in terms of MW would 
be to depolymerise the chain with NaNO2 (Mao et al., 2004) and subsequently fractionate 
it with semi-preparative GPC (Nguyen, Winnik and Buschmann, 2009). However, as 
medium molecular weight Cs, intended for use as a drug delivery vehicle, is considered 
ideal (Bowman and Leong, 2006), the fCs can be considered acceptable for use in future 
NP formulations. Interestingly, the commercial SACs was found to possess the highest 
MW in addition to the largest spread of variation (165±39 kDa) and although this product 
has not been sold as an ultrapure, highly characterised, Cs, it is worth noting for other 
researchers, considering its employment in various applications. Lastly, the MW of the 
fCs was found to increase after synthesis to TMC, which was expected due to the addition 
of methyl groups to the free amine residues of the Cs backbone (Verheul et al., 2008).  
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7.3.6 TMC solubility 
Table 7.6 shows the water solubility of the synthesised TMCs (derived from CL113 or 
fungal Cs extracted from A. bisporus), both with and without centrifugal purification 
(Section 7.2.7). As can be seen, a significant improvement in both cTMC and fTMC 
aqueous solubility (1 vs 10 %, at pH 7) was observed by employing the centrifugal clean 
up step (Section 7.2.7). This is an expected result, as any residual, insoluble, O-
methylated (OCH3) and dimethylated (CH3)2 amines would be removed from the final 
product, thus increasing solubility (Verheul et al., 2008). 
Table 7.6 Results of Solubility of Synthesised TMC. 
 Non-Purified Purified 
Conc. (%w/v) fTMC cTMC fTMC cTMC 
1% + + + + 
2% - + + + 
4% - - + + 
6% - - + + 
8% - - + + 
10% - - + + 
Interestingly, without the clean-up step, cTMC showed solubility up to 2 % w/v, whereas 
fTMC to only 1 w/v %, most likely attributable to the higher MW of the fCs, which plays 
an important role in the solubility of the final product, whereby typically, the lower the 
MW, the higher the solubility (Sajomsang et al., 2010).  
7.3.7 1H-NMR - TMC DQ % determination 
Several studies have been performed to determine the optimal DQ% for solubilising TMC 
in neutral aqueous media and for the trans epithelial delivery of low molecular weight 
drug molecules and/or proteins (Mourya and Inamdar, 2009; Vongchan et al., 2011; de 
Britto et al., 2012). For TMC to be soluble in neutral aqueous solvents, it is requisite that 
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the DQ% be ≥ 28 % and, for trans epithelial delivery of both low molecular weight 
compounds and proteins, a DQ% of about 40-50% is generally accepted to be optimum 
(Benediktsdóttir, Baldursson and Másson, 2014). In this work, the calculated DQ% 
(Equation 7.3) of fTMC and cTMC was found to be 45 ± 6 and 40 ± 4 respectively (Table 
7.7) and repeated experiments showed good reproducibility, inferring the suitability of 
the synthesised polymers to serve as absorption enhancers. 
Table 7.7 Degree of quaternisation (DQ %) calculated as per Equation 7.3 and 7.4.  
Sample DQ (%) OMe-6 OMe-3 
fTMC 45 ± 5.5 25 ± 6.5 18 ± 4.0 
cTMC 40 ± 3.5 21 ± 2.5 15 ± 2.0 
In this work, chitosan was methylated with methyl iodide to yield TMC (Figure 7.2) and 
the 1H NMR spectrum of the fTMC polymer is presented in Figure 7.8. The amino groups 
in the C-2 position of Cs were methylated to form quaternary amino groups with fixed 
positive charges on the repeating units of the TMC polymer chain. According to the 
results of previous studies (Domard et al., 1987; Sieval et al., 1998), the peak at 3.8 ppm, 
that was not detected in the 1H NMR spectrum of Cs (Figure 7.5 and 7.6), is attributable 
to the nine hydrogen atoms of the methyl groups pertaining to trimethylated amino 
groups, and the peaks between 4.9 and 5.9 ppm are assigned to the 1H protons, which 
were taken as the reference signal. 
An overview of the 1H-NMR results of the O-methylated TMCs is presented in Table 7.7. 
Although O-methylation is a well-known side-reaction in TMC synthesis, that reduces 
the aqueous solubility of the product, there are relatively few studies that report the extent 
of this side reaction (Verheul et al., 2008). The spectrum of fTMC synthesised showed 
O-methylation of the hydroxyl groups at the C-3 and C-6 of the glucosamine units (peaks 
observed at 4.0 and 3.9 ppm, respectively) showing that OMe-6 and OMe-3 were 25 and 
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18%, respectively (Equation 7.4). As the C-6 hydroxyl groups are less sterically hindered 
than the hydroxyl groups on the C-3, a higher degree of methylation is observed (Verheul 
et al., 2008). 
 
Figure 7.8 1H-NMR-spectra of fTMC with a DQ of approximately 45 % at 80°C in D2O. 
7.3.8 TEER -TMC as a permeation enhancer  
TEER measurements for intestinal membrane models such as Caco-2 human colon 
adenocarcinoma cell monolayers can be used to predict their paracellular permeability. 
When the tight junctions (TJs) are open, the TEER of Caco-2 cell monolayers is 
significantly reduced due to the passing of ions via their paracellular route (Hidalgo, Raub 
and Borchardt, 1989). TEER has been applied to study the permeation enhancer (PE) 
effects of compounds such as polyacrylic acid, polycarbophil and TMC, over recent years 
(Aungst, 2000; Liu et al., 2008; Maher, Mrsny and Brayden, 2016), the latter having been 
shown to exhibit a reversible time and dose dependant decrease, thus indicating its ability 
to open the TJs (Ranaldi et al., 2002). 
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The initial studies in this work looked to compare the TEER measurements across Caco-
2 cells incubated with fTMC and cTMC to the well-established PE, sodium caprate (C10) 
(Brayden, Gleeson and Walsh, 2014) at 0.1 % w/v, vs HBSS as reference (Figure 7.9).  
 
Figure 7.9 TEER assessment of commercial (cTMC) and fungal (fTMC) derived TMC 
(0.1% w/v) using C10 (0.1% w/v, 10mM) as a positive control. Error bars represent the 
standard deviation of six measurements.  
It was observed that a significant reduction to TEER occurred for both TMCs vs HBSS 
alone, and no significant difference between cTMC and fTMC was apparent (50±4 % vs 
47±6 %, respectively) at the test concentrations employed (0.1% w/v). It is has previously 
been shown that a decrease of TEER, to a value not exceeding 50% of the initial reference 
value (HBSS), is insufficient to permit paracellular transport of the marker substances 
(Borchard et al., 1996). C10 at 0.1 % w/v (10 mM) comfortably achieved a reduction of 
TEER to 94±4% (Figure 7.9). However, as concentrations of C10 exceeding 10 mM have 
been shown to elicit substantial cytotoxicity (Gleeson et al., 2015), it was decided to 
increase the TMC concentration for further investigation, whilst maintaining C10 (10 
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mM) as positive control. Additionally, as the ultimate goal of this work was to produce 
and assess fungal derived fTMC as a PE, it was decided that fTMC be solely evaluated 
for further investigation. 
Figure 7.10 presents the TEER assessment of fTMC ranging from 0.2-0.6 % w/v. As can 
be seen, after 120 min incubation, the initial TEER value in Caco-2 cell monolayers 
incubated with fTMC, across all test concentrations, decreased by ≥ 75 %. This is 
consistent with reports from Kotzé et al., (1998), whereby increased TMC concentrations 
(0.25-1.5 % w/v) lead to further decreases in TEER values, on Caco-2 monolayers. It has 
recently been reported that exposure of C10 at 10 and 12 mM to Caco-2 monolayers 
irreversibly reduced TEER ≈90% after 15 min (Brayden, Maher, et al., 2015). The 
observations in this work are in line with those reported, as the greatest reduction in TEER 
was again observed for C10 (94 %). However, this decrease in TEER value may be 
attributable to a decrease in cell viability after long periods of incubation (Marušić et al., 
2013). To assess whether this was the case, all test compounds were removed from the 
monolayers after the 120 min exposure and replaced with DMEM to determine the 
recovery of the TEER after 24 hr. A recovery of TEER after the experiments would imply 
that the cells were undamaged and functionally intact and, as the results in Figure 7.10 
shows, the TEER of the fTMC monolayer partially recovered after removal of the 
solutions (≥60 % of initial reference value), whereas that exposed to C10 did not (≈8 %).  
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It has also been proposed that, due to the high viscosity and adhesive nature of TMC, the 
reversibility of TEER decrease is gradual, owing to the fact that complete removal of the 
polymer prior to recovery is unlikely without incurring some damage to the cells 
(Borchard et al., 1996; Verheul et al., 2008). 
 
Figure 7.10 TEER assessment of fTMC concentrations (0.2-0.6 w/v %) on Caco-2 cell 
monolayers. C10 (0.1 % w/v) was used as a positive control. Error bars represent the 
standard deviation of six measurements.  
It has been established that Cs unmodified or TMC with DQ% less than 18 % is unable 
to significantly reduce TEER. However, at DQ% of 40-60 %, a decrease in TEER of 
Caco-2 cells and increased mannitol permeation at pH 7.4 can be achieved (Amidi et al., 
2010). This study concluded that the prepared fTMC was capable of transiently and 
reversibly opening the tight junctions between Caco-2 cells and thus merits further 
investigation as a PE. 
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7.4 Conclusion 
In this work, CT has been extracted from A. bisporus with equivalent purity and DA% to 
a commercial standard, as determined by 13C NMR. The extracted CT was then 
derivatised to Cs, the optimum method for production being identified as microwave 
extraction. The Cs produced using this method showed equivalent purity and DDA% to 
that of commercial fungal Cs purchased from Sigma Aldrich and that of ultrapure CL113 
from NovaMatrix, as identified by 1H-NMR and FTIR spectroscopy. As Cs, a positively 
charged polyelectrolyte, has shown promising potential as a drug delivery vehicle, this 
may be an application for future use of the product. Lastly, fungal and commercial Cs 
were then chemically modified to TMC and assessed for permeation enhancing effects 
using TEER, showing its potential application as a PE. Based on the present knowledge 
identified in this work, A. bisporus can be considered as a good source of CT that can be 
easily isolated without aggressive treatments, subsequently deacetylated for the 
production of Cs and chemically modified to TMC, showing these by-products have 
potential use for many different practical applications. 
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8 FUNGAL CHITOSAN NANOPARTICLES 
COATED WITH ZEIN FOR IMPROVED 
ORAL DELIVERY OF SELENOCYSTINE 
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The work presented in this chapter contains the following elements of research: 
An unpublished study of the validation of an extraction and characterisation of 
selenoamino acids from Irish mushrooms with the objective of demonstrating the 
availability of the species for supplement production in the Irish context (Sections 8.2.2-
8.2.3 and 8.3.1-8.3.2).  
A study of the formulation of SeCys2 into nanoparticles produced from A. bisporus origin 
chitosan, using results from previous chapters to demonstrate the feasibility of a 
supplement formulation containing using mushrooms origin ingredients. This work will 
be submitted as: 
Vozza, G., Khalid, M.D, Forde S, Byrne, H. J., Ryan, S and Frias, J. (2018). Fungal 
chitosan nanoparticles coated with zein for improved delivery of selenocystine. To the 
Journal of Innovative Food Science and Emerging Technologies (IFSET), May 2018. 
Vozza, G., was the primary author, Khalid, M.D., helped develop the formulation process, 
Forde, S, conducted experiments in Section 8.3.6 and Byrne, H. J., Frias, J. and Ryan S 
contributed to layout, design and proofing. 
  
 281 
Abstract 
Selenoamino acids (SeAAs), have been shown to possess antioxidant and anticancer 
properties. SeAAs, especially selenocystine (SeCys2) and selenomethionine (SeMet) 
have been shown to accumulate in mushroom bodies supplemented with Se during 
cultivation. In this work, a Reverse phase, high performance liquid chromatography, 
Photodiode Array Detector (RP-HPLC-PDA) method was validated to analyse the SeAAs 
content of Se supplemented A. bisporus. The predominant species found was SeCys2, at 
616 ± 23 µg/g dried mushroom powder (DMP), while 18 ± 9 µg/g DMP of SeMet was 
identified, inferring that Se supplemented mushrooms may be a viable source for organic 
Se (291±7 µg/g of Total Se). SeCys2, however, can be toxic above the recommended 
nutritional intake level, and thus improved, targeted delivery methods are desirable. 
SeCys2 was encapsulated into nanoparticles (NPs) composed of fungal derived chitosan 
(fCs), via ionotropic gelation with tripolyphosphate (TPP), then coated by zein (a maize 
derived prolamine rich protein). Optimum NP physicochemical properties for oral 
delivery were obtained at a 6:1 ratio of Cs:TPP, with a 1:0.75 mass ratio of Cs:zein 
coating (diameter ~300 nm, polydispersity index ~0.3, zeta potential >38mV). Scanning 
electron microscopy (SEM) analysis showed spheroidal, well distributed particles. An 
encapsulation efficiency of 84.4 % was achieved. Cytotoxicity studies of SeCys2 loaded 
NPs elicited no decrease in cellular viability in Caco-2 (intestinal) cells after 4hrs 
exposure, although a significant reduction was observed, when compared to pure SeCys2, 
for all test concentrations in HepG2 liver cells, after 72 hr exposure. Accelerated thermal 
stability testing of the NPs indicated good stability under normal storage conditions. 
Lastly, the sustained release profile of the formulation showed that 32 ± 4.5 % of SeCys2 
was released from the fCs NPs after 2 hr in simulated gastric fluid, followed by 30 ± 2 % 
release in simulated intestinal fluid for 4 hr. 
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Keywords 
Agaricus bisporus, Fungal chitosan, selenium, zein, selenocystine, nanoparticles, oral 
delivery. 
Abbreviations 
fCs, fungal chitosan; CL113, PROTASAN™ UP; DLS, dynamic light scattering; EE%, 
Encapsulation efficiency; GRAS, Generally recognised as safe; LDV, laser doppler 
velocimetry; MSC, methylselenocysteine; NP, nanoparticle; PDI, Polydispersity; 
SeCys2, selenocystine; SeMet, Selenomethionine; TPP, Tripolyphosphate; ZP, Zeta 
potential. CT, Chitin; DDA%, Degree of Deacetylation. 
8.1 Introduction 
Selenium is an essential micronutrient in human and animal nutrition (Rayman, 2000) 
that exists in a wide array of different forms, both organic and inorganic. Selenite and 
selenate salts are the most common inorganic forms, whereas selenoamino acids 
(SeAAs), such as selenocystine (SeCys2), selenomethionine (SeMet), and 
methylselenocysteine (MSC) are the most commonly found forms in foods from the 
Agaricus, Brassica and Allium families (Montes-Bayón, M. J D Molet, et al., 2006; 
Maseko et al., 2013; Reilly et al., 2014). Health benefits of Se originating from MSC and 
SeCys2 have been linked to the body’s endogenous antioxidant defence system, 
protecting cellular components such as cell membranes, lipids, lipoproteins and DNA 
from oxidative damage by free radicals, reactive oxygen and reactive nitrogen species 
(Ponnampalam et al., 2009). As oxidative damage is linked to the development of 
cardiovascular and neurodegenerative diseases as well as cancers, several experimental 
in vivo studies of the effects of administration of Se compounds have been undertaken 
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(Valko et al., 2007; Lobo et al., 2010; de Souza et al., 2014). SeCys2 has been shown to 
reduce tobacco-derived nitrosamine-induced lung tumour growth and enhance hepatic 
chemoprotective enzyme activities in mice (Fan et al., 2013), SeMet may have some 
potential in degenerative disease by decreasing oxidative stress of small molecule 
antioxidants used as a buffer for free radicals in brain tissue (Song et al., 2014; Reddy et 
al., 2017), whereas MSC has been shown to offer selective protection against organ 
specific toxicity induced by clinically active antitumor agents, cisplatin, oxaliplatin, and 
irinotecan in rat models (Cao et al., 2014). A number of benefits regarding oncology 
treatments due the modulation of the therapeutic efficacy and selectivity of anticancer 
drugs has been reported for these SeAAs also (Evans, Khairuddin and Jameson, 2017). 
Although essential, Se possesses a low therapeutic index, meaning that there is a fine line 
between beneficial and toxic doses. Generally, organic Se shows a greater degree of 
bioavailability than the inorganic forms, as well as a higher threshold for toxicity 
(Amoako, Uden and Tyson, 2009). Despite the associated health benefits, Se intake in 
Ireland is remarkably low, whereby, nearly 50% of females and 20% of males aged 
between 18 – 64 years fail to meet the average recommended requirement (ARR) of 40 
µg/day (Murphy and Cashman, 2002). This low Se intake in the Irish population has been 
attributed to the drop in imports of high-protein wheat for bread-making flour from North 
America and Canada (Barclay and Macpherson, 1992), which are Se-rich in comparison 
to Irish flour varieties (Murphy and Cashman, 2001).  
Selenium-fortified A. bisporus have demonstrated the ability to assimilate inorganic Se 
(such as sodium selenite) from the growth substrate and convert it to organic forms, such 
as SeMet, MSC and SeCys2 (Maseko et al., 2013)  For this, mushrooms have been 
proposed as a potential source of Se for Se deficient populations (Falandysz, 2008; 
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Maseko et al., 2013). While A. bisporus generally contain an average of only >1 µg Se/g 
dry weight (Savic et al., 2012), when cultivated in substrates containing Se in either 
inorganic or organic forms, they exhibit much higher concentrations, ranging from 354 ± 
0.19 µg/g to 707 ± 37.3 µg/g of Se (Gergely et al., 2006; Savic et al., 2012).  
The predominant form of Se identified in A. bisporus is SeCys2 (Maseko et al., 2013), 
which has been shown to exert similar toxicity as that of inorganic forms such as selenite 
(Takahashi, Suzuki and Ogra, 2017). Additionally, Se from A. bisporus has been reported 
to have poor bioavailability (Thiry et al., 2012), which is further retarded upon cooking 
(Khanam and Platel, 2016). As such, the efficacy of SeCys2 can be limited by its potential 
to reach the target site of the jejunum for therapeutic action, thus reducing its 
bioavailability. To identify Se species present in A. bisporus, it is first necessary to isolate 
fractions of Se from the fruiting bodies of the mushrooms and identify the species present. 
However, to date, no robust method for complete extraction and analysis of Se from food 
sources has been developed (Thiry et al., 2012). Careful optimisation of extraction 
procedures is an essential requirement for Se speciation analysis of solid samples, in order 
to achieve high extraction efficiencies that also mitigate interconversion of the original 
species present (Dumont, Vanhaecke and Cornelis, 2006). It is generally recognised that 
a single step extraction is insufficient for Se liberation due to the varied matrix 
associations of Se in real samples (Pyrzyńska, 1996). For example, hot water extraction 
has been employed as a Se leaching solution for three edible wild mushroom species 
(Macrolepiota procera, Lepista luscina and Boletus luridus), although only 47% of the 
total Se content present in the sample (present in water soluble proteins) could be 
recovered (Huerta, Sánchez and Sanz-Medel, 2005). As many Se species are protein 
bound, several authors have utilised strong acids in extraction procedures, in order to 
increase liberation of Se from various matrices (Casiot et al., 1999; Wrobel et al., 2003). 
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Additionally, proteolytic enzymes have been employed for extracting SeAAs 
incorporated into proteins due to their ability to cleave peptide bonds (Montes-Bayón, 
Maria José Díaz Molet, et al., 2006). Also, inorganic forms of Se have been found to 
become entrapped physically or chemically into cell walls and as such, acids and non-
proteolytic enzymes such as driselase have been used in Se extraction (Infante, Hearn and 
Catterick, 2005).  
A dedicated analytical approach must be adopted in all areas of interest in the field of Se 
speciation, especially in the case of the separation technique preceding element or 
molecule specific detection. A massive challenge to the analyst is the myriad of Se species 
with different physicochemical properties present in biological systems. Se species must 
be unambiguously separated, identified and correctly quantified after they are extracted 
from a given matrix. However, interconversion amongst Se species upon extraction from 
a food matrix is a common obstacle that needs to be overcome in speciation analysis 
(Uden et al., 2004).  
In this work, Se species were extracted from Se supplemented A. bisporus samples, using 
protease enzymes or HCL (0.1 M), under microwave or sonic energy respectively. Se 
species were then separated by Reverse phase, high performance liquid chromatography 
(RP-HPLC) coupled to a Photodiode Array Detector (PDA) and subjected to a validation 
protocol, based on approved guidelines (EMEA, 1995), to assess its suitability for routine 
work. 
All considered, an opportunity presents for developing a drug delivery system that 
optimises SeCys2 bioavailability, whilst reducing its toxic side effects. One approach is 
the use of colloidal drug carriers that can provide site specific or targeted bioactive (BA) 
delivery combined with optimal BA release profiles. Nanoparticle (NP) delivery systems 
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have shown a higher mobility and cellular uptake compared to systems of larger size 
which may offer an advantage to the delivery of BA compounds. Mohanraj & Cheng 
(2007) compared the uptake of 1 and 10 µm particles to that of 100 nm particles in in 
vitro models, observing that an increase of 2.5-6 fold higher uptake respectively for the 
smaller sized particles. Etheridge et al. (2013) observed that the effect of particle size on 
cellular intake can also be influenced by the constituent material and the particle 
geometry, a consequence of reduced intestinal clearance mechanisms and an increase in 
the mass to surface ratio interaction with the biological support. 
In recent years, a wide array of constituents, such as natural and synthetic polymers, 
lipids, and proteins, have been employed to prepare BA containing nanocarriers (Puri et 
al., 2009; Elzoghby, Samy and Elgindy, 2012; Pridgen, Alexis and Farokhzad, 2015). 
Among the materials proposed for mucosal delivery, polysaccharides have received 
increasing attention because of their physical and biological properties (Rampino et al., 
2013). The natural polymer chitosan (Cs) is a positively charged mucopolysaccharide, 
closely related to cellulose and derived from chitin (CT), the second most abundant 
polymer in nature (Kean and Thanou, 2010). Cs has been used for the development and 
formulation of nanoparticles by ionotropic gelation due to its physicochemical and 
biological properties (H. Zhang et al., 2015; Mohammed et al., 2017). This bioactivity 
includes improved adherence to mucosal surfaces, increased drug residence time (Ryan 
et al., 2012), and protection of the bioactive drug from intestinal proteases (Ryan et al., 
2013; Amaro et al., 2015). Cs can be dissolved in acidic media, due to protonation of the 
amine residues present in the polymer backbone. Ionotropic gelation allows for the 
formation of NPs from Cs via crosslinking with oppositely-charged electrolytes (such as 
tripolyphosphate (TPP)) under mild conditions in which amino acids and peptides will 
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remain reasonably stable (Janes, Calvo and Alonso, 2001; Wang et al., 2011; Chen et al., 
2013). 
Typically, Cs is manufactured commercially on a large scale by alkaline N-deacetylation 
of crustacean origin CT (Philibert, Lee and Fabien, 2017). However, the preparation of 
Cs with controlled properties, by means of microorganisms such as fungi is of increasing 
interest as it offers several advantages over its crustacean counterparts. For example, 
fungal Cs (fCs) has significantly lower heavy metal association than that of crustaceans, 
allowing for milder production methods in its isolation, and year-round growth that is not 
seasonally dependant (Muzzarelli et al., 2012). In this context, production and 
purification of Cs from the cell walls of waste fungal mycelium may offer the advantage 
of being more sustainable with potential for a more consistent product.  
To date, the vast majority of Cs research in a drug delivery context has used crustacean 
derived Cs (Ryan et al., 2013; Umerska, Corrigan and Tajber, 2014; Diop et al., 2015; 
Danish et al., 2017a),  For example, PROTASAN™ CL113, an ultrapure commercial Cs, 
derived from crustacean shells and sold by NovaMatrix, FMC Corporations, has been 
previously promoted for its ability to encapsulate and deliver food derived BAs such as 
Retinyl Palmitate (a vitamin A isomer) and possesses the following physicochemical 
properties: MW of 110-150 kDa, DDA% ≥80 % and minimal metal contamination 
(Fernández‐Gutiérrez et al., 2015). However, one drawback of NPs formulated with Cs 
is that the ability of the BA to be encapsulated within the NP matrix is often limited by 
the availability of its the ionisable groups (Lin, Liu and Ping, 2007). Additionally, they 
can often display fast release rates in the stomach environment, due to the enhanced 
solubility of Cs at acidic pH (Mohammed et al., 2017). To overcome these limitations, 
coating of Cs NPs with anionic polyelectrolytes has been investigated (Banerjee et al., 
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2016). Zein a GRAS approved prolamine-rich protein derived from maize, has been used 
in the formulation and coating of peptide oral delivery systems (Y. Zhang et al., 2015), 
to increase encapsulation efficiency (Luo and Wang, 2014) and improve the control of 
gastric release of labile bioactives (Luo et al., 2010; Paliwal and Palakurthi, 2014). By 
exploiting the physical interactions between protein and polysaccharide (in this instance 
zein and Cs), it is possible to improve and broaden the range of the physical and chemical 
stability properties of the NP delivery systems (Benshitrit et al., 2012). 
In the previous work of Vozza et al., (2018a, Chapter 5) a Design of Experiments (DoE) 
approach was used to establish optimum formulation conditions that would produce 
SeAA (SeMet) loaded NPs, via ionotropic gelation. DoE identified the conditions of mass 
ratio 6:1 (Cs:TPP), with TPP dissolved in NaOH (0.1 M) and Cs dissolved in acetate 
buffer (pH 3) prior to crosslinking, produced NPs with physicochemical properties (Size 
~ 300 nm, PDI <0.5 and ZP >30 mV) suitable for oral delivery (des Rieux et al., 2006). 
Additionally, by coating the produced NPs with zein, the encapsulation efficiency (EE%) 
was significantly improved from < 65% to >80%.  
In a further study, Vozza et al., (2018b, Chapter 6), employed the optimised formulation 
conditions to encapsulate SeCys2 and MSC, based on the rationale that SeCys2 (with a 
pKa of 4.7 (Lacourciere and Stadtman, 1999)), and MSC (with a pKa of 4.9 (Mishra, 
Priyadarsini and Mohan, 2007)), contain comparably ionisable groups to SeMet. The 
findings showed that, by employing the previously established DoE parameters, similar 
formulations (e.g. physicochemical properties and EE%) to those achieved for the SeMet 
loaded NPs could be produced.  
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As the Cs employed for the NP formulations in Vozza et al., (2018a, 2018b, Chapters 4-
6), was CL113, a further study by Vozza et al., (2018c, Chapter 7) looked at the extraction 
of CT from the edible basidiomycete mushroom A. bisporus and its derivatisation to fCs, 
with equivalent properties (DDA%, MW and purity) to that of CL113. 
The aim of this study was to qualitatively and quantitatively identify SeAAs present in A. 
bisporus as a potential source for organic Se and to build directly on the previous work 
on encapsulation in Cs NPs. This was achieved by applying the optimum DoE 
formulation conditions, detailed in Vozza et al., (2018a, 2018b, Chapters 4-6), to fCs, 
produced as per Vozza et al., (2018c, Chapter 7) with synthetic SeCys2 (to avoid natural 
variance from A. bisporus SeCys2). Once the encapsulating fCs NPs were prepared, they 
were extensively assessed for their physicochemical properties, morphology, thermal 
stability, cytotoxicity and in vitro controlled release, utilising the methods developed in 
the previous studies (Vozza et al., 2018a, Chapter 5). 
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8.2 Materials and Methods 
 
8.2.1 Materials 
Fungal Cs (fCs), with MW of 156±24 kDa and degree of deacetylation (DDA%) of 86 % 
was derived as per Vozza et al., (2018c, Chapter 7), Seleno-DL-cystine (>98 % purity), 
D (+) - Trehalose dihydrate, Sodium Tripolyphosphate (TPP), and zein, of ≥99 % purity, 
were obtained from Sigma Aldrich, Ireland. Acetic acid, ACS reagent, ≥99.7%, sodium 
hydroxide solution 50 wt % in H2O, hydrochloric acid (HCL) 37 wt % in H2O were 
purchased from Fisher Scientific, Ireland. All other reagents, chemicals and solvents were 
of analytical grade from Sigma Aldrich, Ireland. Deionised water (dH2O) ≥18 MΩcm 
was obtained using Millipore Simplicity® Water Purification System and used for all 
manipulations unless otherwise specified. 
8.2.2 RP-HPLC-PDA Method Validation 
RP-HPLC-PDA was employed to quantify the SeAAs present in the mushroom samples, 
as previously described (Ward, Connolly and Murphy, 2012) with the following 
modifications. Samples were analysed with a Waters 2998 HPLC coupled to a Photodiode 
Array Detector, (Waters, USA), using a Pursuit 5 C18, 250 x 4.6 mm column, (Agilent 
Technologies, UK). Isocratic elution was carried out at a flow rate of 0.8 mL/min, column 
temperature 45.0 ± 5.0 °C with a mobile phase of water/methanol/trifluoroacetic acid 
(97.9:2.0:0.1). Samples were monitored according to their UV absorbance at 218 nm. 
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The chromatographic method was validated for linearity, precision, accuracy, limit of 
detection (LOD) and limit of quantification (LOQ). To establish linearity, primary 
standard stock solutions for SeMet, MSC and SeCys2 were prepared separately in aqueous 
tris hydrochloride (10 mM) at 1 mg/mL concentration. Solutions were further diluted with 
the mobile phase to obtain eight working standard solutions of 4-500 μg/ml and ran on 
RP-HPLC-PDA, under the conditions denoted in Section 8.2.2. Assay precision was 
estimated by analysing each standard compound in six replicates and expressed as 
percentage of relative standard deviation (%RSD). All the samples were prepared freshly 
at the same nominal concentration, injected on three separated days (inter-day precision) 
and calculated based on retention time (RT) and peak area of each standard compound. 
The accuracy of the method was validated based on determination of percentage recovery 
of standard compounds after spiking the sample with known concentrations of standard 
compounds. The limit of detection (LOD) and limit of quantification (LOQ) were 
established by analysing the standard deviation (STD) of the calibration curve and its 
slope (S) using the multipliers suggested by the International Conference on 
Harmonisation guidelines (ICH, 2005), of 3.3 for LOD or 10 for LOQ and calculated 
using Equations 8.1 and 8.2. All values were calculated as means ± standard deviation of 
three replicates and repeated twice, (n = 6). 
𝑳𝑶𝑫 =
𝟑. 𝟑 × 𝑺𝑻𝑫
𝑺
 
(Equation 8.1) 
𝑳𝑶𝑫 =
𝟏𝟎 × 𝑺𝑻𝑫
𝑺
 
(Equation 8.2) 
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8.2.3 Sample extraction 
A. bisporus samples supplemented with sodium selenite (60 mg/L) on day 4 of 
production, were provided by Monaghan Mushrooms (MM), Tyholland Farm, 
Monaghan, Ireland. Mushroom bodies were freeze-dried, ground to a powder (DMP), 
sieved through a 500 uM sieve and stored in a desiccator at room temperature for further 
analyses. To identify SeAA species present, mushroom samples were subjected to acid 
or enzymatic digestions. For acid extractions, HCL (1 mL,1 M) was added to DMP (40 
mg), sonicated (55 ºC, 1 hr) in a Bransen 2200 water bath sonicator (Bransen Ultrasonics, 
UK) and centrifuged (14,000 rpm, 15 min, 4 ºC) to obtain clear supernatant. The samples 
were then diluted 1:2 with mobile phase, filtered (0.25 μm) and ran on RP-HPLC-PDA 
as per Section 8.2.2, both with and without SeAA spike additions. In terms of enzymatic 
extractions, Protease XIV (0.5 mL, 60 mg/mL) was added to DMP (40 mg) and vortex 
mixed (1 min), then ultrasonicated for 30 s at 45 % amplitude and the probe tip washed 
with 0.25 mL of protease solution to ensure maximum recovery of the analytes. Samples 
were then placed into individual microwave vessels (EasyPrep™, CEM, UK) and 
subjected to microwave irradiation (MARS5, CEM, UK), for 15 mins at 80 W, followed 
by a 30 min cool down period. The resultant extracts were then centrifuged (14,000 rpm, 
15 min, 4 °C) to obtain the clear supernatant and the pellet washed with H2O (1 mL). The 
final volume was then made up to 5 mL using mobile phase, before removing an aliquot 
(2 mL) for filtration (0.25 μm), dilution (1:2) and spike addition, prior to RP-HPLC-PDA 
analysis. 
Measurements of Se totals were conducted by an accredited third-party laboratory 
(Eurofins, Ireland), using ICP-MS and used for comparison against the developed RP-
HPLC-PDA method. 
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8.2.4 Preparation of Se loaded fCs nanoparticles, coated with zein - 
Particle size, PDI and ZP  
fCs (Vozza et al, 2018c, Chapter 7), SeCys2 loaded NPs were formed via the ionotropic 
gelation method (Vozza et al, 2018b, Chapter 6) with small modifications from the 
original method from Calvo et al., (1997). In Brief, aqueous TPP solution (3 mg/mL) was 
prepared in NaOH (0.01 M), with a SeCys2 concentration of 400 ug/mL. and added in 
equal volumetric proportions to stirring fCs solution (3 mg/mL, 700 rpm) prepared in 
acetate buffer (pH 3). The NPs formed were left to stabilise for 30 min, after which 
absolute EtOH (8 mL) was added whilst the stirring speed (700 rpm) of the solution was 
maintained. Filtered zein (2 mL, 5.625 mg/mL), dissolved in aqueous EtOH (80% v/v), 
was then added dropwise to the solution to yield zein:Cs NPs of mass ratio 0.75:1 and 
left to stabilise for 30 min. NPs were isolated by centrifugation (3000 rpm, 30 min) using 
a 20 kDa MWCO (Vivaspin 20, Sartorius) centrifugal filter. Filtered EtOH (80% v/v) 
(equivalent in volume to the recovered supernatant) was added to the purified NPs and 
subsequently sonicated at 35% amplitude for 30 s with 5 s pulse intervals. The NP 
formulations were then concentrated under vacuum (175 mbar) at 40 °C until EtOH was 
completely removed. To ensure stability of the optimised formulation after lyophilisation, 
10 mL of the cryoprotectant trehalose 5 % w/v in H2O were added to each formulation 
and they were lyophilised for 36 hr (Danish et al, 2017b) 
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8.2.5 Physicochemical characterisation of SeCys2 loaded NPs 
 
8.2.5.1 Particle size, PDI and Zeta potential  
Dynamic light scattering (DLS) was used to determine the mean particle size and 
polydispersity index (PDI) of the NP formulation. Laser doppler velocimetry (LDV) was 
used to measure the zeta potential (ZP). Both DLS and LDV analysis were performed 
with a Zetasizer Nano series Nano-ZS ZEN3600 fitted with a 633 nm laser (Malvern 
Instruments Ltd., UK), using a folded capillary cuvette (Folded capillary cell-DTS1060, 
Malvern, UK), at 25 °C. The values presented herein were acquired from three separate 
experiments, each of which included three replicates. N=3 (Chapter 3, Section 3.2.1). 
8.2.5.2 Scanning electron microscopy (SEM)  
SEM analysis was used to visualise the morphology of the NPs formed at an accelerating 
voltage of 20 kV, using a secondary electron detector (Hitachi, SU6600 FESEM, USA). 
NP solutions were spin coated onto Si wafers, dried at room temperature and then sputter 
coated with 4 nm Au/Pd prior to imaging (Mukhopadhyay et al., 2013), (Chapter 3, 
Section 3.2.2). 
8.2.5.3 Encapsulation efficiency of SeCys in Cs:TPP nanoparticles  
The EE% of SeCys2 in the fCs NPs was determined by the separation and quantification 
of SeCys2 left in the supernatant after ultracentrifugation isolation of the formed NPs, 
using the RP-HPLC-PDA method denoted in Section 8.2.2.  
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The encapsulation efficiency was calculated using Equation 8.3 (Xu and Du, 2003), 
(Chapter 3, Section 3.2.3): 
 𝑬𝑬% =
𝑻𝒐𝒕𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑺𝒆 𝑴𝒆𝒕−𝑭𝒓𝒆𝒆 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑺𝒆𝑴𝒆𝒕
𝑻𝒐𝒕𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒇 𝑺𝒆𝑴𝒆𝒕
 𝑿 𝟏𝟎𝟎 
(Equation 8.3) 
8.2.6 Cytotoxicity 
The potential cytotoxicity of pure SeCys2, unloaded and SeCys2 loaded fCs NPs, was 
studied in Caco-2 human epithelial cells, and HepG2 human liver hepatocellular cells. 
Both cell lines are routinely employed to assess the potential toxicity of orally delivered 
compounds (Gleeson et al., 2015; Brayden et al., 2015). Caco-2 and HepG2 cells were 
seeded at a density of 2 x 104 cells/well and cultured on 96 well plates in Dulbecco's 
Modified Eagle Medium (DMEM) and Eagle's Minimum Essential Medium (EMEM) 
respectively, supplemented with 10 % foetal bovine serum, 1 % L-glutamine, 1 % 
penicillin-streptomycin and 1 % non-essential amino acids at 37 °C in a humidified 
incubator with 5 % CO2 and 95 % O2. Time points were selected with the intention to 
mimic in vivo conditions for each cell type. As the maximum time NPs will be exposed 
to the intestine, a 4 hr exposure time was used in Caco-2 cell lines (Neves et al., 2016), 
while to mimic the liver exposure, a 72-h exposure time was used for HepG2 cell lines 
(Brayden et al., 2014). Triton X-100™ (0.05%) was used as a positive control. The 
concentrations of the test compounds applied were 0.25, 2.5, 5, 10, 25, 50 and 100 uM. 
After exposure, treatments were removed and replaced with MTS(3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium). 
Optical density (OD) was measured at 490 nm using a microplate reader (TECAN 
GENios, Grodig, Austria). Each value presented was normalised against untreated control 
and calculated from three separate experiments, each of which included six replicates. 
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8.2.7 Accelerated stability analysis 
NPs were suspended at a concentration of 0.1 mg/mL, in aqueous KCl solution (10 mM) 
and stored at accelerated conditions: 60 °C for 720 min, 70 °C for 300 min and 80 °C for 
120 min (Danish et al., 2017a). The particle size, PDI and zeta potential were measured 
using the Nanosizer ZS (Malvern Instruments Ltd, UK) over time intervals to determine 
the degree of degradation. The generated data was then analysed via R software (R Core 
Team, 2016). The temperature dependence of the kinetic parameters of SeMet-loaded 
NPs stability was measured by calculating the observed rate constants. This was plotted 
in an Arrhenius representation and apparent activation energy, Ea and reaction rate 
constant, kref were calculated according to Equation 8.4: 
𝑷 = 𝑷𝒐 + 𝒆
𝒍𝒏 (𝒌)−
𝑬𝒂
𝑹 (
𝟏
𝑻−
𝟏
𝑻𝒓𝒆𝒇
)
𝒕 
(Equation 8.4) 
where P is the property (particle size, PDI or ZP) at time t, Po is the initial property 
conditions, k is the apparent zero order reaction constant, Ea is the energy of activation, 
R is the universal gas constant, T is the temperature of the experiment in Kelvin (K) and 
Tref is the reference temperature (343 K). 
8.2.8 In vitro controlled release studies 
SeCys2 release from the NPs was carried out using a dialysis bag diffusion technique 
(Hosseinzadeh et al., 2012) over 6 hr (Calderon L. et al., 2013; Yoon et al., 2014). Freeze 
dried SeCys2 loaded fCs NPs, coated with zein, were suspended in 5 mL H2O and 
sonicated at 35 % amplitude for 30 s with 5 s intervals and placed into a Float-A-
Lyzer®G2 dialysis membrane with a pore size of 25 kDa (Spectrum Laboratories, USA). 
The sample was placed into 40 mL of simulated gastric fluid (SGF) or simulated intestinal 
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fluid (SIF) specified according to the British Pharmacopoeia (Pharmacopoeia, 2016). 
SGF was composed of 0.1 M HCL and SIF was composed of 1 volume of 0.2 M trisodium 
phosphate dodecahydrate and 3 volumes of 0.1 M HCL (adjusted to pH 6.8), without 
enzymes (British Pharmacopoeia Commission, 2016). Samples were placed in a 
thermostatic shaker at 37 ºC and agitated at 100 rpm. At predetermined time points, 1 mL 
of release fluid was analysed and replaced with simulated fluid to maintain sink 
conditions. 
SeCys2 release was measured by RP-HPLC-PDA (Section 8.2.5). Equation 8.5 was used 
to determine the % drug release: 
𝑫𝒓𝒖𝒈𝒓𝒆𝒍 % =
𝑫(𝒕)
𝑫(𝒍)
∗ 𝟏𝟎𝟎 
(Equation 8.5) 
where 𝐷𝑟𝑢𝑔𝑟𝑒𝑙 is the percentage of SeCys2 released, D(l) represents the concentration of 
SeCys2 loaded and D(t) represents the amount of SeCys2 released at time t, respectively. 
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8.3 Results and Discussion 
 
8.3.1 RP-HPLC-PDA Method Validation 
Most often, for Se speciation analysis in food samples, Liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) is the method commonly employed, owing to its 
excellent sensitivity and short run time (Schaumlöffel and Tholey, 2011). However, the 
apparatus is expensive and many analytical laboratories cannot support such equipment 
because of the high maintenance costs (Capelo et al., 2006). 
In this work, RP-HPLC-PDA was employed for the determination of SeAAs (SeCys2, 
SeMet and MSC) in A. bisporus, supplemented with sodium selenite. The proposed 
method was validated with respect to linearity, LOD, LOQ, recoveries and precision 
according to the International Conference on Harmonization (ICH) guidelines for method 
validation (ICH, 2005). The linearity of calibration curves was calculated using linear 
regression analysis of area versus concentration, for eight concentration levels of each 
standard compound, injected in triplicate. Table 8.1 shows the regression equation and 
correlation coefficient relationship between concentrations and peak area. Over the range 
tested (5-400 ug/mL), all the analytes exhibited a good linearity with correlation 
coefficients ranging from 0.9995 to 0.9998. The LOD and LOQ were estimated from the 
calibration curve and values subsequently ranged from 0.33 to 2.64 µg/L and 1–8 µg/mL, 
respectively (Table 8.1). The precision of the method was assessed by the percent relative 
standard deviation (%RSD) using retention times and peak areas of standard compounds. 
The results suggest a satisfactory intermediate precision value (%RSD) which ranged 
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from 0.5 to 4.43 and 2.87–3.78 with respect to retention time and peak-area, respectively 
(Table 8.1). 
Table 8.1 Precision of the method, linearity data for calibration curves and retention 
time (RT) of reference SeAAs studied. LOD and LOQ calcula ted according to Equations 
8.1 & 8.2. RSD (%): percentage relative standard deviation of mean recovery. N=6.  
SeAA 
Linearity 
range 
(ug/mL) 
Retention 
time (min) 
Slope (m) Intercept (c) 
Correlation 
coefficient 
(R2) 
SeCys2 4-500 4.33 5.30±0.80 12.95±7.42 0.9998 
MSC 4-500 7.24 8.80±0.40 16.81±12.86 0.9997 
SeMet 4-500 15.60 9.54±0.10 11.80±27.59 0.9995 
SeAA 
Recovery 
(%) 
LOD 
(ug/mL) 
LOQ 
(ug/mL) 
RSD (%) 
RT 
RSD (%) 
Peak area 
SeCys2 96 2.6 8.0 0.52 3.78 
MSC 94 1.3 4.0 2.45 2.87 
SeMet 88 0.3 1.0 4.43 3.40 
For evaluation of the accuracy of the method, recovery assays were performed, whereby 
mushroom extracts were spiked with a known amount of standard compound and the 
percentage recoveries were determined to range from 88-96 % (Table 8.1). These findings 
suggest that the proposed RP-HPLC-PDA method is sufficiently accurate and sensitive 
for the determination of the SeAAs selected for assessment in in vitro studies, without 
the use of expensive instrumentation setups such as LC-MS/MS. 
8.3.2 Qualitative and Quantitative analysis of SeAAs in A. bisporus 
The first part of this experiment focused on comparing the acidic and protease extractions 
for the three SeAAs (SeCys2, SeMet and MSC) selected for study in the dried mushroom 
powder (DMP) samples. As can be seen in Figure 8.1, significantly more SeCys2 and 
SeMet (66-fold and 5-fold higher, respectively) was liberated from the DMP through use 
of a proteolytic digestion when compared to that of acidic digestion. The enzymatic 
hydrolysis was most likely better equipped to liberate SeMet and SeCys2 associated with 
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high molecular weight compounds (such as proteins) from the mushroom matrix, due to 
them being protein bound (Kápolna et al., 2007). Although MSC has been identified by 
others in Se supplemented A. bisporus samples (Gergely et al., 2006; Maseko et al., 
2013), spike additions failed to identify MSC in the DMP investigated in this study. MSC 
is a non-protein bound, water soluble SeAA and as such it was expected to be present in 
the acid extractions (Gergely et al., 2006). However, as concentrations of MSC present 
in Se supplemented mushrooms are reported to be ≈ 0.8 ug/mL (Maseko et al., 2013) and 
the validated RP-HPLC-PDA method having an LOD of 1.3 ug/mL (for MSC), it is likely 
that it is present in the DMP but not detectable by the RP-HPLC-PDA method employed. 
 
Figure 8.1 Comparison of acid and protease extractions for the liberation of SeCys 2 (A) 
and SeMet (B) from DMP. N=3. 
Table 8.2, shows the quantitative data for SeMet and SeCys2 identified in the DMP after 
protease digestion, the latter being shown to be the predominant species, present at 616 ± 
23 µg/g DMP, while a modest amount of 18 ± 9 µg/g DMP SeMet was identified. Se 
equivalent values were then calculated for the identified SeAAs (40 and 45 % of SeMet 
and SeCys2 exist as Se, respectively), tallied together, and compared to total Se values as 
identified by the third party accredited lab Eurofins, Ireland (Table 8.2). 
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Table 8.2 Concentration of Se species in DMP after protease extraction, determined by 
RP-HPLC-PDA. N=6. 
SeAA Se AA µg/g DMP Se equivalent µg/g DMP 
SeCys2 616.69 ± 23.64 283.68 ± 10.87 
SeMet 18.97 ± 9.64 7.59 ± 3.85 
MSC n.d n.d 
Sum of Speciesa 635.66 ± 16.64 291.27 ± 7.36 
Total Seb - 356.25 ± 61.87 
n.d (not determined), a Sum of SeCys2 and SeMet as determined by RP-HPLC-PDA, b Total Se, 
as measured by ICP-MS, Eurofins, Ireland. 
The total Se identified using the RP-HPLC-PDA method developed was 291 ± 7 µg/g vs 
356 ± 61 µg/g from Eurofins (Figure 8.2), showing that approx. 80 % of the total Se 
content was identified using the current method. Several other SeAA species, such as 
selenite, selenite, selenoethionine, have been reported to be present in Se supplemented 
A. bisporus (Stefánka et al., 2001; Haberhauer-Troyer et al., 2003), which were not 
targeted for identification in this study and could account for the discrepancy in Se totals. 
 
Figure 8.2 Se totals, Eurofins vs developed RP-HPLC-PDA method. N=3. 
Although Se totals for A. bisporus have been reported previously, there appears to be 
several conflicting findings. For example, Maseko (2013), found total Se to be 137 ug/g 
of dried stalks and mushroom caps. However, in that study, the Se provided to the 
mushroom bodies during cultivation was as sodium selenite at a maximum of 40 mg/L, 
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which is less than the 60 mg/L used in the A. bisporus provided by Monaghan 
mushrooms. On the other hand, Gergely et al., (2006) reported the ability of A. bisporus 
to accumulate 770.7 ± 37.3 μg/g after supplementation of mushroom compost with only 
10 mg/kg of selenised yeast, and Werner and Beelman, (2002), demonstrated the ability 
of A. bisporus to accumulate Se up to 1300 µg/g DMP, after supplementing cultivation 
media with up to 300 mg/L. Perhaps the reason for the reported discrepancies in these 
studies is related to the variances in the cultivation or extraction methods. Moreover, it is 
worth noting that these studies did not test/validate the robustness of the employed 
analytical methods for Se determination or use certified reference material as a reference 
check point. The current study, however, did assess the suitability of the analytical 
method for employment in Se determination, in addition to employing an independent 
ISO accredited third party laboratory to assess the provided samples for Se content and 
thus comparison with the proposed RP-HPLC-PDA method. Overall, given the high 
concentrations of Se present in the fungal samples (291 µg/g DMP, equivalent to 23 ug/g 
fresh weight), Se supplemented mushrooms may be a feasible source for Se in the diet. 
To meet the Se recommended daily allowance (RDA) (40 ug/day), ingestion of just 2 g 
fresh mushroom bodies would be required. However, it is worth noting that Se from A. 
bisporus has been reported to have poor bioavailability (Thiry et al., 2012), which is 
further retarded upon cooking (Khanam and Platel, 2016). As such, the efficacy of the 
predominant Se species present in the supplemented mushroom bodies (SeCys2) may be 
limited by its potential to reach the target site of the jejunum for therapeutic action, thus 
encapsulating SeCys2 into a NP delivery system may offer an advantage. 
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8.3.3 Characterisation of fCs NPs loaded with SeCys2 - Particle size, 
PDI and surface charge 
Table 8.3 displays the physicochemical properties of the SeCys2 loaded NPs produced 
with the fCs developed in Vozza et al., (2018c, Chapter 7) For ease of comparison, the 
properties of NPs produced with CL113 (Vozza et al., 2018b, Chapter 6) are displayed in 
this table also. No significant difference between size and PDI of the fCs and CL113 NPs 
was observed, although for ZP and EE%, NPs formulated with fCs were significantly 
higher vs the CL113 NPs (ZP 38 vs 31 mV, EE% 84 vs 80 %) (Table 8.3). 
Table 8.3 Physiochemical results for SeCys2 loaded NPs, coated with zein. Size, PDI, 
ZP and EE% are presented for each NP formulated with either fCs or CL113. N=3.  
fCs SeCys2 NPs Size (nm) PDI ZP EE% 
Average 299.5 ± 47.1 0.324 ± 0.176 38.7 ± 2.1 84.4 ± 1.2 
CL113 SeCys2 NPs Size (nm) PDI ZP EE% 
Average 262.1 ± 11.1 0.243 ± 0.061 31.5 ± 1.0 78.9 ± 1.5 
Previous observations have shown the importance of the final Cs:TPP mass ratio, the 
formulation media pH and zein coating mass ratio in determining the physicochemical 
properties of ionotropic formed Cs NPs (Vozza et al., 2018a, Vozza et al., 2018b,  
Chapters 4-6). Other variables which have been shown to affect Cs NP properties (e.g. 
size, PDI, ZP and morphology) include the ionic strength of the formulation medium, 
concentration of both polyelectrolytes prior to crosslinking and the degree of 
deacetylation (DDA%)/MW of the employed Cs (Qinna et al., 2015). It is worth noting 
that the latter two factors confer different properties to Cs, which can affect properties 
associated with the NPs it produces: 
• Cs ability to complex with opposing charged polyelectrolytes is dependent on the 
DDA% (Anitha et al., 2014) 
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• NP dimensions and ZP; larger size and higher ZP reported with higher MW and 
DDA% Cs (Alameh et al., 2017)  
• NP toxicity; lower MW and DDA%, reported to have less toxicity than that of high 
MW Cs (Kean and Thanou, 2010) 
• NP EE%; higher in NPs produced with high MW and DDA% Cs (Jelvehgari et al., 
2010) 
• Release kinetics; Slower  for high MW Cs NPs (Gan and Wang, 2007) 
The DDA% and MW of the Cs used to produce NPs play a significant role in their final 
properties. Vozza et al., (2018b Chapter 7), 1H-NMR calculated the DDA% of CL113 
and fCs, to be 85 ± 4% and 86 ±6 % respectively. As such, the variance between the ZP 
and EE% values for the produced NPs is unlikely to be related to the DDA% of the Cs 
used for their production. In this regard, for CL113 vs fCs NPs, the apparent difference 
in ZP and EE%, may be a result of a difference in their MW (156±24 vs 110±6 kDa).Gan 
and Wang, (2007), reported that the EE% of BSA in Cs NPs was increased from 61.1 to 
69.9 and 78.2 % as a result of an increase in Cs molecular weight from low to medium 
and high, indicating that the longer Cs chains could offer more reactive sites for the 
formation of hydrogen bonds with the BSA protein molecules. Additionally, at low pH, 
Cs is fully extended in solution and the higher the MW weight of Cs, the greater the 
electrostatic repulsion between the primary amines on the backbone (thus reduced steric 
hinderance), which would allow for increased interactions between opposing 
polyelectrolytes and thus increased EE% (Almalik et al., 2013). With this in mind, it is 
reasonable to suggest that the higher MW of the fCs used to produce the NPs in this work 
allowed for higher EE% and ZP compared to their CL113 counterparts, which is 
consistent with the findings of other authors (Ing et al., 2012). 
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8.3.4 NP morphology - Scanning electron microscopy 
Figure 8.3 shows the SEM images of SeCys2 loaded NPs formulated with fCs (A) or 
CL113 (B). Spheroidal, well distributed particles with slightly irregular surface 
morphology were observed for SeCys2 loaded CL113 NPs (8.3 B). This may be 
attributable to the electrostatic interaction of the negatively charged carboxyl groups of 
zein facilitating a thin layer membrane around the positively charged amines residues of 
Cs (Luo et al., 2011) with variation in surface density of zein protein on the Cs NP surface 
and porosity of Cs core (Pan et al., 2015). Additionally, low MW Cs NPs have been 
reported to facilitate surface binding of negatively charged polyelectrolytes such as 
hyaluronic acid, due to their less porous more compact dimensions (Almalik et al., 2013). 
fCs NPs showed smooth, dense, spheroidal morphologies with higher polydispersity than 
that of the CL113 NPs, which agrees with the DLS observations for PDI (Table 8.3). This 
may be related to the distribution of the polymer chains of fCs in comparison to CL113, 
which is certified to possess a MW of 110-150 kDa, and as such is likely fractionally 
separated to this range prior to sale. The larger the spread of the Cs chain lengths, the 
larger the variance in NP PDI to be expected. Additionally, hyaluronic acid has appeared 
to diffuse more deeply into the bulk of high MW Cs NPs, reducing the observable surface 
coating appearance via SEM and atomic force microscopy (Almalik et al., 2013), which 
agrees with the observed properties of the higher MW fCs NPs. In terms of the particle 
size, comparing SEM and DLS measurements, larger sizes were observed by SEM 
imaging (approx. 90-150 nm larger), which may be due to the rapid evaporation of 
residual ethanol (present in the final suspension media) during the spin casting process 
and subsequent flattening of the particles on the grid (da Rosa et al., 2015). 
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Figure 8.3 SEM image of (A) SeCys2 fCs NPs and (B) SeCys2 CL113 NPs coated with 
zein. 
8.3.5 Accelerated stability analysis of fungal derived fCs NPs loaded 
with SeCys2 
Figure 8.4 shows the kinetic behaviour of the SeCys2 loaded fCs NP properties: size (A), 
PDI (B) and ZP (C), at temperatures ranging from 60-80 °C. The stability of the NPs 
decreased with increasing temperature. Little change was detected for all properties at 60 
°C, over the course of 720 min, whereas a more pronounced influence on size and PDI 
and a decrease in ZP was observed at 70 °C after 300 min. At 80 °C, destabilisation of 
the NP complexes was evident according to all properties, whereby size increased from 
approximately 300 nm to > 700 nm, PDI from approximately 0.2 to >0.9 and ZP reduced 
from approximately 36 mV to < 18 mV, indicating that aggregation of the NPs had 
occurred (Wu, Zhang and Watanabe, 2011). 
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Figure 8.4 (1) Particle size, (2) PDI and (3) ZP analysis of fCs SeCys2 loaded NPs 
exposed to (a) 60 °C, (b) 70 °C and (c) 80 °C, over time periods of 120, 300 and 720 
min, respectively. N=3. 
The one-step nonlinear regression analysis of the kinetic experiments shows that the 
particle size and PDI of SeCys2 loaded fCs NPs fit to a zero-order kinetic behaviour, with 
an Arrhenius dependence of ln (kref@70 °C) = 6.43 ± 4.12 min−1 and Ea = 291.35 ± 
62.35 kJ/mol for size, and a ln (kref@70 °C) = 0.026 ± 0.007 min−1, and an Ea = 192.39 
± 24.05 kJ/mol for PDI respectively (Figure 8.4). Regarding ZP, an apparent first order 
mechanism fits the data better than an apparent zero order model, with an Arrhenius 
dependence of ln (kref@70 °C) = 0.051 ± 0.004 min−1 and Ea = 148.10 ± 6.581 kJ/mol. 
Lastly, a linear correlation is evident between 1/T and ln k, indicating that the 
formulations will be stable under normal storage conditions (Figure 8.5). 
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Figure 8.5 Arrhenius plots for the PDI, Size and ZP accelerated studies of SeCys 2 
loaded NPs. N=3. 
No significant difference in kinetic behaviour was observed between the SeCys2 loaded 
CL113 and fCs NPs properties (size (A), PDI (B) and ZP (C)) at temperatures ranging 
from 60-80 °C. As shown previously by Vozza et al., (2018a, 2018b, Chapters 5 & 6), 
the SeAAs (SeMet, MSC or SeCys2) used to load the NPs did not have an effect on the 
formulation stability, which lends weight to the argument that the contributing factors to 
the formulation stability lies with the Cs:zein complex rather than the loaded SeAA. The 
complexation of protein (in this instance zein) with polysaccharide (Cs) systems involves 
non-covalent interactions that can change the interfacial behaviour and stability of food 
colloids (Ghosh et al., 2012). When Cs is blended with a polymer, the miscibility between 
their molecules is a very significant factor, especially for the mechanical properties of the 
blend (Sakurai, Maegawa and Takahashi, 2000). For example, previous differential 
scanning calorimetry studies have shown that pure zein has a transition temperature 
around 150 °C, which was attributed to thermal denaturation of this protein (Neo et al., 
2013). By harnessing the thermal stability of Cs (transition temperature of 203°C) and 
combining it with the aromatic side groups and double bonds of zein, it is possible to 
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greatly increase the stability of labile nutraceuticals against thermal degradation and 
oligomerization (Torres-Giner, Ocio and Lagaron, 2009; Luo et al., 2013). 
Zein coated tablets exhibit stronger resistance to abrasion, high humidity and high 
temperatures than a variety of commercial sugar-coated tablets (Y. Zhang et al., 2015). 
Moreover, it has been reported that the bi-layer approach for encapsulation of BAs leads 
to a better control of the NP interface structure, charge, thickness and permeability, and 
substantially enhanced stability (Hu and McClements, 2014). Notably, the net attractive 
and net repulsive strength character of protein–polysaccharide non-covalent physical 
interactions can vary substantially, depending primarily on environmental conditions 
such as pH, ionic strength, and temperature (Semenova et al., 2014). In this work, the 
conditions (presence of salt) used to prepare the NPs, in addition to the strong bonding 
between the zein and Cs complex, may have been a contributing factor to the enhanced 
stability of the formulation and is consistent with our previous observations (Danish, et 
al., 2017a; Vozza et al., 2018a, 2018b). 
8.3.6 Cytotoxicity assessment of fungal derived Cs NPs loaded with 
SeCys2 
In the work of Vozza et al., (2018b, Chapter 6), the tested concentrations of native SeCys2 
and loaded CLL3 NPs (25, 50 & 100 uM) where more reflective of supra-nutritional Se 
levels, reported to be involved in the prevention of several types of cancer, including lung, 
colorectal, and prostate cancers (Rikiishi, 2007; Suzuki et al., 2010; Bao et al., 2015). To 
gain more insight into the potential cytotoxicity of SeCys2 as a basal nutritional 
supplement (in native form and encapsulated within fCs NPs), additional test 
concentrations for nutritionally low (0.25, 2.5 uM) and adequate (5, 10 uM), Se status, 
were investigated (Hawkes et al., 2008). The supra-nutritional concentrations (25, 50 and 
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100 uM), were also assessed, to maintain consistency in comparing the SeCys2 loaded 
CL113 NPs to the fCs NPs, in Caco-2 human epithelial cells, and HepG2 human liver 
hepatocellular cells, using the MTS assay. As the NPs will be exposed to the intestinal 
epithelium following oral delivery (leading to its facilitated transport and uptake), time 
points were selected with the intention to mimic in vivo conditions for each cell type, to 
assess the potential cytotoxicity of the formulated NPs (Gleeson et al., 2015; Brayden et 
al., 2015). Caco-2 cells were exposed for 4h (Figure 8.6, A, B)) and HepG2 cells for 72h 
(Figure 8.7, A).  
In Caco-2 exposures, no cytotoxicity was observed for SeCys2 native, unloaded or SeCys2 
loaded NPs, in comparison to the negative control, across all tested concentrations (Figure 
8.6 A, B). This is consistent with previous observations (Vozza et al., 2018b, Chapter6) 
and in agreement with the works of others (Marschall et al., 2016; Takahashi, Suzuki and 
Ogra, 2017).  
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Figure 8.6 Cytotoxicity assessment of  SeCys2,  unloaded fCs NPs and  
SeCys2 loaded fCs NPs, exposed for 4h in Caco2 cell lines at (a) low (0.25, 2.5 uM) and 
adequate nutritional level (5-10 uM) and (b) supra-nutritional level (25-100 uM) 
concentrations. Percentage (%) of MTS converted was compared to untreated control. 
1-Way ANOVA with Dunnett’s post-test *** p< 0.001. Each value presented was 
normalised against untreated control and calculated from three separate experiments, 
each of which included six replicates. N=3. 
Regarding native SeCys2 exposure to HepG2 cell lines, no significant toxicity was 
observed for test concentrations ranging from 0.25-5 uM (≤94 % viability). However, a 
dose dependant reduction in cell viability was observed for concentrations exceeding 5 
uM, which levelled off at 50 uM test concentrations (≤40 % viability). As can be seen in 
Figure 8.7 A, the encapsulation of SeCys2 within the fCs NP matrix conferred protection 
to the HepG2 cells after 72 hr exposure, from 0.25-25 uM test concentrations. However, 
this shielding effect was lost at concentrations >50 uM, showing equivalent toxicity to 
that of the native SeCys2 (≤40 % viability). Nevertheless, the IC50 of native SeCys2 was 
found to be 12.8 ± 3.6 uM vs 32.5 ± 1.4 uM for SeCys2 loaded fCs NPs, showing that the 
cytotoxic effects of pure SeCys2 can be reduced with the applied formulation (Figure 8.7 
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Similar results for the toxicity of native SeCys2 were observed by Takahashi, Suzuki and 
Ogra, (2017), who reported no significant change in the viability of Caco-2 cell lines after 
6 hr, although significant toxicity to HepG2 cells was observed at 100 uM, comparable 
to that of the inorganic form selenite, after prolonged exposure (48 hr). As the toxicity of 
SeCys2 has been shown to be comparable to that of selenite, it has been proposed by 
others that the cellular overload of metabolites (such as selenide moieties (-Se-) and (HSe-
) produced during selenoprotein formation or excretion (Rayman, Infante and Sargent, 
2008; Marschall et al., 2016) is responsible for this affect. This is conceivable, as the 
reduction of SeCys2 to SeCys in the cell would result in the generation of a highly reactive 
and sensitive to oxidation selenyl group (-SeH), whose relatively low pKa of 5.2 would 
promote the formation of (-Se-) at physiological pH (Iwaoka, 2014).  
Lastly, the unloaded NPs showed a significant proliferative effect in HepG2 cells over 
the range of 0.25-50 uM test concentrations, although at 100 uM, this effect was lost. 
Previous studies have shown the combination of zeins demonstrated cytocompatibility 
with NIH 3T3 and human liver cells (HL-7702) in terms of cell adhesion and proliferation 
(Dong, Sun and Wang, 2004), and an increase in fibroblast production caused by the 
presence of Cs (Rajam et al., 2011). Thus, it is reasonable to suggest that the observed 
protective effects of the encapsulated native SeCys2 is attributable to the fCs:zein NP 
matrix.   
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Figure 8.7: (A) Cytotoxicity assessment of  SeCys2,  unloaded fCs NPs and 
 SeCys2 loaded fCs NPs, exposed at test concentrations of 0.25-100 uM, for 72 hr 
in HepG2 cell lines. MTS converted was compared to untreated control. (B) Dose -
response curve was constructed by plotting cell viability versus log concentration of ( -
●-) SeCys2 and (-■-) SeCys2 loaded fCs NPs, and (C) corresponding IC 50 values of  
SeCys2 and  SeCys2 loaded fCs NPs. * p< 0.05, ** p< 0.01, *** P< 0.001, 1-Way 
ANOVA with Dunnett’s post-test (A), 2-Way ANOVA with Bonferroni post-test (B), 
and Students t-test (C). N=3. 
8.3.7 In vitro release studies 
Figure 8.8 shows the cumulative release profile of the SeCys2 loaded fCs NPs, coated 
with zein, after subjection to 2 hrs in an SGF environment (pH 1.2) representative of the 
stomach, followed by a compartmental change to SIF (pH 6.8), representative of the 
intestine, for 4 hrs. For ease of comparison, the release of SeCys2 from NPs produced 
with CL113 (Vozza et al., 2018b, Chapter 6) is displayed in this figure also. As can be 
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seen, 32 ± 4.5 % of SeCys2 was released from the fCs NPs after 2 hr in SGF, followed by 
30 ± 2 % release in SIF for 4 hr. In comparison, the release of SeCys2 from NPs 
formulated with CL113 was significantly faster in SGF (45 ± 4 %) after 2 hr, with a 
marginally slower release (24 ± 4 %), compared to fCs NPs, after subjection to a SIF 
environment (4 hr).  
Three basic mechanisms that are typically employed to describe the release of drugs from 
polymeric particles are, swelling/erosion, diffusion, and degradation (Liechty et al., 
2010). The prominence of each can depend on the conditions of the environment. 
Therefore, the release kinetics of SeCys2 loaded fCs NPs were monitored sequentially in 
SGF and SIF controlled release experiments. As two different simulated fluids were used 
for this study, representing the pH environment in the stomach (SGF) and the jejunum 
target site in the intestine (SIF), their release profile was modelled using a swelling, 
Peppas equation (8.6) and (8.7) (Siepmann and Peppas, 2011, Danish et al., 2017a). 
For the SGF: 
𝑴𝒕
𝑴∞
= 𝒌𝒔𝟏 ∗ √𝒕𝒊𝒎𝒆 + 𝒌𝒔𝟐 ∗ 𝒕𝒊𝒎𝒆 
(Equation 8.6) 
where 𝑀𝑡 is the diffused mass at a given time, 𝑀∞ is the asymptotic diffused mass at 
infinite time, and ks1 and ks2 are the diffusive and relaxation rate constants respectively. 
For the SIF: 
𝑴𝒕
𝑴∞
−
𝑴𝟏𝟐𝟎
𝑴∞
= 𝒌𝒊𝟏 ∗ (√𝒕𝒊𝒎𝒆 − 𝟏𝟐𝟎) + 𝒌𝒊𝟐 ∗ (𝒕𝒊𝒎𝒆 − 𝟏𝟐𝟎) 
(Equation 8.7) 
where M120 is the predicted diffused mass at the time of changing from SGF to SIF (120 
min), ki1 and ki2 are diffusive and relaxation rate constants. 
 315 
 
Figure 8.8 Release kinetics of SeCys2 loaded CL113 (–○–) and fCs (--●--) NPs, coated 
with zein, after 2 hr in SGF (pH 1.2) and 4 hrs in SIF (pH 6.8). Lines indicate the model 
predictions of Equations 8.6 and 8.7. N=3. 
The release of SeCys2 from the CL113 and fCs nanoparticles was best fitted with a 
combination of diffusion and relaxation mechanisms. The fits of the model are illustrated 
by solid lines in Figure 8.8. Table 8.4 presents the fitted values for the rate constants in 
SGF (ks) and SIF (ki) for both SeCys2 loaded (CL113and fCs) NPs, divided into diffusion 
and relaxation mechanisms (1 and 2) (Equations 8.6 & 8.7). 
For SeCys2 loaded fCs NPs, subjected to the simulated stomach environment (SGF, pH 
1.2), no statistically significant ks1 parameter was found, indicating that the primary 
mechanism for release in the stomach was via relaxation, i.e. slower release, approaching 
zero-order kinetics. Conversely, after 2 hr subjected to the SGF environment, a 
compartmental change was employed to mimic the movement of the SeCys2 fCs NPs to 
the intestinal environment (SIF, pH 6.8), whereupon a diffusion (ki1) mechanism was 
observed (p<0.05) indicating that the primary mechanism for release in the stomach was 
via diffusion, i.e. slower release, approaching zero-order kinetics. 
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In contrast, a combination of ki1 and ki2 mechanisms in the stomach (SGF) was observed 
for the release of the SeCys2 loaded CL113 NPs and no statistically significant ki2 
parameter was found for the intestinal compartment, indicating that, in the small intestine 
(jejunum), at pH 6.8, relaxation is the primary mechanism of release for SeCys2. 
Table 8.4 Swellable model parameters for kinetic release studies of SeCys 2 loaded fCs 
or CL113 NPs, coated with zein. ks represents the stomach compartment and ki the 
intestinal compartment, divided into diffusion and relaxation mechanisms ( 1 and 2). All 
parameters listed where statistically significant, ( ∗p < 0.05). 
CL113 SeCys2 loaded NPs 
Coefficients Estimate (min-1/2) 
ks1 2.29±0.68 
ks2 0.22±0.07 
ki1 1.15±0.20 
fCs SeCys2 loaded NPs 
ks2 0.24±0.05 
ki1 1.98±0.16 
As the only variable between these two formulations relates to the Cs used to produce the 
NPs, which matched regarding DDA%, it is conceivable that the reduced release rate 
observed for the fCs NPs may be related to the MW of the precursor fCs being higher 
than that of CL113 (156±24 vs 110±6 kDa). On exposure to the dissolution fluids (SGF 
and SIF), the Cs complex will become hydrated forming a viscous gel layer that slows 
down further seeping-in of dissolution fluids towards the core of the NP (Miladi et al., 
2015). The subsequent Cs swelling under these conditions allows for the drug release to 
follow a diffusion oriented mechanism, which is then typically trailed by the mechanical 
erosion of the swollen Cs hydrogel (Mohammed et al., 2017). In tandem, subsequent 
hydration and swelling of the system is heavily dependent upon whether the Cs erodes 
further. With this in mind, it was observed that the release of SeCys2 from both Cs:zein 
NPs was pH dependent, indicative of Cs solubility in acidic media (Yuan et al., 2013), 
although the slower release observed for the fCs NPs was most likely attributed to its 
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higher MW. For example, Gan and Wang, (2007), showed that the release kinetics of 
BSA from Cs NPs decreased significantly upon increasing molecular weights. The 
reduction observed in that study was postulated to arise from the protein requiring 
increased swelling and degradation of the NPs which was hindered by a greater crosslink 
density of TPP with high MW, causing increased chain packing and rigidity, as well as 
increased inter-chain bonding. Additionally, the higher the MW, the larger proportion of 
(-NH2) residues, allowing for the encapsulated drug to be associated multiple sites on the 
Cs polymer, thus reducing the overall release from the system (Dash et al., 2011). Overall, 
despite the high-water solubility of SeCys2 there was good control of drug release in the 
simulated physiological environment of stomach and small intestine for both fCs and 
CL113 NPs, with fCs displaying the most optimum release profile, most likely a 
consequence of higher MW. 
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8.4 Conclusion 
A RP-HPLC-PDA method was validated to analyse Se supplemented A. bisporus. The 
predominant species was SeCys2 at 616 ± 23 µg/g DMP, with modest amounts of SeMet 
identified also, inferring that Se supplemented mushrooms may be a feasible source for 
organic Se. fCs was then used to formulate SeCys2 loaded NPs, with optimum properties 
for oral delivery formed by coating the produced NPs at a 1:0.75 mass ratio of Cs:zein, 
resulting in sizes of 299.5 ± 47.1 nm, PDI 0.324 ± 0.176, ZP 38.7 ± 2.1, and EE% of 84.4 
± 1.2. SEM analysis showed smooth spheroidal, well distributed particles were produced. 
MTS cytotoxicity studies on SeCys2 loaded NPs showed no decrease in cellular viability 
in Caco-2 (intestinal) cells after 4 hr exposures across all test concentrations. However, a 
significant reduction was observed when compared to pure SeCys2, across all test 
concentrations in HepG2 liver cells after 72 hr exposure. Accelerated thermal stability of 
the produced NPs indicated good stability under normal storage conditions. After 6 hr 
exposure to simulated gastrointestinal tract environments, the sustained release profile of 
the formulation showed that 62.0 ± 2.5 % SeCys2 was released. By encapsulating SeCys2 
into a NP delivery system, improved oral administration of this molecule may be 
achieved, which could be of beneficial use for the supplementation of food products with 
these essential nutrients. All assessments on the fCs NPs properties were compared 
against SeCys2 CL113 NPs developed in previous work by Vozza et al., (2018b, Chapter 
6), showing that equivalent NPs formulations could be produced. This study provides 
robust methods to formulate and assess SeCys2 fCs NPs, in addition to the speciation 
analysis of SeAAs in supplemented A. bisporus, inferring that the encapsulation of 
SeCys2 into a NP delivery system can be achieved using food-derived components whilst 
also providing a viable approach to oral administration of this molecule.  
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9.1 Overview 
Nanotechnology has been touted as the next revolution in many industries, including the 
pharmaceutical and food industry (Srinivas et al., 2010; Safari and Zarnegar, 2014; 
Divya, 2015). It is not surprising that the nutraceutical industry has expanded within the 
past two decades (DeFelice 1995; Verbeke 2005; Lagos et al. 2015) given that consumers 
now acknowledge the ability of certain foods to reduce disease risk or improve health 
(Hasler, 2000). Aqueous solubility and permeability of BA compounds have been 
highlighted among the major challenges in early and late product research and 
development (R&D), affecting up to 40 % of drugs on the pharmaceutical market (Censi 
and Di Martino, 2015). Attrition of many molecules in the pharmaceutical R&D program 
can be ascribed to lack of efficacy and the onset of secondary effects (Basavaraj and 
Betageri, 2014). The oral route, being the most popular, can be particularly challenging 
due to the harsh environment of the associated biological fluids  found in the GIT, leading 
to limited absorption and limited bioavailability, (Sosnik, das Neves and Sarmento, 
2014). That considered, an opportunity presents itself for development of a drug delivery 
carrier system that can optimise stability and bioavailability, whilst reducing its toxic side 
effects. One approach is the use of colloidal drug carriers that can provide site specific or 
targeted BA delivery, combined with optimal BA release profiles (Joye, Davidov-Pardo 
and McClements, 2014). 
This project was carried out at the food and pharma interface, to produce oral 
formulations of nutraceutical SeAAs, which have been reported to possess narrow 
therapeutic indices and to be poorly absorbed in the small intestinal epithelium (Amoako, 
Uden and Tyson, 2009). Pharmaceutical drug delivery formulation techniques, such as 
ionotropic gelation, were employed to produce NP delivery systems that could potentially 
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improve the permeation, bioavailability and toxicity of the SeAAs. In tandem, process 
techniques common to the food industry, such as DoE (statistical experimental designs), 
were used to develop optimum NP formulations for oral delivery. The precise conditions 
identified through efficient estimation of process parameters enabled the production of 
NPs with target physicochemical properties (size, PDI and ZP), as identified by DLS. In 
vitro evaluation of the produced NPs was then conducted to assess the likelihood of oral 
compatibility in terms of stability, cytotoxicity and release profiles. Lastly, mushroom 
by-products were isolated and purified for the formulation of these NP systems.   
9.2 Research Findings 
In Chapter 4, a CCD and mathematical modelling approach was employed to assess the 
method of ionic gelation between the biopolymer chitosan (Cs) and tripolyphosphate 
(TPP), for production of NPs with physicochemical properties suitable for oral delivery. 
The mass ratio of Cs:TPP is one of the most influential variables that determines the size, 
PDI, ZP and morphology of ionotropically formed Cs NPs. The results of the CCD design 
identified that, at approximate concentrations of Cs (1.68 - 1.8 mg/mL) and intermediate 
concentrations of TPP (0.20 - 0.37 mg/mL), a feasible region was identified in which NP 
target properties could be achieved. The physicochemical properties of the NPs produced 
from the validation of the CCD study were assessed by DLS, showing that, under 
optimum conditions of Cs:TPP (6:1), NPs with sizes of 161 ± 43 nm, PDI of 0.39 ± 0.02 
and ZP of 42 ± 3 could be produced. The information acquired from the CCD enabled 
further development and understanding of the model variables for NP production. 
In Chapter 5, the main variables which affect EE%, particle size, PDI and ZP were 
optimised by use of a BBD. The SeAA, SeMet, was used as a prototype encapsulant, and 
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increasing the EE% of SeMet in the formulation was one of the driving targets for study. 
It was in this work that the importance of ionisable groups present on the BA to be 
encapsulated was highlighted, and a fundamental understanding of the formulation 
variables was gained. Through modulation of the formulation media pH, it was possible 
to induce higher protonation of Cs and ionisation of SeMet and thus electrostatic 
interactions between the two. This modification resulted in an increase of the EE% of the 
NPs from 39 ± 3 % to 66 ± 1 %, whilst their physicochemical properties remained within 
the target range for oral delivery. To further increase the EE%, the NPs were coated with 
the prolamine rich protein zein, which resulted in a final EE% of >80%, with NP 
diameters of 377±47nm, whilst the PDI and ZP values were maintained. Once satisfactory 
NPs for oral delivery were attained, it was necessary to then assess their suitability as a 
delivery system in vitro. Techniques were developed to evaluate their stability, 
cytotoxicity and release profiles and overall, the NPs performed well, showing high 
colloidal stability and thermal resistance over prolonged periods of time and no decrease 
in cellular viability in either Caco-2 or HepG2 cells after 4 and 72 hr exposures, 
respectively. Lastly, after 6 hr exposure to simulated intestinal buffers, the cumulative 
release profile of SeMet from the NPs showed that ≤ 60% of the drug had been released, 
indicating that degradation of the NP was slow and thus the mechanism may be 
diffusion/relaxation oriented. Overall, the findings inferred that it was possible to use 
DoE for the encapsulation of SeMet into a NP delivery system comprising food-derived 
components and that the oral administration of this molecule was plausible. 
The strength of the DoE methodology was then tested in Chapter 6, in which the 
optimised formulation conditions, as previously identified, were employed to encapsulate 
the SeAAs SeCys2 and MSC. The rationale for this approach was based on the fact that 
SeCys2 and MSC contain comparable ionisable groups to SeMet and, as such, similar 
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formulations (e.g. physicochemical properties and EE%) as those achieved for the SeMet 
loaded NPs could be achieved. It was here that the reliability and usefulness of DoE was 
evidenced, as the responses that were estimated using the derived quadratic polynomial 
equations in Chapter 5, produced SeCys2 and MSC loaded NPs, with equivalent 
physicochemical properties to those of SeMet. Differences between the encapsulated 
SeAAs were then identified by the in vitro techniques developed previously, whereby 
SeMet and MSC were shown to elicit little to no toxicity at test concentrations of 25-
100uM in Caco-2 and HepG2 cell lines after 4 and 72 hr exposures. Although native 
SeCys2 mirrored SeMet and MSC in terms of no apparent toxicity to Caco-2 cell lines, it 
elicited significant toxicity in HepG2 cells, across all tested concentrations. The 
feasibility of the formulation was then evidenced, as the encapsulation of SeCys2 within 
the Cs:zein NP matrix conferred protection to the HepG2 cells after 72 hr exposure, 
indicating that, at the test concentrations used in the study (25-100 uM), the cytotoxic 
effects of pure SeCys2 could be reduced. Interestingly, variances in the release profiles of 
the SeAAs were identified in this work, appearing to be intrinsically linked with their 
pKa values. A slower release in the stomach was observed for SeAAs with increasing 
pKa (SeCys2, pKa=4.66 < MSC, pKa=4.93 < SeMet, pka= 5.53) and it was postulated that this 
systematic variance was attributable to their chargeable properties and interactions with 
the protonated 1º amines of Cs. In terms of stability, all formulations displayed high 
colloidal stability and thermal resistance over prolonged periods of time, independent of 
the encapsulated SeAA, with evidence that the Cs:zein matrix was responsible for this 
stability. 
In Chapters 4-6, all the NPs developed were produced using PROTASAN™ UP (CL113), 
a well-known commercially pure Cs derived from crustaceans. Chapter 7 then looked at 
extracting chitin (the precursor to Cs) from the edible basidiomycete mushroom A. 
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bisporus and its subsequent derivatisation to Cs using microwave radiation. The target of 
that study was to reduce the time taken for the production of Cs compared to traditional 
methods and to produce a product with equivalent properties (such as DDA% and MW) 
to CL113, that could be potentially used in future NP formulations. The study indicated 
that fungal Cs (fCs) could be produced with equivalent DDA% to that of CL113 (86±6 
vs 85±4 %). Notably, the produced fCs possessed a higher MW (180±19 vs 110±4 kDa), 
although it still fell within the medium molecular range suitable for oral delivery (110-
225 kDa) (Bowman and Leong, 2006)). Once Cs with satisfactory properties was 
produced from the A. bisporus samples, a further modification was investigated, whereby 
the free amine groups present on the polymer backbone, were subjected to exhaustive 
methylation to give rise to trimethyl-chitosan (TMC). TMC was then assessed in vitro 
and showed potential application as a permeation enhancer. Based on the findings of 
Chapter 7, A. bisporus can be considered as a good source of chitin that can be easily 
isolated without aggressive treatments, subsequently deacetylated for the production of 
Cs and chemically modified to TMC, showing these by-products have potential use for 
many different practical applications. 
Lastly, in Chapter 8, fCs was used to formulate NPs loaded with synthetic SeCys2 by 
employing the optimised formulation conditions previously identified (Chapter 5). Once 
again, the robustness of the DoE formulation model was evidenced, as although fCs was 
used in place of CL113, NPs with equivalent physicochemical properties (sizes of 299.5 
± 47.1 nm, PDI 0.324 ± 0.176, ZP 38.7 ± 2.1, and EE% of 84.4 ± 1.2) were produced. 
The effect of Cs MW on NP production was also highlighted in this study, whereby the 
higher MW fCs NPs showed increased EE% / ZP values and a slower controlled release 
profile, most likely attributable to the larger proportion of ˚1 amines present on the 
polymer backbone available to interact with the ionised groups of SeCys2. No apparent 
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toxicity to Caco-2 cell lines was observed after 4 hr exposure, although, for HepG2 cells, 
the IC50 of native SeCys2 was found to be 12.8 ± 3.6 uM vs 32.5 ± 1.4 uM for SeCys2 
loaded fCs NPs, showing that the cytotoxic effects of pure SeCys2 can be reduced with 
the applied formulation. Finally, a preliminary study to assess the feasibility of Irish 
mushrooms providing Se species for supplementation purposes was conducted. In that 
study, a RP-HPLC-PDA method was validated to analyse Se supplemented A. bisporus 
and the predominant species identified was SeCys2 at 616 ± 23 µg/g DMP. Modest 
amounts of the SeAA, SeMet were also identified, at 18 ± 9 µg/g DMP. These findings 
infer that, Se supplemented mushrooms may be a feasible source for organic Se 
supplementation purposes and warrant further investigation. 
9.3 Considerations and Future Perspectives  
The work in this thesis raises several important points for consideration. Firstly, the 
physicochemical properties of the carrier system are critical considerations and 
ultimately, the desired targets (e.g. size, PDI, ZP) will rely heavily on the desired delivery 
route. Time spent on achieving these target properties can be substantially reduced, by 
employing a DoE approach, to develop optimum processes, via efficient screening of 
process parameters. In this work, a robust formulation model was produced using SeMet 
as a prototype encapsulant, which allowed for the subsequent encapsulation of 
structurally similar SeAAs, in a fraction of the time it would take compared to a OFAT 
approach, proving the benefits of a systematic approach to NP carrier design. While for 
the food industry, DoE has become standard practice for R&D of improved 
manufacturing processes (Carneiro and Azevedo, 2017), in comparison, the 
pharmaceutical industry has been late in adopting these paradigms (Politis et al., 2017). 
The FDA, have recognised that “quality cannot be tested into products, i.e. quality should 
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be built in by design” (Ich.org, 2009) and the benefits of a DoE approach have started to 
become apparent to the industry (Politis et al., 2017). The work in this thesis shows that 
an experimental planning approach together with a knowledge of the physical chemistry 
phenomena involved can enable the achievement of formulation target properties with 
application to similar targets/cargo successfully.  
Further exploration of the application of other DoE strategies might increase research 
efficiencies, for example with the extension from laboratory experiments in this thesis to 
industrially oriented experiment DoE such as Taguchi methodology. The Taguchi method 
utilises orthogonal array (OA), signal-to-noise ratios (𝑆/𝑁), main effects, and analysis of 
variance (ANOVA) (Fei, Mehat and Kamaruddin, 2013). OA provides a set of well-
balanced (minimum experimental runs) experiments and 𝑆/𝑁, which are logarithmic 
functions of desired output, which serve as objective functions for optimisation (Datta, 
Bandyopadhyay and Pal, 2008). The approach provides an easy to interpret set of results 
that help experimenters determine the appropriate set of factor levels to create a robust 
system that performs on target. Static mixers are composed of several tortuous motionless 
elements, that allow for rapid combination of flow streams through mixers with low 
energy requirement, low cost, compact space requirement and continuous operation 
(Dong et al., 2013). As such, coupling of a static mixer system with a Taguchi DoE 
method may offer a future approach for industrial scale up of the NPs developed in this 
work.  
Regarding the use of these SeAA loaded NPs for supplementation purposes, this current 
work optimised physicochemical properties (size, PDI, ZP and morphology) suitable for 
oral delivery, in addition to ensuring high enough encapsulation of the cargo for 
commercial applications. These formulations were then screened in vitro to assess their 
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stability, release profiles and potential cytotoxicity for suitability for oral delivery. The 
findings of this work indicate that the formulation will be orally compatible and suitable 
for supplementation purposes.  
The role of selenocompounds as potent cancer chemopreventive agents has been 
evidenced in several epidemiological studies, preclinical investigations and clinical 
intervention trials. However, these reports have often conflicted (Novotny et al., 2010; 
Mandair et al., 2014) and accumulated evidence suggests that the important determinants 
of the chemopreventive activities of Se compounds are both dose and chemical species 
dependant (El-Bayoumy, Sinha and Richie Jr, 2015). Additionally, the metabolic 
products from the various Se forms present in food and Se supplements, aimed at 
increasing selenium body status, are typically based on the indirect analysis of 
selenoproteins such as glutathione peroxidase (GPX) and selenoprotein P, as they are the 
major forms of Se present in the body (Kieliszek and Błażejak, 2013). The question, 
however, regarding what happens to selenium, from when it is ingested until it is excreted 
from the body, largely remains open (Kokarnig et al., 2015). The antioxidant properties 
of the GPX selenoproteins, have been presumed to be the main factor in preventing 
carcinogenesis, largely based on animal and cellular studies (Chen, Prabhu and Mastro, 
2013). However, this is likely to be an oversimplification, and emerging evidence 
suggests that certain forms of Se might exclusively elevate the level of Se-binding protein 
(SBP) (suggested to play a role in tumour suppression) rather than GPX (Mandair et al., 
2014). Amoako et al., addressed the issue of stability of un-encapsulated Se species in 
selenium supplements (comprising multiple complex species in yeast-based and non-
yeast-based supplements), exposing their predisposition to interconvert at the expense of 
long-term stability (Amoako, Uden and Tyson, 2009). No other work has focused on the 
encapsulation of organic Se species prior to their assessment as either supplementary, 
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chemo-preventative or therapeutic agents. The evidence provided in this thesis presents 
a formulation cargo system that can be used in future research in Se 
supplementation/therapy which may prevent biases in this research area and possibly lead 
to industrial applications.  
Lastly, the SeCys2 fCs NPs formulation developed in this work, may warrant a future 
investigation as a potential chemotherapeutic, based on literature evidence and the ability 
of the formulation to provide stability against Se degradation. Over the last decade, 
chemotherapy and targeted therapy combinations have helped to significantly improve 
patient outcomes (Kemp et al., 2016). Although chemotherapeutic agents can be highly 
effective, small biological differences in the host and cancer cells makes treatment more 
challenging (Hoelder, Clarke and Workman, 2012). Often, antineoplastic agents are toxic 
chemicals and biologics designed to destroy cancer cells. However, while exerting their 
desired pharmacological effects, they can often precipitate severe toxic effects. Nausea, 
hair loss, compromised immune system, cardiotoxicity, are some of the adverse physical 
effects of these agents (Keefe and Bateman, 2012). As such, strategies are evolving to 
reduce or eliminate these unfavourable side effects by targeted delivery of the 
chemotherapeutic agent to the specific areas of cancer (Byers et al., 2016). Molecular 
targeting for cancer chemoprevention has recently been focused on intracellular-
signalling cascades (Wada, 2012). The anticancer activity of Se has been postulated to 
include inhibition of cell proliferation, modulation of redox state, detoxification of 
carcinogen, stimulation of the immune system, inhibition of angiogenesis and induction 
of cell apoptosis (Sanmartín et al., 2011; Narayan et al., 2015; Wrobel, Power and 
Toborek, 2016). In an in vitro study, SeCys2 was identified as a novel agent with a broad-
spectrum of antitumour activity, whereby a panel of eight human cancer cell lines was 
shown to be susceptible to SeCys2, with IC50 values ranging from 3.6 to 37.0 μM (Chen 
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and Wong, 2009). More specifically, SeCys2 has been reported to induce normalisation 
of the tumour vasculature, and a 4-fold increase in intra-tumoral doxorubicin levels, upon 
oral administration in mouse models, indicating its selective uptake by tumour tissues in 
vivo (Fernandes and Gandin, 2015). Studies by Estevez et al., assessed the effects of Cs 
stabilised, elemental Se (Se0) NPs on cell proliferation, apoptosis and cell cycle pattern 
in HepG2 cells and compared their peformance to other Se species. They found that the 
Se0 NPs, stabilised with Cs, modestly inhibit a key enzyme known as CDK1, which is 
responsible for cell division and postulated that Se could be used as a chemotherapeutic 
by causing cell cycle arrest in cancer cells through CDK1 inhibition. Interestingly, they 
observed that native SeCys2 induced a more potent inhibitory effect on CDK1, but argued 
that strong inhibition of this enzyme would likely be toxic to both cancerous and healthy 
cells (Estevez et al., 2014). It is worth noting that, in that study, the authors neglected to 
stabilise the SeCys2 with Cs for use as a control, so a true conclusion cannot be drawn on 
whether the Se0 NPs were solely responsible for the observed effects and not the synergy 
between the Cs and Se0 complex.  
A challenge in the use of Se as a cancer therapeutic is to deliver redox active selenium, 
preferentially directly to the tumour and/or metastatic cells (Misra et al., 2015). 
Interestingly, a significant number of Cs-based NPs have been reported to be selectively 
accumulated into tumour sites, primarily owing to the enhanced permeability and 
retention (EPR) effect (Prabaharan, 2008; Na et al., 2011; Maeda, Nakamura and Fang, 
2013). The EPR affect relates to the defective tumour vasculature and disorganised 
endothelium with poor lymphatic drainage at the tumour sites, allowing for the selective 
accumulation of macromolecular drugs in tumour tissues (Wolinsky and Grinstaff, 2008). 
As Cs is biodegradable and easily metabolised from the body, it has become quite 
clinically attractive for use in drug delivery applications (Kumari, Yadav and Yadav, 
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2010). Moreover, the biocompatibility of Cs is dependent on its purity, MW, and DDA% 
and, as this work evidenced, can be modulated accordingly, given the right production 
conditions. Considering the apparent selective cancer targeting properties of both SeCys2 
and Cs and the reported antitumour activity of SeCys2, in addition to the observed ability 
of Cs to confer protection to non-cancerous cells, it seems reasonable to suggest that the 
SeCys2 loaded fCs NPs, as described in this work, may warrant investigation as anticancer 
formulations.  
Crustacean derived Cs is dependent on the source itself, whereby, to yield a product with 
reproducible properties, the same species must be harvested, at the same time 
(seasonally), in the same geographical location and at the same life stage cycle and 
different batch materials require different processing conditions (Weinhold et al., 2009). 
fCs offers several advantages over its crustacean counterparts, owing to the highly 
controlled environments in which it is cultivated, year-round growth that is not seasonally 
dependant and significantly lower heavy metal association than that of crustaceans 
(Muzzarelli et al., 2012). The present work shows the reproducibility of laboratory based 
fCs production as well as the ability to match industry standards. However, to make fCs 
sustainable and competitive in the market, especially for pharmaceutical applications, the 
assessment of reproducibility of fCs product batches is imperative. Currently, there are 
two companies that are actively selling enzymatically derived fCs for weight-loss 
products (Kiytozyme, Belgium) and for R&D applications (Mycodev, Canada) at a cost 
range of €177-213 per gram (www.sigmaaldrich.com). There are many potential reasons 
for this apparent high cost, which may relate to the enzymes being employed, the initial 
investment cost of the scale-up instrumentation and their subsequent energy 
consumption. Although it is difficult to provide an exact comparison of cost of the fCs 
produced in this small-scale work, with that of commercially available products, a crude 
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estimate can be made. For instance, the initial investment of a MARS 6, 40 vessel 
turntable microwave, as used in this project, is €15,000 and it can process 10 g of chitin 
at a time, using > 400 mL of NaOH (30 % w/v, ≈ €15) with a 15 min reaction time in a 
600W microwave at a cost €23.79 per Kwh (www.energyusecalculator.com, accessed in 
May 2018). The weight yield of fCs using this method is 5.5g, with a DDA% of 86 ± 6 % 
and MW of 180±19 kDa. Excluding the initial €15,000 investment of the microwave, the 
apparent cost of fCs using the method developed in this research is ≈ €6.2/g, showing 
considerable potential for a mark-up that would quickly recover the initial investment 
cost and offer a significantly more competitive price compared to the current market 
providers.  
Consumers may see purchasing non-animal products as an ethical obligation, whilst 
others trade it off against price and other product attributes (Vanhonacker et al., 2007; 
Vanhonacker and Verbeke, 2014). Varying preferences and perceptions may also stem 
from norms and values within specific subcultures, such as those linked to religious (e.g. 
pigs in Muslim and cows in Hinduism countries) and cultural differences at the national 
level (Van Riemsdijk et al., 2017). Regardless, with the rise in consumer demand for non-
animal constituents in food (Bord Bia Insight Centre, 2016), cosmetic (Hennigs, 
Karampournioti and Wiedmann, 2016) and pharmaceutical (Murtaugh et al., 2017) 
products, industrial companies are very interested in fungal-based alternatives, (Martin 
Zaki, Lambson Ltd, private communication) for use in product formulations. As such, 
fCs, produced as per this current work, may be well placed to address this demand and 
would warrant further investigation.   
Additionally, in this thesis, the Cs derivative TMC, which is a permeation enhancer 
presently used in both academic and pharmaceutical research and development (Kulkarni 
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et al., 2017), was produced from fungal chitosan. A recommendation for future work 
regarding further optimisation of TMC production from fCs would be the employment of 
parallel synthesis for potential optimisation of the DDQ % and further reduction in the 
extent of O-methylation. For example, variation of the alkylhalides (e.g. chloromethane, 
bromomethane), bases (e.g. KOH, K2CO3), and/or aprotic solvents (e.g. DMF, DMSO) 
employed may identify improved synthetic routes. It would also be interesting to employ 
a CCD to investigate the use of microwave irradiation for the synthesis of TMC, which 
would allow for both optimisation and comparison to the conventional method employed 
in this research, as it may result in a significantly reduced production time, similar to that 
attained for the fCs. 
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